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PREFACE 
by Professor A. CARRELLI, 
Vice-President of the European Atomic Energy Community 
Every noteworthy advance made by scientific research can be said to be always 
closely linked with a further development of our understanding. That is to say that 
the enrichment of our knowledge is essentially connected with some greater quantity 
of experimental data that we can gather by increasing our awareness of the external 
world; the larger body of information gathered then raises a broader uncertainty 
which drives the human mind, faced with more complicated problems, to formulate 
concepts of yet greater depth and significance. 
The development of the optical microscope and, more recently the electronic 
microscope, to mention only two of the more important examples out of many, 
opened up immense and profoundly significant fields of research to biologists, but 
who would presume that this system had brought us to the furthest bounds of 
knowledge, especially in so complex a field as that of life processes ? 
The recent advances in biochemistry, the achievements made in the field of 
physiology and genetics, have substantially added to our knowledge of the life 
processes, but problem after problem faces the inquirer each time another stage 
is reached on the difficult road of research. 
And now, with Fermi's discoveries, which have led in recent times to the 
synthetizing of radioactive isotopes of every chemical element, a new field has 
opened up, offering marvellous promise to both biological and chemical research. 
The presence, in a limited quantity of material, of radioactive substances endows 
that portion of material with peculiar electrical properties. Modern physical methods 
detect such properties with exceptional sensitivity. Minute traces of radioactive 
matter can be picked up, so that by introducing into the complex metabolism that 
takes place in the biological field a compound in which certain atoms are radioactive 
isotopes, that compound can be followed along the whole of its route by this highly 
sensitive method, providing the biologist with information that would be absolutely 
unthinkable with the customary methods. 
Such, then, is the essential use of « artificial » radioactivity in biology, but at 
the very outset this ingenious method raises the problem of preparing and utilizing 
the compounds containing the labelled molecules. Of particular importance is the 
use of suitably labelled proteins. A new and highly intricate branch of research has 
thus grown up. 
An idea of the complexity and importance of the questions this method has 
posed to researchers can be obtained from the pages of this book, which contains 
the numerous papers presented at the Pisa Colloquium. 
xv 
This publication shows the intricacy and significance of this field of research 
in present-day biology, thus demonstrating the usefulness of these meetings, which 
bring together an ever-growing number of research scientists, who are tackling the 
complex phenomenon of life with vision and constantly encouraging prospects. 
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OPENING ADDRESS 
by Professor G. MONASTERIO, 
Director of the Medical Clinic and the Nuclear Medicine Center, Pisa 
The use of radioactive labelled proteins has made it possible to obtain informa­
tion of utmost importance both to the physiologist and to the clinician. 
The interest for these tracers appears evident from their numerous applications 
to experimental and diagnostic investigations. Among the labelled proteins stands 
out the human serum albumin, which, tagged usually with iodine-131 and more 
recently with chromium-51, has found its way to a variety of applications. 
The radioactive labelling, more often with iodine-131, of some proteic hormones 
has made it possible to study in vivo their metabolism and mechanism of action, 
to assess, under pathologic conditions, the nature of the different sensitivity of the 
organism to some of them, especially to insulin, and to approach the problem of 
their assay with radioimmunological methods. 
Over the last few years the information derived from the use of labelled pro­
teins has been piling up. Usually, γ-emitting radioisotopes have been chosen as 
labels for the proteins, since they allow their detection in vivo by external counting. 
However, the results obtained have been often conflicting even in the same group 
of workers and in spite of the accuracy of the employed technique. 
The reasons for such discrepancies have been attributed to the alterations 
of the proteins during the labelling process and, sometimes, to the inadequacy 
of the analytical procedures which have been used. It is, of course, a fundamental 
prerequisite that the labelling process does not modify the physical and chemical 
properties of the molecules to such extent that the biological characteristics of the 
proteins be altered. Only if this requirement is satisfied, the labelled proteins maybe 
considered as physiological tracers, i. e., it can be assumed that their behaviour 
is equal to that of the corresponding proteins of the organism. 
This fundamental problem was the subject, some nine years ago, in November 
1956, of a comprehensive and detailed discussion at a conference sponsored by the 
New York Academy of Sciences under the chairmanship of S. P. Masouredis. At 
that meeting, the first two communications were presented by W. L. Hughes and 
by A. S. McFarlane, whom we have the pleasure to have with us this morning. 
Some of the technical problems which were set forth at that time have now 
been answered more or less completely, making thus possible to secure more reliable 
informations through the use of proteic tracers. 
It was deeply felt, therefore, the need to bring again together the workers inte­
rested to these problems for a new extensive discussion. The initiative for the present 
meeting is merit of the European Atomic Energy Community under the auspices 
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of which the congress is being held. To the European Atomic Energy Community, 
I wish to express my thanks for choosing Pisa as the place for this conference and 
for assigning to the Medical Clinic of this University the task of organizing it. 
The subject of the congress might seem far from the field of interests of an 
Institute of Internal Medicine, since the meeting is focused on technical problems 
more or less foreign to a physician. However, these problems have been raised, to 
a large extent, by the physician himself, since their solution is a necessary step for 
any methodological progress in the experimental and diagnostic investigation with 
radioactive tracers. 
It is true, on the other hand, that the solution of the problems involved in 
labelling proteins is not to be expected from the physician or from any worker in 
a single branch of the basic sciences, since it demands, because of its complexity, 
the joint effort of people with différent knowledge and experience. 
It occurs quite often, in fact, that the fundamental problems for the physio-
logist, and, more generally, for the biologist, derive from the clinical observations 
which inspire the work of these researchers. The solution of these problems, how-
ever, as well as almost any progress in medicine, depends on the close cooperation 
of mathematicians, chemists, physicists and physicians, on the applications of expe-
rimental and analytical methods of the basic sciences, and on the full and timely 
usage of the means provided by an ever growing technology. In this regard electronic 
computers deserve special mention. 
Owing to the numerous and complex attributions of an Institute of Internal 
Medicine, which include teaching, research, and care of patients, it would be neces-
sary to set up, within such an Institute, largely independent departments where 
basic sciences, technology and clinical problems may be brought in contact with 
each other. It should thus be possible to solve several problems and to promote 
the progress in medicine. There is now a trend to accomplish this integration of 
different scientific disciplines in autonomous Institutes the attributions of which 
comprehend only research activities and exclude teaching responsibilities and care 
of patients. In these Institutes scientists of different background can work together 
in close cooperation entirely dedicated to research problems. It should thus be 
possible to develop new and more advanced methods, which are instrumental to 
any progress in the various fields of medicine. 
Only through a working integration of mathematicians, chemists, physicists 
and physicians the growing gap between medicine and basic sciences may be bridged 
and clinical medicine may take up, on a larger and firmer ground, the characteristics 
of biological science which become it. 
This congress, that brings together, for a few days and with a program of inten-
sive talks, workers in clinical medicine and medical biology with those in funda-
mental disciplines, offers me the opportunity to stress the need for such coopera-
tion and to point out the so often recurrent mistake of believing that the clinician 
attributions have nothing to do with such problems. In medicine, as I have already 
XVIII 
remarked, the work of the researcher is the more fruitful the more is inspired to the 
direct clinical observation. Without the close cooperation of the clinician, the work 
of the isolated researcher is bound to become sterile, since most of the times is the 
former to raise the problems of actual interest. Furthermore, the clinician stimulates 
the researcher with his urgency for the solution of a problem and checks in man 
the validity of the results. 
It is well known, on the other hand, that in other applied sciences and parti-
cularly in those of very recent origin such as the space sciences, the more difficult 
problems have been overcome only through a wide and close cooperation among 
different disciplines and the progress itself of the basic sciences and technology has 
been promoted by the need and urgency of solving these problems. 
It is thus understandable the reason for which the clinician is so sensitive to 
the solution of the most various problems, even when the methods involved appear 
quite foreign to the domain of his competence and interests. 
It is thus explained also the program of the congress and its attendance by 
many clinicians and researchers of clinical extraction. In fact, after the first and 
second session, biological aspects of labelling the proteins in general on and the 
plasma proteins in particular, the application to metabolic studies of these tracers, 
i.e., proteic hormones and plasma proteins, will be treated tomorrow, and finally, 
the discussion will center on the theoretical problems, the solution of which is essen-
tial for a correct analysis and interpretation of the results obtained with the proteic 
tracers. 
In the act of giving my warm welcome to all the researchers here gathered even 
from distant countries, I wish to express them my personal thanks and those of 
my collaborators of the Medical Clinic of Pisa for having accepted the EURATOM 
invitation to participate actively to this congress. I wish also to thank Prof. Ales-
sandro Faedo "Magnifico Rettore" of our University for offering us his generous 
hospitality. 
I take the opportunity of this meeting to renew the feelings of my obligation 
to Euratom for having acknowledged with the organization of this congress both 
the paramount interest of these problems and in general of the applications of the 
atomic energy to the scientific research in medicine, and the work accomplished 
by the researchers of Pisa during the last three years under the Contract of Asso-
ciation with the Euratom and the Free University of Brussels. 
I wish that the results of our proceedings may show the Euratom that some 
convictions periodically inspiring its policy, and in force of which medicine is consi-
dered the Cinderella of the various applied sciences, are quite groundless. I express 
the hope, in fact, that the results so far obtained may prove the validity and pro-
ductivity of the effort devoted to sponsor and promote research in this field. 
Asa matter of fact, setting aside any other considerations, it is just in this field 
of scientific investigation that, on the basis of the experience so far available, the 
fastest progresses with the minimum cost may be expected; it may be foreseen, the-
xix 
refore, the highest revenue of the means employed. It is in this field that the Euratom 
might reasonably pursue the design of attaining in a short time a position of pro-
minence whereas, in other fields, where incomparably larger means are required, 
such a design would be extremely aleatory and in any case realizable only in a very 
long run. 
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ABSTRACT 
The labeling of proteins is discussed in general terms with emphasis on the 
advantages and limitations of various techniques. The practical advantages of iodi-
nation and some of the complications which affect interpretations are reviewed 
in the light of present information as to the mechanism of iodination and the role 
of the tyrosyl group in protein structure and function. Some new approaches to 
these problems are suggested. 
Labeled proteins are used primarily as tracers for the purpose of understanding 
the function of the native unlabeled protein, and therefore should differ from the 
unlabeled protein by a minimal amount, or at least by an amount too small to 
be recognized by the biological system under investigation. The ideal label would 
therefore appear to be an isotope of an element contained in the molecule under 
study. In the case of proteins this would then usually be an isotope of carbon, hydro-
gen, nitrogen, or sulfur. Moreover, the isotope should occur in the protein as an 
atomic replacement linked in a normal way to the neighbouring atoms. If it is to 
be used to follow the fate of the protein, it must remain with the protein until the 
protein is destroyed, and if it is intended to follow the fate of a degradative frag-
ment, it must likewise remain with the fragment. 
To be sure, even isotopes of the same element are not handled identically or 
else present day methods of separating isotopes would be impossible. However, 
since isotopes differ only in mass, their chemical properties are different primarily 
in processes affected by mass such as diffusion or kinetic processes involving the 
transfer of an atom. Even in these instances the small difference in mass minimizes 
these effects for all the biologically important isotopes excepting those of hydrogen. 
In the case of hydrogen while large isotope effects may be observed in hydrogen 
transfer processes, when the isotope remains attached to the same organic grouping 
during a reaction process, its effects are minimal. 
Protein molecules are still beyond the synthetic prowess of the chemist and 
so the incorporation of a label into the native protein must be done biosynthetically 
via a labeled intermediate as first developed by Hevesy (1). These processes utilize 
the isotope inefficiently and demand the chemical isolation of the particular protein 
under study since all the proteins are labeled by the process. Furthermore, the data 
obtained may be difficult to interpret because of reutilization : that is, the label 
may transfer during the study to a new molecule of the same species which cannot 
( ' ) The author is indebted to the U. S. Atomic Energy Commission for its continued support 
of his work on the preparation and exprimental use of labeled proteins. 
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be distinguished from the original molecule. In this case additional information 
concerning the extent of this back-reaction must be obtained ,2). In human experi-
mentation the method is also complicated by the large radiation dose to which the 
subject is exposed. 
Consequently, most labeled proteins are prepared in vitro. This might be done 
by appropriate exchange of a radioactive atom with its stable isotope in the protein 
as, for example, a triton for a proton. However, this procedure although it has 
proven useful in studies of protein structure <3) does not seem applicable to biolo-
gical studies because proton exchange takes place under physiological conditions 
and therefore would continue to occur during a physiological study. Perhaps the 
exchange of labeled terminal amino acids might be carried out enzymatically. How-
ever, such groups could be subsequently lost by similar enzymatic action in vivo. 
Other types of hydrogen exchange are possible and may prove valuable in 
the future. Thus oxytocin has been labeled by iodination followed by catalytic 
deiodination with tritium gas to restore biological activity as a tritiated 
hormone (4). Also the Wilzbach technique has been applied to proteins (5). In this 
process the protein is exposed to a large amount of tritium gas. Exchange of tritium 
with hydrogen in any position of the protein molecule can occur through radiation 
processes. These may involve either the production of energetic tritium atoms which 
exchange with a hydrogen in the protein or the production of protein radicals by 
the loss of hydrogen which can recapture a tritium. In any case successful exchanges 
are always accompanied by a variety of degradative changes so that the isolation 
of labeled but undamaged molecules is extremely difficult or probably impossible 
in the case of proteins containing thousands of bonds sensitive to rupture by the 
radiation. 
For many purposes the introduction of new and foreign labeled groupings 
into the protein molecule has proven most practical. In every instance where this 
is done the effects on the original protein must be ascertained both at the chemical 
and at the biological level. Such precise re-assessment of the labeled molecule is 
frequently arduous. However, the advantages to be obtained in terms of practical 
results are usually worth the effort. An immediate advantage of these procedures 
over biosynthesis is that frequently the native protein is already available in a highly 
purified state. This obviates repetition at a micro level, of the usually involved proce-
dures for isolation and characterization of the protein. In addition, as already poin-
ted out, the isotopie yields are much better since only the desired protein is labeled. 
The choice of a label will depend upon the nature of the protein as well as 
on the type of study to be undertaken. Fortunately, a wide variety of radioisotopes 
with different radiant energies and half-lives are available, so that the first consi-
deration should be the chemical properties to be achieved. In principle, any intro-
duced group must change the properties of the original molecule. However, the 
degree of change will be related to the degree of conformational alteration both 
of the protein as a whole and of its reactive site. One might predict the change in 
chemical and biological properties would be related to the mass and electrical charge 
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of the introduced group and to its position relative to the functional part of the 
protein. Since proteins contain thousands of atoms, the change in mass would 
appear trivial, and since the reactive site of a protein molecule usually appears to 
involve a small fraction of the molecule, the chances of a successful modification 
would seem good. 
However, it must be remembered that the active site frequently contains some 
of the most reactive groups in the molecule so that finding a reagent which will 
not affect these groups may be very difficult. Furthermore, the identity of the func-
tionally important groupings is still not known for most proteins, and in fact, modi-
fications of the type we are discussing have proven most useful in discovering the 
functionally important groups. Returning to our principle of producing the small-
est possible percentage change in the protein, the group introduced should be as 
small as possible, but more important it should not introduce new charge or change 
the charge distribution on the protein. Therefore, the introduction of a single atom 
would usually seem preferable and the halogens have proven most successful. We 
shall return to these shortly. 
Of course, the atom introduced should remain attached to the protein through-
out the study and hence a co-valent bond not attacked by the usual substances 
present in biological fluids would seem necessary. This requirement appears to 
rule out most metals for labeling purposes since they form ionic bonds which ex-
change readily with water. However, in certain favorable circumstances as with 
iron in hemoglobin or with manganese in an active site, as we shall see in the following 
papers, coordination may complex the metal sufficiently firmly for biological stu-
dies. Similarly, chromium can be used because its complexes in the valence 3 state 
are extremely sluggish. This too will be discussed in detail in succeeding papers. 
Some metal-carbon bonds would have sufficient stability as for example, the C-
Hg bond. However, the preparation of these usually must be done in the absence 
of active hydrogen, a condition hard to achieve with a protein. 
Among the non-metals useful in labeling, besides the seventh group of the 
periodic table, (the halogens), we might also consider the fourth, fifth, and sixth 
groups, represented by carbon, nitrogen, and oxygen. However, these elements 
present complications in that their stable valence states are 4, 3, and 2 respectively, 
requiring the introduction of several atoms to satisfy their valency and frequently 
leading to the introduction of a charged group into the protein. In the case of car-
bon, the smallest group to be introduced would be methyl (CH3). Actually, this 
grouping is not larger than bromine but the usual manner of its introduction via 
methylating reagents involves the esterification of a carboxyl grouping (which 
changes the charge on the protein and forms a labile derivative) or to the replace-
ment of an active hydrogen of a sulfhydryl, or imidazyl group. If the methylating 
reagent could be directed specifically to an amino group the changes produced 
should be minimal and a very useful derivative should result, although the long 
half-life of carbon-14 would preclude the possibility of obtaining the high specific 
activity necessary for some tracer studies. 
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Nitrogen and oxygen do not have useful radionuclides, but the elements below 
them in the periodic table, phosphorus and sulfur do. However, their stable valence 
states of -f- 5 and + 6 respectively, require the simultaneous introduction of several 
other atoms, usually oxygen. Thus, the hydroxyl groups of serine or threonine may 
be phosphorylated with POCl;i, but this introduces the charged -O-P = (OH)2 
O 
group into the molecule. Perhaps the most useful phosphorous derivative has pro-
ven to be diisopropyl fluoro phosphate (DFP), which will attack a variety of active 
hydrogens but has found use as a specific reagent because it attacks the active site 
of certain esterases such as choline esterase and chymotrypsin much more rapidly. 
The stability of the bond formed is sufficient to permit the isolation of phosphory-
lated peptides upon hydrolysis of the inactivated enzyme <(i). This suggests that 
such labeled derivatives might also prove valuable in studying the metabolic fate 
of these proteins in the plasma similar to studies which have been carried out with 
DFP labeled erythrocytes. Chlorosulfonic acid has been used to label the hydroxyl 
groups. This introduces an acid sulfate group with its attendant charge and thus 
changes the properties of the protein, at least in its region. However, methane sul-
fonyl chloride should obviate this difficulty. This has been rarely used, but the 
corresponding benzene sulfonyl chloride as its para-iodo derivative (pipsyl chloride) 
has found wide use in labeling proteins for peptide sequence studies since the result-
ing sulfonamide bond resists acid hydrolysis ,7). 
Now we have progressed into the specific organic reagents for proteins and to 
attempt to even cite these would consume my remaining time so let us return to 
halogenation. Halogens form reasonably stable bonds with carbon in a variety 
of compounds either by the displacement of hydrogen or by addition to an unsa-
turated carbon-carbon bond. Fortunately many of these reactions are slow, and 
in aqueous solutions only a limited number of the more rapid reactions need be 
considered. The reactions of iodine with proteins were discussed by Ramachandran 
ten years ago (8) in an excellent review which needs few additions to bring it up to 
date. Since the halogens are increasingly reactive in the order iodine, bromine, chlorine, 
fluorine, the other halogens possess still broader spectra of reactions. In addition, they 
possess no isotopes of wide biological applicability, excepting 82Br and so will not 
be discussed further here. (Astatine, (element 85), the last of the halogens has no 
stable isotopes and thus presents interesting problems with reactions at truly tracer 
concentrations. It has been possible to bind astatine to protein, although whether 
the reaction occurred with tyrosyl residues in an entirely analogous fashion to iodine 
was not clear(!l).) 
Iodine possesses about 2 dozen radio-nuclides and some of these shown in 
Figure 1 have found wide utility. The radio-isotope is usually obtained as the iodide 
with or without added carrier 127I. If adequate care has been taken to exclude all 
stable iodine in its preparation the limiting specific activity must depend on its 
half-life. However, in practice other isotopes are always present limiting the specific 
activities which can be obtained (10). 
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FIGURE I. 
Iodide, of course, cannot form stable linkage with protein. Protein labeling 
reported by the simple addition of radio­iodide may have involved higher oxidation 
states of iodine perhaps brought about by radiation­induced peroxides. Alternately 
the iodide may have reacted with radiation­induced protein radicals to form a co­
valent bond. In any case such radiation­induced events are rare and very inefficient. 
Therefore the first step in iodination is to convert the iodine to a higher oxidation 
state, usually of 0 or of + 1. This may be most simply done by the addition of 
carrier iodine, or better of tri­iodide ion since iodine dissolves in water only to the 
extent of 1 milli­molar. The following equilibria then apply : (Figure 2). 
h 
ï . 
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O H ­
HOI 
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RNH, 
L + I ­
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FIGURE 2. — Equilibria of Iodine with Solvents 
Chemists are still not in agreement as to the identity of the active iodinating 
species; iodine, hypoiodous acid, and hypoiodinium ¡on have all been implicated. 
The first reaction in any case can be used to control the rate of reaction since the 
concentration of free iodine is inversely related to the iodide concentration. Hypo­
iodous acid and hypoiodinium ion concentrations also depend upon that of iodide 
but in these cases a second iodide ion is produced in their formation so that the concen­
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tration of these species depends inversely upon the square of the iodide concentra-
tion. Reaction 5 which is essentially irreversible in alkaline solution, acts to remove 
the iodinating species converting it to iodate and iodide. However, it occurs at an 
unappreciable rate below pH 10. The last reaction can occur with ammonia or 
the amino groups of proteins or with other nitrogenous bases such as sulfonamides 
or succinimide but is rapidly reversible and results in no permanent binding of 
iodine. However, like reaction 1, it may limit the rate of other iodinating reactions. 
When an iodine solution containing these species is added to protein, addi-
tional reactions occur (Figure 3). These processes are either irreversible (or essen-
tially so) in that the equilibrium is far to the right, as in the case of SH oxidation. 
The reactions with sulfhydryl always occur first. However, they do not result in stable 
bonding of iodine. Whenever geometrical factors permit, the third and fourth reac-
tions of Figure 3 take place, liberating all of the iodine as iodide ion. In the case 
of monothiol proteins such as serum albumin, in which the formation of disulfide 
link is sterically difficult, only the third reaction occurs and two equivalents of 
iodine are consumed, but the sulfenyl iodide must hydrolyze rapidly, since the 
final product is devoid of iodine (11). Consequently, in any labeling experiment 
HOI + RSH -> RSI + HOH 
RSH + RSI -» R-S-S-R- + H+ + I~ 
I 
HOI + R - —OH - R - >—OH + HOH 
HOI + R —< 
2 R — 
FIGURE 3. Iodine Reactions with Protein 
the first iodine consumed, equivalent to the SH content of the solution, must be 
considered lost for purposes of labeling. The rate of SH oxidation depends inversely 
on the hydrogen and the iodide ion concentrations suggesting that either hypo-
iodous acid or thiolate anion is the active species. Aside from causing a poor yield 
in labeling, the oxidation of SH groups will of course be disastrous for proteins 
whose function requires a sulfhydryl group, and some method of protecting these 
groups should be developed. Metals can be readily reacted with SH groups but 
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do not protect against iodination. Alkylating reagents will protect but are difficult 
to remove. Cunningham and Nuenke have produced mixed disulfides by reacting 
the sulfenyl iodide reaction product of a protein with a small mercaptan (12). This 
process might be used before labeling the protein and permit subsequent resto-
ration of the sulfhydryl after iodination by dissociation of the disulfide bond with 
an excess of mercaptan. 
The reaction with tyrosyl residues is the basis of all iodine tagging of proteins. 
The kinetics of this reaction have recently been reinvestigated with acetyl tyrosine 
by Mayberry et al. <13' 14) who prefer to write the reaction as illustrated in Figure 4. 
They assume the rate determining step is the second reaction involving the base 
catalyzed displacement of a proton from a quinoid form. 
This mechanism is consistent with their data and explains the general base 
catalysis of the reaction, the dependence of the rate on the hydroxyl ion concen-
tration, and on the square of the iodide concentration. Obviously, alternate mecha-
nisms involving 1+ or HOI could also be formulated to fit the data. However, the 
requirement for a phenolate ion which is implied by the non-reactivity of O-sub-
stituted phenols makes hypoiodous acid difficult to accept. This mechanism also 
explains the labeling of iodotyrosines by exchange with molecular iodine, which 
has been shown to proceed more rapidly than iodination itself. Mayberry et al. <15) 
have also measured the rate of entry of the second iodine atom to form diiodoacetyl 
tyrosine and find it is 30 times slower than the first when the rate measurement 
is based on the concentration of the respective phenolate ions. Therefore at neutral 
pH where both tyrosine and its monoiodo derivative are present in the unionized 
form, the rates of iodination must be about equal since the phenolic pK's are 10.2 
and 8.8 respectively. Consequently with incomplete iodination the presence of 
both mono and diiodo tyrosyl residues, which is frequently observed, is to be 
expected. 
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The mildest and best method of iodination is that using iodine in excess iodide 
(I7 reagent), and rates are readily controlled by the amount of iodide present. How­
ever, since all iodine atoms are equivalent, the fraction of iodine incorporated varies 
inversely with the excess of iodide used. To increase the fraction of iodine incor­
porated, iodine itself may be used with theoretical yield of 50 %, or ICI may be 
employed with a theoretical yield of 100 % (16). However, any groups such as sulf­
hydryl, which are concomitantly oxidized, will decrease the yield proportionately. 
Therefore, procedures have been developed for regenerating any iodide to reactive 
iodine*. In recent work this is usually done by adding chloramine­T which presu­
mably forms iodine by the following mechanism : 
\~Λ SO, NHCl + 21­ ­> CH:i O SO., NH" + Cl~ + I, CH 
This reaction as developed by Glover et al. (17), also avoids the addition of 
carrier iodine and thus permits the labeling of proteins at the very high specific 
activities which are required for hormonal assay to be discussed later in this confe­
rence. A simple procedure for handling large amounts of radioactivity and assuring 
mixing has been reported by Reith and Brown U8). This method can be performed 
rapidly and followed by the immediate addition of a radioprotective agent, such 
as serum albumin, to minimize radiation damage (35). 
However, hidden changes may be produced in the protein by this reaction since 
part of the iodine formed may cycle between the reagent and the protein alter­
nately reducing the reagent and oxidizing the protein. Such changes may be appre­
ciable and still go undetected unless efforts are made to measure the amount of 
chloramine­T consumed as well as the iodine incorporated. In addition chloramine­T, 
or any other oxidant powerful enough to oxidize iodine, may attack the protein 
directly. The vigorous nature of these reagents has been observed by Koshland 
who was able not only to iodinate tyrosine and histidine but to destroy methionine 
and tryptophan in gamma globulin by exposure to an excess of iodine chloride 
at pH 9 and 5° C "9 ) . McFarlane has controlled the process by careful stoichio­
metric addition with rapid complete mixing (jet iodination) (20). 
The presence in a given protein of tyrosyl residues of varying reactivity is fre­
quently noted both by spectrophotometric studies and by iodination in which a 
portion of the residues remain unreacted even after vigorous treatment. This has 
been studied in greatest detail in ribonuclease by Scheraga et al. <21' 22) who believe 
they can identify spectrophotometrically 3 reactive and 3 inert or "buried" tyrosyls 
on the basis of differences in the dissociation of their phenolic hydroxyl groups. 
Since the complete amino acid sequence of ribonuclease is known, more detailed 
¡nformation can be obtained by peptide analysis of iodinated ribonuclease. Iodine 
(*) In the next paper Dr. Rosa will describe a simple but elegant method in which he oxidizes 
the iodide to iodine in an electrolytic cell. 
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readily reacts with 3 of the 6 tyrosyl residues to give an enzymically active product 
and two of the unattacked tyrosines have been identified as residues # 25 and 97. 
This has been confirmed by Donovan <23). 
Pressman et al. <24) have found that the terminal tyrosyl in chymotrypsin iodi-
nates three times faster than the other tyrosyls in this molecule. Iodo-insulin has 
been the subject of many investigations, but since it will be discussed repeatedly 
in the next papers I will not mention it further here. 
Pressman's group have also iodinated proteins in the presence of specific small 
interacting molecules, and found that the protein sites responsible for binding the 
small molecule were then protected and not altered by iodination. Thus, heavy 
iodination of serum albumin (44 atoms iodine) decreased the binding of p-iodo-
benzoate ions by 50 %, but this decrease could be prevented when iodination to 
the same extent took place in the presence of excess p-iodobenzoate. The presence 
of p-iodobenzoate did not protect the site binding methyl orange (25). 
Pressman has also provided evidence that some antibody sites may contain 
essential tyrosyl residues since iodination decreased the affinity of the antibody 
for an anionic hapten containing a phenyl arsonic acid group. This decrease could 
be prevented if the hapten was present during iodination (26). Koshland has confirmed 
this but also shown that this is not invariably so since iodination of an anti-
body to a hapten containing a cationic phenyl ammonium group was not protected 
by the presence of the hapten (27). An explanation of these effects of course does 
not require the hapten to interact directly with the tyrosyl residue of the antibody. 
The mechanism might involve a reversible configurational change exposing a tyrosyl 
residue in the region of the active site, which is prevented by the presence of the 
hapten. Alternately, the presence of an additional negative charge at the antibody 
site might decrease the rate of iodination by depressing the ionization of an adjacent 
phenolic hydroxyl group or by preventing the approach of anions required for base 
catalysis of iodination. 
In the iodination of proteins it is usually impossible to be certain that changes 
arc absolutely limited to the tyrosyl residues, and therefore a recent study on bio-
logically synthesized proteins in which tyrosine was replaced by 3 fluoro-tyrosine 
should be noted. The phenolic hydroxyl of 3 F-tyrosine (like 2 I-tyrosine) is appre-
ciably more acidic than that of tyrosine. A tyrosine requiring mutant of Escherichia 
coli was grown on medium in which 3 F-tyrosine was substituted for tyrosine. While 
the growth rate was slower than in tyrosine medium, nevertheless multiplication did 
occur <28). The ß-galactosidase was studied in some detail both in terms of its enzy-
matic properties and its stability. The fluorinated enzyme was less stable towards 
urea or heat. This might be due to weaker hydrogen bonds involving the phenolic 
hydroxyl since fluorination would facilitate their ionization and dissociation. How-
ever, fluorine substitution had no effect on the Michaelis constant of the enzyme (29). 
It will be interesting to learn what changes may have been produced in other 
enzym ;s. However, these could not have been too great since presumably all of 
the other enzymes in the organism must also have been active in order to permit 
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growth. Therefore, this much alteration of the phenolic pK must be generally per-
missible in protein structure without loss of function, and any case of protein inac-
tivation due to the substitution of a single iodine into tyrosine is worthy of further 
investigation. If such cases are found, a critical comparison of the phenolic pK's 
of both 3-fluoro and 2-iodo substitution will be necessary. If these are comparable, 
then inactivation due to mono-iodo substitution would almost certainly implicate 
steric effects due to the size of the iodine atom. Steric effects have been seen in thy-
ronine derivatives and used to outline certain spatial requirements at the target 
of thyroid hormone action <30). 
Mono-iodo tyrosine has not been reported to be incorporated into proteins. 
However, this may be due to the specificity of the tyrosyl activating enzyme involved 
in synthesis and not to structural requirements of the proteins. Here too it would 
be interesting to see whether tyrosyl attached to transfer RNA could be iodinated 
and then incorporated into protein. In any event the lack of incorporation of iodo-
tyrosine is important for turnover studies since it precludes the reutilization of the 
iodine of iodinated proteins following their catabolism. 
In conclusion, while proteins labeled in vivo by metabolic processes would 
seem to represent the ideal for tracer work, the practical difficulties in their prepa-
ration, isolation, and use make in vitro labeling very attractive. Certain proteins 
can be labeled with iodine without loss of activity or function and perform compa-
rably to those labeled in vivo. In addition, iodine labeled proteins are free from the 
problem of reutilization, which complicates studies with in vivo labeled materials. 
However, the adequacy of iodine labeling for each protein will depend on whether 
it contains essential groups labile to iodine. Such groups may be sulfhydryl or other 
easily oxidized groups or an essential reactive tyrosyl. 
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DISCUSSION 
K. BRUNFELDT {Gentofte) : In addition to the interesting survey given by Dr. 
Hughes, I should like to stress some points, which should be taken into conside-
ration when using labeled proteins : 
1) A change in structure of a protein due to the process of preparation. The weak 
antigenic properties demonstrated by species own proteins, as shown by various 
authors, indicate artefacts even in experiments with well characterized proteins. 
2) Changes brought about by the labeling procedure due to the buffer system, 
use of oxydizing agents, urea, etc. 
3) Modifications in the protein molecule due to the introduction of groups contai-
ning the isotope or the incorporation of the isotope itself. 
4) Radiation damage when radioactive isotopes are used. 
5) The possible effect of disintegrated molecules, if the radioactive isotope is a 
part of the molecule itself, for example 14C in the backbone of a peptide structure. 
No consideration seems to have been given to the use of stable isotopes and I 
should therefore very much appreciate to have your comments on this point. Finally, 
I should like to mention that a loss of biological activity does not necessarily indi-
cate that the labeled group or its surroundings participate in the reaction by which 
the hormonal activity is caused. It may be so that the labeling will cause a reaction 
with other cell components hindering the labeled hormone from reaching the receptor 
system. 
W. L. HUGHES {Chairman) : We ordinarily think of the iodine in tyrosine as 
stable. On the other hand, as I pointed out, iodinated oxytocin has been labeled 
with tritium by catalytic deiodination. Furthermore according to the mechanism 
of iodination which I presented, the reactions are basically reversible. So we must 
always anticipate the possibility that iodine can be lost from the protein. While 
this has been frequently postulated in the past, the evidence has been unconvincing. 
Dr. McFarlane has some new evidence that a small amount of iodine may be coming 
out of the molecule. Would you like to mention this now Dr. McFarlane ? 
A. S. MCFARLANE {London) : It is usually accepted that iodine is very firmly 
bound to proteins but in some recent experiments it has emerged that in fact a steady 
dissociation is going on. This does not arise from enzymic or bacterial action and 
appears to be unavoidable. It proceeds in general at a higher rate with labeled fibri-
nogen that with albumins, but it is never more that about 0.5 % per day. This rate 
of dissociation would not cause any adverse affects in metabolic experiments with 
most small animals in which turnover rates are relatively high, but it could account 
for up to 10 % of the measured turnover rate of albumin in humans. On theoretical 
grounds iodotyrosines should not dissociate at such rates and the possibility cannot 
be excluded that the dissociation is of iodine less firmly bound to other amino acids. 
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V. BOCCI {Siena) : I would like to stress several advantages of the Chloramine 
Τ procedure : 
The labeling efficiency is of about 90 % and the iodine­131, which is firmly 
bound to the proteins, can be recovered almost quantitatively after proteolysis, 
as MIT. Soluble radioactivity is less than 1 % and raises up to about 1.5 % after 
30 days storage at + Io C. 
DEAE cellulose chromatography, Sephadex G­200 filtration and electrophore­
sis on Pevikon block and starch gel show a similar distribution of labeled and unla­
beled proteins. Thus, the presence of altered proteins detectable by these analyses 
is excluded. 
The rat liver retention test and the rabbit total body radioactivity decay curve 
suggest a normal biological behaviour of homologous 131I serum proteins. However 
as I previously reported (Int. J. Àppi. Rad. Isot., 15 : 449­456 [1964]; Nature, 203 : 
888­889 [1964]) it is advisable to use the Chloramine T, controlling two factors : 
Protein Chloramine Τ ratio and the time of oxidation. 
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ABSTRACT 
The effects of various parameters involved in the iodination of proteins have 
been studied, with special reference to human serum albumin and insulin iodination. 
Efforts have been made to separately evaluate the importance of the various 
steps involved in the preparation of a labelled protein in determining its final biolo­
gical behaviour. Extraction and purification of the protein, rôle of­SH groups oxida­
tion, type of labelling procedure employed, effect of the distribution of the labelling 
iodine within the molecule are considered and discussed. 
Attempts are made to correlate the modifications induced by the above factors 
with the biological behaviour of labelled proteins. 
INTRODUCTION 
The use of labelled proteins as tracers in the study of the metabolic processes 
requires that the proteic tracer be identical in its biological behaviour to the cor­
responding native protein. In the course of a research program on the preparation 
of labelled proteins for metabolic studies, the effect of the progressive iodination 
on the biological behaviour of certain proteins was investigated. During this work, 
the specific results of which will be reported in other communications of this sym­
posium, experiments were carried out in the attempt of separately defining the 
influence of the various factors, which intervene in the proteins iodination. This 
communication is substantially based on the results of such experiments. 
An iodinated protein is the final product of a series of operations, the last of 
which is the iodination itself. Each of these operations may evidently interfere on 
the biological behaviour of the proteic tracer. The only way to answer the question 
whether the iodoprotein is or is not an adequate tracer of the native protein is then 
to study separately the contribution of the individual effects. In most cases, the 
isolated protein, before being iodinated, has already suffered the effects of different 
factors capable of affecting its biological properties. The common techniques of 
physico­chemical analysis may represent a first way of choice, allowing to eliminate 
the most grossly altered samples; but usually we lack adequate criteria in order to 
(*) Work performed under Euratom Contract No. 048­64­6 ΒΙΟΙ and Euratom Association 
Contract No. 026­63­4 BIAC. 
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establish a priori whether the isolated protein represents an acceptable starting 
material. Under this respect, the case of human serum albumin (HSA) is a typical 
example. Several lots of HSA, prepared by different producers, were examined, in 
order to select a suitable sample for the labelling (Table 1). 
TABLE I. — SH groups/mole, metal content and fractional catabolic rate values, for some lots of 
human serum-albumin. -SH groups were titrated according to Benesch and Benesch W, and 
to A. C. Allison (2'. Activation analyses were performed in RSI Avogadro reactor, at a thermal 
flux of LIO13 n/cm2.sec^1 (3). Catabolic rate values were calculated by the urine to plasma ratio 
method '4). 
HSA 
lot. 
H D O 
H D 1 
H D 8 
H D 10 
H D l l 
H D 12 
ISI 24 
Mann 
L 2435 
SH groups/mole HSA 
Ag-Tris 
0.037 ~ 0.001 
0.101 4 0.004 
0.26 Τ 0.001 
0.27 4 0.005 
0.184 4 0.007 
0.40 4 0.02 
0.47 Τ 0.001 
HOPh Hg pH2 
0.21 4 0.01 
0.180 Τ 0.003 
0.42 4 0.005 
0.405 4^ 0.05 
Metal content (neutron 
activation analysis) in p.p.m. 
Cu 
15 
11 
17 
21 
18 
Fe 
80 
95 
98 
40 
24 
Zn 
95 
105 
150 
60 
12 
Hg 
0.3 
0.1 
0.1 
0.2 
0.2 
Ag 
0.6 
0.4 
0.5 
0.8 
0.8 
Catabolic rate 
after labelling 
up to 0.5-1 
iodine atoms 
per mol. 
14.91 4 1-97 
15.33 4 5.74 
18.66 4 2.61 
10.60 4 0.91 
11.44 4 1.38 
10.96 4 0.91 
19.53 4 3.59 
16.1 4 2.83 
Titration with silver nitrate in TRIS buffer or phenyl-mercuric hydroxide 
at pH 2 revealed that in some of these lots the content in titratable-SH had been 
reduced to 20-30 % of the original value. The differences in -SH content per mole 
among the various lots of HSA are very likely to be attributed to oxidation pheno­
mena. In fact, another supposition could be that a part of the -SH groups is not 
titratable, because it is blocked by metal impurities collected during the process 
of separation from the plasma; but this hypothesis can be rejected following the 
results of the neutron activation analysis, carried out on the various lots of serum 
albumin : the metal content is too low to account for the titration results. The samples 
of every lot were labelled under standard conditions, up to an iodination degree 
of about 0.5 iodine atoms per molecule. The catabolic rate of each preparation 
was measured in normal subjects. 
The results show remarkable differences among the catabolic rate values of 
the HSA lots. Since we can reasonably presume that the iodination process, by 
itself, equally affects every lot, it is evident that the observed differences in the meta­
bolic behaviour reveal differences already existing in the starting material. These 
differences could not be foreseen through the above mentioned analyses. In fact, 
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Lot ISI 
CR = 19.5 
Lot HD 11 
CR = 11.5 
CR = mean catabolic rate on 7 days 
FIGURE 1. — Tiselius electrophoresis of two lots of native human serum albumin. (On the left) lot 
ISI, having a mean fractional catabolic rate of 19.5 % (7 days). On the right, lot HD11, having 
a mean fractional catabolic rate of 11.5 % (7 days). 
no correlation was found among the metabolic behaviour, the extent of sulphydryl 
oxidation, and the electrophoretic properties. All the samples were found to be 
homogeneous, according to the free boundary electrophoresis and the ultracentri-
fugation. Tiselius patterns of two HSA lots, having catabolic rate values of 11 % 
and 19 % respectively, do not show any noticeable difference (Figure 1). 
Another factor, which could be able to affect the behaviour of HSA, is the 
pasteurization treatment, which is known to favour the formation of high molecular 
weight aggregates (5). In Table II the fractional catabolic rate values are reported 
of two preparations of radioiodinated HSA, coming from batches HD12 and HD12 
bis respectively; the second batch is an aliquot part of the first one, subjected to 
the pasteurization process. The two preparations were iodinated at a very low spe­
cific activity (4-6 μΟ/π^) with 131I and 125I respectively and injected into the same 
subject. No significant difference could be demonstrated in their metabolic beha­
viour. 
Coming now to the iodination procedure, there is no doubt that the behaviour 
of a tagged protein depends on a large amount on the labelling technique. In the 
last years the traditional methods were abandoned and replaced by more sophisti-
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TABLE Π. — Effect of pasteurization, on the metabolic behaviour of Iodinated Human Serum 
Albumin 
Lot 
HD 12 
H D 12 Β 
Id3 
0.68 
0.67 
Catabolic rate 
% d a y " 1 0 0 
10.96 4 0.91 
11.1 4 1.01 
Note 
131I-labelled, 
not pasteurized 
125I-labelled, 
pasteurized 
' Iodination degree, iodine atoms/mole HSA. 
° Mean value over 7 days. 
cated ones. This trend has been justified by the fact that it has been experimentally 
observed that some methods give rise to the formation of metabolically hetero­
geneous iodinated products. As a matter of fact, part of the discrepancies existing 
in the literature concerning iodinated HSA, are due to the use of different iodination 
techniques. In order to investigate separately the different factors which intervene 
during the iodination process, we have developed a special method which allows 
to operate under controlled conditions. Since the method has been already exten­
sively described (0' 7) we shall only briefly recall the aspects of it which are relevant 
to the present studies. 
Iodination takes place in an electrolytic cell, which is outlined in Figure 2. 
The protein is dissolved in a 9 °/00 NaCl solution containing potassium iodide, label­
led with 131I or 126I. The anode is made of a platinum vessel of a large surface; the 
cathode is isolated by a cellophane membrane and the contact between cathode 
and anode is assured by NaCl solution. Polarization of the system gives rise to the 
formation of elemental iodine at the anode. 
The rate of iodine formation depends on the current flowing in the electrolytic 
circuit. The current is adjustable through a power supply, which permits to feed 
the system with the wanted current value and thus to obtain the desired rate of 
formation of elemental iodine. Some experiments were performed in order to esta­
blish whether the conditions in which iodination takes place may affect the protein, 
independently from the effect of the iodine. An experiment was directed to assess the 
effect, on the titratable — SH of the HSA, of a 24 hrs exposure in the cell, in absence 
of KI, that is without formation of elemental iodine. No modification has been 
detected, allowing to conclude that the method itself does not show oxidative side 
effects. In order to investigate the effects of the iodination procedure on the meta­
bolic behaviour of the HSA, the following experiment was carried out (Figure 3). 
A HSA preparation was divided in two aliquots. Both were electrolytically iodinated 
in standard conditions, up to an average content of 0.5 iodine atoms per molecule, 
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1-10 ml. plat inum vessel (anode) 
2-Cellophane membrane 
3-0,9mm. platinum wire (cathode) 
FIGURE 2. — Electrolytic cell for protein iodination. 
using 131I in one case and 125I in the other. Both preparations were dialyzed against 
distilled water. The preparation iodinated with 125I was then reintroduced into the 
cell, with a fresh solution of 125I labelled KI, in presence of sodium thiosulphate. 
The latter competes with the protein towards elemental iodine, thus preventing 
the iodination of additional tyrosine residues. After 24 hrs of electrolysis, during 
which, in the absence of thiosulphate, the protein would have been iodinated up to 
an average iodine content of 24 iodine atoms per molecule, the solution was extrac­
ted and dialyzed. 
The iodination degree was found to be unmodified. The two preparations were 
then injected into the same subject and their fractional catabolic rate was measured. 
The results are essentially identical for the two prepara ions, confirming that the 
method is "per se" devoid of effects on the protein metabolic behaviour. HSA is 
an adequate material for simultaneously studying the oxidation of definite func­
tional groups and the iodination of tyrosine residues. In Figure 4 an experiment of 
progressive HSA iodination by electrolysis at 300 μΑ is reported; in the course 
of it we followed the two chemical processes due to the iodine, that is the oxidation 
of the sulphydry] groups and the substitution into the tyrosyl residues. On the abs-
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HSA-lot HD 12 
131I iodination 
I. D = 0.5 
I 
Dialysis 
I 
y 
125I iodination 
I. D = 0.5 
I 
4 
Dialysis 
I 
24 hrs electrolysis 
KI, 1 2 5I-Na 2S 20 3 
Injection into the same subject 
i 
C. R. = 11.7 ± 0 . 9 % C. R. = 11.4 ± 0.9 % 
FIGURE 3. — Effect of the iodination procedure on the metabolic behaviour of HSA. 
(•iTitratableSH groups per HSA molecule 
(*)/iM Iodine bound per HSA/.M 
10 „ 
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FIGURE 4. — Electrolytic iodination of human serum albumin at 0.3 mA : HSA cone. 10 mg/ml: 
KI, 125I-Iabelled (200 μ C), 1.5.10~3 M; NaCl, 0.9 mg/ml. Total volume 10 ml. 
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cissas are reported the μΜ of elemental iodine formed in the solution at a constant 
rate, which is proportional to the current of 300 μ A. On the ordinates, the number 
of titratable ­SH groups per HSA molecule is reported, on the left side; on the right 
side the μΜ of bound iodine per molecule of HSA, that is the iodination degree, are 
reported. Oxidation of the sulphydryl groups was followed by titrating aliquots 
of the solution by an amperometric system and by measuring at the same time, the 
amount of protein­bound iodine by paper electrophoresis. The slow rate of iodine 
formation permitted to follow easily the process. As one can see, the oxidation of 
the sulphydryls is completed, when the substitution into the tyrosyl residues begins. 
This fact has been well known since a long time (8) : so that it seems surprising 
the claim of some Authors (9) that have reported to have iodinated HSA without 
­SH oxidation. On the contrary, ­SH oxidation has to be accepted as an unavoidable 
preliminary effect, whenever the iodination of HSA is performed. Now, can this 
oxidative process interfere with the metabolic behaviour of the iodinated human 
serum albumin ? Some of the results obtained when comparing albumin batches 
(see Table I) may throw some light on this problem. 
The iodination process of the various batches of native albumins has been 
proved to complete the oxidation of the ­SH groups. Now, if the sulphydryl played 
really a primary rôle in affecting the metabolic behaviour of the albumin, the iodi­
nated albumins, in which all the ­SH groups have completely disappeared, should 
have to show, all, degradation rates of the same order. The abolishment of the 
­SH by the iodine would have, in this case, to efface the differences, which may 
exist initially among the different batches of serum albumin. Since, as we have seen, 
this does not agree with the experimental data, it would seem possible to conclude 
that the oxidation only of ­SH groups, both during the isolation step and during 
the iodination, does not appreciably affect the degradation rate of serum albumin. 
The second process, that is tyrosine substitution, proceeds according the stoi­
cheiometry of the reaction between the tyrosine and the iodine, up to an iodination 
degree of 15­16 iodine atoms per molecule. If we look at the process of tyrosine 
iodination, we should be induced to consider it as an entirely isolated process from 
a chemical standpoint. However, an additional source of variability operates inde­
pendently, along all the course of tyrosyne group iodination : this parameter is the 
actual distribution of iodine among and within the various molecules. This factor 
must necessarily have significant bearing on the properties of the iodinated protein, 
as judged from its metabolic behaviour. 
A iodinated protein must be considered as a population of not homogeneous 
molecules, as far as their iodine content is concerned. In the case of HSA, Oncley 
(1°' has proposed a distribution of binomial type. According to this hypothesis, 
preparations of HSA iodinated at an average substitution degree of 0.5 and 1 iodine 
atoms per molecule, would have the distributions reported in Figure 5. 
In the upper side of the figure, the relative percentages of molecules containing 
0, 1, 2, 3 and 4 iodine atoms per molecule are reported. As it can be seen, in serumal­
bumins at iodination degrees of 0.5 and 1, about 8 % and 27 % respectively of the 
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FIGURE 5. — Intermolecular distribution of iodine in iodinated HSA, following a binomial law. 
molecules contain more than one iodine atom. When the labelled albumin is used 
as a metabolic tracer, only the molecules actually containing iodine are counted. 
In the lower part of the figure, the relative percentages of iodine in each class of 
iodinated molecules are reported. At iodination degrees 0.5 and 1, about 39 % 
and 60 % respectively of iodine is bound to molecules containing more than one 
iodine atom. Obviously there is no possibility of direct proof of the validity of this 
distribution hypothesis. 
In an attempt to approach this problem, we have measured in preparations 
of iodinated HSA the amount of mono- and di-iodotyrosine residues, which must 
in some way be related to the distribution of the iodine. 
In figure 6 the results are reported of two experiments of progressive iodina­
tion of HSA, performed at different formation rates of the elemental iodine. In 
one case, the current being kept constant at 300 μ A, the iodine developed at a rate 
of 0.09 μΜ/min; in the second case the current was 3 m A and the iodine formation 
rate was tenfold higher. The fraction of substituted tyrosines as di-iodo form in 
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FIGURE 6. See text. 
preparations at the same iodination degree, varies according to the iodine forma­
tion rate. The preparations obtained with higher formation rates always contained 
relatively larger amount of DIT. On the contrary, the two curves are superposable 
at the low values of the iodination degree. 
The results show that the rate of iodine formation definitely affects the distri­
bution of the iodine. Several Authors have recommended a slow addition of the 
elemental iodine to the protein solution, with the aim of minimizing possible oxi­
dative side effects. On the contrary, it is highly probable that the slow iodine addi­
tion rather than minimizing side effects leads to iodine distributions different from 
those obtained when the elemental iodine is rapidly added. 
In figure 7 are reported the percentages of substituted residues as di­iodo form, 
found in preparations of iodinated HSA, obtained with different iodination methods. 
A comparison is made among iodoalbumins prepared according to three different 
techniques : iodide­iodate, iodine monochloride and electrolysis at two different 
iodine formation rates (0.3 and 3 mA). At a low iodination degree, the two chemically 
labelled preparations and the preparation electrolytically labelled at 3 mA do not 
differ from the one obtained at 0.3 mA, that is with a much slower rate of iodine 
formation. This is easily explained by the high number of available tyrosyl residues, 
that makes extremely unlikely the formation of di­iodinated residues at this level 
of iodination. On the contrary, at higher iodination degree, the 0.3 mA preparation 
definitely differs from the others, in which the iodine has been formed at a very 
fast rate. On the other hand, it cannot be excluded that differences in the iodine 
distribution may also occur at low iodination degrees. These will not be detected 
by using our empirical criterium of estimating the relative amount of mono­ and 
di­iodo residues, because at this level only monoiodinated tyrosines are formed. 
Under this respect, another point must be taken into account, that is the pos­
sibility of heterogeneities deriving not only from intermolecular, but also from intra­
molecular differences in iodine distribution. This means that molecules containing 
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I O D I N A T I O N PROCEDURES 
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1 = ELECTROLYTIC ( 3 . 0 mA) 
IODINE MONOCHLORIDE 
FIGURE 7. — Di-iodinated tyrosine residues found in preparations of 125I-labelled human serum 
albumin, iodinated according to different procedures. The results are expressed as % of di-
iodinated tyrosine residues (DIT), on the total number of iodinated tyrosine residues (MIT 
+ DIT). 
the same number of iodine atoms can differ from each other as far as the distri­
bution of iodine among the tyrosyl residues within a single molecule is concerned. 
Insulin provides a good example of this kind. As it is known, the insulin mono­
mer contains four tyrosine residues, two in each chain. It has been proved that, 
at the same iodination degree, the distribution of iodine among the tyrosine resi­
dues of the A and Β chains depends on the pH at which iodination takes place (11). 
In figure 8 two preparations of iodinated insulin of the same iodination degree 
are compared : the former prepared at pH 1.5, according the Springell's method <U), 
the latter prepared at pH 7.6 by electrolysis. The preparations differ in their content 
of mono and di-iodinated residues, measured by total hydrolysis. But these diffe­
rences are found also when the isolated A chains are analyzed. In the lower part 
of the figure the insulin primary structure, according to Sanger, is represented toge­
ther with the distribution of iodine on the four tyrosine residues. These data were 
measured by complete fragmentation of the iodo insulin electrolytically prepared 
at pH 7.6; it is evident that these data should not agree with the total number of 
the mono and di-iodinated residues found both in A chain and in the whole mole­
cule of insulin, iodinated at a pH 1.5. This latter must therefore have a different 
internal distribution. 
It remains to be established whether a difference in the distribution may bring 
to different results, when the biological behaviour of the iodinated proteins is com­
pared. Fraenkel-Conrat, in 1950 ( l i ), noticed that two preparations of iodinated 
insulin, obtained with different methods, but having the same iodination degree, 
showed remarkable differences in their biological activity. Fraenkel-Conrat mea­
sured the number of mono and di-iodinated residues contained in the two prepa-
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FIGURE 8. — % of tyrosine residues found under uniodinated form (Tyr) and under mono-(MIT) 
or di-iodinated form (DIT) in insulin preparations iodinated at pH 1.0 and 7.5, up to an 
iodination degree of 2.4 at. I/mol. 
On the left, results of the hydrolysis performed on the iodinated insulins. On the right, results 
of the hydrolysis performed on the A chains, electrophoretically separated after cleavage of 
the inter-chains di-thio bonds (12'. In the tables, results of the hydrolysis performed on the 
each containing one tyrosine residue (see four fragments A1-A14, 
text). 
A15"A21> B 1" B 22 ' B23"B30' 
rations and obtained different results, what let him presume that the differences 
in biological activity could be accounted for by differences in the iodine distribution. 
In conclusion, the biological behaviour of an iodinated protein is largely depen-
dent on the preparative conditions. A special care is required in controlling the 
various factors, which intervene in the iodination; as a general statement, the methods, 
in which strong oxidizing agents are avoided and the iodine is either introduced 
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in already oxidized form or generated under mild conditions should be preferred. 
Finally, the distribution factor, both at intermolecular and intramolecular level, 
should always be considered in evaluating experiments of progressive iodination, 
not only when they are performed to assess the adequacy of an iodinated protein 
as a metabolic tracer, but also when attempting to interpret the biological changes 
associated with the progressive iodination. 
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DISCUSSION 
W. L. HUGHES (Chairman) : Dr. Rosa has developed an important new procedure 
for iodinating proteins. However to better evaluate his process I would like to know : 
1) The electro-chemical efficiency. How many faradays does it take to introduce 
one gram-atom of iodine ? If it takes many faradays, then what chemical changes 
are being produced by the rest of the current ? 
2) What is the explanation for the variation of the ratio of MIT to DIT with cur­
rent density? Could this be due to reaction of the protein adsorbed on the platinum 
anode ? Such adsorption might unfold the protein and permit easier iodination. 
U. ROSA (Saluggia) : Unfortunately, due to the short time, it was not possible 
to give all the details of the method. The oxidation of the iodide ions to elemental 
iodine is quantitative in our process, that is we have a 100 % current yield. As it 
was shown in Figure 4, all the electrolysis current is consumed to generate iodine; 
with the exception of the first part of the process, iodine reacts stoicheiometrically 
with tyrosine residues. 
R. S. YALOW (7Veu> York) : The degradation rate of 11.5 % per day is faster 
than the usual values reported for the best of lhe human serum albumin prepara­
tions. Can you compare your values directly with degradation rates of about 3.5 % 
total albumin per day and account for the difference ? 
L. DONATO (Pisa) : The values reported by Dr. Rosa were expressed in % of 
the intravascular pool and not of the total protein mass. This probably explains 
the apparently high value, when compared to the 3.5 % figure, which refers to the 
total protein mass. 
A. S. MACFARLANE (London) : With reference to Mrs. Yalow's question, I 
was quite happy about the catabolic rates which Dr. Rosa and his collaborators 
obtained for these human albumins. However the catabolic rate is not a particu­
larly sensitive criterion of iodination. The equilibrium distribution between intra-
and extravascular spaces as measured by extrapolating the plasma specific activity 
curve or the fraction of the injected dose which appears in the urine in the first day 
are both much more sensitive and I wonder whether Dr. Rosa has any data on either 
of these ? 
L. DONATO : I do not have these data available now but the fractions of inject­
ed dose that appear in the urines at various times were calculated in all cases because 
they are required for calculation of the catabolic rate as fraction of the intravas­
cular pool. These data are supplied in Dr. Bianchi's paper. 
F. C. GREENWOOD (London) : Dr. Rosa and Dr. Hughes have mentioned Chlo­
ramine Τ as a strong oxidizing agent and postulated effects on a molecule during 
radioiodination. The radioiodination of proteins by the Chloramine Τ method 
was developed primarily for the preparation of labeled protein hormones for use 
in vivo radioimmunoassays (Greenwood, Hunter and Glover, 1963, Biochem. J., 
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89 : 114). No effect of Chloramine Τ per se on the immunological properties of 
growth hormone was detected. The use of this method (Bocci, 1964, Int. J. Applied 
Radioisotopes, 15 : 449) for the preparation of labeled albumin for in vivo studies 
has been reported. An effect of Chloramine Τ per se on the biological properties 
in this situation may or may not be present. For radioimmunological work Chlo­
ramine Τ is no problem, but radioimmunoassays have other problems. 
W. L. HUGHES (Boston) : I would like to make another comment relative to 
your distribution of mono­ and diiodotyrosine which I thought was very interesting, 
that is this large difference of rate of iodination which you observed particularly 
electrolytically and not so much in the other procedures. I am wondering, could this 
perhaps be due to the fact that iodination might be taking place at the electrode? In 
this case lower current values would favour monoiodination as the diffusion process 
would have the time to renew the protein layer. If you are iodinating at slow rate you 
have more chance to diffuse at the electrode. In addition, a process taking place at 
the electrode could open up or expose tyrosine residues normally buried and so you 
could monoiodinate it. 
U. ROSA : This point should be discussed in the light of some results, which 
will be reported at the next session, concerning our experiments on the metabolic 
behaviour of serumalbumins labeled at different values of iodination degree. We have 
found that preparations having nine or ten iodine atoms per mol. showed the same 
value of the catabolic rate as the preparations having 0.5 iodine atoms per mol. 
This could be tentatively considered a proof that the method by itself is not able to 
interfere on the conformation of the protein. 
On the other hand, I agree with you that iodination probably takes place on the 
electrode; we have found that the surface of the anode plays a rôle in the process, 
in the sense that a too small anodic surface does not allow the process to take place. 
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ABSTRACT 
Valid data can only be obtained from turnover experiments with labelled plasma 
proteins if the protein for labelling is of adequate purity and if it is known that the 
labelled protein is handled by the body in the same way as the native protein. 
Evidence that the controlled introduction of limited amounts of iodine into 
the protein molecule does not produce denaturation has been provided by the com-
parison of the behaviour of iodine labelled proteins in animals with similar proteins 
labelled biosynthetically with 14C, and also by a simultaneous comparison in a 
human analbuminaemic subject of the removal rate of unlabelled albumin with 
that of a trace dose of the same albumin labelled with 131I. 
However, proteins can be readily denatured during the procedures necessary 
for their isolation in a state of purity and because of variable factors in the labelling 
technique it is necessary to assess the quality of individual labelled preparations. 
Even for a human labelled protein this may be done in animals. Since grossly dena-
tured proteins are rapidly removed by the reticuloendothelial cells the amount 
of activity retained in the RE system of the liver shortly after injection is an index 
of gross denaturation. Also, minor differences in the behaviour of labelled hete-
rologous proteins can be detected by injecting them into tolerant animals. 
Evidence of denaturation is also apparent after injecting labelled proteins into 
humans. A pure undenatured protein will give a constant rate of breakdown through-
out the period of study; thus a falling catabolic rate indicates either denaturation 
or heterogeneity of the labelled protein. In particular, the breakdown rate, calcu-
lated from the urinary excretion rate of the label, should not be greater during 
the first 24 hours than on subsequent days. 
It is essential in any valid tracer study of plasma protein metabolism to use 
labelled proteins that behave in the body identically with the native ones. Although 
protein molecules in general are essentially altered by the insertion of iodine pro-
vided certain precautions are taken this does not appear to affect seriously their 
physiological behaviour. In addition their use especially in the study of plasma 
protein metabolism, both in man and in animals, has three main advantages : 
firstly, the label is not reincorporated into protein once it is liberated by cata-
bolism, provided, of course, that uptake of radioiodine by the thyroid is effectively 
blocked with large doses of stable iodine. Secondly the label remains firmly attached 
until the protein is catabolised, the iodine being rapidly excreted, and thirdly, label-
ling can be performed in vitro thus obtaining very high specific activities. On the 
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other hand the use of purified proteins and variabilities in labelling procedures 
make it easy to obtain denatured products which, after injection, give data which 
possibly bear little relationship to the behaviour of the native protein. 
The validity of iodine as a trace label for plasma proteins has been demons­
trated by a comparison in animals between proteins labelled biosynthetically with 
carbon-14 and similar proteins labelled with radioactive iodine (1· 2). In addition, 
one of Bennhold's analbuminaemic patients was given a large infusion of unla­
beled albumin and a trace quantity of the same protein labelled with radioactive 
iodine (3), and the specific activity of albumin was found to remain constant for 
many weeks while the albumin concentration fell steadily. Both these experiments 
demonstrate that the introduction of iodine under carefully controlled conditions(4) 
can provide a perfectly satisfactory product, but it will be necessary to check this 
for new proteins and new methods of labelling. 
For satisfactory metabolic experiments using radioactive iodine labelled pro­
teins the following criteria should be observed : 1) all the radioactivity in the injec­
ted material should be protein bound, 2) it would be bound to a single homogeneous 
protein, and 3) denatured labelled protein should not be present. 
The first of these, namely that all the activity is protein bound, is easily exa­
mined, either by precipitating the protein usually with trichloroacetic acid and mea­
suring the activity in the supernatant, or by separating large and small molecules 
by gel filtration. A simple column of Sephadex G 25 suffices for this, but the use 
of a gel bed of Sephadex G 100, 150, or 200, will give information both about the 
proportion of activity present as small molecules, and the homogeneity of the label­
led protein. Good preparations give symmetrical peaks which become asymmetric 
in the presence of polymers. 
The second requirement, namely that all the radioactivity should be bound 
to a single plasma protein, can also be examined by in vitro techniques. Although 
it is desirable to use pure proteins for labelling, this ideal is seldom attainable. Since 
some proteins have variable avidities for iodine a trace amount of contaminating 
protein may be associated with significant amounts of the total radioactivity. It 
is important to examine the distribution of radioactivity by techniques such as 
electrophoresis, gel filtration, etc. When contamination is present the labelled mate­
rial together with unlabelled whole serum may be refractionated. Indeed it is some­
times necessary to iodinate a mixture of proteins, then to mix this with some fresh 
serum and re-isolate. In this way a single labelled protein may be obtained without 
ever freeing it completely from other proteins. 
The third requirement, that the labelled plasma protein should be essentially 
undenatured, is not so easy to fulfil because of difficulty in recognising small pro­
portions of denatured protein in the product. For instance, labelled proteins that 
are identical with the~native ones by in vitro tests may nevertheless be catabolised 
more rapidly. 
Altered proteins fall into two main groups; those in which denaturation is 
gross and which are rejected by the body within a few minutes; and those in which 
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the alteration is minor and which are retained but are catabolised more rapidly 
than the native protein. 
Two animal tests have been devised for demonstrating denaturation in human 
plasma proteins <δ>. The first takes advantage of the rapidity with which some foreign 
molecules are taken up by the reticulo-endothelial system of the liver. In a preli­
minary study trace amounts of soluble heat denatured labelled albumin (6) were 
injected into rats which were killed at intervals and the blood perfused out with 
physiological saline. Figure 1 shows total radioactivities in various organs and 
protein bound and free activities in the perfusate. The results demonstrate complete 
clearance of denatured protein from the blood by the liver with a survival time of 
the denatured molecules in the liver of only eight minutes. Between the eighth and 
fifteenth minute a high proportion of the denatured molecules were in the liver, 
though never 100 % of the dose because later protein molecules were arriving in 
the liver when iodine from the first had already been discharged into the blood 
stream. The proportion of the injected dose retained by the liver at about twelve 
minutes has been arbitrarily used as a measure of gross denaturation, deliberately 
heat-denatured albumins giving values in the region of 70 %, and good quality 
ones less than 1.5 %. 
Minor alterations in protein molecules are more difficult to detect. Where 
a good quality preparation is available this may be compared with the suspect label-
IOO 
Activity in 
; the perfused 
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protein bound activity 
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minutes 
FIGURE 1. — Diagram illustrating the distribution of radioactivity after the intravenous injection 
of 1 mg of soluble heat denatured albumin into a rat 
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led protein and the use of two iodine isotopes permits this to be done in the same 
animal. 
Figure 2 shows a comparison between an undenatured human albumin and 
a similar albumin altered in the process of isolation from plasma. Since immune 
rejection of labelled heterologous proteins would seriously interfere with this test 
after a few days a rabbit was used which had been made tolerant to human plasma 
at birth. Plasma activities relative to total protein concentrations are expressed as 
a percentage of the value for the first plasma sample. Total body activities for 131I 
were measured directly in a ring of Geiger Muller tubes, and total body 125I acti-
vities were derived indirectly from the urinary excretion. Catabolic rates were cal-
culated from daily losses of total body activity related to the mean plasma radio-
activity on the same day, no correction being made for delay in iodide excretion 
from the body iodide pool. These results showed that the suspect albumin was 
catabolised faster than the comparison human albumin, and also that its rate of 
catabolism decreased progressively presumably because some molecules have been 
more damaged than others. 
The undenatured albumin used as a reference protein in this and subsequent 
experiments was supplied by Behringewerke, and was prepared by repeated salt 
precipitation. This albumin was used in Bennhold's case of analbuminaemia, and 
has been extensively examined in vitro and biologically in animals and humans. 
The labelled material contains less than 2.5 % of heterogenous protein, much of 
which is albumin polymer. 
In the experiment shown in Figure 2, no correction was made for delay in 
iodide excretion caused by the iodide pool. When protein catabolism is rapid as 
in case of fibrinogen the quantity of activity retained in this pool can be high, so 
40 
20 
x .plasma 
Catabolism e/0IV pool per aay 
15 Days 
FIGURE 2. — Comparison in a tolerant rabbit of good quality human albumin, labelled with 131I 
and a human albumin isolated (using Rivanol-ammonium sulphate and ether) labelled with 
125 J 
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that the urinary activity ceases to reflect closely the rate of iodide liberated by cata-
bolism, and the total body activity can be considerably higher than the retained 
protein bound activity. 
Since plasma iodide concentration is a balance between the rate of liberation 
of the label and iodide excretion, this value should remain constant during the 
experiment. The finding of high plasma non-protein bound activity shortly after 
injection indicates some denatured protein (7' 8' 9). 
Although this type of double label experiment gives the clearest indication 
of denaturation the work involved is considerable, and a simpler test has been 
devised. In our experience the proportion of an injected human protein which is 
retained in a fully grown tolerant rabbit on a given day is remarkably constant. 
However, this proportion varies between rabbits, and for comparable results to 
be obtained an independently labelled reference protein must be used in the same 
animal within a short interval. If the survival of activity associated with the dena-
tured protein is expressed as a fraction of that of the undenatured one (Figures 3 
and 4) the results from the two animals are comparable. Figure 3 shows the total 
body activities obtained after the injection of undenatured iodinated human albumin 
and deliberately overiodinated. Figure 4 shows the same data, with the suspect 
protein expressed in relation to the undenatured albumin in two different rabbits. 
Figure 5 shows the relative retention of iodinated albumins subjected to different 
100 
FIGURE 3. — Total body activities in two tolerant rabbits after the successive injections of two 
good quality labelled albumins and over iodinated albumin 
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undenatured albumin 
FIGURE 4. — The data from Figure 3; the denatured albumin is expressed as a per cent of the 
undenatured albumin 
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2-3 mg/ml protein concentration 
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degrees of self irradiation <10· u ) . Also on this diagram is shown the relative reten­
tions of the same protein in a tolerant rabbit and in a human subject. Figure 6 shows 
relative retentions obtained with albumins iodinated at various iodine levels. Also 
shown are the relative retentions of overiodinated human albumin in humans cal­
culated from the work of Berson and Yalow (12). Above 2.9 atoms per molecule 
the catabolic rate increased progressively and below a mean level of 1.5 atoms per 
molecule the catabolic rate was constant. In an experiment with a mean level of 
one atom of iodine to one hundred protein molecules a significant increase in cata­
bolic rate was found. However, when the preparation was examined 12 % of the 
activity was found to be associated with a contaminating protein — presumably 
one with a higher avidity for iodine. This was removed by refractionating the label­
led material and the resulting labelled albumin gave relative retentions identical 
with albumin labelled at one atom per molecule. This was also found by McFarlane 
in comparing very different levels of iodine substitution in rabbit albumin. The 
observation that albumin labelled at a mean substitution of 1.5 atoms showed no 
evidence of denaturation taken in conjunction with considerations of random dis­
tribution of the label indicated that albumin can bind more than one iodine with­
out overt signs of denaturation. Other protein molecules, however, for instance 
haptoglobin, transferrin, arosomucoid, and fibrinogen can only be satisfactorily 
labelled at lower levels and it appears that no generalisation is possible regarding 
o 0-3 a toms of iodine per molecule of albumin 
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FIGURE 6. — Relative retentions of albumin iodinated to different mean atoms per molecule 
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"physiological" levels of iodine substitution. Figure 7 shows the relative retention 
of albumins separated from plasma in a variety of ways. Each of these was labelled 
at a mean of less than one atom of iodine per molecule. In these and the types of 
denaturation discussed the retention curves all suggested the presence of a range 
of molecules with very different catabolic rates. 
Examples of a constant difference in the elimination rates of two proteins 
are shown in Figures 8 and 9. Figure 8 shows the results obtained after injecting 
a mixture of totally denatured albumin and undenatured albumin, the retention 
rapidly dropping to 60 % and the behaviour thereafter being that of undenatured 
protein. Figure 9 shows the results obtained in comparing good quality human 
albumin in rabbits with undenatured rabbit albumin in rabbits, the small diffe­
rences between rabbit and human albumin presumably accounting for the more 
rapid catabolism of the latter. The mechanism by which this accelerated catabo­
lism is effected is unknown. Also in Figure 9 the behaviour of normal human trans­
ferrin was related in much the same way to that of normal human albumin in a 
human subject. In both cases catabolism was faster than that of the reference pro­
tein and the constancy of the rates was reflected by the linearity. This type of com­
parison between different proteins can only give useful information if the intra/ 
extra vascular pool ratios and transfer rates are similar — as they are for transferrin 
and albumin. 
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FIGURE 7. — Relative retention of albumins isolated by different techniques from plasma; all 
iodinated at below one atom per molecule 
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FIGURE 9. — A) Relative retention in rabbits relating good human albumin to good rabbit albumin. 
B) Relative retention in two humans relating good transferrin to good albumin. 
In both these experiments the straight line formed by the relative retention indicates that both 
proteins are catabolised at a uniform rate. 
All the preceding data concern the comparison of a suspect protein with an 
undenatured one. Where this cannot be done, as for instance with a newly isolated 
protein, the only criterion available for the absence of traces of denatured protein 
is the finding of a constant rate of breakdown throughout the exepriment. Fortu­
nately, experience shows that it is difficult to change albumin, gammaglobulin, 
transferrin, and haptoglobin in such a way that they are catabolised at a uniformly 
faster rate than the native proteins, though this may not be true for all proteins. 
It has also not proved possible to alter a protein so that it survives in the body Ion-
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ger than the native one, the only exception to this being possibly transferrin poly-
mer. This protein forms polymers in vitro which can be isolated from the mono-
meric form and labelled. When these were injected into normal subjects together 
with distinctively labelled monomer the fractional catabolism of the polymeric 
form was always slower than the monomer. 
To summarize, denaturation of protein molecules can be classified as two types, 
namely, gross denaturation is easily detectable (because the molecules are removed 
rapidly from the circulation) and a measure of which can be obtained from the 
retention in the rat liver, and denaturation which requires the use of a reference 
undenatured protein for its recognition. Where no protein that is known to be under-
natured is available, the only absolute evidence for the absence of denaturation is 
the comparison with the same protein labelled biosynthetically with 14C. However, 
because all the proteins studied have shown random degrees of alteration when 
damaged, the finding of a constant fractional catabolism throughout the experiment 
gives some presumptive evidence for the absence of denaturation. Catabolism can 
be calculated from urinary data alone only if the rate is relatively low. With more 
rapidly metabolised proteins it is essential to measure the level of non-protein bound 
activity in the plasma or to correct the urinary data for the presence of the iodide 
pool. I suggest that data of this type should be quoted in all papers on the metabo-
lism of plasma proteins as evidence for the absence of denaturation. 
Finally, as you will appreciate from published work, denaturation arising from 
faulty iodination or self-radiation damage can be easily avoided, but in my opinion 
the isolation of pure proteins in an undenatured state is not always so easy; and 
this may be by far the most common cause of misleading results in experiments 
using iodine labelled proteins. 
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DISCUSSION 
A. ANDERER (Tübingen) : I just want to look at the problem from an immuno­
chemical point of view. If one uses substituted proteins even in tolerant animals, 
a breakage of the tolerance may be expected and a specific titer against the carrier 
moiety of these substituted proteins may be obtained. With reference to this, I 
will just mention the recent papers of Feldman Q). This indicates that iodinated 
proteins behave like substituted proteins, since it could be definitely proved that 
one has an antigenic specificity against the iodinated tyrosine residue in the pro­
tein (2). You interpret your results only in terms of denaturation, but could it not 
be possible that the different metabolic rate you find is due to breakage of tolerance 
and the regaining antigenicity of the protein sample ? 
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T. FREEMAN : I do not think so because these animals were used repeatedly. 
Time after time we got the same survival of albumin in the first experiment as we 
got in the last experiment, having done some 60 or 70 turnovers on the same rabbit. 
If this was due to breaking of tolerance I would have expected some change to occur 
between the first and the last experiment. 
A. ANDERER : I think the change has not been so big. If you look at Feldman's 
experiments, some animals respond and some do not, but he finally could prove 
precipitating antiserum against the carrier moiety of the chemically substituted 
proteins. He used gammaglobulin. 
T. FREEMAN : Well, they were made tolerant with unlabeled human plasma 
and when they were injected with iodinated albumin there was no immune brake 
in the body activity curve. 
Α. ANDERER : May be that is the difference. Feldman uses X­Ray irradiated 
animals. 
W. L. HUGHES (Chairman) : Does the normal rabbit in the beginning has the 
same catabolic rate as the tolerant rabbit after it becomes immunized ? 
T. FREEMAN : The rabbits were made tolerant at birth. The tolerance does 
not seem to change the rate of catabolism. Up to the moment of getting an immune 
brake, non­tolerant rabbits behave in the same way. 
ÜBER DIE BEI DER REAKTION VON PROTEINEN 
MIT RADIOAKTIVEM JOD 
UND CHROM MARKIERTEN AMINOSÄUREN 
E. NIEMANN 
Farbwerke Hoechst AG, Frankfurt (Main)­Höchst, Deutschland 
ZUSAMMENFASSUNG 
Bei der Markierung von Proteinen mit Chrom und Jod werden diese Elemente 
von bestimmten, für sie spezifischen Aminosäuren gebunden. Es wurden Insulin, 
dessen isolierte Ketten A und B, sowie Glucagon und Albumin mit elementarem 
Jod markiert und dabei die angebotenen Jodmengen variiert. Das Verhältnis der 
in diesen Eiweißen gebildeten Jodtyrosine und ­histidine ließ sich nach enzymatischer 
Hydrolyse der Eiweiße mit Hilfe papierelektrophoretischer und ­chromatogra­
phischer Methoden quantitativ bestimmen. Im Insulin wird Tyrosin bevorzugt 
und erst bei hohem Jodangebot Histidin jodiert; dagegen bilden sich im Glucagon 
und der isolierten Insulinkette Β schon bei der Substitution von ~ 1 Jodatom pro 
Molekül Eiweiß Jodhistidine neben Jodtyrosinen. Im Albumin bleibt in einem 
Jodierungsbereich bis zu 3 Atomen Jod pro Molekül das Verhältnis der Mono­
und Dijodtyrosine im Gegensatz zu den anderen Proteinen angenähert gleich. 
Die Chromierungsreaktion wurde am Beispiel des Albumins untersucht. Durch 
vergleichende Chromierungen von Albuminderivaten und durch die enzymatische 
Hydrolyse des Chromalbumins konnte bewiesen werden, daß Chrom über die freien 
Carboxylgruppen der Glutaminsäure des Proteinmoleküls gebunden wird. 
ABSTRACT 
Chromium and iodine atoms, in use for the labelling of proteins, are bound to 
definite amino acids which are specific for these elements. The following materials 
were labelled with elemental iodine varying the amount of iodine over a wide range : 
insulin, chains A and Β of insulin, glucagon and albumin. After enzymatic hydrolysis, 
the ratio of iodotyrosines and iodohistidines formed was determined, using paper chro­
matography and electrophoresis. The hydrolysis of iodinated insulin yielded iodo­
tyrosines; iodohistidines were formed only under higher degrees of iodination. In the 
case of glucagon and isolated chain Β of insulin, iodohistidines appeared as well as 
iodotyrosines, even with an iodination degree of only one atom iodine per protein mole­
cule. In contrast to the behaviour of other proteins, the ratio between the two iodo­
tyrosines in iodinated albumin does not change with the degree of iodination, up to 
3 atoms iodine per molecule. 
Albumin was taken to study the reaction of trivalent chromium on proteins. Enzy­
matic hydrolysis of chromium labelled albumin showed the chromium to be bound 
to the free carboxyl groups of glutamic acid. For further confirmation the binding 
powers of albumin derivatives for chromium were examined. 
Die Verteilung der Jodatome in jodmarkierten Proteinen ist durch die Struktur 
der Proteinmoleküle bedingt und außerdem von der Jodierungstechnik und der 
dabei zur Reaktion kommenden Jodmenge abhängig. Wir haben das Auftreten 
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bestimmter Jodaminosäuren bei der Jodmarkierung von Insulin, dessen isolierten 
Ketten A und B, Glucagon und Albumin untersucht und die Ergebnisse verglichen. 
Die Präparate waren nach folgendem Prinzip jodiert : Elementares Jod der gefor­
derten spezifischen Aktivität wird in eine geringe Menge eines mit Wasser misch­
baren organischen Lösungsmittels eindestilliert. Diese Lösung setzt man tropfen­
weise einer gepufferten Eiweißlösung geeigenten pH­Wertes zu. Man vermeidet 
somit die Einwirkung eines anderen Oxydationsmittels auf das Protein. Die Jodie­
rung ist nach fünf Minuten beendet. Man erhält Reaktionsausbeuten bis zu 95 % 
der Theorie in bezug auf Jod. Insulin z. B. nimmt unter diesen Bedingungen bei 
entsprechendem Jodangebot noch neun Jodatome pro Molekül bei gleicher Reak­
tionsausbeute auf. 
Die jodmarkierten Eiweiße lassen sich mit Pepsin, Chymotrypsin und Amino­
peptidase, isoliert aus Nierenpartikeln (Pfleiderer u. Celliers (1)) spalten. Man kann 
dabei oft auf die Anwendung von Pepsin oder Chymotrypsin verzichten; dies ist 
jedoch im Einzelfall zu entscheiden. Für die Hydrolyse haben wir abweichend von 
den sonst üblichen optimalen Bedingungen die Temperatur auf 30 °C und den 
pH­Wert auf 7,4 festgesetzt, um eine Jodabspaltung aus den während der Reaktion 
freigesetzten Jodaminosäuren soweit wie möglich zu vermeiden. 
Für die Auftrennung der jodmarkierten Aminosäuren in den verschiedenen Eiweiß­
hydrolysaten sind die Papierchromatographie und die Papierelektrophorese ein­
gesetzt worden. Abbildung 1 zeigt die elektrophoretische Trennung von Mono­
und Dijodtyrosin, sowie Mono­ und Dijodhistidin. 
DJ Τ 
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ABBILDUNG 1. — Elektrophoretische Trennung jodierter Aminosäuren in Ameisensäure/Eisessig 
pH 2,0; 60 V/ cm; 2 Std. 
(MJT = Monojodtyrosin, DJT = Dijodtyrosin, 
MJH = Monojodhistidin, DJH = Dijodhistidin). 
In Tabelle I ist die Aktivitätsverteilung in verschiedenen Jodinsulinhydrolysaten 
zusammengestellt. Bei einem Jodierungsgrad unter Eins lassen sich als Jodierungs­
produkte nur Mono­ und Dijodtyrosin nachweisen, wie auch De Zoeten u. De 
Bruin <2), sowie Rosa et al<3) gezeigt haben. Ein Insulinpräparat mit etwa drei Ato­
men Jod pro Molekül enthält außerdem Spuren jodierten Histidins. Die Hydrolyse 
der noch höher jodierten Präparate, die nun auch Dijodhistidin liefern, war nur 
schwierig auszuwerten, da das Protein enzymatisch nicht quantitativ gespalten 
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TABELLE I. — Aktivitätsverteilung in Jodinsulin­Hydrolysaten 
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Atome Jod 
pro 
Molekül 
Insulin 
0,6 
2,7 
6,1 
8,1 
% der Gesamtaktivität 
Monojod­ Dijod­
Tyrosin 
63 37 
20 79 
10 70 
3 60 
Monojod­ Dijod­
Histidin 
< 1 — 
4 3 
6 7 
freies 
Jod 
3 
4 
Protein­
Rückstand 
10 
20 
TABELLE II. — Aktivitätsverteilung in enzymatischen Hydrolysaten jodmarkierter Proteine 
Kette A 
(oxyd.) 
Kette Β 
(oxyd.) 
Glucagon 
Atome Jod 
pro 
Molekül 
Protein 
0,9 
1,1 
0,08 
0,7 
2,2 
3,6 
Monojod­ Dijod­
Tyrosin 
60 40 
52 45 
89 9 
75 14 
28 52 
11 62 
% der Gesamtaktivität 
Monojod­ Dijod­
Histidin 
freies 
Jod 
_ _ 1 _ 
3 
— — 
— 
2 
7 2 2 
6 8 2 
6 II 2 
Protein­
Rückstand 
— 
— 
— 
— 
4 
8 
TABELLE III. — Aktivitätsverteilung in Jodalbumin­Hydrolysaten 
Atome Jod 
pro Molekül 
Protein 
0.2 
0,3 
0,9 
2,6 
% der Gesamtaktivität 
Monojod­ Dijod­
Tyrosin 
76 22 
75 23 
87 11 
81 15 
freies Jod 
2 
2 
2 
4 
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werden konnte und Dijodhistidin leicht in Monojodhistidin und Jod zerfällt. Die 
enzymatische Hydrolyse kann man durch Zugabe von Cystein, das die Disulfid­
brücken des Insulins öffnet, quantitativ zu Ende führen, jedoch wird dann auch 
das Dijodhistidin zu Monojodhistidin reduziert. Untersucht man die jodierten 
Insulinketten oder jodmarkiertes Glucagon, kommt man zu dem in Tabelle II dar­
gestellten Ergebnis. Sowohl in der Kette Β als auch im Glucagon bildet sich Jod­
histidin schon bei der Anlagerung von einem Jodatom pro Molekül Protein. In 
beiden Proteinen muß also das Histidin, bedingt durch die Struktur der Moleküle, 
leichter zugänglich sein als im Insulin. Die Aminosäuresequenz des Glucagons 
beginnt z. B. mit Histidin. Die bemerkenswert hohe Dijodhistidinbildung in Glu­
cagon höheren Jodierungsgrades ist wahrscheinlich eine Funktion des bei der 
Jodierungsreaktion angewendeten pH­Wertes, wie aus an Histidin ausgeführten 
Versuchen geschlossen werden kann. Albumin zeigt im Gegensatz zu den 
bisher besprochenen Proteinen bei einem Jodierungsgrad von 0,2­2,5 Atomen Jod 
pro Molekül ein einheitliches Verteilungsbild u.z. 75­87 % der Gesamtaktivität 
als Monojodtyrosin und den Rest als Dijodtyrosin. Das bedeutet, 14­7 % der jodier­
ten Aminosäuren sind Dijodtyrosi (Tabelle III). 
Albumin reagiert — wie bekannt — unter einfachen Reaktionsbedingungen 
auch mit Kationen. In der medizinischen Diagnostik eingeführt ist insbesondere 
das Cfiromhumanalbumin­51Cr (Waldmann <4)). In einem chrommarkierten Albu­
min ist die Bindung zwischen den dreiwertigen Chromionen und dem Eiweiß sehr 
mm mm 
h -ι I- ri ν 
Albumin Succin -
albumin 
Albumin Methyl-
albuminal 
ABBILDUNG 2. — Vergleich der elektrophoretischen Wanderung von Albumin, Succinalbumin 
und Methylalbuminat bei pH 8,6. 
JOD UND CHROM MARKIERTEN PROTEINEN 47 
stabil. Weder in saurem noch in alkalischem pH­Bereich verliert die Verbindung 
Chrom. Das Präparat ist mit (NH.,)2S04 fällbar und lediglich unter Einwirkung 
von Trichloressigsäure lassen sich von dem markierten Eiweiß einige Prozent des 
gebundenen Chroms abspalten. 
Die Reaktion des Albumins bei einem Angebot von einem Chromion pro 
Molekül Eiweiß verläuft in kurzer Zeit quantitativ. Erst bei höherem Chroman­
gebot sinken die Reaktionsausbeuten. Sie können aber durch Verlängerung der 
Reaktionszeit oder Entfaltung der Albuminmoleküle mit Harnstoff wieder ge­
steigert werden. Polyacrylamid­, Papier­ und Immunelektrophorese, sowie Unter­
suchungen in der Ultrazentrifuge haben gezeigt, daß die Proteinmoleküle durch 
die Chromierung vernetzt werden. 
Für die Bindung zweiwertiger Metallionen an Proteine werden in der Literatur 
immer wieder die Aminosäuren Cystein, Histidin oder aber z. B. im Falle des Trans­
ferrins Tyrosin (Jones u. Perkins (5)) diskutiert. Zur Klärung der Chromalbumin­
bindung haben wir Chromalbumin­51Cr enzymatisch hydrolysiert, außerdem Albu­
min durch spezifische Reaktionen verändert und an diesen Präparaten die Chro­
mierbarkeit geprüft, um die für diese Reaktion funktionellen Gruppen der Amino­
säuren festlegen zu können. Die Albuminderivate wurden zunächst durch ihr 
elektrophoretisches Verhalten bei pH 8,6 im Vergleich zum Humanalbumin cha­
rakterisiert. Beispiele sind in Abbildung 2 dargestellt. Weder durch die photooxy­
dative Zerstörung des Histidins (6) noch durch die Jodierung des Tyrosins werden 
die Ausbeuten der Chromierungsreaktion herabgesetzt (Tabelle IV). Damit war die 
Beteiligung von Histidin und Tyrosin and der Bindung der Chromionen unwahr­
scheinlich. Die Jodierung, hier ausgeführt mit einem Angebot von zehn Mol Jod 
TABELLE IV. — Chromierung verschiedener Derivate von Humanalbumin unter gleichen 
Reaktionsbedingungen 
(Ansatz : 0,7 χ 10~6 M Albumin; 1,6 χ 10~6 Μ Chrom) 
Veränderung 
des Albuminmoleküls 
Photooxydation des Histidins 
Jodierung des Tyrosins . . . . 
Succinierung freier Aminogrup­
pen mit Bernsteinsäurean­
Veresterung freier Carboxyl­
gruppen mit Methanol/HCI 
Chromierbarkeit 
im Vergleich zu Albumin 
unverändert 
unverändert 
erhöht 
erniedrigt 
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pro Mol Albumin führt gleichzeitig zur Oxydation freier SH­Gruppen, so daß die 
Bindung des Chroms über Cystein ebenfalls nicht wahrscheinlich ist. Die Anla­
gerung von Bernsteinsäureanhydrid m führt zur Bildung neuer Carboxylgruppen 
H 
N — C — C H , — CH., — C O O H in dem Proteinverband. So veränderte Prä­
II o 
parate binden mehr Chrom als das Albumin. Nach Veresterung der in dem Albu­
minmolekül vorhandenen freien Carboxylgruppen mit Methanol/HCl (it) beobach­
teten wir eine geringere Chrombindung. Hieraus folgt, daß die Chromierungsreaktion 
allein an den freien Carboxylgruppen abläuft. 
f W O -»»M i 
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ABBILDUNG 3. — Elektrophoretische Trennung des Chromalbumin­olCr­Hydrolysates in 
Pyridin/Eisessig pH 6,5; 50 V/cm; I Std. 
a) Anfärbung der Aminosäuren mit Ninhydrin 
b) Diagramm der Radioaktivität. 
Die enzymatische Hydrolyse des Chromalbumins­51Cr führte zu dem gleichen 
Ergebnis. Als Beispiel für die Untersuchung sei hier ein Albuminpräparat, das 
mit 0,2 Atomen Chrom pro Molekül Albumin vernetzt war, aufgeführt. Für die 
enzymatische Hydrolyse wurden Pepsin, Trypsin oder Chymotrypsin und Amino­
peptidase verwendet. Die papierelektrophoretische Auftrennung des lyophilisierten 
Hydrolysates zeigte eine radioaktiv markierte Substanz, die weder bei pH 2,0 noch 
Hist, Lysin 
» ! i l ' I I K ! 
Aspar. Gtutam. Bu'ndw. Chrom- Cnrom-
jâurz saun kompiix bmjihx 
a) 
I t I I 1 I r t -
b) 
¿Ut, T*K». te-*· & f *'*?· ^ 
ABBILDUNG 4. — Identifikation 
von Glutamisäure im Chrom-
ami nosäure-Hydrolysat 
a) Elektrophorese pH 6,5; 
50 V/cm; 1 Std. 
b) C h r o m a t o g r a p h i e in 
n - Butanol - Pyridin - Eis-
essig-Wasser (375 : 250 : 
75 : 300). 
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pH 6,5 (Abbildung 3a u. b) wandert. Wir haben diese Radiochrom Verbindung 
nach elektrophoretischer Abtrennung der nicht markierten Aminosäuren bei pH 
2,0 aus einzelnen Papierbögen eluiert und das Eluat mehrere Stunden mit Salzsäure 
hydrolysiert. In dem Hydrolysat ließ sich neben freien aktiven Chromionen allein 
die Glutaminsäure sowohl papierelektrophoretisch als auch papierchromatographisch 
nachweisen (Abb. Aa u. b). Chromalbumin­51Cr­Präparate, die mehr als ein Chro­
matom pro Molekül Albumin enthalten, lassen sich unter den gegebenen Bedin­
gungen enzymatisch nicht quantitativ spalten, so daß man aus dem auch in diesen 
Teilhydrolysaten gefundenen Glutaminsäure­Chrom­Komplex nur bedingt darauf 
schließen darf, daß die Vernetzung der Albuminmoleküle mit Chromionen aus­
schließlich über diese Aminosäure erfolgt und nicht auch Asparaginsäure beteiligt 
ist. Die Ergebnisse stützen die von Perkins 1961 <9) aufgestellte Hypothese, daß 
das zweiwertige Zink von Albumin über freie Carboxylgruppen gebunden wird. 
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DISCUSSION 
Y. COHEN (Paris) : Je voudrais savoir si l'orateur considère une albumine marquée 
au chrome comme une albumine non dénaturée ? 
E. NIEMANN : Ich würde es als denaturiert bezeichnen, da bei der Chromierung 
des Albumins die Albuminmoleküle vernetzen. Die Vernetzung ist eine Funktion 
der angebotenen Chrommenge und außerdem eine Funktion der Zeit. Für biolo-
gische Studien ist, glaube ich, das Präparat nicht in wertvoller Weise zu verwenden. 
E. REGOECZI (London) : I would like to ask Dr. Niemann about the distribu-
tion of MIT and DIT in albumin hydrolysates as obtained after iodinations at 
different substitution ratios. The data shown in one of the slides suggest that low 
iodination ratios (e.g. 0.2 atom per mol.) gave less MIT and more DIT than did 
higher ones. Can these observations be reconciled with the binomial distribution 
law for the iodine label in a solution of homogenous protein? Should not one expect 
the reverse to be true ? 
E. NIEMANN : Ich wollte mit der Tabelle nur zeigen, dass wir in einer Versuchs-
reihe von 0,2 bis 2 Atomen Jod pro Molekül Albumin keinen signifikanten Unter-
schied gefunden haben. Es handelt sich hier um Schwankungsbreiten der Reaktion 
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ABSTRACT 
Various methods of labelling proteins with tritium are found in the literature. 
A simple method was developed in our laboratories for the labelling of several 
proteins and precursors. Experiments were performed by bringing boron trifluoride 
complex of tritiated acetic acid into contact with the protein to be labelled and 
shaking the mixture. This procedure offered mild reaction conditions. Preparation 
of the reagent and labelling reactions are also simple and require no special appa-
ratus. Labelling of human albumin, ovoalbumin, ribonucleo-proteides, somato-
tropin, insulin and beta-lipoproteide were investigated. Purity control and identi-
fication of the labelled products obtained were performed by Immunoelectropho-
resis. Specific activities obtainable, purity and biological activity of the products 
and comparison of the new method with other labelling procedures are discussed. 
In the field of protein labelling various methods are known in the literature. 
The Wilzbach gas exposure technique (1), biosynthetic methods using labelled pre-
cursors (2) and synthetic methods for preparing labelled derivatives (3) from proteins 
have been used successfully. These methods are rather complicated and require 
special apparatus. In case of hydrogenolysis of iodinated peptides, a method deve-
loped by Roche et al. (4>, the use of special equipment for handling tritrium gas 
is also necessary. 
In our laboratoires a simple exchange reaction has been used for labelling 
organic compounds. This reaction is a modification of the method reported by 
Yavorsky and Gorin <5). In the Yavorsky method the boron trifluoride complex 
of tritiated phosphoric acid is the reagent which is applicable for labelling organic 
compounds in a heterogeneous exchange reaction. The strongly acidic medium, 
however, causes decomposition in some cases. Therefore the application of a weaker 
acid-complex seemed to us to be more advantageous in labelling of some "acid-sen-
sitive" compounds. The boron trifluoride complex of acetic acid was found to be 
useful for this purpose. Preparation of this reagent is very simple and can be per-
formed in any chemical or biochemical laboratory without the need of any special 
equipment. It is a stable compound and can be purified by distillation. Exchange 
reactions by using the complex are simple too and can be effected by contacting 
or shaking the material to be labelled with the reagent. Sometimes acetic acid can 
be used as solvent and so the reaction takes place in homogeneous phase. The equi-
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librium can be reached within a few hours at room temperature. No special purifi­
cation of the labelled compound is necessary in general. Specific activities obtai­
nable are naturally lower than those obtained by using the Yavorsky reagent. 
As protein precursors some amino acids were treated with the reagent. It can 
be seen from the Table I that in labelling of amino acids a sufficient activity yield 
can be obtained. The rate of the exchange reaction was found to be markedly depen­
dent on temperature. This is shown in Table II, where results obtained in labelling 
of DL­phenylalanine can be seen. 
Preliminary experiments were performed with a few dipeptides. Glycyl­DL­
alanine, glycyl­DL­leucine and glycyl­L­tyrosine (50 mg of each) were exposed to 
TABLE I. — Labelling of amino acids with acetic acid­boron trifluoride reagent at room temperature 
for 20 hours 
Compound 
(weight 5 g) 
DL­Alanine 
DL­Valine 
DL­Leucine 
DL­Phenylalanine 
L­Tryptophane 
L­Tvrosine 
Reagent 
weight 
(mg) 
1,000 
1,000 
1,000 
1,000 
1,000 
1,000 
1,000 
activity 
(mC) 
10.9 
10.9 
10.9 
10.9 
131.2 
133.7 
133.7 
Specific 
activity 
(mC/g) 
0.14 
0.13 
0.11 
0.16 
2.00 
2.52 
0.91 
Activity 
yield 
(%) 
0.64 
0.60 
0.50 
0.70 
0.75 
0.94 
0.34 
TABLE II. — Temperature dependence of the exchange reaction in case of DL­phenylalanine 
Time of reaction 
at 100 °C 
0 
2 
4 
6 
12 
20 
at 24 °C 
24 
22 
20 
18 
12 
4 
Specific 
activity 
(mC/g) 
2.00 
1.34 
1.52 
1.87 
2.83 
3.75 
Activity 
yield 
œ 
0.76 
0.51 
0.58 
0.71 
1.08 
1.43 
Substrate : 500 mg. 
Reagent : 1,000 mg (131.2 mC). 
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the reagent for a period of two hours. Chromatographic investigation of the pro­
ducts showed that no destruction of the peptide bonds occured during the labelling. 
Specific activities and activity yields are shown in Table III. 
TABLE III. — Results of labelling of some dipeptides 
Compound 
(weight 50 mg) 
Glycyl­alanine 
Glycyl­DL­leucine . . . . 
Glycyl­L­tyrosine 
Reagent 
weight 
(mg) 
1,000 
1,000 
1,000 
activity 
(mC) 
216 
216 
216 
Specific 
activity 
(mC/g) 
0.148 
0.148 
0.456 
Activity 
yield 
(%) 
0.003 
0.005 
0.010 
All of the amino acids and dipeptides were chemically and radiochemically 
pure after labelling as proved by chromatography. 
One of the "acid sensitive" compounds which could not be labelled by using 
the Yavorsky reagent, was cholesterol. Exchange reactions with the acetic acid­
boron trifluoride reagent, however, resulted labelled cholesterol with very good 
activity yields and high chemical and radiochemical purity. 
All of these results allowed us to hope that this reaction can serve as a simple 
method for labelling proteins. 
ß­lipoprotein isolated from rabbit blood was firstly investigated (6). The com­
pound in a 5 % sodium chloride solution was lyophylized and the protein­salt 
mixture (400 mg) was shaken with the reagent (3.7 g = 130 mC) for 24 hours at 
room temperature. Then the tritiated complex was decomposed by adding water 
with subsequent lyophylization. Labil tritium was washed out with distilled water 
by repeated lyophylization. The labelled product was used in the salt solution 
without any further purification. The solution had a specific activity of Q.1\LC¡ 
ml. Immunoelectrophoresis and subsequent autoradiography (using Kodak AR­
IO stripping film) showed that the labelled ß­lipoprotein remained practically unaltered 
during the exchange reaction and shows the same behaviour in living organism as 
the unlabelled compound. 
A ribonucleoprotein preparate was sucessfully labelled in the same way. The 
labelled product (1.8 μΟ/η^) shows only a slight degradation in immunoelectro­
phoretic and subsequent autoradiographic investigation. 
The hormonal polypeptides, somatotropin and insulin, gave good results in 
preliminary experiments. 
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In labelling experiments of human albumin and ovoalbumin considerable 
or total denaturation of the proteins occured, so these experiments must be consi­
dered as unsuccessful. 
These results show that the method is suitable for labelling of some proteins 
while others undergo decomposition under these circumstances. A more detailed 
investigation of the reaction is in progress. 
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DISCUSSION 
K. BRUNFELDT (Gentofte) : 1 should like to know whether you could give some 
information on the degree of destruction during the tritium labeling of insulin. 
T. GOSZTONYI : 1 cannot say anything about this problem as our experiments 
in labeling insulin are only preliminary experiments. I can only say that after purifica-
tion we could isolate labeled insulin but I cannot say anymore about degradation 
degree at present. 
W. L. HUGHES (Chairman) : Can you say what position is labeled in the protein 
and was the lipid labeled too ? 
T. GOSZTONYI : Not now, but we are dealing with this problem. It seems so 
that mainly the tertiary carbon hydrogen bonds, and especially the aromatic carbon 
hydrogen bonds, are affected in the labeling process. 
On the other hand, I cannot say whether the lipids are labeled. Anyway in 
labeling of cholesterol very good labeling results can be obtained so we consider 
that both, protein and cholesterol perhaps could be labeled. 

LABELLED PLASMA PROTEINS 
FOR METABOLIC STUDIES 
Chairman : A. S. McFARLANE 
National Institute for Medical Research, London, Great Britain 
PRELIMINARY REMARKS BY THE CHAIRMAN 
The first three papers in this session will deal with criteria for the preparation 
and proper use of individual labelled plasma proteins, namely albumin, γ-globulin 
and fibrinogen. These ought to be non-controversial, but we may get divergent 
expressions of opinion in the discussion of the last two which deal with the important 
physiological matter of regulation of synthesis and catabolism. In this connection 
I would ask all participants to make it quite clear whether they are referring to 
absolute or fractional rates. Synthesis rates are inferred from iodine data obtained 
in steady state conditions —· as they must be — and what is actually measured is 
the slope of the plasma specific activity curve, so that the result is a fractional rate 
and one which refers to the total body pool. On the other hand when catabolism 
is measured from so-called U/P ratios the result is expressed as a fraction of the 
plasma pool. In discussions of regulation mechanisms it can be important to make 
a clear distinction between these two and indeed I would ask all speakers to refer 
as far as possible to what was actually measured without any assumptions about 
steady state conditions. 

IODINATED ALBUMIN AS A METABOLIC TRACER (*) 
R. BIANCHI i 0 ) , U. ROSA (*), G. FEDERIGHI (°), G. F. PENNISI (*), 
G. A. SCASSELLATI (*) and L. DONATO (°) 
(°) Medical Clinic and Center of Nuclear Medicine, University of Pisa, Italy. 
(*) SORIN, Nuclear Research Center, Saluggia, Italy. 
ABSTRACT 
A selected preparation of HSA has been used to study the effect of progressive 
iodination on the biological behaviour of the labeled protein, as judged from its 
catabolic rate. 
Iodination up to 24 iodine atoms per albumin molecule has been performed 
under standardized and controlled conditions. Preparations were tested for their 
catabolic rate level in normal humans. The amount of MIT (**) and DIT (**) 
residues at various degrees of iodination were determined. 
The existence of a limiting value of iodination degree below which the cata-
bolic rate is little affected by the degree of iodination was observed. This limiting 
value has been shown to vary widely with the conditions under which iodination is 
performed, and to be related to the internal distribution of iodine inside the molecule. 
INTRODUCTION 
The question whether iodinated albumin can be considered an adequate biolo-
gical tracer has been matter of extensive studies. Most of the recent data tend to 
suggest that under appropriate labelling conditions 131I-albumin may be considered 
to fulfil the requirements for tracer studies. However, some experiments with 35S 
labelled proteins (1' seem to contradict this conclusion. 
Although these latter results are largely open to criticism (2,3) we thought 
advisable to approach the problem by directly studying the processes through which 
the progressive iodination modifies the biological behaviour of HSA (**>. 
Experiments attempting to correlate the process of iodination with the biolo-
gical behaviour of HSA have so far received little attention and non-systematic 
contributions (4). 
The proper use of this approach demands that the process of iodination be 
entirely isolated from other processes occurring simultaneously. A preliminary requi-
rement to this sort of study was therefore the establishment of adequate conditions 
both from the point of view of the preparation of the tracer and of the measurement 
of the selected biological parameter. 
(*) Work performed under Euratom Association Contract No. 026-63-4 BIAC and Euratom 
Contract No. 048-64-6 BIOL 
(**) MIT : monoiodotyrosine; DIT : diiodotyrosine; 
HSA : human serum albumin. 
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EXPERIMENTS PERFORMED AND RESULTS 
Labelling procedure. The preparation method for a study of progressive iodi-
nation should permit to iodinate proteins in the mildest possible conditions, such 
that tyrosine iodination be the only occurring reaction, without parallel processes 
going on simultaneously. 
The method of electrolytic iodination seemed to us well suited for these pur-
poses <5). In fact it permits to carry out the iodination under controlled conditions, 
so that iodine is discharged at a preestablished rate, and it reacts stoicheiometically 
with the protein tyrosine (6). 
Moreover, the method by itself has been shown to be devoid of effects on the 
protein <6). 
Selection of albumin batch. On the basis of studies on different albumin batches 
that were reported in a previous paper (6), it was decided to select the preparations on 
the basis of their behaviour in humans, choosing the lot yielding the lowest value 
for fractional catabolic rate (FCR) at an iodination degree (I.D.) of 0.5-1 iodine 
atoms per molecule (¡.a.m.). 
Table I presents the level of the FCR for the selected albumin batch (A), 
iodinated at I.D. of 0.5-1, and measured in a group of 6 normal subjects. 
TABLE I 
Evaluation of Selected Albumin Batch (A) 
Mean value and standard deviation of the fractional catabolic rate of a selected albumin batch, 
measured in 6 normal subjects, after iodination between 0.5 and 1.0 ¡.a.m. 
Cases No. 
6 
Iodination 
degree 
0.5-1 
Catabolic rate 
% day- i 
10.84 
Standard 
deviation 
0.45 
Variance analysis of the results. It is shown that the F values for intra- and inter-subjects varia-
bility (resp. days and subjects in the table) do not attain significant values. 
Source of variation 
Days 
Subjects 
Error 
Sum 
of squares 
13.2 
6.6 
38.9 
Degree 
of freedom 
5 
5 
25 
Mean 
square 
2.64 
1.32 
1.56 
F value 
1.69 
0.85 
Feos = 0.00 "0.01 = 9.47 
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The FCR was determined from the urine­to­plasma ratio of activity. 
The mean catabolic rate was 10.84 % per day and both intra­and inter­subjects 
variations are very small, despite the fact that all the values, including that of the 
first day, were taken into account. Both variations did not reach statistical signi­
ficance as shown by the variance analysis, the results of which are also reported in 
the table. 
These observations were performed over a six days period. This observation 
time is short when compared with the duration of albumin metabolic studies. How­
ever, it proved long enough to provide us meaningful informations concerning the 
FCR of the preparations. 
To eliminate inter­subjects variability, in some cases two albumin preparations 
were injected into the same subject, labelled with 131I and 125I respectively. 
Effect of progressive iodination. A series of preparations were obtained from the 
selected batch A, iodinated at increasing I.D., up to 26 ¡.a.m. 
All the iodination procedures were carried out in the cold, and excess iodine remo­
ved by dialysis. Care was also taken to avoid effects due to self­irradiation by using 
very low specific activity in the case of 131I (less than 10 ^C/mg) and injecting all the 
preparations not later than 48 hours from labelling. The FCR of each preparation 
was measured in normal subject. Several points were measured with the double 
tracer technique using a preparation iodinated between 0.5 and 1 as reference. 
In Figure 1 are reported the FCR values in the range of I.D. between 0.5 and 
26 i.a.m. The two standard deviation ranges for preparations iodinated between 0.5 
and 1 are also reported in the figure. 
It is evident that up to an I.D. of the order of about 10 the average FCR does 
not exceed the two sigma range for the preparations iodinated between 0.5 and 
1 i.a.m. 
ALBUMIN BATCH A 
ELECTROLYTIC IODINATION 
5 10 15 20 25 
AVERAGE IODINE CONTENT (atoms/mole) 
FIGURE 1. — Average FCR of HSA preparations progressively iodinated from 0.5 to 26 i.a.m. 
The 2σ range refers to the preparations iodinated between 0.5 and 1 i.a.m. 
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Above this level, FCR rises progressively to reach a value of the order of 60 % 
per day for an I.D. of about 24. 
The electrophoretic behaviour of each preparation was also tested. Free boun-
dary electrophoresis did not show substantial changes in homogeneity for preparations 
with iodine content ranging from 0.5 to 16 i.a.m. 
Agar gel electrophoresis revealed only an increased mobility for increasing 
value of the I.D., without apparent inhomogeneity or trailing effects, as shown in 
Figure 2. 
« ^ AV fcii* 
FIGURE 2. — T1SELIUS ELECTROPHORESIS OF NATIVE HUMAN SERUM ALBUMIN 
(on the left) AND OVERIODINATED (16 at. I/mol) SERUM ALBUMIN (on the right). 
I 
ELECTROPHORESIS ON AGAR GEL OF : 
A) Oveiiodinated serum albumin (16 at. I/mol). 
B) Native serum albumin. 
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These findings rule out the occurrence of gross alteration products, a conclu­
sion which is supported by the apparent constancy of the daily values of the FCR 
in each preparation, including those above the I.D. of 11. Examples of this pattern 
are shown in Figure 3. 
These findings indicate that iodinated HSA preparations above an I.D. of 11 are 
handled as new species with FCR values higher than that of low iodinated prepara­
tions. However, this increase in the degradation rate for increasing iodine content, 
has nothing in common with the behaviour of grossly denatured preparations, in 
which the daily catabolic rate rapidly and continuously decreases in successive days. 
Comparison with other methods of iodination. On the basis of the above findings 
we thought of interest to use the double tracer technique to compare the metabolic 
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FIGURE 4. — FCR values of HSA preparations from the same batch, iodinated at increasing I.D. 
with different techniques. 
The vertical lines connect values obtained in the same experiment, in which a double tracer 
technique (" ' l and 1 " I ) was used to compare in the same subject the FCR of two preparations obtained 
from the same batch, at the same I.D., with different techniques. The dotted line is replotted from 
Figure 1. 
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behaviour observed with the electrolytic method with that of preparations obtained 
from the same batch using the iodide-iodate or the iodine-monochloride proce-
dures <6). In Figure 4 the results are compared at different I.D. 
It is evident that at an I.D. between 0.5 and 1 i.a.m. the various methods show 
small differences, with the possible exception of somewhat higher levels for the iodide-
iodate method. On the other hand, as soon as the I.D. rises above 2 or 3, while the 
electrolytically labelled proteins maintain a constant value of FCR, both the iodide-
iodate and the iodine-monochloride labelled proteins, show increasingly higher 
values of FCR, and grossly inhomogeneous handling. An example is shown in 
Figure 5. 
Comparison with other albumin batches. Besides the differences due to various 
iodination methods, similar differences could derive from the properties of the 
starting material. 
Figure 6 presents the results of the FCR studies performed on a different batch 
of HSA (batch B) subjected to progressive iodination under the same conditions 
used for batch A. 
The trend shown by this preparation is similar to that of batch A, with the 
only difference that the FCR starts to increase at I.D. of about 5-6 i.a.m. As for the 
previous batch, no substantial heterogeneities were observed, neither in the daily 
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FIGURE 5. — Values of daily FCR for two preparations of HSA of the same batch (A) iodinated at 
the same I.D. and injected into the same subject. In the upper part the results of the preparation 
labelled with the ICI method (125I), in the lower part these of the preparation electrolytically 
labelled (131I). 
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HSA BATCH A 
5 10 15 20 25 
AVERAGE IODINE CONTENT (a toms/mole) 
FIGURE 6. — Comparison of the FCR values of 2 batches of HSA submitted to progressive 
iodination. The line referring to batch A has been replotted from Figure 1. 
values of FCR, nor in the electrophoretic behaviour. In this case also, the behaviour 
definitely differs from that of grossly altered preparations. 
Intramolecular distribution of iodine. In the hypothesis that the explanation of 
the above findings could be related to the intramolecular distribution of iodine, the 
amount of mono­iodo and di­iodo tyrosine residues at various I.D. was measured on 
the preparations obtained from batch A. 
The results are presented in Figure 7. It can be seen that the percentage of the 
actual free tyrosine residues decreases progressively to about 20 % of its original 
value, as the iodine content increases from 0 to 11 i.a.m. The remaining 20 % of free 
tyrosine disappears at a much slower rate, since the iodine content has to reach a 
level of 25 before free tyrosines disappear entirely. 
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FIGURE 7. — Percent of free tyrosine residues and fraction of iodinated residues in DIT form, versus 
increasing I.D. in the selected albumin batch submitted to progressive iodination. The line 
describing the average catabolic rate has been replotted from Figure 1. 
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This indicates that most of the additional iodine which reacts with the protein, 
above an I.D. of 10-11 i.a.m., is used to transform mono-iodo into di-iodo dérivâtes 
as shown by the increase of the latter. 
On the other hand, effects other than iodination of tyrosine, probably involving 
histidine residues, appear above a level of 15. This explains why in this range DIT 
percentage rises at a slower rate than expected. 
DISCUSSION AND CONCLUSIONS 
When the behaviour of free tyrosines is compared with that of FCR of pro-
gressively iodinated albumin (both are shown in Figure 6) it seems possible to con-
clude that, with a proper choice of starting material and iodination conditions, most 
of the tyrosines residues in the protein can be substituted without appreciable changes 
of their catabolic rate. 
We do not believe that the critical value, above which a deviation of FCR 
occurs, could be further displaced towards higher I.D. by acting on the various 
parameters. In fact, the conditions of this experiment can probably be considered as 
the mildest possible from the point of view of iodination : the rate of reaction and the 
amount of reacting iodine are minimal, the albumin concentration is maximal, and 
no side reactions occur. Further slowing of the rate of discharge of elemental iodine 
or increase of the albumin concentration did not result in appreciable differences of 
the observed FCR. 
These observations permit to conclude that the isolated tyrosine iodination pro-
cess, by itself, has to reach an I.D. of about 10-11 for affecting the metabolic behaviour 
of the protein. 
The increase of FCR that occurs in the range from 10 to 15 i.a.m., within which 
side effects have not yet appeared, indicates that at this level the process of tyrosine 
substitution has determined a critical intramolecular condition, resulting in a modi-
fication of the metabolic behaviour of the protein. 
On the other hand, the results of studies with other iodination procedures and 
with different albumin batches, indicate that a critical intramolecular condition can 
be attained at much lower iodination degrees. The higher probability of attaining a 
critical intramolecular condition at lower I.D., could be inherent in methods like the 
iodide-iodate and the iodine-monochloride techniques. On the other hand, the same 
result could be a consequence of changes occurring during isolation and purification 
of the protein. 
All these data point to the importance of the distribution of iodine within the 
molecule, as a determinant of its metabolic fate. 
Too little information is presently available to grant more than pure speculative 
reasoning on this subject. However, it seems now obvious to us that further investi-
gation of the protein changes about the I.D. of 10 should provide valuable informa-
tion of the mechanism by which iodine affects the behaviour of the protein. 
IODINATED ALBUMIN AS TRACER 69 
As a side consequence, but relevant to the aim of this work, the demonstration 
that, in absence of side effects, iodination may reach a very high level before a critical 
intramolecular structure is attained, proves the adequacy of low iodinated albumin 
preparations as metabolic tracers. 
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DISCUSSION 
E. TRIANTAPHYLLIDIS (Paris) : Avez-vous injecté dans chaque cas la même 
quantité de radioactivité ou bien cette quantité variait-elle avec le degré d'iodu-
ration ? 
R. BIANCHI : The amount of injected radioactivity was about 50 microcuries 
in all cases. 
E. TRIANTAPHYLLIDIS : Y-a-t-il une différence de mobilité électrophorétique entre 
l'albumine ordinaire et l'albumine faiblement iodée? 
U. ROSA (Saluggia) : Il y a une différence de mobilité négligeable entre l'albumine 
marquée à 0,5 atome d'iode/molécule et l'albumine native. Par contre nous avons 
remarqué des différences significatives dans le cas des albumines hautement iodées, 
notamment pour des taux d'iodination de l'ordre de 6 à 7 atomes d'iode par molécule. 
M. A. ROTHSCHILD (New York) : Are your control curves followed for a long 
enough period to determinate the validity of the preparation ? Other studies have 
shown that iodination at the level you describe did result in alterations in the plasma 
decay curve. According to Berson and Yalow, these changes made their appearance 
only after the curves were followed for some weeks (Berson, S. A. and Yalow, R. S., 
Schreiber, S. S. and Post, J., J. Clin. Inv., 33 : 746, 1953). 
R. BIANCHI : As I have pointed out in my presentation, our experimental period 
was of short duration for practical purposes; on the other hand, the values of the 
fractional catabolic rate obtained by us, and expressed as percent of plasma albumin, 
are in excellent agreement with that of the various AA. who prolonged the experi-
ment for 3 or 4 weeks. 
It is well established that under steady state conditions the fraction of plasma 
radioiodinated albumin degraded per day is constant from the beginning of the 
study; our studies rely on this evidence and have confirmed it. 
On the other hand if the fractional catabolic rate is expressed in percent of 
the total activity retained in the body it necessarily shows higher values in the first 
few days, progressively decreasing towards a constant value that is reached after 
some time. This pattern, to which I think Dr. Rothschild refers, is implicit in such 
a calculation method, which yields the rate of change of the tracer content in the 
entire body, and does not necessarily imply denaturation of the label. 
BASIC ASPECTS OF GAMMAGLOBULIN METABOLISM 
S. Β. ANDERSEN 
Department of Clinical Physiology, Glostrup Hospital, Copenhagen, Denmark 
ABSTRACT 
YG­globulin comprises far the greatest part of the protein in the gamma fraction 
of human serum. The present review is concerned with metabolic studies using 
131I­TG­globulin, with the evidence which can be presented for the validity of such 
studies, and how the homogeneity of the labelled protein can be controlled. Evidence 
is presented that YG­globulin from a kinetical point of view is catabolized intra­
"vascularly. 
The catabolic pathways of TG­globulin are discussed and it is concluded that YG­
globulin may be catabolized by a non­specific process in the gastrointestinal tract, 
liver and lungs. Finally it is emphasized that a satisfactory mathematical model 
must be used for the calculations and normal values for yG­globulin metabolism 
is given. 
I have been requested to concentrate on the basic aspects of metabolic studies 
with iodinated gammaglobulin, and particularly to present evidence for the vali­
dity of such studies. 
In the paper by Freeman '*' general criteria for evaluating the quality of iodine 
labelled plasma proteins were already given. I am going to apply these criteria to 
gammaglobulin and, in addition, to discuss where and how gammaglobulin is 
catabolized. Finally, I shall say a few words about calculation methods and give 
my own normal values for the metabolism of YG­globulin in man. 
Freeman pointed out that valid data can be obtained only if the labelled pro­
tein is homogeneous metabolically. By this expression is meant that all the labelled 
molecules must have the same chance of being catabolized. None of them must 
have a greater tendency to be broken down than the others. Otherwise it would 
be impossible to analyze the kinetics of the molecules and the metabolic parameters 
could not be calculated. 
Metabolic heterogeneity may be due either to impurity or to denaturation. 
The results of the earliest studies of gammaglobulin — and of some of the latest 
■— are questionable on account of both these factors. 
It is well known to day that the gamma fraction of human serum consists of 
the three immunoglobulins : yG­globulin, γΜ­globulin and γΑ­globulin. Cohen 
and Freeman (1) have shown that γΜ­globulin is catabolized much more rapidly 
than yG­globulin. A mixture of immunoglobulins, therefore, is heterogeneous 
metabolically and cannot be used in metabolic studies. A complete account of the 
metabolism of the gamma fraction should be based on knowledge of the metabo­
(*) These Proceedings, p. 31 
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lism of each of the immunoglobulins. However, yG-globulin is found in far the 
greatest concentration. Thus the metabolism of this immunoglobulin will represent 
the metabolism of the gamma fraction fairly well. 
The purity of a labelled preparation of yG-globulin should be tested by several 
different physico-chemical methods, as for instance paper electrophoresis, Immu-
noelectrophoresis, autoradiography and ultracentrifugation. But it is not enough 
to show that the protein is pure. Metabolic heterogeneity may also be due to dena-
turation, either on account of the fractionation method or on account of the iodi-
nation. 
The ordinary Colin fractionation with cold ethanol will always denature yG-
globulin. This method should not be used to isolate yG-globulin for metabolic 
studies. Column chromatography on DEAE cellulose or DEAE Sephadex is much 
more gentle. We have used this method — which is quite simple — for the last five 
or six years with satisfactory results. 
The iodination of the protein should not be too heavy, at most two or three 
atoms of iodine per molecule of yG-globulin — preferably less. It is essential to 
use a method in which strong organic solutions are not employed. We have used 
the iodine monochloride method '21 for a number of years. It is easy to use and has 
proven very satisfactory. 
CONTROL FOR METABOLIC HETEROGENEITY 
The question is now to demonstrate if the labelled yG-globulin is hetereogenous 
metabolically. Physico-chemical methods are usually not sensitive enough for demons-
trating denaturation. They will only reveal severe changes in the structure of the 
protein molecules which will produce gross biological denaturation of the pro-
tein. The most sensitive physico-chemical test for denaturation is probably column 
chromatography on ion exchanger cellulose. Labelled yG-globulin should show 
the same pattern on DEAE cellulose as the genuine protein. 
The best way of testing the labelled yG-globulin is to employ biological methods. 
In practice this can be done by evaluating the results of the turnover study. The 
excretion of radioactive iodide in the urine during the first 24 hours should not be 
greater than on subsequent days. Iodide liberated during catabolism of protein in 
the beginning of the study will have to fill up the iodide pool before any excretion 
can take place. 
In addition, the ratio between urinary activity and plasma activity should be 
constant throughout the study. A falling ratio would indicate metabolic hetero-
geneity of the labelled protein. 
An example is shown in Figure 1. The average urinary excretion is shown for 
21 normal subjects. The daily value for urine/plasma ratio (U/P) has been expressed 
in per cent of the average for the whole period in order to calculate the average 
variation for all subjects. It is apparent that the excretion during the first day is 
low and that the U/P ratio is fairly constant throughout the study. A small devia-
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tion from this pattern can be explained by the effect of the iodide pool, which I 
will discuss later. 
We have one more rather simple biological test to our disposal, namely simul­
taneous determination of plasma volume with T­1824 and the labelled protein <3). 
This can be done when the turnover determination is started. Denatured labelled 
Fd •IOC 
%· 
loo ·■ 
60 "■ 
60 --
40 --
2 0 - -
1C 12 R 
DAYS 
FIGURE 1. — Variations in daily ratios between urinary activity and plasma activity during meta­
bolic studies with "'[­labelled yG­globulin. In order to compare results from all subjects the 
daily values (F(¡) are expressed in percent of the average value (Fav) f ° r the whole period for 
each subject. The vertical lines indicate the standard error of the mean. 
protein will rapidly be taken up by the liver. If a denatured preparation has been 
used, plasma volume will be considerably greater determined with this, than with 
T­1824. 
INTRAVASCULAR CATABOLISM 
The metabolic parameters we are interested in are shown in Figure 2 : intra­
vascular mass, extravascular mass, rate of synthesis and fractional catabolic rate. 
The yG­globulin seems to be catabolized in connection with the intravascular mass. 
In our opinion, therefore, the catabolic rate should be related to the intravascular 
mass. The fractional catabolic rate denotes that fraction of the intravascular mass, 
which is catabolized daily. This parameter indicates how fast the protein is broken 
down after production. The reciprocal value of the fractional catabolic rate is the 
same as the mean life time for a protein molecule in the intravascular mass. 
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RATE OF SYNTHESIS 
( g r a m / d a y ) 
INTRAVASC. 
MASS 
EXTRAVASO. 
MASS 
FRACTIONAL 
CATABOLIC RATE 
(V. of i n t r a v a s c . m a s s / d a y ) 
FIGURE 2. — Model of the parameters of yG-globulin metabolism. Exchange of protein between 
intravascular and extravascular compartment is symbolized by k1 and k2, which reflects the 
capillary permeability and lymphatic flow rate, respectively. 
The yG-globulin has been considered to be broken down intravascularly because 
the activity excreted in the urine is a constant fraction of the plasma activity, even 
during the process of establishing equilibrium between extravascular and intra­
vascular labelled protein. But this is not quite the case. As mentioned previously 
the U/P ratio of activity is usually low the first day or two of the study and relative­
ly high the following days. Subsequently the fractions might be decreasing slightly. 
This pattern may be due either to extravascular degradation of the yG-globulin 
or to the effect of the iodide pool, if denaturation of the preparation can be excluded. 
In order to clarify these points a mathematical model which takes the iodide 
pool into account was used (Figure 3). The plasma curve is composed of a sum of 
Ρ 
k3 
E 
Ν f 
I 
k5 
υ 
FIGURE 3. — Metabolism of yG-globulin : Mathematical model which includes the iodide pool : 
Ρ = activity intravascularly. E = activity extravascularly. I = activity in iodide pool. 
U = activity excreted in the urine. k s = urinary excretion rate of iodide. 
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two or three exponentials. The form of the plasma curve is unaffected of the site 
of degradation. It is therefore possible to calculate the urinary excretion curve if 
1) the protein is assumed to be broken down intravascularly only or 2) the protein 
is assumed to be broken down extravascularly only (4). The excretion rate from the 
iodide pool, k5, is about 1.5 days -1 (5). 
These curves are shown in Figure 4 for normal subjects and in Figure 5 for 
patients with cirrhosis of the liver. It is apparent that the experimental data follow 
the theoretical curve for intravascular degradation very closely. It is seen that a 
slight fall in the U/P ratio is not greater than should be expected theoretically if 
the iodide pool is taken into account, indicating metabolic homogeneity of the 
labelled yG-globulin. 
■ 100 
Fav 
% 100 
DAYS 
FIGURE 4. — Theoretical ( ) and experimental ( · · ) variations in urinary 
excretion of activity in metabolic studies with 131I-yG-globulin. The experimental U/P ratios 
are calculated relatively (symbols as in Figure 1) from the results of 21 studies in normal 
subjects. 
These findings, of course, do not mean that yG-globulin is catabolized in 
the blood stream. In fact we know that incubation with blood or plasma has no 
effect on labelled yG-globulin. But these findings suggest that it is broken down 
at extravascular sites in so rapid exchange with plasma that the specific activity 
there is identical with that of plasma. 
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FIGURE 5. — Theoretical compared with experimental variations in U/P ratios in cirrhosis of the 
liver (Symbols as in Figure 4) 
CATABOLISM 
In recent years it has been shown that certain types of hypoproteinemia are 
caused by leakage of plasma proteins into the gastrointestinal tract and subsequent 
digestion by the intestinal enzymes. It has been suggested that the same mechanism 
may play a role for the catabolism of yG-globulin in normal subjects, because 
gammaglobulin has been found both in saliva and in gastric and intestinal juice. 
A couple of years ago we made an experimental study of the transfer of pro-
teinbound radioactivity from the plasma to the lumen of isolated intestinal segments 
in dogs <6). We calculated that an average of 40 % of gammaglobulin was broken 
down in the intestinal lumen. 
The intestinal segments were isolated between tape ligatures and then rinsed 
with saline through a thin Nelaton catheter. The question arises, of course, if the 
transfer of yG-globulin might be caused by the trauma from the surgical procedure. 
We have the following arguments in favour of the validity of our study : 
1. When a segment was subdivided with one more tape ligature the transfer 
rate of protein to the lumen of the gut was not increased. 
2. We found a significant correlation between the exchange rate (from plasma 
to extravascular compartments) and that fraction of the gammaglobulin which 
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was catabolized in the gut. These two parameters were determined independently in 
two different experiments. It is improbable, therefore, that the transfer we measured 
was artificial, because an artefact most likely would not be correlated to a physio-
logical parameter. 
3. In each experiment the rinsing was repeated from two to four times on each 
segment. The transfer rate was the same from time to time. It is unlikely that the 
rinsing or the surgical procedure should have damaged the mucosa. Otherwise the 
transfer rate would not have been constant. 
However, experiments of the above mentioned type is open to criticism of ob-
vious reasons. In addition, studies with 51Cr-labelled albumin show insignificant 
excretion of activity in feces of normals <7). The question of gastrointestinal degra-
dation in normal subjects has not been finally settled. The crucial experiment remains 
to be planned and carried out. 
Gammaglobulin might also be catabolized universally, for instance in connec-
tion with its function as an antibody. After combination with antigenic substances 
invading the body the antigen-antibody-complex should be catabolized after phago-
cytosis in the reticulo-endothelia! system. The following observation suggests that 
this mechanism is of little quantitative significance. 
In rabbits it is possible to produce high concentrations of gammaglobulin 
in serum by hyperimmunisation with a polyvalent pneumococci vaccine. The increase 
in gammaglobulin is due almost entirely to specific antibody. The synthetic rate 
of gammaglobulin increased from 0.5 to 4.3 grams/day while the fractional cata-
bolic rate was unchanged, 35 per cent of the intravascular mass per day (ln). Under 
the assumption that the increase in the synthetic rate is antibody against the pneu-
mococci, it is easy to calculate that each pneumococci must have stimulated the 
production of five thousand million antibody molecules. 
Even if each pneumococci was able to bind several millions antibody molecules 
under the formation of an antigen-antibody-complex, the production of antibody 
would be several thousand times greater than necessary to neutralize the injected 
pneumococci. 
Therefore, it is doubtful if gammaglobulin to any significant degree is catabo-
lized through an antigen-antibody-reaction. The catabolic mechanism is probably 
an unspecific process the nature of which we know little of. 
M E T A B O L I S M O F yc-GLOBULiN IN N O R M A L S 
In addition to the conditions previously mentioned two more have to be ful-
filled before results of turnover studies can be accepted : the subject must be in a 
metabolic steady state and a satisfactory mathematical model must be used for 
the calculations. 
The mathematical analysis is based on the assumption that the metabolic para-
meters are constant during the study. At present no satisfactory mathematical 
model exists with which it is possible to calculate all parameters under unsteady 
state conditions. It is necessary, therefore, to ensure that the subject is in a steady 
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state. We use the following criteria : 1) the weight of the patient must be constant 
during the study, 2) the concentration of the protein must be constant, 3) the plasma 
curve and the whole body curve must be parallel when the final slope is obtained. 
A satisfactory mathematical model should reflect the conditions in the body 
as close as possible. yG-globulin seems to be catabolized intravascularly. Several 
models take this into account <u ' 12). Alternatively can be used a model which is 
independent of the site of catabolism. The most general one has been developed 
by Nosslin (13). Previous models assume that extravascular protein is localized in 
one or two compartments. Nosslin's model operates with an infinity of extravascu­
lar compartments which may be interconnected in any possible way. The protein 
may be catabolized from any one or more compartments. The only basic assumption 
is that the protein from the protein producing cells should be released primarily 
to the blood stream. Nosslin's calculations are very simple. The fractional cata­
bolic rate is identical with the reciprocal value of the area under the plasma curve. 
The total body mass of the protein is related to the intravascular mass as the area 
under the whole body curve is related to the area under the plasma curve. 
In table I are shown the normal values for yG-globulin metabolism. The frac­
tional catabolic rate is about 7 %/day and the rate of synthesis is an average of 
TABLE I. — Metabolism of vG-globulin in 21 normal subjects 
Serum y-globulin (g/1) 
Plasma volume (1) 
Plasma pool (g) 
Total body pool (g) 
Fractional catabolic rate ( VJday) 
Rate of synthesis (g/day) 
Mean 
12.7 
2.8 
36 
69 
6.9 
2.5 
Range 
9.8-15.8 
1.9-3.7 
22-53 
42-104 
4.3-9.3 
1.4-4.0 
2.5 grams/day. These values are higher than those reported from other laboratories. 
This may be due to actual differences in the metabolism of yG-globulin in diffe­
rent populations. But it may also be due to errors in the measurements. One of the 
most frequent ones is insufficient urine collections. This error is difficult to control 
— unless whole body counting is employed — and until new evidence has been 
presented I am reluctant to accept values for a European population much lower 
than those we have found in Copenhagen. 
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DISCUSSION 
M. A. ROTHSCHILD (New York) : Do you believe that the catabolism in the 
gastrointestinal tract is related to specific process or may it represent the simple 
transudation of serum ? 
S. B. ANDERSEN : In experiments similar to ours other investigators have found 
transfer of 131I-labeled albumin to the lumen of intestinal segments. Even if this is 
not conclusive evidence that gastrointestinal loss of plasma protein takes place, 
I think that this suggests a bulk loss of serum. The gastrointestinal catabolism the-
refore should not be a specific process. 
G. MILHAUD (Paris) : How did you estimate the daily synthetic rate of gamma-
globulin ? 
S. B. ANDERSEN : The subject I studied was as far as I could judge in a meta-
bolic steady state. So when 1 know the fractional catabolic rate and the intravas-
cular mass then I know the synthesis rate also in g/day, because these two should 
be equal. 
L. O. PLANTIN (Stockholm) : With respect to the completeness of urine collec-
tion 1 would like to show the results from two investigations where there can be no 
question about incomplete urine collection. 
The first figure shows the turnover curves in a patient with cerebral hemor-
rhage. Urine was collected through a catheter "à demeure". We note that the frac-
tional catabolic rate (U/P ratio) is constant throughout the investigation period of 
60 days. The extravascular curve is far from parallel with the plasma curve and 
seems to be almost at a constant level and is still over 30 % of the given dose after 
60 days. 
The second figure shows the turnover in a healthy male, who was injected with 
131I-gammaglobulin and where in addition to urine collection whole body measure-
ments were made for over 50 days. In this case we obtain parallel curves for extra-
vascular and plasma activity. The retained dose curve, obtained in the usual way 
by subtracting urine excretion from the given dose, is very close to the whole 
body curve. The difference can be explained by loss of some iodide activity through 
the sweat. These two results suggest that there can and must be some other expla-
nation to deviating plasma and extravascular curves than incomplete urine collec-
tion. I would also like to ask if Dr. Andersen's whole body curves were obtained 
by actual whole body measurements or by calculations from the urine excretion. 
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$ 2 DISCUSSION 
T. FREEMAN (London) : I have a comment in connection with this question. 
Measuring both total body counting and urine activities we quite frequently have 
found a discrepancy between these two. In some of these instances we think we 
have collected all the urine, so loss of activity must be by some other ways, but we 
could find no evidence of this in feces or sweat. 
Concerning gammaglobulin catabolism in hypergammaglobulinemia, I have 
had different results from Dr. Andersen, in that those patients we have studied 
with a high gammaglobulin concentration have had increased gammaglobulin 
catabolism. Many of these were patients with myeloma, and this may be a special 
case but it was also found in hypergammaglobulinemia from other causes. 
In relation to the gastrointestinal tract as a site for catabolism of gammaglo-
bulin and other plasma proteins, 1 would like to point out that Waldman's work 
with chromium labeled albumin and copper labeled ceruloplasmin is against this. 
Both these proteins when given by mouth can be recovered quantitatively in the 
feces, however if they are given intravenously little or no activity can be found 
in the stool, in spite of the fact that they can survive in the blood stream for several 
days. 
S. B. ANDERSEN : There may be two explanations for deviating retained curve 
and plasma curve if the curve of retained dose is calculated from the urine excre-
tions of activity : 1) insufficient collections of excreted activity, 2) the subject is not 
in a steady state condition. 
In the first case the insufficient collection of excreted activity may be due to 
incomplete urine collection or to loss of activity by other routes than urine (or 
feces). These other routes may be sweat. Even in a climate as cold as in Denmark 
this may account for significant amounts. I have studied the excretion of iodide 
in myself being sure that the urine collections were complete. I could only account 
for about 95 % of the injected dose. Nothing was retained in the body as controlled 
by total body counting. This shows that even if you have a complete urine collec-
tion you may very well have an insufficient collection of excreted activity. It is there-
fore important to control the results by total body counting. 
The other possibility that Dr. Plantin's patient was in an unsteady state is 
not quite improbable considering the disease of the patient. Both possibilities might 
play a rôle for the finding of deviating curves. As answer to Dr. Plantin's last question 
I can inform that our results from the last two years have been controlled by total 
body counting. 
As for Dr. Freeman's comment on hypergammaglobulinemia 1 do not quite 
agree. In 21 patients with cirrhosis of the liver the fractional catabolic rate was 
increased in five only, four of which were treated with 30-60 mg of prednisone daily. 
These findings show that the fractional catabolic rate in hypergammaglobulinemia 
due to liver cirrhosis most often is within normal limits. In patients with parapro-
teinemia fractional catabolic rate was increased in four out of fifteen. Three of 
these had myeloma in a very advanced stage. They died within 2 months of the 
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study. These observations show that the fractional catabolic rate in hypergamma-
globulinemia due to paraproteinemia most often also is within normal limits. 
Concerning Dr. Freeman's comment on the gastrointestinal tract as a site for 
catabolism of gammaglobulin and possibly other plasma proteins 1 fully agree with 
him that we have no conclusive evidence for this. On the other hand Dr. Waldman's 
finding with 51Cr-labeled albumin may not reflect the true conditions. We know 
that 51Cr-labeled albumin is denatured and that denatured proteins are taken up 
by reticulo-endothelial cells. The low fecal excretion of 51Cr after intravenous injec-
tion might then be due to the fact that reticulo-endothelial cells in the gastrointestinal 
mucosa took up the molecules of 51Cr-labeled albumin during the passage from 
the blood stream to the lumen of the gut. There is some evidence for this conception. 
Dr. Wetterfors has shown in irrigation experiments with dog intestines that 51Cr-
labeled albumin passes more slowly from the blood to the lumen of the gut than to 
131I-labeled albumin. Of course other explanations than phagocytosis by reticulo-
endothelial cells might explain this finding. 
Y. COHEN (Paris) : J'ai été très intéressé par la communication du Dr. Andersen 
et je voudrais lui poser la question suivante : A-t-il une idée de la localisation dans 
l'intestin de la zone de dégradation de la gammaglobuline, soit au niveau cellulaire 
(glandes de Liberkuhn, cellules de Panetti, cellules à plateau strié), soit dans les 
voies lymphatiques ou les plaques de Peyer, etc.. 
S. B. ANDERSEN : l imagine that the intestinal catabolism of gammaglobulin 
occurs in the lumen of the gut under the influence of intestinal proteolytic enzymes. 
After passage through the capillary wall the protein may pass between the epithelial 
cells of the mucosa. This has not been shown in normal subjects. But in patients 
suffering from protein losing gastroenteropathy electron microscopy has shown 
spaces between the epithelial cells suggesting that something is passing. If the same 
took place — on a smaller scale — in normal subjects we had an explanation of the 
route of transfer of gammaglobulin from the blood stream to the lumen of the gut. 
P. DYKES (Birmingham) : Elevation of the fractional catabolic rate on the 
second and third days after injection might well be explained by catabolism not 
from a space in immediate juxtaposition with the plasma, but from a space which 
equilibrates with a transfer half time of about 24 hours. In kinetic studies such an 
early compartment exists and probably represents the liver and viscera. 
S. B. ANDERSEN : I have never calculated the variations in fractional catabolic 
rate under the assumption that the gammaglobulin is catabolized in an extravas-
cular compartment with a transfer half time of 24 hours. This would correspond 
to a transfer rate of about 0.7 day -1, a value which is not negligible compared to a 
fractional catabolic rate of almost 0.1 day -1. This means that the specific activity 
of the protein in this hypothetical compartment would definitely be different from 
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the specific activity of the protein in plasma. If I interpret my results correctly the 
catabolism of gammaglobulin should take place in a place in so rapid exchange 
with plasma that the specific activities are identical. Therefore I believe that the 
catabolism of gammaglobulin takes place in a much more rapidly mixing compart-
ment than the one suggested by you. 
THE USE OF "'[­FIBRINOGEN FOR IN VIVO STUDIES 
E. REGOECZI 
National Institute for Medical Research, 
Mill Hill, London, N. W. 7. Great Britain 
ABSTRACT 
Iodinated fibrinogen can be very useful in various in vivo fields of work, such 
as in measuring turnover rates in health and disease, in experimental coagulation 
research (to test the effect of various substances on the coagulability of the blood), 
and in diagnosis (for instance of malignant tumours). 
In the present communication results are reviewed concerning the metabolism 
and distribution of fibrinogen in humans, rabbits and dogs. Various considerations 
are discussed which suggest that masses of fibrinogen catabolized daily per unit 
body wt. are proportional to fibrinogen concentration. Some possible mechanisms 
for this are discussed. 
Several technical criteria for obtaining reliable results with iodine­labelled 
fibrinogen in vivo are outlined. The purification of the protein should be carried out 
quickly and by gentle means and it should be subsequently iodinated at very low 
iodine substitution values. An upper limit for substitution using the iodine mono­
chloride method is set at a mean of 0.5 atoms iodine per molecule of fibrinogen. 
The significance of the body iodide parameters in interpreting in vivo results are 
also pointed out. 
Of the various labelled plasma proteins which have been introduced in recent 
years into biological research, fibrinogen appears to be a particularly interesting 
one because of its specific rôle in blood coagulation. 
Although I27l­fibrinogen was produced and its physicochemical properties 
were investigated by Laki and Steiner u ) as early as 1952, several years elapsed 
before the first attempts were made to carry out in vivo studies with this protein 
labelled with radioactive iodine. Some of the pioneer work <2) seems nowadays 
to be of more or less historical value only, and the beginning of fundamental deve­
lopments dates back not further than 1963, i.e. when McFarlane ,3) described the 
criteria under which the iodine label can be introduced into fibrinogen without 
seriously altering its in vivo behaviour. The work done in this field is still relatively 
small compared with that done on other proteins (e.g. albumin or γ­globulin) and 
available results are difficult to interpret because of the variety of techniques used. 
In the general picture of labelled fibrinogen, which is presented below, emphasis 
has been given to basic technical considerations and numerous matters which still 
require clarification are discussed. 
FIBRINOGEN TURNOVER IN NORMAL HUMANS. 
Relevant data obtained by different workers using ]3,l­fibrinogen are summa­
rized in Table I. 
TABLE I. — 13II-Fibrinogen Metabolism in Normal Humans 
oo 
Reference 
Christensen t') 
(1958) 
Adelson et al. (5) 
McFarlane et al. ("> 
(1964) 
Amris and Amris <7> 
(1964) 
Zetterqvist et al. <"> 
(1964) 
No. 
of cases 
A 
8 
3 
10 
3 
9 
Source 
of 
Fibrinogen 
B 
commercial 
(Cohn Fr. I ?) 
labelled whole 
plasma 
(NH 4) 2S0 4 ppf. 
commercial 
("Kabi") 
Bombäck 's 
Iodine : 
protein 
ratios 
C 
? 
7 
0.5 
0.3-1.0 
1.5 
Biol, half-
life 
(days) 
D 
4.3 
(4.0-4.7) 
2.3 
(1.5-3.0) 
3.1 
(2.1-3.8) 
4.2 
(4.2-4.3) 
4.4/, 4.7'» 
(3.8-6.1) 
Intravascular 
fraction 
V 
/o 
E 
50 
7 
75 
(60-90) 
82 
(75-90) 
7 
Fractional 
catabolic 
rate 
F 
32 
7 
31 
(25-37) 
21 
(19-23) 
7 
Absolute 
catabolic 
rate 
G 
7 
7 
46 
(31-63) 
33 
(17-62) 
7 
C = Iodine atoms incorporated per fibrinogen molecule. 
D = Average biological half-lives measured over single exponential sections of intravascular activity curves and the figures in brackets show the range 
of variation. Indices /and m in Zetterqvist's data denote mean values for the sexes. 
E = Intravascular fibrinogen pool is expressed as fraction of total body fibrinogen. 
F = Per cent intravascular pool broken down per day. 
G = mg fibrinogen catabolised per day per kg body weight. 
C 
c 
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N 
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There is clearly a wide scatter in the results and in some cases important rele­
vant information is not available. Until more results are forthcoming one should 
not be too discouraged even where, as in the data by Adelson and co-workers, 
biological half-lives were only one half of the values given by Zetterqvist et al. How­
ever, discrepancies of this order inevitably pose the question whether the different 
methods of preparing and iodinating fibrinogen for metabolic purposes are fully 
comparable and this is considered further below. 
From McFarlane's and Amris' data in Column G of Table I it follows that 
normal subjects catabolize on an average 43 mg fibrinogen/day/kg body wt. This 
is based on altogether 13 observations, and because of the fluctuating levels of plasma 
fibrinogen it is important that the number of these investigations should be enlarged 
in order to facilitate statistical analysis of the physiological range of fibrinogen 
catabolism. A typical experiment from McFarlane's collection is shown in Figure 1. 
FIGURE 1. — Catabolism of 131I-fibrinogen in a normal human. Catabolic rates (lower diagram) 
are urine radioactivities expressed as percentage of the mean protein-bound radioactivity in 
the plasma (o) for each collection period. Total body radioactivities(Δ) were calculated from 
the cumulative excretion of the dose. 
FIBRINOGEN METABOLISM IN LABORATORY ANIMALS. 
Two sets of experimental data each from normal dogs and rabbits are shown 
in Table II. They reflect satisfactory reproducibility within a species, and also a 
similar general pattern of fibrinogen turnover in the two species. Unfortunately, 
values for absolute catabolic rates in the dog experiments were not calculated. 
Since, however, the concentration of plasma fibrinogen in the dog <12) is similar 
to that in rabbits, it seems justified to assume that absolute catabolic rates in dogs 
and rabbits are essentially the same. Moreover, a comparison of corresponding 
values in Tables I and II suggests that, on a basis of body weight, the absolute amount 
of fibrinogen catabolized per kg of human is very similar in magnitude to that in 
adult rabbits and possibly in the dog as well. Incidentally, most of the data under­
lying the above deduction were obtained using salt-precipitated [(NH4)2S04] fibri­
nogen which appears to give more reproducible results. 
E. REGOECZI 
TABLE II. — u lI-Fibrinogen Turnover in Dogs (D) and Rabbits (R) 
Reference 
Lewis et al. <9> 
(1961) 
Adelson et al. (5) 
(1961) 
Regoeczi et al. ("') 
(1964) 
Atencio and Reeve <"> 
(1965) 
Species 
D 
D 
R 
R 
No. 
of 
cases 
A 
20 
4 
25 
(52/+20«) 
14 
(72/ + 7°) 
Biol, half-
life 
(days) 
D 
2.4 
(1.8-3.1) 
2.3 
(1.7-3.0) 
2.7 
(2.1-3.5) 
2.VJ, 2.40 
(2.0-2.7) 
Intravas-
cular 
fraction 
(%) 
E 
66 
75« 
79 
(65-85) 
572/, 760 
(48-85) 
Fractional 
catabolic 
rate 
F 
42« 
40« 
34 
(25-43) 
442/370 
(28-53) 
Absolute 
catabolic 
rate 
G 
7 
9 
41 
(18-63) 
502/, 380 
(31-73) 
For (D), (E), (F), and (G) see Table I. Indices y and o refer to values obtained in young and 
older animals respectively. 
" These approximate figures are not contained in the original papers but were calculated from 
graphs or data given in their publications. 
The half-life of 131l-labelled fibrinogen in rats has been reported to be 1.2 
days (13). 
KINETIC CONSIDERATIONS. 
Christensen (4) observed that whereas the prevailing plasma fibrinogen concen-
tration in several healthy humans varied greatly nevertheless the biological half-
life of 131I-fibrinogen was remarkably constant. In view of a possible significance 
which this phenomenon might have in relation to the mechanism of fibrinogen meta-
bolism, Regoeczi et al. (14) compared the behaviour of biologically screened <15) 
labelled fibrinogen in the same animals before and after artificially increasing the 
pool size by means of bacterial endotoxin injections. They found that whereas 
131I-specific activities of circulating fibrinogen fell sharply after the injection with 
increasing pool sizes yet the slopes of the protein-bound radioactivity per unit volume 
of plasma either remained unchanged or became only slightly accelerated. In addi-
tion it is a matter of common experience with fibrinogen that those considerable 
fluctuations of the pool size which occur under "physiological" conditions (possi-
bly accentuated by minor injuries and excitement due to blood sampling and hand-
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ling) do not coincide with any substantial changes in the radioactivity curves. 
Thus plots of specific activities on the one hand and protein-bound activities per 
ml of plasma on the other can be divergent in the case of fibrinogen in a way which 
is never observed with iodinated albumin. 
These observations point to a considerable constancy in the fractional cata-
bolic rate of fibrinogen, and this appears to hold over a wide range irrespective 
of the size of the fibrinogen pool. The available data indicate, therefore, that fibri-
nogen catabolism is a first-order kinetic process (s ' 10), although the underlying 
mechanism by which this is achieved is not at all clear. 
Relationships between concentration and catabolism of various plasma pro-
teins have been established by numerous investigators and Freeman (16> has reviewed 
their data in addition to his own. He concludes that fractional catabolic rates can 
be related either directly or inversely to protein concentrations, e.g. albumin and 
Ycrglobulin a r e directly related and haptoglobin and transferrin inversely. Fibri-
nogen with its fractional catabolic rate showing no significant dependence on pro-
tein concentration does not fit into either category, and it must be assumed to have 
a different normal catabolic pathway. 
INTERSTITIAL FIBRINOGEN. 
The presence of fibrinogen in the extravascular space has been known for some 
time <17), but until recently quantitative assessments were subject to controversy. 
As discussed further below, partial denaturation of the fibrinogen molecule in the 
course of purifying the protein or iodinating it greatly reduces the reliability of the 
labelled fibrinogen as an indicator of the distribution of the native protein (3). Impro-
ved labelled proteins is the most likely explanation for the remarkable apparent 
shrinkage of extravascular fibrinogen pool values from 50-85 % of the total body 
fibrinogen a few years ago to 15-35 % in the most recent literature. 
ntercepts : A = 7 7 % 
B = 59°/b 
C=66°/o 
FIGURE 2. — Variations in the ¡ntra/extravascular distribution ratios of fibrinogen in three rabbits 
(2.79-3.04 kg body wt.) as indicated by the extrapolation value of the mI-fibrinogen curves. 
Each animal was injected with an aliquot of the same batch of labelled material. 
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Using 131I­fibrinogen which was prepared under certain conditions (Cf. below) 
most of the intravascular radioactivity curves in adult humans and rabbits extra­
polate at zero time to 70­80 % of the administered dose, but deviations in both 
directions are not uncommon (Cf. Figure 2). Results obtained by Atencio and 
Reeve ( l l ) in rabbits of two different age groups suggest that the ratio of intra­ to 
extravascular fibrinogen increases with the age of the animal (Cf. Table ΙΓ). 
Intravenously injected labelled fibrinogen equilibrates with the extravascular 
compartment in a noticeably shorter time than does albumin. The single exponen­
tial slope of intravascular fibrinogen is reached in humans (6· 18) within 2 days and 
in dogs (5> 9) and rabbits (10· U) in 24­36 hours, in spite of the fact that considerably 
more albumin than fibrinogen is being transferred across the capillary wall. (The 
ratio of the two fluxes in the rabbit is about 2:1 calculated as fractions of the i.v. 
pool and 27:1 in terms of protein masses.) Calculations also showed that the mean 
transit time of 99 % of the fibrinogen molecules within the extravascular compart­
ment is only half that of albumin ( " · l 9 ) . 
These results show that the fluid extravascular space which is accessible to 
fibrinogen is considerably smaller than to other plasma proteins, but is approxi­
mately of the same order as that presented to other non­protein macromole­
cules <20·2". Many other observations, for example the distribution of fibrinogen 
in tissues as revealed by means of fluorescent antibodies (l7), and analyses of lymph 
from different regions (22), all support this conclusion. Furthermore, it is possible — 
and indeed some unpublished results by McFarlane strongly uphold this view — 
that the interstitial distribution of this protein is not uniform, muscle lymph in 
particular having little or no fibrinogen. Clearly a comprehensive and quantitative 
histo­anatomical description of the interstitial fibrinogen pool is still required. 
THEORIES OF THE NORMAL CATABOLISM OF FIBRINOGEN. 
Fibrin deposits are known to play an important rôle in the pathology of athe­
rosclerosis (23), and in view of the rapid turnover of coagulation factors it has also 
been suggested that fibrin would be essential for the maintenance of the integrity 
of the vascular endothelium (24). This interesting hypothesis was given a dynamic 
aspect in 1956 by Astrup (25) who claimed that continuous formation and lysis of 
fibrin films proceeds on the surface of vessels under physiological conditions. Since 
then a number of experiments which were designed to identify a possible mechanism 
for this in fact gave results which are not wholly in favour of its existence. The tur­
nover of 131l­fibrinogen is not affected by heparinisation (9) nor by experimental 
hypoprothrombinæmia produced by coumarin dérivâtes (3· 5 · 9 ) . Platelet survival 
is greatly altered in hypo­ and hypercoagulable states, but without reference to the 
behaviour of fibrinogen <5). In patients with haemophilia A ( 8 · 2 6 ) (classical haemo­
philia, Factor VIH deficiency), or hypoproconvertinæmia <8) (Factor VII defi­
ciency) or von Willebrand's disease '8) the fractional catabolic rate was essentially 
the same as in subjects with normal coagulation of blood. Similarly, antifibrino­
lytic treatment also does not seem to delay the in vivo breakdown of labelled fibri­
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nogen (l3,27-29>. For these reasons, the widely shared view today is that even if some 
fibrinogen is steadily converted into fibrin in healthy subjects, the proportion which 
this represents of the total catabolized fibrinogen is insignificant. 
In the author's opinion, the normal degradation of fibrinogen is most likely 
to take place during transcapillary transport of fibrinogen, so that breakdown 
occurs either entirely within the vascular endothelium or is at least initiated there. 
This concept emerges from a simple consideration, namely that fibrinogen while 
moving through the endothelial cells must face a unique exposure to enzymic action, 
partly because of the pronounced tendency of plasminogen to complex with fibrin­
ogen (30) and partly because the activator of plasminogen is localized to the vas­
cular endothelium (31-34>. Thus, the fibrinogen molecule as it leaves the capillary 
system can be visualized in a greatly simplified form as a substrate-proenzyme 
complex passing through a barrier of the activator. Unlike the situation in the kidney 
where electronmicroscopic evidence supports the existence of pores in the glome­
rular capillaries it is believed that in other organs transmitted substances must 
pass through the endothelial cytoplasm (cytopempsis) (35). It is conceivable that 
under these favourable conditions, all three substances being brought together 
within the same cell, plasminogen activation with subsequent destruction of the 
"attached" fibrinogen occurs, and is responsible for the phenomenon of "cata­
bolism". 
This theory would provide an acceptable explanation for the first order kinetic 
nature of fibrinogen catabolism (Cf. above), but it could not explain the apparent 
ineffectiveness of epsilon aminocaproic acid on normal fibrinogen turnover. 
TECHNICAL CONSIDERATIONS 
Fibrinogen in our experience is more susceptible to denaturation changes 
during iodination than is albumin and in this connection it would be helpful to 
know of the experiences of others. Some points which are regarded as important 
in our laboratory will be discussed briefly below. 
PREPARATION AND IODINATION OF FIBRINOGEN. 
A fibrinogen preparation for metabolic purposes should be at least 90 % clot-
table in terms of protein-bound radioactivity. The use of partially purified materials, 
for example with clottabilities ranging from 50 to 70 %, has repeatedly been des­
cribed and the disadvantages of this were thought to have been overcome by mea­
suring only clot radioactivities in the samples. However, neither total body nor 
urinary activities can have any unequivocal meaning in such an experiment in which 
a contaminated similarly labelled protein, usually γ-globulin, is present. Moreover, 
unavoidable occlusion of other (radioactive) proteins (36·37· 38> in the clot may 
give rise to additional errors. 
Fibronogen better than 90 % pure can be prepared by a number of methods 
and the residual non-clottable materials may be classified as (a) non-specific con-
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taminants, i.e. proteins not involved in coagulation, (b) specific contaminants, and 
(c) occasionally some denatured incoagulable fibrinogen. Since this large molecule 
is readily denatured, we prefer to prepare the protein immediately before iodination 
and to carry out the latter procedure as quickly as possible — for example avoiding 
prolonged dialysis. Contact with organic solvents should also be avoided but repea-
ted precipitations using ammonium sulphate in decreasing (from 25 to 20 %) satu-
rations <31 appears to cause no damage. Labelled fibrinogen prepared in this way 
and injected into rabbits showed no signs of denaturation and circulating protein-
bound radioactivities were 94-98 % clottable with thrombin (39). 
Fibrinogen prepared by almost any method contains plasminogen, and fur-
ther investigations are required to decide whether this may have implications for 
turnover studies. The difficulties of obtaining a plasminogen-free fibrinogen which 
could be used for comparison are well known. Plasminogen can be removed by 
Mosesson's procedure (40) but judged by the low solubility of the final product 
the method appears to be somewhat drastic for subsequent in vivo purposes. The 
method proposed by Brakman (41) is milder but unfortunately is not completely 
satisfactory with human material. 
Mosesson and Finlayson f42-44) have recently shown that purified fibrinogen 
can be subfractionated on DEAE-cellulose and this may prove to have metabolic 
implications. However, we feel — perhaps without a good experimental basis — 
that the use of fibrinogen prepared by adsorption procedures for subsequent iodi-
nation purposes is dangerous. 
The crucial point in iodinating fibrinogen is that as shown by McFarlane <3> 
this protein cannot be associated with more than 0.5 atoms of iodine per molecule 
of fibrinogen without essentially altering its in vivo behaviour relatively to that 
of the biosynthetic carbon-labelled protein. Using ratios higher than this, certain 
fractions of the injected material are removed from the circulation by rapid initial 
catabolism, giving rise — as already mentioned — to overestimates of the size of 
the extravascular fibrinogen pool. The validity of this critical 0.5 level has fully 
been confirmed by other investigators ("· l9). Preparations iodinated at even lower 
rates have been claimed by Atencio et al. (l9) to behave in vivo indistinguishably 
from the 0.5-atom fibrinogen. 
Iodination ratios must of course be visualized as mean values for the random 
distribution of the label in a population of protein molecules with a given number 
of reactive sites. Relevant calculations using Oncley's data '45) show that after iodi-
nating at a mean value of 0.5 atoms, about 62 % of the protein is labelled with 
1 atom, about 30 % with 2 and the remaining 8 % with 3 or 4 atoms of iodine. How-
ever, working at a mean value of 2.0 the proportion of the molecules with more than 
one atom becomes much higher, now only 13 % being tagged with 1, 28 % with 2, 
another 28 % with 3-and about 30 % with 4 to 7 atoms of iodine. Whereas when 
albumin is "multi-iodinated" within reasonable limits in this way, it still behaves 
normally in vivo, but fibrinogen is clearly "over-iodinated". 
Finally, it seems worth mentioning that the recommanded upper iodination 
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ratio of 0.5 is in sensu stricto only 0.25, the fibrinogen molecule being most probably 
a dimer (46). Since at a mean value of 0.25 atoms about 80 % of the labelling is with 
1 atom iodine, 19 % with 2 and only 1 % with more than two, the biological con-
clusion seems to be that fibrinogen molecules having more than two atoms of iodine 
are recognizably different in the body from the native protein. 
DETECTING DENATURED LABELLED MATERIAL. 
Evidence for the presence of such material can be obtained by observing the 
behaviour of 
a) intravascular non-precipitable radioactivities. 
b) urinary excretion of the liberated label. 
c) slope of the total body activity curves, 
— especially by comparing the values measured over the first 48 hours with those 
obtained during the rest of the experiment (3, 47). 
A low extrapolation value of the intravascular protein-bound radioactivity 
curve at zero time alone does not necessarily indicate a bad preparation because 
of the physiological variations in the pool ratios (Figure 2). 
The question, whether the in vivo behaviour of an iodinated fibrinogen prepa-
ration can be predicted on the basis of comparative clottability measurements before 
and after iodination, has to be left open until evidence is obtained that losses in 
clottability and the extent of denaturation in biological sense are proportional. 
To evaluate various methods of preparing fibrinogen for labelling, the prepa-
rations should be compared in the same animal at the same time using different 
labels. Figure 3 shows that minor alterations may otherwise remain undetectable.. 
5 
— 
I - fibrinogen 
(noli»«) 
FIGURE 3. — The in vivo behaviour of labelled fibrinogen after freeze-drying. A preparation was 
divided into two and each labelled with a different iodine isotope and then one aliquot was 
freeze-dried. The curves obtained after injecting a mixture of both showed that about 6-7 %, 
of the freezed-dried material has been removed by rapid initial catabolism. Thereafter the slopes 
were identical. 
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IODIDE PARAMETERS AND FIBRINOGEN TURNOVER. 
For a given renal excretion rate of inactive iodide the amount of non­precipi­
table plasma radioactivity (measured conventionally as a fraction of the total radio­
activity in the sample) is substantially higher during fibrinogen turnover than in 
studies with albumin, because of its faster catabolic rate. Therefore, e.g. "TCA­
values" which in rabbits are usually below 1 % 24 hours after injecting albumin, are 
in the case of fibrinogen normally 1.5­2.5 %. 
FIGURE 4. — Atypical ]31I­fibrinogen turnover : Fluctuating total body radioactivity in a rabbit 
( Δ ) with intercurrent urinary infection (unsterile catheter). Non­precipitable radioactivities 
in the plasma (lower diagram) were also elevated and their absolute values multiplied by the 
131I­iodide space factor provided a means of obtaining a more satisfactory curve for the total 
body protein­bound radioactivity (LJ). 
FIGURE 5. — Plasma protein­bound ( c ) and total body ( Δ ) radioactivities in a rabbit after i.v. 
injection of 2.5 nig 131I­fibrin. This was separated from a spontaneously clotted labelled fibri­
nogen preparation and was solubilized in a minimal amount of urea for injection. The discre­
pancy between the.disappearance rates of this material from the plasma and the body is ob­
bious. The amounts of retained liberated label in the body were calculated as explained in 
Figure 4 and the values thus obtained ( □ ) show that throughout the whole experiment prac­
tically all protein­bound radioactivity has been retained in the intravascular compartment. 
The arrows indicate injections of 1 g epsilon aminocaproic acid. 
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Indeed, situations not infrequently arise with fibrinogen in which rates of 131I­
liberation from the protein greatly exceed the rates of excretion, thus giving rise 
to underestimates of catabolic rates. Thus activity may accumulate because of a 
renal defect in iodide excretion or because of a greatly accelerated liberation, for 
example in any condition in which a significant portion of the labelled fibrinogen 
is converted to fibrin in the body (Figures 4 and 5). 
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DISCUSSION 
L. DONATO (Pisa) : After the work reported this morning by Dr. Rosa, it seems 
to me that we can safely state that at the same iodination degree quite different 
distributions of iodine within and between the molecules can take place. The vali-
dity of approximating this latter distribution on the basis of the Oncley's binomial 
equation is therefore questionable. 
E. REGOECZI : McFarlane found by animal test using his ICI method that above 
a mean of 0.6 atom of iodine considerable proportions of denaturated fibrinogen 
were present. We have no means of ascertaining whether this arose from random 
or non-random distribution of the label. The experimental error in McFarlane's 
comparison between 131I-and 14C-labeled proteins also cannot be stated precisely 
but probably did not exceed ± 5 %. 
1 agree with Prof. Donato that Dr. Rosa's electrolytic method may in prin-
ciple give more uniform distribution of the iodine and if it does then it may be pos-
sible to agree on a higher permissible mean level of iodine substitution. However,. 
it seems to me that this must be demonstrated by in vivo methods. 
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OF PLASMA PROTEIN METABOLISM (*) 
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ABSTRACT 
The metabolism of albumin and γ­globulin has been studied using proteins 
labeled with 131I. The balance between serum protein degradation and synthesis has 
been altered in an attempt to determine the reaction of each to various stimuli. 
Albumin degradation is increased following the administration of exogenous adreno­
cortical and thyroid hormones, and in the presence of an elevated albumin pool 
following albumin infusions. Albumin degradation is depressed when the serum 
albumin level and/or pool size are low. In contrast albumin synthesis is not sensitive 
to low levels of serum albumin per se but is capable of significant increments upon 
the administration of adrenocortical and thyroid hormones. Albumin synthesis is 
depressed in the presence of increased colloids other than albumin. 
Gammaglobulin degradation is elevated when the pool size is increased during 
hyperimmunization but is unaltered during cortisone administration. Gammaglobulin 
synthesis is not stimulated by cortisone but is capable of marked increments following 
an appropriate antigenic stimulation. 
Serum protein degradation appears to be related to the concentration of the 
protein, or to the pool size or both. In vitro incubation and perfusion studies indicated 
that while many tissues possess the potential for degradation of the serum proteins 
the accessibility to a degradative site may play a limiting rôle. 
The synthetic mechanism is not related to pool size or concentration nor are 
degradation and synthesis interdependent. A colloid osmotic mechanism affecting 
control by regulating albumin synthesis is postulated. 
Significant advances have been made in the field of protein metabolism through 
the use of labeled proteins to study endogenous protein turnover. This discussion 
shall be limited primarily to the use of the iodine label for this technique has a unique 
advantage based upon the fact that in the absence of thyroidal accumulation of 
iodide released from degraded protein there is quantitative excretion of these pro­
ducts of degradation in the urine α · 3 ) . Before reviewing some of the experimental 
data a closer view of the method is important. 
The labeled protein must be metabolically indistinguishable from native pro­
tein ,4) (Figure 1). Heavy iodination (5' 6), exposure to excessive radiation (7>, and 
(*) Supported in part by United States Public Health Service Grant AM­02489. 
100 Μ. Α. ROTHSCHILD, M. ORATZ AND S. S. SCHREIBER 
1. Labeled protein indistinguishable from native protein. 
2. Label not reutilized. 
3. "Iodide" release reflects degradation. 
4. Excretion of "iodide" very rapid in comparison to degradation. 
5. Protein distribution between intravascular and extravascular spaces rapid in comparison 
to degradation. 
6. Excretion of "iodide" parallels intravascular distribution of labeled protein. 
FIGURE 1. — Important factors in the use of 131I labeled proteins 
significant denaturation during separation must be avoided <8). The label, once 
removed must not be reutilized or reincorporated and be quantitatively excreted 
<6). As pointed out by Hughes <e), there is no evidence for exchange between cold 
12"I-labeled protein and 131-iodide and it has been clearly shown that the turnover 
of 131I-labeIed albumin and globulin parallels the metabolism of 14C endogenously 
labeled proteins (1). Furthermore these studies add support to the concept that 
simple deiodination does not occur and in vitro studies have repeatedly failed to 
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FIGURE 2. — 131I-albumin metabolism 
Sample set of curves for a typical rabbit experiment. Curve I. Distribution curve. 
Curve II. Plasma concentration. Curve III. Urinary excretion (See text) (5>. 
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reveal any significant release of non precipitable material when incubated with tissue 
homogenates and thus while degradation did not occur neither did simple deiodi-
nation (9). In other studies Beeken employing subcellular fractions has demons­
trated equivalent rates of release of tyrosine or peptides and non precipitable 131I<10). 
So far we have mentioned only basic properties of the label. Now there are 
three main physiological principles which are also vital to the proper interpretation 
of turnover data employing the iodine tag. Berson, Yalow, Reeve, Lewellin, 
McFarlane, Matthews, Campbell and Freeman <n·19' among others have described 
detailed mathematical approaches fox the evaluation of such data and these factors 
have been stressed. First the excretion of the products of degradation are rapid in 
comparison to degradation so that the latter becomes the rate limiting factor (2, 
4 '5). Second—distribution between intravascular and extravascular areas is also extre­
mely rapid in comparison to degradation — the intravascular pool equilibrating 
with the extravascular pools at rates with half times of a few hours to a day whereas 
degradation is normally described with a half time of many days (2~4· 5"7' n"19).Third, 
the excretion of the label parallels the concentration in the plasma, and not that 
in extracellular sites (11). 
A sample set of curves that would be obtained in an ideal metabolic study in 
a rabbit are shown in Figure 2 (δ). Curve II is the raw plasma data plotted as % 
dose/100 ml and Curve III represents the daily urinary excretion. If the plasma 
curve is corrected for the amount of tracer excreted per day then Curve 1 is derived. 
After a few days all change in this curve can be accounted for by excretion indicating 
that loss from the plasma due to continued expansion of the 131l-albumin into a 
larger volume has been completed and thus if this curve remains horizontal then 
distribution equilibrium has been achieved. Employing this iodine label there are 
three individual methods for the calculation of protein degradation. One is to use 
the raw plasma data deriving the rate of metabolism from the slope of a plasma 
decay curve <3). The second is to rely on the rate of urinary excretion of breakdown 
products l l l ), and the third is to relate, in some fashion, the daily urinary excretion 
to the mean plasma concentration for that day (13· 20). This maybe called the clea­
rance procedure (Figure 3). The renal clearance of plasma iodide is determined 
from the quotient of the urinary excretion on any day and the mean plasma concen­
tration for that day. The product of this value and the mean serum protein concen­
tration results in a value for protein degradation. Such a procedure is independent 
1. Renal clearance 
ml/day 
2. Metabolic clearance 
g/day 
Urinary excretion fi.c/day 
Plasma concentration μΰ/ιτιΐ 
Renal clearance X Plasma albumin 
ml/day g/ml 
FIGURE 3. — Methods for determining metabolic clearance (30) 
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of pool size measurements (17) and thus valid in non-steady states. Many modifi­
cations of the basic method of calculation have been proposed. Suffice it to say 
that in steady state conditions all methods agree and in the non-steady state all 
methods that relate the daily plasma activity to the urinary excretion also result 
in values for the amount of protein metabolized which are in good agreement with 
each other. In terms of measuring synthesis, a convenient procedure is to remeasure 
the protein pool size by means of a 2nd injection (Figure 4). Following the initial 
injection and an appropriate control period, experimental procedures are instituted 
A L B U M I N I 1 3 1 
CONTROL 
A L B U M I N I 1 3 1 
EXPERIMENTAL 
TOTAL EXCHANGEABLE 
ALBUMIN 
ALBUMIN DEGRADATION 
SYNTHESIS 
ALBUMIN 
DEGRADATION 
TOTAL EXCHANGEABLE 
ALBUMIN 
CHANGE IN ALBUMIN SYNTHESIS = ITEAE - TEAC) + CHANGE IN DEGRADATION 
+ 10g = [20g - 20g ] + [+10g ] 
FIGURE 4. — Reinjection technique for the measurement of protein synthesis following a control 
and an experimental period 
and degradation determined daily by means of a clearance method. A 2nd injection 
is then made and the pool size re-evaluated. By comparing changes in the pool 
size to the changes in degradation it is possible to determine if synthesis has kept 
pace with, lagged behind, or remained unaltered during the changes in degradation. 
In regulating protein metabolism there must be a balance between protein 
production and degradation. In reviewing some of the factors affecting these various 
parameters 1 shall dwell mainly with serum albumin and γ-globulin. 
While decreases in the serum albumin level are frequently seen in various disease 
states (21), hyperalbuminemia is not seen except perhaps in acute dehydration. Fur­
thermore, while plasmapheresis experiments had shown that the loss of protein 
could be remade 122), such changes could have been mediated via alterations in 
degradation and not an increase in synthesis. Studies in patients with proteinuria 
seemed to support this concept (23). The urinary excretion of radioactivity was divi­
ded between 131I bound to and excreted with albumin and 131I which was non pre­
cipitable and derived from degraded protein. Between one quarter and one-half 
of the excreted 131I was still precipitable and thus albumin degradation was decrea­
sed. Since these subjects were in steady state conditions with regard to albumin 
metabolism, albumin synthesis was equal to the sum of the amount of albumin 
lost and degraded and albumin synthesis was not increased. It is interesting to spe­
culate that the decrease in degradation may be an attempt to compensate for these 
renal losses for an increase in albumin synthesis would result in simply a greater 
urinary loss of protein. 
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In order to determine if albumin production was capable of increasing it was 
decided to use excess thyroid as a stimulus. The patients were injected with 131I-
albumin and control values for albumin distribution and degradation obtained (24). 
During the control period serum albumin levels remained constant and there were 
no changes in albumin distribution. At this point desiccated thyroid in doses of 
10-16 grains per day were administered and observations continued. As the thyroid 
was administered the amount of radioactivity excreted in the urine increased and 
the slope of the plasma decay curve increased. Calculations revealed that the amount 
of albumin degraded increased in every study. A 2nd dose of 131I-albumin was inject­
ed and albumin distribution remeasured. In this group of patients albumin degra­
dation increased by 30 % and 80 grams of albumin were degraded in excess of the 
control period. The total exchangeable albumin pool had fallen only slightly indi­
cating that albumin synthesis must have increased to prevent the loss of exchan­
geable albumin in the face of the absolute increase in degradation (Figure 5). 
ALBUMIN DEGRADATION TOTAL EXCHANGEABI E ALBUMIN 
FIGURE 5. — Albumin metabolism and thyroid administration. 
During the administration of thyroid 80 grams of albumin were degraded in excess of an equi­
valent control period. There was a loss of exchangeable albumin of 15 grams. 
In another group of patients and in rabbits the effects of cortisone acetate 
were studied in order to determine if albumin synthesis would be altered in associa­
tion with the expected increase in albumin degradation. In both groups studied 
there was a rapid increase in the amount of albumin degraded averaging 58 % in 
the rabbits and 30 % in the patients. However, albumin synthesis also rose and in 
response to this appropriate stimulus, albumin synthesis was capable of keeping 
pace with degradation and no loss of albumin occurred (25"2?'. Cortisone was cata­
bolic in terms of albumin but was not as had been felt antianabolic. 
The metabolism of γ-globulin, however, is not affected in the same way by 
cortisone. Cortisone acetate 4 mg/kg/day was administered to 4 rabbits over a 
two week period and the studies conducted as described above (Figure 6). Following 
cortisone the γ-globulin pool fell 23 %, γ-globulin degradation was unaltered and 
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GAMMA GLOBULIN POOL 
GAMMA GLOBULIN DEGRADATION 
GAMMA GLOBULIN SYNTHESIS ■ 
- 3 0 -10 O IO 3 0 
7. DECREASE % INCREASE 
FIGURE 6. — Cortisone and γ­globulin metabolism. 
The effects of cortisone acetate 4 mg/kg/day on the metabolism of γ­globulin. 
γ­globulin synthesis fell 22 % from 259 mg/day to 201 mg/day (8). While these 
changes are not marked, they clearly show that the fractional rate of γ­globulin 
degradation is increased but synthesis is not stimulated by cortisone as is the pro­
duction of albumin. The administration of thyroid, however, has been reported to 
increase γ­globulin turnover (2B' 30). Thus thyroid hormone is capable of producing 
perhaps a rather non specific increase in protein turnover while the reaction of 
these same proteins to the adrenocortical hormones is very specific. The direction 
of change of the protein pool in the presence of these stimuli is dependent on the 
predominant effect of these hormones on degradation or synthesis. 
Now that it was clear that both the synthetic and degradative systems were 
capable of being accelerated how could they be inhibited? It had long been obser­
ved that in many disease states there appeared to be a depression of the serum albu­
min level whenever the globulin fraction of the blood increased (31_36). This possible 
dependent relationship suggested to Bjørneboe in 1945 that colloid content might 
somehow play a rôle in protein metabolism perhaps by altering protein distribution. 
A colloid osmotic regulatory system responsible for these reciprocal changes was 
suggested <35· 3B'. In order to study this question rabbits were injected with ,31I­albu­
min and following control observations, high molecular weight dextran was infused136'. 
After a new equilibrium state had been achieved, 131I­albumin was re­injected 
and the pool size remeasured (Figure 7). Albumin degradation fell 22 % and the 
exchangeable albumin pool decreased 16 % indicating that at some point albumin 
synthesis must have fallen below albumin degradation. In the presence of another 
colloid, albumin levels fell and these low albumin levels per se did not result in an 
increment in albumin production. 
This study was extended employing rabbits hyperimmunized with a polyva­
lent pneumococcal antigen according to the method of Bjørneboe (3". During the 
rapid development of hypergammaglobulinemia the exact same sequence of events 
occurred as during the dextran infusions. Albumin levels fell as the γ­globulin con­
centration rose and a decrease in degradation occurred which was most marked 
when the albumin pool size had fallen to low levels. Finally a new steady state was 
achieved at which time the exchangeable albumin pool had fallen and albumin 
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Albumin Oeqrodotion Toiol Exchangeable Alban-
FIGURE 7. — Dextran and albumin metabolism. 
The effect of dextran, average molecular wt. 188,000 in doses of 1.5 g/day on albumin meta­
bolism. The exchangeable albumin pool decreased in the face of a fall in albumin degradation indi­
cating that albumin synthesis must have decreased even further. 
synthesis and degradation were at new but lower levels. Total protein concentra­
tion increased 52 %, albumin levels fell 38 %, exchangeable albumin decreased 
30 % due mainly to a 23 % decrease in albumin synthesis from a mean of 273 mg/ 
kg/day to 217 mg/kg/day (Figure 8) (37'. 
While this depression of albumin production was taking place, gamma globulin 
synthesis was markedly accelerated (33· 39) (Figure 9). Gamma globulin degrada­
tion rose rapidly as the γ-globulin levels rose and exceeded the control value by 
450 % to a level of 330 mg/kg/day. A 2nd injection of 131I^-globulin indicated a 
pool size nearly 6 times the initial value while γ-globulin synthesis increased 700%. 
TOTAL PROTEIN 
SERUM ALBUMIN 
EXCHANGEABLE ALBUMIN 
ALBUMIN DEGRADATION 
ALBUMIN SYNTHESIS 
-50 -25 
% DECREASE 
25 50 75 
'/. INCREASE 
FIGURE 8. — Hyperimmunization and albumin metabolism. 
The effects of rapid hyperimmunization on albumin metabolism. The total protein concentration 
rose 52 % while there was a decrease in the serum albumin level and exchangeable albumin pool 
due mainly to a decrease in albumin synthesis. 
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GAMMA GLOBULIN DEGRADATION 
TOTAL EXCHANGEABLE GAMMA GLOBULIN 
GAMMA GLOBULIN SYNTHESIS 
SERUM ALBUMIN CONCENTRATION 
3 0 0 5 0 0 
% INCREASE 
FIGURE 9. — Hyperimmunization and γ-globulin metabolism. 
The effects of rapid hyperimmunization on γ-globulin metabolism. While the serum albumin 
level decreased, there were marked increases in the γ-globulin levels, pool size and synthesis. 
Serum albumin levels decreased 27 % or about 1 g/100 ml. At peak production 
γ-globulin synthesis required about 1/3 of the average daily nitrogen intake; and, 
as been suggested in other diseases when the globulin levels are markedly elevated, 
it seemed possible that the rapid production of one protein might competitively 
interfere with the synthesis of others (33). In order to investigate this possibility, 
two groups of studies were performed. The first involved the infusion of pooled 
γ-globulin into rabbits. The infusion of 7-10 g of γ-globulin over a 10-16 day period 
resulted in a depression of the albumin pool from 13.5-8.4 g due to a decrease in albu­
min synthesis from 1070 mg/day to 744 mg/day u o ' . These studies confirmed the 
results during hyperimmunization and during dextran administration. During the 
infusion of γ-globulin there was no excess demand on the body's own amino acid 
pool. The second study was undertaken to see if the rapid hyperimmunization would 
in any way effect the production or destruction of a protein not involved in mainte­
nance of colloid osmotic pressure. Hemoglobin seemed to fit this criterion and in 7 
rabbits values for red cell mass, total circulating hemoglobin and red blood cell 
survival were obtained using 51Cr labelled red cells. Values for serum protein, serum 
albumin and hemoglobin concentrations were obtained before, during and after 
the rapid hyperimmunization. Total protein rose 25 % associated with a 22 % 
fall in circulating albumin levels from 3.2 to 2.5 g/100 ml. There were no significant 
changes in red cell mass or hemoglobin and the red cell survival time of about 2 
weeks was not altered. These studies indicate that during rapid hyperimmunization 
the production of hemoglobin is not affected and excessive colloid accumulation 
appears to be prevented by a specific decrease in albumin production (41), and prob­
ably not secondary to a nitrogen lack. 
So far we have dealt mainly with some mechanisms controlling protein syn­
thesis. Now for a moment let us turn to degradation. Albumin degradation is low 
in conditions where the serum albumin level is depressed <35-3G· 40·47· 48'. Actually 
albumin degradation has been observed not to fall until the serum albumin levels 
had started to decrease during hyperimmunization (37, and at the end of the study 
the values for albumin degradation and synthesis agreed indicating equilibrium at 
a new steady state (37). Also an absolute decrease in degradation has been seen in 
some patients with proteinuria and hypoalbuminemia (22). It should be pointed 
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out that alterations in degradation may be missed if only the fractional rate of tur­
nover is used t36· 37). In hyperimmunized rabbits and following dextran infusions 
the fractional rate of loss of 131l­albumin from the plasma is unaltered yet there 
are marked changes in the amount of albumin degraded per day. On the other 
hand elevations in the serum proteins are associated with changes in degradative 
rates; both the absolute amount degraded and the fractional rate. Bjørneboe, Ander­
sen and others have demonstrated this point (38), and in rabbits as the γ­globulin 
levels rose, γ­globulin degradation increased from 8 to 12 % per day (3i". Fahey 
has shown that the fractional rate of degradation may increase until the γ­globulin 
levels reached 2­3 g/100 ml after that the fractional rate remained relatively stable— 
only the absolute amount of γ­globulin degraded increasing (4!l'. During albumin 
infusions the fractional turnover rate of 131I­albumin increased 22 % (50). 
While these data suggest that the plasma protein degradation is probably rela­
ted to serum levels or pool size or both there are no conclusive data on the site of 
plasma protein degradation. It is well appreciated that the site of plasma protein 
degradation is probably in close approximation to the plasma (4> π · 51) and not in 
distant extra plasma sites but the specific area is still a mystery. Tissue homogenates 
fail to release non precipitable iodide after incubation with labeled gammaglobulin 
or albumin. However, perfusion of the kidney and spleen with 131I­Iabeled albumin 
and globulin demonstrated an increase in non­precipitable 131I. During perfusion 
of the dog kidney with 131I­albumin, non­precipitable activity increased at a rate 
of about 100 % per hour, but no increase occurred when 131I­gammaglobulin was 
used. In splenic perfusions the rate of release of 131I was 50 % per hour for 131l­
albumin and 25 % per hour when gammaglobulin was used as the substrate <¿2). 
While the reasons for these differences are not clear, it is tempting to speculate 
that many tissues possess the capacity to degrade protein and the limiting factor is 
the accessibility of the degrading site for this protein. 
Finally, let us turn to protein distribution. While most serum proteins rapidly 
achieve equilibrium between intravascular and extravascular sites with specific 
rates of equilibration, different tissues maintain different concentrations in their 
interstitial fluid. For example, the skin contains very large amounts of exchangeable 
protein in its interstitial fluid whereas the liver has only very limited amounts of 
protein so located (52' E3). In terms of albumin it is interesting to return to the obser­
vation that albumin production is not stimulated by low plasma albumin levels 
ver se for it may be that if a colloid osmotic regulatory system does exist such a 
mechanism may be located in an extravascular site. In exploring this possibility 
hepatic albumin distribution was measured in control rabbits and in rabbits recei­
ving 1.5 g dextran daily where the synthesis of albumin was depressed. 14C­sucrose 
was used to measure extracellular fluid and 131I­albumin to measure the plasma 
volume and the 14C and 1311 activity per gram of liver compared to that contained 
in 1 ml of plasma. In addition, studies were performed in these two groups of rabbits 
employing 131I­aIbumin to measure both albumin metabolism and equilibrium 
albumin distribution. Six to 10 min prior to sacrifice the rabbits were given 125I­albu­
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min, the livers removed and again the 131I and 125I per gram of tissue compared to 
that contained in one ml of plasma. In these groups of rabbits albumin metabolism 
was measured before and after dextran while the hepatic spaces were determined 
in separate sets of rabbits. The 131I­albumin served to measure hepatic exchangeable 
albumin while J25I­albumin, the hepatic plasma albumin, the difference being the 
albumin located in the interstitial space.While albumin degradation exchangeable albu­
min and albumin levels fell, the amount of albumin located in the hepatic intersitial 
space increased some 93 % from 27­52 mg/100 g wet liver (Figure 10). There was no 
significant change in hepatic interstitial volume. These results are in accord with 
theconcept that extravascular protein distribution may play a rôle in regulatingprotein 
synthesis. 
SER'.iK. ALBUMIN 
TOTAL EXCHANGEABLE ALBUMIN 
ALBUMIN DEGRADATION 
HEPATIC INTERSTITIAL ALBUMIN 
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FIGURE 10. — Albumin metabolism and hepatic albumin distribution during dextran administration. 
While the serum albumin level, exchangeable albumin pool and albumin degradation decreased, 
hepatic interstitial albumin increased from 27 to 52 mg/100 g wet liver weight. 
The experiments that I have briefly outlined above have given us some insight 
into the forces and counter forces influencing protein metabolism. Degradation 
seems to be related to concentration, can be stimulated by hormonal action and the 
site of degradation may well be a more general one than we believe. Synthesis seems 
capable of marked increments and while the most potent stimulus for γ­globulin 
is an appropriate antigenic exposure, albumin production may well be controlled 
by the effective colloid concentration. The mechanisms affecting protein degrada­
tion and synthesis are still unclear, and further work is necessary before the regu­
latory systems that keep protein metabolism in balance, the interplay of one protein 
with another become understood. 
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ABSTRACT 
Catabolism of plasma proteins has been shown to be related to their concen­
tration, but the nature of this relationship is to date unclear. A study was under­
taken in human subjects, in whom hypoalbuminemia was the result of cirrhosis 
o the liver. The rate of catabolism was found to be unexpectedly low, and well 
below that anticipated from the plasma concentration. Albumin infusions resulted 
in the return to normal of both the serum concentration and the fractional rate of 
catabolism. The data appear to support the hypothesis that the rate of catabolism 
is dependent upon plasma concentration, by a square law relationship. 
Study of catabolism of human γ­globulin in rabbits has shown that an S10 
fraction, believed to represent a dimer form, has a plasma disappearance rate indis­
tinguishable from that of the normal S7, suggesting that at least for this protein, 
the dimer does not represent the normal route of catabolism. 
It has been demonstrated that the rate of catabolism of plasma albumin is 
related to its concentration, and most authors have concluded that this relationship 
is linear (1 ,2). The evidence for this conclusion is, however, meagre and largely 
confined to short term animal experiments <3 '4 '5). In addition, much of the suppor­
ting evidence comes from work on other plasma proteins such as γ­globulin <6) 
and fibrinogen (7), and there is no reason to believe that different proteins are cata­
bolised in the same way. Patients suffering from hypoalbuminemia due to congenital 
causes ( ,), to cirrhosis (0 ,10), and to malnutrition (11), have all been shown to have 
depressed fractional rates of catabolism. 
The present study describes observations in human patients suffering from 
cirrhosis of the liver, in whom the serum albumin concentration was raised to nor­
mal by infusions of human serum albumin. Observations are also described of 
rates of catabolism in rabbits of 7S and IOS human γ­globulin fractions; the IOS 
was believed to be a dimer, probably formed in the preparation and sterilisation 
of the γ­globulin. 
METHODS 
All subjects suffered from hypoalbuminemia, the result of cirrhosis of the 
liver in all except one. Liver biopsy in this patient was virtually normal, and hypo­
albuminemia may here have been nutritional in origin. All patients received potas­
sium iodide (200 mg/day) throughout the study, and were either at rest in bed or 
ambulant to a minor extent. Occasional measurements of creatinine content suggest­
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ed satisfactorily complete urine collections; the estimations did not vary by more 
than 10 % from the mean value for each patient except in a few specimens which 
were discarded. All patients were on a normal diet apart from restriction of sodium 
intake where this was necessary. 
Albumin and γ­globulin were prepared by an ether fractionation process at 
the Lister Institute of Preventive Medicine, and labelled with 131I and 125I by the 
iodine monochloride method of McFarlane (12). The mean ratio of iodide bound 
to protein was less than one atom per molecule. Previous examination of the γ­
globulin by ultracentrifugation revealed 81 % 7S, 0.5 % 19S macroglobulin, 9.5 % 
10S, and 9 % 4.5S. Electrophoresis on cellulose acetate at pH 8.6 showed that 81 % 
of the radioactivity was associated with γ­globulin, 6 % with ß­globulins, 9 % 
with α­globulins, and 4 % with albumin <13). 
The labelled albumin was injected intravenously, and the γ­globulin adminis­
tered intramuscularly or intravenously. In the latter instance, it was mixed with an 
excess of unlabelled albumin and injected slowly over a ten minute period. Venous 
blood samples were taken ten minutes after albumin injection from which to esti­
mate plasma volume, and further samples were taken daily or as necessary. The 
blood was taken into E. D. T. A. and the plasma separated. Unlabelled albumin, 
also obtained from the Lister Institute, was infused intravenously at the rate of fifty 
grammes per day. The infusions were given daily for several days, followed by an 
observational period, also of several days, during which time measurements were 
made of the fractional catabolic rate. 
The total protein concentration was estimated by the biuret method (14), and 
the albumin and γ­globulin percentages by electrophoretic separation on filter 
paper <15). The radioactivity of plasma and urine samples was measured by scin­
tillation counting in a well type sodium iodide crystal. 
Pure preparations of albumin and γ­globulin were obtained for specific activity 
measurements by cold ethanol fractionation of plasma <13). 
Calculations were made of plasma volume, also of fractional and absolute 
rates of protein catabolism on the basis of urine and plasma radioactivity, and 
plasma protein concentrations. The value for absolute catabolic rate was obtained 
in two different ways by using not only urine : plasma ratios (U/P %) (Protein 
Method), but also plasma albumin and γ­globulin specific activity measurements 
related to total urine radioactivity (Specific Activity Method). 
RESULTS AND DISCUSSION 
Serial daily measurements of catabolic rate in a cirrhotic patient being infused 
with human albumin revealed a progressive rise in the fractional rate as the serum 
concentration increased. Hence, a scheme of step­wise rise in concentration was 
designed by short intermittent courses of infusion, leaving periods of a few days 
between each, when it was hoped the serum concentration would remain reasonably 
constant. Mean values for each period have been reported fully elsewhere (10), and 
are plotted in Figure 1. It is clear that these data do not fit a simple linear relation­
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ship, but may be better described by a square law function, illustrated by the sketched 
dotted line. If both axes were plotted logarithmically, this curve would become a 
straight line, with a slope of two. This has been done (Figure 2a and b), and regression 
equations fitted. From the two equations of y.x and x.y, and using the ratio of the 
error variances on each axis <16), the regression line of the functional relationship 
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FIGURE 1. — The relationship between the rate of albumin catabolism (protein method) and serum 
concentration 
(Symbols in this and succeeding figures refer to individual patients). 
has been drawn, its calculated slope being 2.47. This value does not differ signifi­
cantly from 2.0. When the abscissa is changed to total plasma albumin (Figure 2b), 
similar equations are obtained, with slopes of 1.9 and 2.4 for y.x and x.y respectively. 
The functional relationship cannot here be calculated, however, as the additional 
source of variance on the abscissa, plasma volume, is not easily definable. It is, 
however, probable that abscissal variance is hereby increased, and the equation 
for the functional relationship must have a slope of a little less than 2.4. 
Unfortunately, both axes in these figures contain the measurement of plasma 
albumin concentration, and it was fortunate that a further comparison was possible 
which was not open to this objection. These values, obtained by the Specific Activity 
method, have been plotted in Figure 3a and b, and again the slopes of the calculated 
relationship do not differ significantly from 2.0. The slope of the functional relation­
ship for Figure 2a is 3.30, and the two slopes drawn in Figure 3b are 1.4 and 4.0. 
Nonetheless, it was possible that catabolic rate was grossly affected by the 
sudden changes in blood volume and nitrogen balance induced by albumin infusions, 
and so measurements were made in three patients several months later during the 
116 P. W. DYKES, J. W. L. DAVIES, C. R. RICKETTS AND D. R. STANWORTH 
maintenance period and at differing albumin concentrations. These values are 
plotted separately (Figure 4a and b) and again the values for the slope do not differ 
significantly from two (2.15 for the functional relationship illustrated in Figure 4a, 
and 1.83 and 2.01 for Figure 4b). A further test of the effects which rapid infusion 
might have on protein catabolism was made by using labelled γ­globulin. This 
was injected at the same time as the labelled albumin, and after five days, catabolic 
rate was measured during the whole observational period. No consistent change 
occurred either in plasma concentration or in catabolic rate, thus adding further 
support to the specificity of the albumin changes. It is further concluded that in 
man, albumin and γ­globulin catabolism are entirely separate metabolic processes. 
Although a second order reaction had not previously been suggested relating 
the rate of catabolism and plasma protein concentration, a number of studies in 
the literature contain data bearing upon such an hypothesis. Most of the authors 
have not considered this relationship in any detail, but their data can be used to 
test the present hypothesis. Six reports contain sufficient information to enable 
this comparison to be made. Two were published soon after the introduction of 
isotope labelled proteins into clinical research <9, 17, 18), the others more recently 
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FIGURE 2. The relationship, albumin catabolic rate (protein method) against plasma concen­
tration (a), and against total plasma albumin (b) 
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The relationship between serum albumin concentration and its rate of catabolism 
Source 
Starling (1951) 
Berson and Yalow (1953) . . . 
Jeejeebhoy (Pers. Commun.) . . 
Jeejeebhoy (1962) 
Wilkinson and Mendenhall (1963) 
Cohen and Hansen (1962) . . . 
Picou and Waterlow (1962) . . . 
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FIGURE 3. — The relationship, albumin catabolic rate (specific activity method) against plasma 
concentration (a), and against total plasma albumin (b) 
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di, i9, 20, 2D There ¡S; ¡ n addition, a useful report by Bennhold and Kallee (8) of 
a patient with idiopathic hypoproteinemia in whom the abnormality is apparently 
due to defective synthesis. Patients in the other series suffered from cirrhosis of 
the liver, kwashiorkor, and protein losing enteropathy. Data are not always avai­
lable in exactly the same form as that used here, but within the limits of the infor­
mation provided, it has been converted to values as closely comparable as possible. 
Regression coefficients [b(y.x) and \¡b(x.y)] are listed in the table, where it is appa­
rent that with the exception of data from Sterling and from Picou and Waterlow, 
all studies are consistent with a square law relationship. It is probable that the pro­
tein used by Sterling, showing very high rates of catabolism, was not of satisfactory 
biological standard, thus leaving only one important study not in agreement with 
the present hypothesis. 
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FIGURE 4. — The relationship, albumin catabolic rate (protein method) against plasma concentra­
tion (a), and against total circulating albumin (¿) for observations which are unaffected by 
the period of rapid infusions. 
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Further, Cohen and Hansen (U) also published data on rates of γ-globulin 
catabolism which appeared to support a square law relationship for this protein, 
and Sell (22) has also reported rising fractional rates of catabolism in mice. 
Thus, it appears that the rate of catabolism of human albumin is not related 
linearly to its serum concentration or intravascular pool size, but by a more complex 
function which probably follows the kinetics of a second order reaction. The under­
lying physiological reasons for this are unclear, but one of the more probable is that 
the route of catabolism is via a dimer formed within the distribution of albumin 
and rapidly broken down at catabolic sites. This possibility has the advantage of 
explaining simply the site of albumin catabolism, i.e. the blood or tissues in close 
association where protein concentration is high. 
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fractions of human γ-globulin, one predominantly 7S (X), the other predominantly IOS (φ). 
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In searching for a readily available, undenatured dimer, a fractionation of 
American Red Cross γ-globulin on Sephadex G. 200 was found to concentrate 
a 10S fraction. A sample thus prepared and containing 60 % 10S was injected into 
normal rabbits together with 7S γ-globulin prepared from the same source, and 
labelled with a different isotope of iodine. This procedure has been carried out 
in six rabbits, and in each instance, the rate of distribution and catabolism of the 
two fractions was found to be identical (Figure 4). Twenty-four hours after intra­
venous injection of these fractions, a plasma sample was examined ultracentri-
fugally, and preliminary observations suggest that the isotopes were distributed in 
the same proportion as in the injected solution. Thus, this particular dimer does 
not appear to be the route of catabolism in the species tested, and further studies 
must be carried out both to test the validity of the present hypothesis, and to explore 
possible underlying reasons. 
REFERENCES 
1. A. S. MCFARLANE. — The behaviour of 1:"I-labelled plasma proteins. Ann. N. Y. Acad. Sci., 
70 : 19 (1957). 
2. D. GiTLiN and C. A. JANEWAY. — Some isotopie studies on the distribution and metabolism 
of plasma proteins. Advanc biol. med. Phys., 7 : 249 (1960). 
3. M. A. ROTHSCHILD, M. ORATZ, E. WIMER and S. S. SCHREIBER. — Studies on albumin synthe­
sis : the effects of dextran and cortisone on albumin metabolism in rabbits studied with 131I-
albumin. J. clin. Invest., 40 : 545 (1961). 
4. M. A. ROTHSCHILD, M. ORATZ, E. C. FRANKLIN and S. S. SCHREIBER. — The effect of hyper­
gammaglobulinemia on albumin metabolism in hyperimmunised rabbits studied with m I -
albumin. J. clin. Invest., 41 : 1564 (1962). 
5. W. FRIEDBERG. — Serum-albumin metabolism in X-irradiated mice with implanted rat bone 
marrow. Int. J. Rad. Biol., 2 : 186 (I960). 
6. S. J. ZAK and R. A. GOOD. — Immunochemical studies of human serum gammaglobulins. 
J. clin. Invest., 38 : 579 (1959). 
7. E. L. REGOECZI, G. E. HENLEY, R. C. HOLLOWAY and A. S. MCFARLANE. — Turnover of 131I-
labelled fibrinogen in fever. Brit. J. exp. Path., 44 : 397 (1963). 
8. Η. BENNHOLD and E. KALLEE. — Comparative studies on the half-life of mI-labelled albumins 
and non-radioactive human serum albumin in a case of analbuminemia. J. clin. Invest., 38 : 
863 (1959). 
9. K. STERLING. — The turnover rate of serum albumin in man as measured by 131I tagged albu­
min. J. clin. Invest., 30 : 1228 (1951). 
10. P. W. DYKES. — (1964), M. D. Thesis, University of Birmingham. 
U . S . COHEN and J. D. L. HANSEN. — Metabolism of albumin and γ-globulin in kwashiorkor. 
Clin. Sci., 23 : 351 (1961). 
12. A. S. MCFARLANE. — Labelling of plasma proteins with radioactive iodine. Biochem. J., 62 : 
135 (1956). 
13. J. W. L. DAVIES, C. R. RICKETTS and J. P. BULL. — Studies of plasma protein metabolism. 
Clin. Sci., 23 : 411 (1962). 
EFFECT OF PLASMA CONCENTRATION ON THE CATABOLIC RATE 121 
14. W. Q. WOLFSON, C. COHN, E. CALVARY and F. ICHIBA. — A rapid procedure for the estimation 
of total protein, true albumin, total globulin, alpha globulin, beta globulin and gammaglobulin 
in 1.0 ml of serum. J. clin. Path., 18 : 723 (1948). 
15. J. HARDWICKE. — The estimation of serum proteins by electrophoresis on filter paper. Biochem. 
J., 57 : 166 (1954). 
16. J. D. BLAINEY and J. R. SQUIRE. — Balance studies in diuresis. Clin. Sci., 19 : 287 (I960). 
17. K. STERLING. — Serum albumin turnover in Laennec's cirrhosis as measured by 131I tagged 
albumin. J. clin. Invest., 30 : 1238 (1951). 
18. S. A. BERSON, R. A. YALOW, S. S. SCHREIBER and J. POST. — Tracer experiments with 13II-label-
led human serum albumin : distribution and degradation studies. J. clin. Invest., 32 : 746 (1953). 
19. D. PICOU and J. C. WATERLOW. — The effect of malnutrition on the metabolism of plasma 
albumin. Clin. Sci., 22 : 459 (1962). 
20. K. N. JEEJEEBHOY. — Cause of hypoalbuminemia in patients with gastrointestinal and cardiac 
disease. Lancet, 1 : 343 (1962). 
21. P. WILKINSON and C. L. MENDENHALL. — Albumin turnover in cirrhosis. Clin. Sci., 25 : 281 
(1963). 
22. S. SELL. — Evidence for species differences in the effect of serum γ-globulin concentration 
on γ-globulin catabolism. / . exp. Med., 120 : 967 (1964). 
DISCUSSION 
C. M. E. MATTHEWS (London) : I would like to ask Dr. Rothschild how he 
decides when a new steady state has been reached ? A constant protein concentra­
tion in the plasma is not sufficient necessarily to indicate a steady state. I think 
it is dangerous to equate synthesis with catabolism under such circumstances, and 
the measurement of total exchangeable albumin may not be valid. 
Secondly I think albumin synthesis rate can increase as a result of a reduced 
albumin concentration, as I found in plasmapheresis experiments in rabbits, which 
are mentioned in my paper (Effects of plasmapheresis on albumin pools in rabbits 
C. Μ. E. Matthews, J. Clin. Invest., 40 : 603, 1961). 
Finally Dr. Rothschild seemed to imply that a constant ratio of intravascular 
to total retained radioactivity indicated equilibrium between extra- and intravascular 
pools with equal specific activities, but this only means that radioactivities in the 
different pools are decreasing in parallel. 
M. A. ROTHSCHILD : A new steady state was determined to be present with 
respect to albumin in exactly the same way as during the original control period. 
Not only were the serum albumin levels constant but also the plasma decay curve 
was stable and the distribution curve determined from the second dose of 131I-albu-
min remained at a horizontal asymptote indicating equilibrium of this dose and 
thus the experimental pool could be determined. 
In the conditions mentioned, namely, during proteinuria, and during the 
infusion of dextran and gammaglobulin and associated with the rapid development 
of hypergammaglobulinemia, low serum albumin levels per se did not result in a 
change or stimulate albumin synthesis to increase. Plasmapheresis removes all the 
serum proteins and probably results in changes in distribution as well as alterations 
in degradation and synthesis as you have shown. This is a different state from one 
in which one serum colloid or protein is increased and another appears to decrease. 
It is interesting to consider that when the additional colloid is albumin excessive 
colloidal accumulation is prevented by an increase in the fractional and absolute 
rates of albumin degradation. Albumin synthesis remains unaltered. Synthesis and 
degradation are thus not interdependent. 
It is well to point out again that the specific activity in the various body 
compartments are slightly different but as long as distribution is rapid in compa­
rison to degradation then changes in specific activity in one area will rapidly be 
reflected in another and the measurements of pool size will be valid. Actually any 
technique under these states will result in valid determinations. 
A. H. GORDON (London) : Dr. Rothschild's sytem in which gammaglobulin 
is injected daily into rabbits may well yield important results because by this mean 
colloid osmotic pressure can be altered without the introduction of any substance 
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not normally present in the blood. However as he has himself pointed out, the 
much greater molecular size of gammaglobulin as compared with albumin must 
mean that plasma colloid osmotic pressure is reduced as a result of the gamma-
globulin injection. If as he suggests colloid osmotic pressure is a controlling factor 
for the rate of synthesis of albumin, it would seem to follow that this rate should 
be increased and not decreased as he has in fact found to occur in these conditions. 
Since the colloid osmotic pressure of the interstitial fluid, which he believes may be 
responsible in the control of the albumin synthesis rate, must presumably follow 
changes in the plasma colloid osmotic pressure, it would seem to be more useful 
to look for other quite different factors controlling this rate. 
An example of control of the rate of synthesis of a group of plasma glycopro-
teins by a factor in rat blood may be mentioned. Blood taken from rats two days 
after injection of an irritant substance has been found to increase synthesis of cer-
tain globulins by the isolated perfused rat liver. In view of this observation of the 
effect of a factor in blood on the rate of synthesis of certain plasma proteins, increased 
attention to the possible existence of messenger substances responsible for the con-
trol of plasma protein synthesis rates may be more rewarding than further investiga-
tion of factors such as colloid osmotic pressure. 
M. A. ROTHSCHILD : Following the infusion of gammaglobulin the loss in 
the serum albumin was not compensated by the increase in gammaglobulin levels 
in terms of colloid osmotic pressure and a similar observation was made after dex-
tran infusions. However the site of albumin production is in contact with extra-
vascular fluid and in the liver, at least, changes in interstitial colloid content do 
not necessarily parallel those of the plasma. Also the existence of such a colloid 
osmotic regulatory system was proposed because there are many other experimental 
and clinical observations where reciprocal depressions of serum albumin occur 
in the face of significant gammaglobulin elevations. Finally since albumin is the 
most important serum protein for maintaining colloid osmotic pressure, alterations 
in a regulatory system aimed at maintaining a steady colloid state would not neces-
sarily influence the metabolism of other proteins. Their production would probably 
be related to other specific functions. While many experimental data seem to favor 
the existence of a colloid osmotic system, I agree that the proof of the existence 
and the importance of this mechanism must await further evidence. I did not mean 
to exclude other stimuli which alter protein metabolism, such as the hormone, action 
nitrogen intake or health and environment. All of these alter protein turnover, 
perhaps by other independent methods. 
W. MULLIGAN (Glasgow) : The apparent reciprocal relationship between gamma-
globulin and albumin concentrations has often been attributed to a homeostatic 
adjustment in colloid osmotic pressure. An interesting example occurs in the young 
calf which is born without gammaglobulin but where the level raises markedly 
during the first 24 hours of life associated with the absorption of colostral globulins. 
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Pierce at Cambridge some years ago noted a drop in albumin levels associated with 
the increase in gammaglobulin and suggested that this might be due to the main-
tenance of colloid osmotic pressure. We have looked for the same phenomenon 
in the baby pig during the first few hours of life but failed to find it. In fact albumin 
and gammaglobulin levels rose at the same time. 
In considering whether colloid osmotic pressure is really involved in these 
adjustments in concentration it would appear to be important that workers should 
actually measure colloid osmotic pressure in these various situations. 
E. REGOECZI (London) : In discussing regulatory mechanisms for controlling 
plasma protein levels, 1 feel fibrinogen deserves at least brief mention. Dr. Roth-
schild has shown results obtained with 131I-aIbumin from which he concluded that 
albumin synthesis was not related to the concentration or to the pool size of the 
protein. This may not be true for fibrinogen. So e.g. Miller et al. found in liver 
perfusion experiments that net fibrinogen synthesis was a function of the fibrinogen 
concentration in the perfusing blood, although unpublished data by Gordon are 
not fully in favour of Miller's observations. Moreover, Mutschler and I have obser-
ved using livers from acutely defibrinated rats (i.e. injecting Malayan viper venom) 
that significantly increased quantities of fibrinogen were synthesized even when 
the organ was perfused with blood from normal rats. Evidently fibrinogen has a 
different mechanism for the regulation of its synthesis than the one described for 
albumin. 
LABELLED PLASMA PROTEINS 
FOR METABOLIC STUDIES 
President : J. COURSAGET 
Département de Biologie du C. Ε. Α., C. E. Ν. Saclay, France 
REMARQUES PRÉLIMINAIRES 
C'est pour moi un grand honneur d'avoir été appelé à présider cette séance 
et je crains fort de vous décevoir en succédant à de distingués collègues beaucoup 
mieux qualifiés. S'il m'est, en effet, arrivé voici quelque quinze années de préparer 
des protéines plasmatiques marquées avec divers isotopes stables afin d'en étudier 
le comportement biologique, je n'ai guère participé aux intéressants développements 
intervenus depuis lors dans ce domaine. 
Les communications qui nous ont déjà été présentées nous ont montré que, 
grâce principalement aux isotopes radioactifs 131 et 125 de l'iode, d'importants 
progrès ont été réalisés depuis l'époque où nous ne disposions que du carbone­13 
et de l'azote­15. Cependant la relative facilité de marquage des protéines par iodation 
soulève le sérieux problème de l'identité de comportement des protéines chargées 
d'atomes d'iode et des protéines naturelles correspondantes. Nous payons ainsi 
d'une inquiétude nouvelle une plus grande aisance expérimentale. 
Et je crois que l'on n'insistera jamais assez sur l'importance des preuves de vali­
dité, appropriées à chaque recherche particulière, du marquage par addition d'atomes 
lourds à une molécule organique, surtout si l'on désire explorer ses propiétés spé­
cifiques, enzymologiques ou immunologiques. 
En ce qui concerne les études cinétiques, il est tentant certes d'admettre l'hypo­
thèse que les processus en cause sont du premier ordre et les relations exponentielles 
obtenues sont aisées à manier. Cependant, les modèles proposés sur cette base com­
portent des espaces, des compartiments dont la signification physiologique n'est 
pas toujours claire. La réalité biologique ne saurait certainement, dans nombre 
de cas, être schématisée de manière aussi brutale. Nous devons espérer que les calcu­
latrices électroniques permettront dans l'avenir de saisir cette réalité avec une plus 
grande finesse. 
Mais ce sont sans doute les mécanismes intervenant dans les processus de la 
biosynthèse et de la dégradation métabolique des protéines plasmatiques qui demeu­
rent les points les plus obscurs. En contraste avec les importants progrès réalisés 
durant ces récentes années en matière de régulation de la biosynthèse des protéines 
cellulaires, nous demeurons très ignorants des facteurs fondamentaux qui assurent 
l'homéostasie des protéines dans le plasma. Cette situation est particulièrement 
gênante pour l'interprétation des résultats obtenus au cours d'états pathologiques. 
Sans doute quelques suggestions ont­elles été présentées, mais elles demeurent 
hautement hypothétiques et il faut espérer que des progrès significatifs pourront 
être réalisés au cours des prochaines années. 
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LABELLED HOMOLOGOUS PLASMA PROTEINS 
AMONG SUBCELLULAR PARTICLES OF RAT LIVER 
A. H. GORDON and P. JACQUES (*) 
National Institute for Medical Research, Mill Hill, 
London, Great Britain 
ABSTRACT 
1U5I labelled rat albumin and I31I rat transferrin were screened separately and 
injected into rats. 
After periods from 5 min to 6 h the livers were perfused with saline and 
fractionated by a method similar to that of de Duve et al. (1955). 
As has been previously observed with heterologous proteins the specific activities 
of the light mitochondrial (Iysosorae rich) fractions (L.) derived from both 125I­albu­
min and from mI­transferrin were greater than those from any of the other fractions. 
In contrast however, to results with heterologous proteins no systematic change 
in the distribution pattern with time after dosage was seen. Another difference was 
that much more activity appeared in the 1 χ I0'; g. min supernatant fraction (S.). 
As the transferrin to albumin ratio in this fraction was much higher than that in 
the plasma of the liver donor this high value of the S fraction cannot be explained 
only by residual plasma. The ratio of the specific activities of the L to S fraction 
was found to be more than twice as high for transferrin as for albumin. The distribu­
tion pattern of non protein radioactivity was in general rather similar to that found 
for the proteins, thus suggesting proteolysis of homologous proteins inside the 
granules. 
Previous work has indicated that catabolism of varying proportions of some 
plasma proteins takes place in the liver (Gordon. 1963). Thus in the isolated perfused 
rat liver larger proportions of both transferrin and γ­globulin (Cohen, Gordon and 
Matthews, 1962) are catabolised than of albumin (Cohen and Gordon, 1958). How­
ever, in experiments of this kind with plasma proteins which circulated beforehand 
for 48 hours in another rat, the rate of catabolism in the perfused liver never exceeded 
30 % ofthat known to occur in the whole animal. The aim of the present experi­
ments was to obtain some information about the cellular sites of that catabolism. 
For this purpose, two homologous proteins, albumin and transferrin labelled with 
J31I or 12,I and screened, were injected together into rats. After appropriate intervals, 
the livers were perfused briefly with cold saline, homogenized in 0.25 M sucrose 
and fractionated by differential centrifugation; the scheme adopted was essentially 
that described by de Duve et al. (1955) except that the microsomal and supernatant 
fractions were separated after 1 X IO6 g. min only. 
(*) Chercheur Qualifié of the Fonds National Belge de la Recherche Scientifique. 
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RESULTS 
The amounts of the two injected isotopes retained in the liver after perfusion 
with saline at various periods after the original injection are shown in Figure 1. 
The observed radioactivities per g wet liver have been expressed as the volumes 
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Figure 1 
of plasma occupied by each labelled protein before entry into the liver. Evidently, 
on average, transferrin has been concentrated by a factor of 2 compared with albu­
min. Treatment with TCA indicated that approximately 12 % of each isotope in 
the liver was present in combination with products of catabolism as compared 
with 0.6 % of each in the blood. 
Figure 2 illustrates the distribution of the radioactive proteins and their split 
products in five experiments; that of lysosomal acid phosphatase is also given for 
comparison. On average 35 % of albumin and 65 of transferrin can be sedimented 
at 106 g. min. At shorter times after injection, the specific activities of both albumin 
and transferrin were found to be highest in the L fraction where lysosomes and 
microbodies were mostly concentrated; later, higher values, especially of albumin, 
were found in the supernatant. Considering only the particulate fractions, the L 
fraction from both proteins always showed highest specific activity at all times 
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Figure 2 
investigated. This was also true for the catabolic products of the injected proteins; 
their distribution paralleled that of the corresponding protein except for a short 
period after injection when they were more concentrated in the supernatant. To 
investigate the possible importance of adsorption to cell particles, plasma contai­
ning both proteins was added to the liver homogenate of an uninjected rat; 97 % 
of albumin was recovered in the supernatant and the 20 % of sedimented trans­
ferrin was found distributed evenly between the particulate fractions. 
DISCUSSION 
An appreciable fraction of both proteins after having been taken up by the 
liver became bound in cytoplasmic granules. The lysosomal nature of these granules, 
130 Α. Η. GORDON AND P. JACQUES 
already suggested by the peak of specific activity in fraction L, has been established 
with albumin in an experiment in which the albumin was injected together with 
Triton WR-1339 six hours before fractionation (Jacques and Wattiaux, 1964). 
As with endocytized peroxidase the equilibrium density of lysosomes and the gra­
nules bearing both 125I-albumin and its split products was considerably lowered 
in a gradient of hypertonic sucrose whereas that of mitochondria and microbodies 
remained unchanged. Although cytoplasmic particles (phagosomes) have not yet 
been proved to be the only conveyors of ingested proteins from the plasma to the 
lysosomes, endocytosis remains the most likely mechanism of uptake (Novikoff, 
1961; de Duve and Wattiaux, 1966). If in fact evidence can be provided that little 
redistribution of the catabolic products takes place during isolation, then the simi­
larity of distribution of these substances and that of the original proteins in sucrose 
gradients and after fractionations such as that shown in Figure 2 indicates the impor­
tance of the acid cathepsins as the agents causing the breakdown of native plasma 
proteins inside the lysosomes. A mechanism of this type has been postulated for 
131I-insulin (Jacques and Wattiaux- De Coninck, unpublished) and human 
131I-serum albumin (Mego and McQueen, 1965) after pinocytosis by rat liver. 
As plasma proteins do not accumulate in the liver, there must be an exact 
balance, in vivo, between their rate of entry and their rate of disappearance. Mini­
mum rates of entry of albumin and transferrin are known because the rates of cata­
bolism of both these proteins have been measured in the perfused rat liver (Cohen 
and Gordon, 1958; Gordon, 1963). As already mentioned, equilibrium had appa­
rently been established in the present experiments as early as 5 min after injection 
of the albumin and transferrin. To our surprise, at this time the amounts of albu­
min and transferrin actually observed in the liver, after careful perfusion with saline, 
were both already more than 10 times the amounts which would have entered the 
TABLE I 
Amounts of each protein found in liver at 5 min after injec­
tion ^ g / g wet wt) 
Amount of each protein which would have entered liver in 
5 min if rate of entry were equal to rate of catabolism 
^ g / g wet wt) 
The same as % of amount actually present at 5 min after 
injection 
Time that would be required for entry of the amount of 
protein found after 5 min if it has entered only at the rate 
of catabolism (hours) 
Albumin 
142 
12 
8.5 
1.0 
Transferrin 
27 
2.1 
7.8 
1.08 
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liver if the rate of entry had been no more than the expected rate of catabolism 
(Table I). The simplest explanation of the large excess of labelled albumin and 
transferrin over the expected amounts would, of course, be the retention in the 
liver of trapped plasma. Although the retention of traces of plasma as a result of 
inefficient perfusion with saline may well have occurred another mechanism also 
seems likely. This conclusion follows from the observation that the ratio of trans­
ferrin to albumin in the liver homogenate is approximately twice that in the plasma 
(Figure 1). Evidently concentration of transferrin relative to albumin has occurred 
during the process of absorption into the cells. 
A L B U M I N 
Proteic I ' Non Proteici' Total J * \ß- Ci ycerophosphat ase 
0 
ι Γ 
I - T R A N S F E R R I N 
50 100 0 50 100 0 50 1001 0 —ι 1 1 ι 1 1 1 1 ι 1 1 1 
N H L />' S ' N M L Ρ' S' 
I I 1 L-
N H L P' S' 
_l I I I 
0 50 100 0 50 100 0 50 1001 0 50 100 
PERCENTAGE OF TOTAL RECOVERED PROTEINS Q: 
Figure 3. — Average distribution patterns. 
An important consequence of the observation of relatively large amounts of 
albumin and transferrin in the liver cells is that if these proteins are not present 
as trapped plasma and have entered the cells at a rate much higher than that needed 
for catabolism then the excess of each protein which has not been catabolised must 
return to the vascular system either directly to the plasma by some kind of regur­
gitation or indirectly via lymph. 
Although the transport of substances conveyed through cells by cytoplasmic 
granules (diacytosis) with little if any enzymic breakdown, has been reported for 
some epithelia (Odor, 1956; Farquhar and Pålade, 1960; Straus, 1961; Brambell 
et al., 1964), the concept of transit of plasma proteins through liver cells is, of course, 
still hypothetical. However, if the existence of such a process can be firmly esta­
blished, a possible explanation would be available for the catabolism of plasma 
proteins in many other organs. Thus, protein molecules slightly altered during 
passage through the liver or the kidney tubules would be picked up by cells of the 
R. E. system wherever these might be found. 
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DISCUSSION 
M. A. ROTHSCHILD (New York) : What fraction of the total radioactivity per 
gram of tissues could be recovered in the subcellular fractions ? 
P. JACQUES : Only a few per cent of the injected labeled proteins were recovered 
in the total liver but as much as seventy per cent of the labeled transferrin present 
in the liver or fifty percent of the albumin could be sedimented with the cytoplasmic 
particles; these are minimal values since the 10° g min supernatant is likely to contain 
micropinocytic vacuoles. 
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AND DEXTRAN AND CORTISONE ADMINISTRATION^) 
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Radioisotope Service, V. A. Hospital, the Department of Medicine, New York University School 
of Medicine, and the Department of Biochemistry, New York University College of Dentistry, 
New York, N. Y. U.S.A. 
ABSTRACT 
Hypoalbuminemia per se does not stimulate albumin production and dextran 
and gammaglobulin infusions depress albumin synthesis suggesting a colloid osmotic 
regulatory mechanism controlling albumin production. Since the plasma colloid 
osmotic pressure was not reduced, this mechanism was postulated to reside in 
hepatic extravascular fluid. This report describes the measurement of hepatic extra-
cellular space (14C-sucrose), plasma albumin (125I-aIbumin), and total exchangeable 
albumin (mI-albumin) in control rabbits, rabbits treated with dextran, and dextran 
and cortisone. Following distribution equilibrium of 131I-albumin, 125I-albumin and 
14C-sucrose were injected, livers and lung removed and tissue radioactivity compared 
with that in the plasma. Hepatic interstitial volume averaged 12 % in all groups. 
During dextran administration total exchangeable albumin fell 20 %, albumin 
degradation fell from 273 to 217 mg/kg/day, hepatic interstitial albumin rose from 
27 to 52 mg/100 g liver weight. Cortisone reversed these findings. Exchangeable 
albumin remained stable and albumin degradation rose from 245 to 320 mg/kg/day. 
Hepatic interstitial albumin decreased to 11 mg/100 g wet liver weight. The available 
hepatic interstitial space for albumin was limited to 10 % of the sucrose space. In 
the lung the pulmonary albumin space approximated 50 % of that for sucrose. 
Albumin is excluded from most of the hepatic interstitial fluid and this volume 
appears to provide a sensitive system for monitoring changes in colloid concentra-
tion. These results support the concept that albumin synthesis may be regulated by 
interstitial albumin or colloid within the liver. 
In previous studies (1) it was observed that the administration of dextran to 
rabbits resulted in a decrease in the serum albumin level and a loss of total exchan-
geable albumin. Similarly, the production of experimental hypergammaglobuli-
nemia has been shown to cause hypoalbuminemia and a lowered albumin pool 
<2' 4). In both situations the decrease in albumin pool size was due to a diminished 
rate of albumin synthesis (1· 4). These observations indicated that albumin synthesis 
was not stimulated by low plasma albumin levels per se and suggested that the 
mechanism responsible for albumin production might respond to changes in colloid 
osmotic pressure. Although the calculated osmotic pressure (5> e> in the plasma was 
not elevated in either circumstance when albumin synthesis was lowered, the pos-
sibility that such a colloid osmotic regulatory system was located within an extra-
vascular site, perhaps within the liver itself, could not be excluded u>. 
(*) Supported in part by United States Public Health Service Grant AM-02489. 
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The present report describes the measurement of albumin metabolism and 
hepatic albumin distribution in rabbits during the control state, in the presence 
of dextran and during dextran and cortisone administration. 
METHODS 
Extracellular space was measured with 14C-sucrose. Following the intravenous 
injection of 20-30 microcuries of 14C-sucrose, bloods were obtained at 20 minute 
intervals for 1 hour then 1-2 microcuries of 131I-albumin were injected in 15 control 
rabbits, 10 rabbits treated with 1.5 g of dextran daily and 10 rabbits treated with 
cortisone acetate 3 mg/kg/day in addition to the dextran for 10-18 days. The animals 
were anesthetized 5 minutes after the injection of 131I-albumin and heparanized 
blood obtained and the livers removed. The concentration of each isotope in liver 
tissue was compared to that in blood giving a simultaneous measurement of hepatic 
plasma volume and hepatic extracellular volume. The difference between these 
two values represents the hepatic extracellular-extravascular volume or interstitial 
volume (Table I). In 9 other rabbits 131I-albumin was injected and metabolic studies 
TABLE I 
A. 1) Tissue extracellular volume 
ml/g 
2) Tissue plasma volume 
ml/g 
B. 1) Tissue exchangeable albumin 
g/100 g wet tissue 
2) Tissue plasma albumin 
g/100 wet tissue 
_ 
— 
= 
= 
Equilibrium 14C-sucrose space 
6-10 minute 131I-albumin space 
Equilibrium l31I-albumin space X 
serum albumin concentration 
6-10 minute 12oI-albumin space X 
serum albumin concentration 
conducted during a control period following which the dextran infusions of 
1.5 grams/day, were instituted for 2 weeks, and albumin metabolism remeasured 
with a 2nd injection of 131I-albumin. After distribution equilibrium this 2nd dose 
of 131I-albumin and following the re-measurement of albumin metabolism, 125I-
albumin was injected, the animals anesthetized and livers removed as described 
above. Thus in these animals albumin metabolism was determined before and during 
dextran treatment as well as simultaneous measurements of total available space 
for albumin distribution in the liver determined with 131l-albumin, and hepatic 
plasma volume determined with 125I-albumin. The product of these spaces and the 
serum albumin concentration represents the hepatic exchangeable albumin and 
plasma albumin. The difference between these·quantities is the albumin located 
in the hepatic interstitial space (Table I). Similar studies were done in 6 rabbits 
injected with both dextran and cortisone, and the hepatic interstitial albumin in 
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both groups was compared to values obtained in 7 control rabbits. Total protein 
was determined by a biuret reaction (7> and protein partition by means of a Kern 
microelectrophoresis unit (1). Dextran was determined by the method of Roe (8). 
RESULTS 
Following the administration of dextran the hepatic extracellular volume 
increased (Table II). This increase was primarily due to an increased hepatic plasma 
volume. Since the total liver water remained unaltered, these changes were at the 
TABLE 
Extracellular volume (ml/100 g) . . . 
Plasma volume (ml/100 g) 
% change 
Interstitial volume (ml/100 g) . . . . 
% change 
Hepatic water (ml/100 g) 
II. — Hepatic spaces 
Control 
21.4 ± 0.9 
9.3 ± 0.6 
12.5 ± 1.1 
74.1 ¿ 1.2 
Dextran 
24.9 ± 1.1 
+ 14 
11.5 zz 0.4 
+ 24 
13.4 ± 1.2 
+ 7 
74.1 ± 1.3 
Dextran + 
Cortisone 
19.8 ± 1.0 
— 20 
10.2 ± 0.7 
— 11 
9.6 ± 1.2 
— 28 
70.5 ± 0.7 
TABLE III. — Albumin metabolism 
Mean 
± SE 
% change . . . 
Ρ value . . . . 
Serum 
albumin 
g/100 ml 
C E 
3.6 2.6 
0.1 0.1 
1—33 
< 0.001 
Τ. Ε. Α. 
g/kg 
C E 
3.3 2.6 
0.2 0.1 
­ 2 1 
< 0.001 
Albumin 
degradation 
mg/kg/day 
C 
273 
17 
E 
217 
15 
—21 
<0 .05 
Hepatic 
interstitial 
albumin 
mg/100 g 
I 
Control* Dextran 
27 52 
6 6 
+93 
< 0 . 0 2 
C = Control. 
E = Experimental. 
* = Mean of 7 control rabbits. 
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expense of cellular water. Upon the addition of cortisone the extracellular space, 
plasma volume and interstitial volume decreased and there was a fall in total hepatic 
water. The effects of dextran on albumin metabolism and distribution are summa­
rized in Table III. Serum albumin fell 33 %, exchangeable albumin pool 21 % 
and albumin degradation fell 21 %. In the face of this decrease in the serum albumin 
levels and the exchangeable albumin pool: hepatic interstitial albumin rose from 
27 to 52 mg/100 gms of wet liver weight .The presence of any dextran in the inters­
titial fluid of the liver would have resulted in an even larger increment in colloid 
concentration than that due to albumin alone. The results of the studies in rabbits 
treated with dextran and cortisone are shown in Table IV. In contrast to the dextran 
rabbits the serum albumin concentration decreased only 18 % and there was no 
change in the exchangeable albumin pool albumin degradation increased by 35 % 
and this change was accompanied by a decrease in hepatic interstitial albumin. 
The addition of cortisone was accompanied by an increase in body plasma volume 
without a decrease in the dextran level in the plasma indicating that extravascular 
dextran was probably shifted into the plasma. This shift of dextran would probably 
result in a greater decrease in interstitial colloid osmotic pressure than the change 
in albumin would indicate. 
TABLE IV. Albumin metabolism 
Mean 
± SE 
% change . . . 
Ρ value . . . . 
Serum 
albumin 
g/100 ml 
1 
C E 
3.4 2.8 
0.1 0.1 
— 18 
<0.01 
Τ. Ε. Α. 
g/kg 
C 
3.0 
0.1 
E 
2.9 
0.1 
—3 
Albumin 
degradation 
mg/k 
C 
245 
10 
g/day 
E 
320 
26 
+ 35 
< 0 . 0 5 
Hepatic 
interstitial 
albumin 
mg/100 g 
| 
Control* 
27 
6 
Dextran 
Corti­
sone 
11 
4 
—60 
<0 .05 
* Mean of 7 control rabbits. 
DISCUSSION 
These studies demonstrate again that albumin synthesis does not increase 
in relation to low levels of serum albumin and that the extracellular distribution 
of albumin doesnot necessarily change in the same direction as the plasma albu­
min concentration. 
Upon the administration of dextran there were changes in the hepatic plasma 
volume and extracellular space which did not exactly parallel the body as a whole. 
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The hepatic extracellular volume did increase but this was primarily due to an 
increase in plasma volume. This change in volume was at the expense of cellular 
water since total liver water remained unaltered. However, in the presence of a 
fall in plasma albumin levels during dextran infusions, the hepatic interstitial albumin 
concentration rose. The presence of any dextran in the interstitial fluid of the liver 
would have resulted in an even large increment in colloid concentration than 
that due to albumin alone. A lowered albumin synthesis was associated with an 
increased interstitial colloid concentration. 
Following the addition of cortisone, the changes within the liver produced by 
dextran were reversed and the extravascular albumin content of the liver decreased. 
The addition of cortisone was also accompanied by an increase in body plasma 
volume without a decrease in the dextran level in the plasma as has been noted 
before (1) indicating that extravascular dextran was probably shifted into the plasma 
resulting in a decrease in interstitial colloid concentration probably more marked 
than the change in albumin level would indicate. 
Previous studies have shown that in the presence of excess adrenocortical hor-
mones the rate of albumin synthesis increases <12) particularly in rabbits pre-trea-
ted with dextran. In the latter group a significant shift in extravascular albumin back 
into the plasma occurred and this sift was again observed. Similar shifts associated 
with increased protein synthesis have been seen with thyroid administration and 
in Kwashiorkor. In the latter, the diminished albumin pool is due largely to a loss 
of extravascular albumin which is replenished by an increase in albumin synthesis 
upon the administration of an adequate diet <13). 
While it is recognized that an unequivocal statement concerning the relation-
ship between albumin synthesis and hepatic interstitial albumin cannot be made 
the concept proposed seems to fit the data. The results of this study show that the 
hepatic interstitial albumin exchangeable with plasma albumin is low and albumin 
synthesis seems to vary inversely with the levels of interstitial albumin or colloid 
within the liver. 
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DISCUSSION 
T. FREEMAN (London) : Your measurement of extravascular liver albumin 
depends on the difference between liver plasma space measured with 125I-albumin 
at 5-10 minutes and liver total extravascular albumin measured with 131I-albumin 
after equilibrium. If the former is erroneously high due to escape of labeled albumin 
prior to sampling the estimate of the extravascular albumin would be erroneously 
low. Could the changes you observe in apparent extravascular albumin after dex-
tran and dextran-cortisone be due to changes in permeability? Can you exclude 
this? 
M. A. ROTHSCHILD : While we have not excluded the possibility of specific 
alterations in sinusoidal permeability, such changes do not seem to explain our 
results. Firstly, in the case of dextran-treated rabbits both the plasma volume and 
total exchangeable albumin space within the liver were elevated above normal. 
If anything the plasma volume increase actually minimized the degree of expansion 
of the available total extravascular space for albumin distribution. In the rabbits 
treated with cortisone, on the other hand, the hepatic plasma pool/100 g wet liver 
weight was small and did not parallel the marked increase in the plasma volume for the 
body as a whole. Thus the data do not seem to indicate a leak at least within the 
liver itself. It is well known that there is extremely rapid equilibrium between the 
plasma and hepatic lymph. It has also been shown that there is no specific removal 
of 131I-albumin into the liver in one passage through the portal circulation. Also, 
in conditions with marked edema and congestive heart failure the ratio of 32P labeled 
red cells to 131I-albumin in whole blood remains constant after the first circulations 
indicate again no significant specific loss of albumin during these early time periods. 
Thus while it is still possible that the hepatic plasma volume may have been ove-
restimated the leak must have been small and furthermore if present would have 
tended to minimize the results. 
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ABSTRACT 
The labelling of a pure protein, a.2­macroglobulin, was effected by ttvo different 
techniques using chloroform or chloramine T. 
This protein was isolated from human plasma by a technique based on the use 
of rivanol and adsorption of the impurities on bentonite and DEAE cellulose. The 
purity of this preparation of oi2­macroglobulin was checked by several techniques 
— electrophoretic and immuno­electrophoretic — and was shown to be homogeneous 
by ultracentrifugation study. 
The half­life of various preparations of this protein was studied in human subjects. 
The results obtained by various labelling techniques are also reported. 
RESUME 
Le marquage d'une protéine pure, l'a2­macroglobuline, a été réalisé par deux 
techniques différentes au chloroforme et à la chloramine T. 
Cette protéine a été isolée pure à partir du plasma humain par une technique 
basée sur l'emploi du rivanol et l'adsorption d'impureté sur bentonite et DEAE 
cellulose. La pureté de cette préparation d'a2­macroglobuline a été vérifiée par 
différentes techniques électrophorétique, immuno­électrophorétique et s'est montrée 
homogène à l'ultracentrifugation. 
La demi­vie de différentes préparations de cette protéine a été étudiée chez 
l'Homme ainsi que les résultats des différents moyens de marquage. 
T E C H N I Q U E D E P R E P A R A T I O N D E L ' O ^ ­ M A C R O G L O B U L I N E 
L'a2­macroglobuline a été préparée à partir du plasma par une technique fai­
sant intervenir successivement plusieurs précipitations par le rivanol, l'adsorption 
du plasminogène contaminant par la bentonite et celle des dernières impuretés 
sur DEAE­cellulose, Γα2­Μ restant non­adsorbée dans les conditions choisies. 
La protéine purifiée peut être ensuite concentrée par les moyens habituels (1). 
L'a2­M s'est révélée homogène à l'ultracentrifugation, en électrophorèse en 
gel d'amidon et en immuno­électrophorèse (Figure 1). 
TECHNIQUES DE MARQUAGE 
Le marquage de Γα.2­Μ par l'iode­131 a été effectué par deux techniques diffé­
rentes. L'une est basée sur l'emploi de la chloramineT comme oxydant (2> 2b,s'3>, l'autre 
sur l'emploi de I03K, en présence de IK et de S04H2, le chloroforme étant utilisé 
comme véhicule (4). Le temps de marquage pour la technique à la chloramineT est 
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d'une minute. En ce qui concerne la deuxième méthode, on prépare le réactif radio-
actif par extraction au chloroforme de l'iode-131, cette préparation est ensuite mise 
en contact avec la solution protéique en assurant une agitation lente et continue 
pendant plusieurs heures. 
Le chloroforme étant très dénaturant pour de nombreuses protéines, il n'est 
pas étonnant que la première technique nous ait donné de meilleurs résultats et 
c'est pourquoi nous l'avons retenue pour des études ultérieures. 
Quel que soit le procédé de marquage on a éliminé l'iode libre par absorption 
sur IRA-400 puis par dialyse contre du citrate trisodique 0,1 M. La teneur de nos 
préparations en iode libre était inférieure à I % dans tous les cas. 
PLASMA 
PRECIPITE 
( 5 % de protéines 
j pH 8,6 
P R E C I P I T A T I O N P A R L E R I V A N O L 
(1,8 volume à 0,5 %) 
SURNAGEANT (à pH 6,4) 
! 
P R E C I P I T A T I O N P A R L E R I V A N O L 
(0,44 volume à 0,5 %) 
PRECIPITE 
SURNAGEANT 
EXTRAIT (NaCi 3 %) EST DIALYSE (2 h contre H.O pH 6,4) 
Puis PRECIPITE par 0,38 volume de rivanol à 0,5 % 
SURNAGEANT 
PRECIPITE 
APRES DISSOLUTION (NaCl 3 % ) , DIALYSE contre H 2 0 
ADSORPTION SUR BENTONITE à pH 8,6 puis 
ADSORPTION SUR DEAE-CELLULOSE, 0,015 M ACETATE pH 5 
«ä-MACROGLOBULINE 
FIGURE 1. — Technique d'isolement de l'^-macroglobuline 
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L'absence de denaturation de l'oc2­M marquée a été vérifiée par électrophorèse 
en gel d'amidon et immuno­électrophorèse. En plus nous avons vérifié si les pro­
priétés biologiques de Γα2­Μ se trouvaient modifiées après marquage et nous avons 
choisi son activité comme antithrombine progressive pour apprécier l'intégrité 
de notre protéine (5). En effet l'a2­M se comporte comme l'antithrombine III et les 
tests ont démontré que la chloramine Tétait moins dénaturante que le chloroforme 
ce qui n'est pas étonnant car on sait que le chloroforme détruit l'activité de l'anti­
thrombine progressive du plasma (tableau I). 
Après ces vérifications in vitro nous avons procédé à l'étude in vivo. 
TABLEAU I. — Etude de l'activité de l 'a2­M marquée comme antithrombine progressive 
Système coagulant : 0,05 ml thrombine 40 u/ml 4­ 0,05 ml de solution à tester + 0,4 ml fibrino­
gène à 1,75 g/L de protéines coagulables 
Témoin : 
Thrombine Roche 40 u/ml 
Tampon citrate 
aü­M non marquée 
(Thrombine Roche 40 u/ml 
+ 
a2­M 1 %) 
a2­M marquée chloroforme 
(Thrombine Roche 40 u/ml 
a2­M marquée 1 %) 
7.2­M marquée chloramine T 
(Thrombine Roche 40 u/ml 
­f 
a2­M marquée 1 %) 
Temps 
d'incubation 
0 mn 
5 mn 
10 mn 
0 mn 
5 mn 
10 mn 
0 mn 
5 mn 
10 mn 
0 mn 
5 mn 
10 mn 
Temps 
de coagulation 
15 s 
16 s 
17 s 
17/18 s 
125 s 
256 s 
18 s 
70 s 
150 s 
18 s 
105 s 
195 s 
INJECTION DES PROTÉINES CHEZ L'HOMME 
L'7.2­M a été injectée à des malades chroniques, ne présentant cliniquement 
ni signe d'insuffisance cardiaque, ni œdèmes ou épanchements dans les séreuses, 
et biologiquement ne présentant ni anémie, ni troubles métaboliques, la vitesse de 
sédimentation et les diagrammes électrophorétiques étant toujours normaux. Le 
premier prélèvement a été fait 15 minutes après l'injection pour le dosage de la radio­
activité de départ; puis toutes les 6 heures pendant 24 heures et enfin tous les deux 
σ2 Μ η° HI 
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jours pendant 16 jours. En ce qui concerne les comptages, ils ont été pratiqués dans 
un compteur à scintillation automatique pendant 10 minutes pour chaque prélèvement. 
Le calcul de la demi­vie et le taux de dégradation ont été faits selon la technique 
proposée par Matthews (6). 
R E S U L T A T S E T D I S C U S S I O N 
Les meilleurs résultats ont été obtenus en utilisant un produit de départ non 
lyophilisé et marqué en présence de chloramine. De cette façon on a pu obtenir 
des courbes de décroissance de radio­activité plasmatique superposables notamment 
chez 4 témoins, à· partir desquelles on a pu définir d'une part une exponentielle 
lente correspondant à la dégradation de la protéine dans le secteur intravasculaire, 
et d'autre part une exponentielle rapide correspondant à l'équilibre de diffusion 
entre le secteur vasculaire et le liquide interstitiel (Figures 2 et 3). Si le marquage 
est effectué sur un produit préalablement lyophilisé ou sur un produit liquide mais 
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en présence de chloroforme, la courbe obtenue débute par une chute rapide de la 
radio­activité dans les deux premières heures, ce qui permet de définir une troisième 
exponentielle, très rapide, et qui indique une certaine denaturation de la protéine 
injectée (Figure 4). L'ensemble des résultats figure sur le tableau II. Comme mesure 
de la demi­vie on obtient pour l'exponentielle lente un chiffre moyen de 10,5 jours 
et pour l'exponentielle rapide un chiffre de 17 h 30 et pour le pourcentage de dégra­
dation quotidien un chiffre moyen de 10,1 % (K 12), établi pour les courbes VI 
et VII en tenant compte de la radio­activité correspondant à la protéine dénaturée 
soit pour la courbe VI 16 % de la radio­activité de départ, et pour la courbe VII 
14 %. Sur le tableau figure également le K 13 (% de protéines intravasculaires 
passant par jour dans le pool extra­vasculaire) et le K31 (% de protéines extra­
vasculaires passant par jour dans le pool intravasculaire). 
TABLEAU II. — Résumé des résultats concernant l'a^­maciOglobuline 
I« 
II 
III 
IV 
ν 
VI« 
VII« 
Etat du 
produit 
avant 
marquage 
Lyophilisé 
Liquide 
Liquide 
Liquide 
Liquide 
Liquide 
Liquide 
Technique 
marquage 
Chloramine 
Chloramine 
Chloramine 
Chloramine 
Chloramine 
IK + 103K+ 
S0 4 H. chlo­
roforme 
IK + 103K + 
S04H2 chlo­
roforme 
Nombre 
d'atomes 
Iode fixé par 
molécule 
PM. 900.000 
1 
3 
3 
3 
3 
0,6 
0,6 
Activité 
spécifi­
que 
μο/ιτ^ 
1,5 
6 
6 
6 
6 
1,9 
1,9 
Pro­
téines 
injec­
tées 
en mg 
70 
15 
15 
15 
15 
50 
50 
Moyenne 
Τ'/, 
en 
jour 
8,5 
9 
11,5 
10 
10,5 
13 
9 
10,5 
Taux de 
dégrada­
tion/jour 
% 
K L . 
/ 
11,7 
9 
9,7 
10,1 
10,3 
13,1 
10,6 
K 1 3 
27 
27 
27 
35 
K 3 1 
60,4 
62,2 
73,1 
59,4 
a Echantillons présentant une troisième exponentielle d'élimination très rapide correspondant 
à une denaturation partielle de la protéine. Les résultats de II à VII correspondent au même 
lot de α,­Μ 
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En conclusion on peut dire que la demi-vie de Γα2-Μ (10,5 jours) est nettement 
plus longue que la demi-vie de l'autre macroglobuline du plasma, la γΜ-globuline, 
qui est d'environ 5 jours chez les sujets normaux (7>. 
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DISCUSSION 
V. Bocci (Sienna) : May I ask what amounts of Chloramine Τ and a2­macro­
globulin you have used ? 
C. REUGE : Le taux de Chloramine est toujours le même; il représente 1 % 
du poids de la protéine. 
G. MILHAUD (Paris) : Je voudrais vous demander si le marquage en présence 
du chloroforme n'a pas un effet sur les lipides que peut contenir votre protéine ? 
C. REUGE : L'a2­macroglobuline ne contient pas de lipide. 
R. NORBERG­STENBECK (Stockholm) : I want to point out that we have prepared 
a2­macroglobulin by combining gel filtration on Sephadex G 200 and zone elec­
trophoresis in Polyvinylchloride according to the following scheme : 
electrophoresis in Polyvinylchloride 
Serum > a2­fraction 
19 S fraction < 
ultrafiltration 
> a2­macroglobulin 
The method is quite simple and gives a pure undenaturated fraction. 
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ABSTRACT 
The commonly accepted site of albumin degradation is the intravascular pool. 
The methods for calculating the catabolic rate assuming intravascular degradation 
are based upon the activity in urine/activity in plasma ratio. The same result can be 
obtained by analysis of the plasma curve. Theoretically, these calculations would 
give the same results after both intravenous and subcutaneous administration of 
iodized albumin. 
In 10 cases, 131I-albumin was injected subcutaneously and the radioactivity was 
measured in urine and in blood samples for three weeks. In 6 of the cases, 125l-albumin 
was simultaneously injected intravenously. 
The urine excretion of activity was almost identical after subcutaneous and 
intravenous administration of albumin, while the plasma activity after subcutaneous 
injection first reached its maximum value after about 5 days. Calculation of the 
intravascular degradation of albumin in accordance with various commonly accepted 
principles leads to the conclusion that 10-20 % of the subcutaneously injected albumin 
is catabolized extravascularly in normal subjects. In patients suffering from protein-
losing diseases, there was found to be a smaller percentage of extravascular albumin 
catabolism than in normal subjects. 
The finding is discussed with particular reference to protein denaturation and 
lymphatic flow. 
When radioiodinated albumin is injected intravenously, the labelled protein 
is broken down and the liberated radioiodide is excreted in the urine. The decline 
of the plasma concentration and the renal excretion of radioiodide run a parallel 
course, which has led to the conclusion that albumin is broken down within or 
close to the intravascular compartment. For the same reason the catabolic rate 
can be calculated from the plasma curve alone or as the renal clearance of labelled 
protein in plasma (U/P ratio). 
In the present investigations the degradation of labelled albumin was measured 
after subcutaneous injection of the protein with the specific purpose to demonstrate 
a possible extravascular site of catabolism. 
METHODS 
Two labelled preparations of human albumin (Behringswerke, Marburg, Ger-
many) were applied, one labelled with 125I, one with 131I. More than 99.5 per cent 
of the label was proteinbound. For each study about 20 \LC\ of either preparation 
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were used. To prevent thyroid uptake of the label, 150 mg of stable KI was give 
orally each day throughout the study beginning 2 days before the injection. A 
patients received simultaneous injections of 125L­aIbumin intravenously and 131 
albumin subcutaneously or into the peritoneal cavity. The dose was given in 1 
ml isotonic saline. 
Daily determinations were performed of plasma activity, renal radioiodic 
excretion and, by external counting, of the radioactivity at the site of subcutaneoi 
injection. The two isotopes were measured separately by means of single chann 
analyzers. 
CALCULATIONS 
ANALYSIS OF PLASMA CURVE. 
A simple way of calculation was given by Nosslin (1). The fractional catabol 
rate (that fraction of the Intravascular pool which is broken per day) is obtaine 
from the reciprocal of the area under the plasma curve (Eq. 1). With a slight tran 
cription the equation is identical to that given by Matthews (2). 
100 Fractional catabolic rate = j ^ — per cent/day (1) 
Jo Cp dt 
where Cp, is the plasma concentration. 
If the degradation occurs only in the intravascular compartment, the an 
| Cp dt) ) will be the same no matter whether the injection is given "momentarily 
(i.e. intravenously) or not. Following subcutaneous injection one may visuali: 
the input function from subcutaneous tissue to plasma pool as a protracted intr 
venous injection, and the area under the ensuing plasma curve should be identic 
to that following a true intravenous injection of the protein provided the plasn 
concentration is given in the same unit. A relative value is applied as unit : observi 
concentration as fraction of the theoretical concentration obtained, if the tot 
injected dose were present in the plasma pool. The latter is known from the simi 
taneous intravenous injection of 125I­albumin. Following subcutaneous injection tl 
area was determined by a combination of weighing and calculation. The area 
the observed part of the curve (until the last plasma sample) was determined 1 
weighing. The rest was calculated, since it had to be extrapolated to infinite. Th 
was possible, because the plasma curve almost invariably assumed a final monoexp 
nential decline. Hence 
Τ 1/2 
Aextrapol. — Q ¿gì Cp¡ (2) 
where 
Aextrapol. = a r e a under extrapolated part of the plasma curve 
Cp; = relative plasma concentration in the last plasma sample 
T 1/2 = halftime (days) of the final exponential decline. 
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Now. the extravascular degradation (D e x t r a v a s c . ) was calculated from 
A- —A 
Dextravasc. = ~ V " " * 100 per cent of DintraVasc. (3) 
A,·,, 
where 
A;i, = area under plasma curve of 125I-albumin after intravenous injection 
A . = area under plasma curve of ,31I-albumin after subcutaneous injection. 
METABOLIC CLEARANCE. 
The fractional catabolic rate was also calculated as the average of daily U/P 
ratio determinations expressed as fraction of the plasma volume l3). 
U/P 
Fractional catabolic rate : ——- day 1 (4) 
CASE MATERIAL 
GROUP 1. 
Six patients from 31 to 81 years of age received subcutaneous and intravenous 
injections. None of them had abnormal gastrointestinal protein loss, oedema or 
ascites. One (No. 3) had a slight proteinuria due to chronic pyelonephritis. The 
diagnoses are listed in table I. 
TABLE I. — Extravascular degradation and subcutaneous elimination rate of labelled albumin in 
6 patients 
Patient 
1 
2 
3 
4 
5 
6 
Age 
78 
79 
81 
43 
46 
31 
Sex 
F 
F 
F 
M 
F 
1 
Diagnosis 
Left hemiparesis 
Senile dementia 
Diabetes 
Chronic pyelone-
phritis 
Disc degeneration 
Cyclic oedema 
Traumatic oedema 
of left leg 
Mean 
Serum 
albumin 
g/100 ml 
3.65 
4.86 
2.12 
4.00 
4.68 
4.70 
4 
Synthetic 
rate of 
albumin 
g/kg/day 
0.146 
0.162 
0.266 
2.205 
0.185 
0.231 
0.206 
Extravascular 
albumin 
degradation 
(Eq. 3, see 
text), % 
29 
19 
8 
1 
14 
8 
13 
Disappea-
rance rate 
from subcut. 
inject, site, 
0.693/T 1/2 
0.20 
0.22 
0.26 
0.53 
0.77 
1.16 
0.52 
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GROUP 2. 
Three patients with cirrhosis of the liver and ascites had intraperitoneal and 
intravenous injections (table II). 
RESULTS 
GROUP 1 (subcutaneous injection). 
In group 1 the albumin synthesis was within normal range in everyone (table I). 
An extravascular degradation was demonstrated in all except one (No. 4). On an 
average it amounted to 13 per cent of the simultaneous "intravascular" degradation 
of 125I­albumin (given intravenously). 
The elimination of 131I­albumin from the subcutaneous injection site was rather 
slow in the 3 first patients, which may be due to the fact that they were elderly bedrid­
den patients (table I, last column). 
A percentage 
Q R (¡.v.) 
0.R (S.CJ 
Qu 
21 DAYS 
FIGURE 1. — Plasma concentration of labelled albumin (top) and urinary radioiodide excretion 
(bottom) following subcutaneous (mI­albumin) and intravenous ('­r'l­albumin) injection. 
The values are relative (per cent of injected dose), and each one represents the average of six 
studies (group 1). 
( ) : 131I­albumin or ,31I (sube). 
( ) : 125I­albumin or 125I (¡.v.). 
EXTRAVASCULAR DEGRADATION OF ALBUMIN 155 
The average renal radioiodide excretion and plasma concentration of all six 
patients are graphically depicted in Figure 1. It is seen that the radioiodide excre­
tion was almost identical after subcutaneous and intravenous injection. 
The fractional catabolic rate calculated from daily U/P-ratios is shown in 
Figure 2. The high catabolic rate of 131I-albumin (given subcutaneously) is obvious. 
20 
15-
10 
5-
U/pX 100 
—ι—r-
6 
—ι—i- i—ι—ι—r 
9 12 15 18 21 DAYS 
FIGURE 2. — Daily fractional catabolic rates calculated as U/P — ratio following subcutaneous 
,3,I-albumin injection ( ) and intravenous 125I-albumin injection ( ). 
Each curve represents the average of six studies. 
TABLE II. — Extravascular degradation of labelled albumin injected intraperitoneally in 3 patients 
with cirrhosis and ascites 
Patient 
1 
2 
3 
Age 
50 
78 
52 
Sex 
F 
F 
F 
Serum albumin, 
g/100 ml 
2.30 
3.00 
2.58 
Synthetic rate 
of albumin, 
g/kg/day 
0.148 
0.103 
0.088 
Extravascular 
albumin 
degradation 
(Eq. 3), % 
0 
11 
13 
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GROUP 2 (intraperitoneal injection). 
The findings in group 2, who received intraperitoneal 131I-albumin and intra­
venous 125I-albumin injections, were similar to those of group 1 (table II). An extra­
vascular degradation was evident in 2 patients. 
DISCUSSION 
The fact that the metabolic clearance (U/P ratio) remains constant from day 
to day after intravenous injection of iodine-labelled albumin has been considered 
a proof that albumin breakdown takes place in the intravascular compartment. 
In the present investigations an extraordinary high U/P ratio was found to be present 
during the first days following subcutaneous injection of labelled albumin. Later, 
when the plasma curve followed an exponential decline, the U/P ratio did not differ 
from that observed for labelled albumin given intravenously. 
An undue high initial excretion of radioiodide in the kidneys usually indicates 
denaturation of the labelled protein. However, denaturation could hardly account 
for the observed high U/P ratio. First, the amount of radioiodide excreted during 
the first days was of the same order of magnitude (as fraction of the injected dose) 
after both intravenous and subcutaneous injection. Furthermore, when the 131I-
labelled albumin preparations used for subcutaneous injection, were given intra­
venously to other patients, no undue high renal radioiodide excretion was observed 
within the first days. As a final check another 131I-albumin preparation was given 
to normal persons. Two had a subcutaneous injection, and 2 an intravenous injec­
tion. The excretion pattern of liberated 131I did not differ from that of the previous 
studies. Consequently, the phenomenon could not be ascribed to the use of denatured 
protein. Still, denaturation might occur somewhere on the absorption route from 
subcutaneous tissue to blood, but this would equal a degradation. 
We therefore conclude that an appreciable part of 131I-labelIed albumin injected 
subcutaneously is broken down in the extravascular compartment before it reaches 
the blood. 
Now the question arises whether this is incompatible with the common methods 
of calculating albumin degradation rate. Many of these methods assume — or 
are claimed to assume — an "intravascular" degradation. However, for the mathe­
matical correctness of the various formulas it is insignificant whether degradation 
occurs intra- or extravascularly, if only the transfer rate of the protein from blood 
to degradation site is much larger than the degradation rate. In fact, Nosslin has 
shown that the formula using the area under the plasma curve (Eq. 1) is valid no 
matter where in the body protein degradation takes place (cited by Andersen 
1964) (1». 
When radioiodinated albumin is given intravenously, a period of 3 to 6 days 
will elapse before an approximate equilibrium is present between specific activity 
in the intra- and the extravascular compartment. However, since the transfer rate 
of albumin from blood to extravascular space is about 150 per cent of the plasma 
pool per day (4), an extravascular degradation site is easily conceivable. Our finding 
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that renal radioiodide excretion during the first days was nearly the same after intra-
venous and subcutaneous injection, actually suggests that the extravascular degra-
dation may take place at any "site" of the extravascular compartment, since the 
subcutaneous tissue of the calf is almost as remote from the blood as it can be. 
Following subcutaneous injection an average of 13 % of the total degradation 
took place extravascularly. This is a minimum figure, since we have no way to assess 
the fraction of extravascular degradation once the labelled protein has reached 
the blood. For the same reason it is not amazing that persons with a high absorption 
rate seemingly had a smaller extravascular degradation (table I). 
As to the actual site of extravascular degradation, the present investigations 
may offer some clue. It is close at hand to consider the lymphatic system a possible 
degradation site, since a similar "extravascular" degradation was found after sub-
cutaneous injection and after injection into ascitic fluid. The lymphatic system repre-
sents the only common absorption route from the 2 injection sites. It is in keeping 
with our findings in two patients with abstructive lymphedema of the legs. In these 
patients the absorption of 131I-albumin injected subcutaneously was very slow and 
the renal 131I-excretion extremely low. 
CONCLUSION 
Following subcutaneous and intraperitoneal injection of radioiodine-labelled 
albumin a high fractional catabolic rate (U/P ratio) was found during the first days 
after the injection. It seems to reflect extravascular degradation of the protein. The 
phenomenon is not incompatible with the common models used for calculation 
of degradation rate, when labelled albumin is given intravenously, but the formulas 
derived from these models can only be applied when the labelled protein is injected 
intravenously. 
The figures given for extravascular degradation are minimum values. The lym-
phatic system is believed to represent an important extravascular degradation site. 
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DISCUSSION 
P. DYKES (Birmingham) : In studying albumin transfer rates between plasma 
and ascitic fluid in humans, I injected 131l­albumin intraperitoneally and measured 
also urinary excretion of 131I. Figures obtained for fractional catabolic rate were 
never high enough to suggest a significant amount of extravascular catabolism. 
K. HØEDT­RASMUSSEN : We have also injected 131I­albumin in the ascitic fluid 
of patient suffering of cirrhosis and our results are the same as yours but you did 
not say what your plasma concentration was at the time you measured the urine 
excretion. The point is that you have an urine excretion in spite of a very low plasma 
concentration. 
M. A. ROTHSCHILD (New York) : It is hard to reconcile this view of an extra­
vascular degradative site particularly in patients with ascites, with Berson and Yalow 
previous studies (Berson S. Α., Yalow T. S., J. Clin. Invest., 33, 322, 1954). These 
authors have clearly shown that following the injection of iodinated human serum 
albumin into ascitic fluid the rate of degradation paralleled the intravascular concen­
tration not that in the ascitic fluid. It is possible that a slight degree of denaturation 
of a small fraction of the tracer protein could account for the high excretion observed 
in the first few days following subcutaneous injection. 
METABOLISME DE LA 131I-SERUMALBUMINE 
CHEZ LE RAT 
G. MILHAUD et P. GUILLIEN 
Laboratoire des Isotopes, Institut Pasteur, Paris 
ABSTRACT 
Rat serumalbumin was prepared and labeled with 131I. After I. V. injection, the 
changes of the specific radioactivity, Rs, with time can be expressed by the relation : 
Rs = A1 e-"u + A2 é?-«2t 
Serumalbumin metabolism can be represented by a two compartments model. 
In the normal rat as well as in the rat with tied ductus lymphaticus we have measured : 
the masses of the compartments, the rate of exchange between the compartments, 
lhe rate of total way out from the pool, the fecal excretion of serumalbumin. 
RÉSUMÉ 
La sérumalbumine de rat a été préparée et marquée à l'iode 131. Après une 
injection I. V., les changements de la radioactivité spécifique, Rs, dans le temps 
peuvent s'exprimer selon l'équation : 
Rs = At e~alt + A2 e- alt 
On peut représenter le métabolisme de la sérumalbumine au moyen d'un modèle 
à deux compartiments. Nous avons mesuré, chez le rat normal et chez le rat à canal 
lymphatique lié, la masse des compartiments, la vitesse d'échange entre les compar-
timents, la vitesse de sortie hors du fonds commun, l'élimination fécale de sérum-
albumine. 
Nous nous sommes proposé d'étudier l'influence de la ligature du canal tho-
racique sur le métabolisme de la sérumalbumine chez le rat. 
L'albumine de rat est précipitée, à partir du sérum, par relargage répété au 
sulfate d'ammoniaque en milieu acide. Le précipité est repris dans du tampon phos-
phate 0,10 M de pH 7,4 et dialyse contre une solution de chlorure de sodium à 
9 %0. L'analyse électrophorétique sur papier montre la présence d'un seul composé 
migrant comme l'albumine (Figure 1). L'albumine est iodée à pH 8, en utilisant le per-
sulfate d'ammonium en présence de carbonate de guanidine pour oxyder l'iodure-
131. La quantité d'iodure utilisée est telle que l'albumine contient environ 1 atome 
d'iode par molécule. Après dialyse, la pureté de la sérumalbumine marquée est 
vérifiée par électrophorèse en milieu gélose suivie de radioautographie à l'aide de 
film Kodak no-screen. Toute la radioactivité est présente dans la tache correspon-
dant à la sérumalbumine. Le rendement en radioactivité varie entre 35 et 45 °/„. 
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A 
1 
FIGURE 1. — Analyse électrophorétique. A : Sérum de rat: B : Albumine de rat 
Nous avons utilisé des rats mâles WISTAR CF, pesant de 130 à 140 g, répartis 
en trois groupes : 
1) Le groupe L comprend 5 rats chez lesquels le canal thoracique est ligaturé 
pour provoquer une stase lymphatique dans le réseau intestinal. Après anesthésie 
à l'éther, la voie d'abord est postéro-latérale gauche, sous la dernière côte; le canal 
thoracique est satellite de l'aorte. Son repérage est facilité par l'administration 
par gavage d'un ml d'huile d'olive, 90 mn avant l'intervention : le canal lympha-
tique apparaît sous forme d'un cordon blanchâtre. 11 est ligaturé à l'aide d'un fil 
de nylon. 
2) Le groupe G comprend 3 rats, chez lesquels la veine cave supérieure gauche 
est ligaturée pour essayer de provoquer une hyperpression dans le système cave 
supérieur gauche, où se déverse le canal thoracique. L'ouverture du thorax se fait 
par exérèse de la partie antéro-latérale de la deuxième côte. Le pneumothorax est 
réduit, après suture serrée de la brèche, par aspiration de l'air restant dans l'hémi-
thorax à l'aide d'une aiguille montée sur une seringue étanche. 
3) Le groupe D comprend 4 rats, chez lesquels la veine cave supérieure droite 
est liée, comme il a été décrit pour le groupe précédent (il existe deux systèmes vei-
neux caves supérieurs chez le rat (1)) : ce groupe sert de groupe témoin. 
Entre le 14e et le 16e jour après l'intervention chirurgicale, on injecte la sérum-
albumine de rat marquée par voie intra-veineuse, puis on prélève du sang par ponc-
tion dans le sinus rétroorbitaire aux temps 0,25; 22; 43; 91 et 163 h. On mesure la 
radioactivité plasmatique à l'aide d'un compteur à scintillation. Les selles sont 
recueillies entre 0 et 48 h après l'injection d'albumine; on administre du carmin 
par gavage, pour délimiter la fin de la période expérimentale. Les selles sont broyées 
au mixer dans de l'eau distillée et comptées, puis la radioactivité liée aux protéines 
est mesurée en précipitant les protéines par l'acide trichloracétique à 10 %. 
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RESULTATS 
La variation de la radioactivité spécifique de la sérumalbumine, Rs, en fonction 
du temps peut être exprimée par la relation : 
Rs = A1 e~al' + A2 e­"2' 
Un modèle très simple, à deux compartiments, peut représenter le métabolisme 
de la sérumalbumine (Figure 2) : 
— le compartiment plasmatique P, sur lequel on fait porter l'entrée et la sortie de 
l'albumine. 
— le compartiment extravasculaire E. 
FIGURE 2. — Représentation schématique du métabolisme de la sérumalbumine chez le rat. Ρ 
et E sont les deux compartiments du fonds commun, Ve, la vitesse d'échange entre Ρ et E; 
Vs désigne la vitesse de synthèse de la sérumalbumine et V j , la vitesse de sortie irréversible. 
Le Tableau I rapporte les valeurs moyennes de P, E et de trois paramètres : 
— la demi­vie de la sérumalbumine, définie comme le temps nécessaire au renou­
vellement de la moitié de la masse totale de l'albumine T y2. 
— la vitesse totale de sortie hors du fonds commun, VT­
— l'excrétion de la sérumalbumine dans les selles, V/. 
TABLEAU I. — Valeur moyenne et erreur­type de la moyenne des masses des compartiments P et 
E, des vitesses VT et Wf et de la demi­vie Τ1/2 de la sérumalbumine dans les différents groupes. 
Grou­
pes 
D 
G 
L 
Nom­
bre 
de 
rats 
4 
3 
5 
P 
(mg) 
420,40±25,225 
423,85± 13,513 
448,73+17,889 
E 
(mg) 
516,94 ±18,575 
439,72.­48,863 
4I0,98± 13,513 
VT 
(mg/j) 
656,37±34,877 
675,25± 15,401 
758,90±32,303 
Yf 
(mg/j) 
50,19± 5,487 
50,19±6,568 
99,09 ±15,946 
T l / 2 (h> 
17,31 ±0,448 
15,41 ±1,309 
13,60±0,615 
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On n'observe aucune différence statistiquement significative, pour ces trois 
paramètres, entre les groupes D et G (Tableau II). Par contre, L diffère de façon 
significative de D : différence hautement significative pour la demi-vie et la vitesse 
totale de sortie, VT; différence significative pour l'excrétion de radioactivité dans 
les selles, V/. Enfin, L diffère de G de façon hautement significative pour la demi-vie 
et de façon significative pour les deux autres paramètres, VT et V/. 
TABLEAU II. — Comparaison des valeurs des vitesses VT et Vf et de la demi-vie T,/2 de la sérum-
albumine dans les différents groupes. 
Groupes 
D et G 
D et L 
G et L 
VT 
+ + 
+ 
vr 
+ 
Ti/a 
+ + 
+ + 
— pas de différence significative. 
+ différence significative P > 0,01. 
+ + différence hautement significative P < 0,01. 
DISCUSSION 
Les résultats obtenus lors de la 'ligature du canal thoracique montrent que 
l'on peut reproduire expérimentalement une entéropathie avec déperdition de sérum-
albumine, comportant une diminution de la demi-vie et une augmentation de l'ex-
crétion fécale de protéines. 11 est, par contre, surprenant que la ligature du système 
cave supérieur gauche n'ait pas provoqué des perturbations analogues, en gênant 
l'afflux de lymphe provenant du canal thoracique. Ceci peut toutefois s'expliquer 
par l'existence d'anastomoses veineuses et lymphatiques entre les systèmes caves 
supérieurs droit et gauche chez le rat, (1), qui pourraient permettre l'établissement 
d'une circulation collatérale importante, 15 jours après l'intervention chirurgicale. 
Chez l'homme, l'atrésie et la compression du canal thoracique ont été constatées, 
notamment dans sa portion sous-diaphragmatique (2). On observe alors, comme chez 
le rat, une entéropathie avec déperdition d'albumine. Enfin, chez l'homme, l'hyper-
pression dans la veine cave supérieure ne suffit pas à provoquer une déperdition de 
protéines, si des anomalies de la circulation lymphatique ne sont pas associées (3). 
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DISCUSSION 
P. VESIN (Paris) : Je voudrais insister sur l'intérêt que représente le modèle 
expérimental que le Dr. Milhaud a réalisé chez le rat pour ceux qui étudient chez 
l'homme les enteropathies avec perte de protéines à l'aide de protéines marquées. 
En effet, il a réalisé non seulement une entéropathie exsudative avec perte de pro-
téines, mais le tableau réalisé est absolument semblable, tant du point de vue bio-
logique que du point de vue clinique, au tableau que l'on observe chez les malades 
présentant des affections lymphatiques localisées à la partie inférieure du canal 
thoracique. 
Le grand intérêt de son travail est que ces malades sont extrêmement 
rares en clinique humaine, et qu'il est par conséquent difficile de faire des études 
sur ce sujet. Or, non seulement par le modèle que le Dr. Milhaud a mis au point 
et qui je pense est assez facilement reproductible du point de vue de la Physiopa-
thologie expérimentale, il sera possible d'étudier le sort de l'albumine marquée, 
mais également d'autres protéines plasmatiques qui sont perturbées dans les ente-
ropathies avec perte de protéines, en particulier les immunoglobulines du système 
Gamma : Gamma A, Gamma M et Gamma G. 

PREPARATION OF Ή SERUM PROTEINS AND THEIR USE 
IN STUDIES ON CATABOLISM OF PROTEINS «*» 
G. B. GERBER, Α. REUTER, F. KENNES and J. REMY-DEFRAIGNE 
Euratom and Centre d'Etude de l'Energie Nucléaire, 
Mol, Belgium 
ABSTRACT 
The concentration of several serum protein fractions decreases after whole­body 
irradiation, an effect which could be due to a decreased synthesis or an increased 
intra­ or extrahepatic catabolism. 
Studies on incorporation of phenylalanine and tryptophan demonstrated that 
synthesis of the fractions involved increases rather than decreases. The aromatic 
aminoacids were chosen since they occur in a relatively large concentration in the 
fractions most affected after irradiation. 
Hepatic catabolism was then investigated. To this end, serum proteins labeled 
with 3H­phenyIalanine were biosynthetically prepared by a rat liver perfusion. 
Labeled serum proteins were then added to livers perfused at different time periods 
after irradiation and the decrease of total activity and specific activity were followed 
over periods of perfusion up to 12 hours. Formation of volatile radioactivity due to 
degradation of liberated phenylalanine was also measured. These data do not 
suggest a difference in hepatic catabolism after irradiation. However, the diffe­
rences in activity, even during a 12 hour period of perfusion, were rather small. 
Next, a mixture of serum proteins labeled with 131I and of serum proteins biosyntheti­
cally prepared with 3H­phenylalanine was injected into rats and the 131I and 3H 
radioactivity in serum proteins, as well as in feces and in urine, was followed in 
normal and X­irradiated rats. These data suggest that extrahepatic loss of proteins 
is responsible for the changes in concentration of serum proteins after irradiation. 
It is well known <13) that the concentration of several serum protein fractions 
is altered in X­irradiated animals, but the interpretation of these changes remains 
uncertain. The changes most notable in rats after total body exposure in the lethal 
dose range are : a decrease in prealbumin, albumin and γ­globulins and an increase 
in αϊ, α2 and β globulins. However, this pattern is not always consistent and depends, 
at least in part, upon the development of the radiation syndrome. A decrease in 
concentration of a protein fraction in the serum such as prealbumin for example, 
could be the result of either a decrease in synthesis, an increase in hepatic or extra­
hepatic catabolism, a change in distribution between vascular and extravascular 
space or of a combination of these factors. 
In our present investigation we have studied some of these factors in the intact 
rat and in the isolated perfused liver. The technique of liver perfusion is very sui­
table for such studies since the isolated liver is capable of synthesizing many serum 
(*) Supported by Euratom Contract No. 053-64-3 ΒΙΟΒ. We are grateful to Mr. Falláis for 
carrying out the iodination. 
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proteins with exception of the γ globulins (4'6). Furthermore, the isolated liver also 
can degrade many serum proteins, although it is not yet clear which importance 
this hepatic catabolism possesses for the intact animal. 
METHODS 
Perfusion of the isolated liver was carried out by a modification of the method 
of Miller (Figure 1) (4' 7). If one works under sterile conditions the liver remains 
viable for up to 12 hours. 
A mixture of 131I serum proteins was prepared by iodination at pH 8. About 
1-2 molecules of iodine were bound pro molecule of protein under these conditions. 
Unreacted iodine was removed by Amberlite and the proteins were screened from 
denatured material by injecting them into a rat for three days. 
f rom 
0 2 lank 
D i a g r a m of the a p p a r a t u s used for 
l i ver p e r f u s i o n 
A inf low c a n n u l a . 
B b i l e c a n n u l a 
F f i l t e r 
H h u m i d i f i e r 
L l i v e r 
M m o t o r 
Ρ pump 
V outf low c a n n . 
FIGURE I. — Schema of the perfusion of the liver 
Serum proteins labeled with 3H-phenylalanine (specific activity 0.8 Ci/mM) 
were prepared biosynthetically in the perfused liver. In a typical experiment, ^ - p h e ­
nylalanine was added to a liver perfusion (volume of perfusate 30 ml) in three doses 
of 12 mCi at 2 hour intervals. Two hours after the last addition, from 20 to 30 % 
of the radioactivity had been incorporated into proteins, the rest had been degraded, 
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131T 
Phenylalanine 3H 
Tryptophan 3H 
Activity (% of total activity) 
Prealbumin 
15.6 
15.8 
25.7 
Albumin 
59.9 
40.8 
14.6 
αϊ globulins a2globulins β globulins 
3.1 
16.0 
12.3 
1.3 6.8 
15.0 11.9 
24.7 20.7 
γ globulins 
12.3 
< i 
< 2 . 0 
FIGURE 2. —· Distribution of label in serum pioteins prepared by iodination or biosynthetically 
from 3H-phenylalanine or 3H-tryptophan in the perfused liver 
mostly to tritiumwater. The distribution of the 3H and 131I label in the different 
fractions, as determined by micro agargel electrophoresis, is shown in Figure 2. 
It can be seen that phenylalanine is incorporated preferentially into prealbumin 
and α globulins, whereas albumin contains relatively little radioactivity. This high 
incorporation into prealbumin and into α and β globulins was the reason why we 
have chosen labeling with phenylalanine or tryptophan for these experiments. 
Tryp t . c d d e d X - i r r a d . 
5 μ « 
50 μΜ 
Ο-^-ΊΙ 
1 2 
T i m e ( h o u r s ) 
FIGURE 3. — Incorporation of 3H-tryptophan (5 μΜ or 50 μΜ) into total serum proteins during 
perfusion of normal and X-irradiated liver (24 hours after 1000 r) 
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RESULTS 
SYNTHESIS OF SERUM PROTEINS. 
Earlier experiments (8) on the perfused rat liver using 3H-phenylaIanine, showed 
that 7 days after a dose of 950 r, synthesis of most serum proteins does not decrease; 
if anything, it rather increases in case of αϊ and ot2 globulins. Other studies (9) have 
confirmed the increased incorporation of 3H phenylalanine into several proteins 
of the intact mouse from the 3rd tot the 5th day after exposure. Maximal incorpo­
ration occurs on the 4th day after irradiation. Recently, we have carried out an 
investigation into metabolism of tryptophan 24 hours after exposure to a dose of 
1,000 r (1°'. In these studies we also followed incorporation of 3H-tryptophan (at 
P r ä a l b u m i n et. G l o b u l i n e 
FIGURE 4. — Incorporation of 3H­tryptophan (5μΜ) into prealbumin and αχ globulins by normal 
and X­irradiated perfused liver 
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a dose level of 5 μΜ) into serum proteins (11). The data (Figure 3) show that incorpo­
ration of tryptophan into total proteins by the irradiated liver is increased slightly. 
The same finding pertains also to some isolated serum protein fractions. The incor­
poration into prealbumin is shown as an example (Figure 4). It appears, however, 
that the rate of incorporation is changed more markedly than the final level of 
incorporation. The increase in incorporation of tryptophan may in part be due to 
the slight reduction in tryptophan catabolism of X-irradiated animals. Nevertheless, 
these experiments confirm that a decrease in synthesis is not the responsible factor 
for the radiation induced decrease in serum proteins. 
10 12 
T i m e ( h o u r s ) 
FIGURE 5. — Degradation of prealbumin in a mixture of serum proteins labeled with 3H-phenyl-
alanine by the perfused normal and X-irradiated liver (3 to 5 days after 950 r). Presented are 
total radioactivity in % of total proteins and specific activity in dpm/^g protein concentration. 
The upper part of the curve presents the decrease in nonvolatile radioactivity. 
HEPATIC CATABOLISM. 
Next hepatic catabolism of serum proteins labeled with 3H-phenylalanine 
was investigated. Seven livers from X-irradiated rats 3 to 5 days after exposure 
to 850 r and 4 livers from normal rats were perfused with a mixture of serum proteins 
labeled with :!H-phenylalanine for time periods up to 12 hours. Samples were taken 
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at two hours intervals and specific and total activity of the serum proteins as well 
as formation of volatile radioactivity (derived from degradation of liberated phe­
nylalanine) was determined. We could not expect that serum proteins of relatively 
slow turnover, such as albumin, would show a noticeable catabolism during the 
12 hour period of perfusion. However, fractions of more rapid turnover could 
have presented significant changes if hepatic catabolism was important. Furthermore, 
if the radiation induced decrease in concentration (up to 20 % per day) of a fraction 
like prealbumin were the result only of an accelerated hepatic catabolism, the alte-
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FIGURE 6. — 131I activity in total rats and 131I and 3H-phenylalanine in serum proteins after an injec­
tion of a mixture of proteins labeled with 131I and 3H-phenylalanine. One group of rats received 
950 r whole-body irradiation at time zero. 
ration should have been recognizable. As the following Figure 5 shows, specific 
activity and total activity of prealbumin decrease significantly during the perfusion. 
The catabolism and turnover of prealbumin is in the order of 20 mg/day for a 
pool of 74 mg in the perfused system, but this calculation is naturally subjected to 
a large error (about 50 %). No significant difference exists between livers from 
normal and X-irradiated rats. On the same figure data on nonvolatile radioactivity 
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are presented. Formation of volatile activity due to degradation of liberated phenyl­
alanine is in the order of 10 % per 24 hours. It is known from our previous experi­
ments, that reutilisation of phenylalanine amounts to about 20 tot 30 %. 
CATABOLISM OF SERUM PROTEINS IN THE TOTAL RAT. 
In the following experiments we studied the catabolism of a mixture of 131I 
and 3H-phenylalanine labeled serum proteins (Figure 2) in the intact rat. Five rats 
were exposed to 800 r whole-body X-irradiation and injected intravenously with 
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FIGURE 7. — Excretion into feces and urine of 131I radioactivity. The experimental groups are the 
same as in Figure 6 
3 ml of the labeled proteins immediately thereafter. Five other rats served as con­
trols. Blood samples from the tail were taken 1 hour, 1, 2, 3, 4, 5, 7 and 9 days after 
injection. Urine and feces were collected separately; however, some mixing of 
urine and feces was unavoidable, especially during the period of diarrhoea of the 
irradiated rats. 
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Data on 131I radioactivity of the total rat as well as of 3H and 131I activity of 
total serum proteins are shown in Figure 6. Radioactivity is retained slightly by 
the X-irradiated rats on the 2nd to 3rd day and again on the 4th-6th day after expo­
sure. This retention is also reflected in the excretion pattern (Figure 7). No difference 
between normal and irradiated rats exists with respect to the 3H of 131I radioactivity 
of circulating total serum proteins up to the 4th day after exposure (Figure 6). Later, 
as the radiation disease enters its lethal stage, radioactivity in proteins of X-irra­
diated rats decreases more rapidly than in those of the controls. 
A similar pattern is seen in the individual protein fractions. Prealbumin is 
shown as an example in Figure 8. The activity time curves for3H and 131I-prealbumin 
are parallel and decrease after the initial period of mixing. At later times, catabolism 
becomes slower. The radioactivity of prealbumin from the X-irradiated animals 
drops suddenly on the 4th day after exposure but afterwards decreases with the 
same slope as in normal rats. 
P r e a l b u m i n 
FIGURE 8. — 131I and 3H radioactivity of prealbumin in normal and X-irradiated rat. The experi­
mental groups are the same as in Figure 6 
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CONCLUSIONS 
Whereas our data are not yet complete and do not allow definite conclusions, 
they suggest that the decrease in certain serum proteins is due to a change in the 
intra­ and extravascular distribution and not to a loss into urine or intestine. Such 
an explanation has been proposed already by Shaber (11) in the case of fibrinogen. 
It is conceivable that the different behaviour of the various protein fractions has 
its cause either in a differential behaviour during transit into the extravascular space 
or in a difference in adjustment of the de novo synthesis to the altered conditions. 
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DISCUSSION 
A. S. MACFARLANE (London) : On ground of expense tritiated proteins are 
likely to replace 14C ones for tracer experiments in the future but using a variety 
of tritiated amino acids many people have not had very happy experiences. For 
instance, glycine labeled in the methyl group was poorly used for plasma protein 
synthesis and almost not at all for porphyrin synthesis. Even phenylalanine labeled 
with tritium in the benzene ring in our hands was not well used although I think 
that Gerber et al. have had most success with this amino end. A new specifically 
labeled lysine from Amersham which we have lately used gave the same incorpo-
ration into plasma protein as its 14C counterpart and at one twentieth the cost. 
Dr. Gerber and his collaborators are to be congratulated on having prepared their 
proteins at 20 % efficiency with the help of the perfused liver whereas we get only 
4-5 % incorporation into total plasma proteins in the intact animal. I think these 
proteins will find increasing use especially as comparison ones for iodine labeled 
proteins. 
G. GERBER : In our experiments we have compared the turnover of the 131I-
labeled proteins with that of the 3H-phenylalanine labeled proteins. In all protein 
fractions we found that the decrease of radioactivity was parallel in both cases. It 
should however be pointed out that due to the fact that a mixture of proteins was 
used which had to be separated by agar electrophoresis before counting, the accuracy 
of this determination is not very large. 
J. COURSAGET (Chairman) : I would like to ask Dr. Gerber what was the irra-
diation dose in his experiment ? 
G. GERBER : We studied incorporation of 3H-tryptophan one day after 1000 r, 
degradation of phenylalanine labeled proteins in the perfused liver 3-5 days after 
exposure to 850 r and the catabolism of 131I and 3H-phenylalanine labeled proteins 
in the intact rat after 850 r. 
J. COURSAGET : In experiments we made 15 years ago on irradiated rabbits, 
we noticed that for doses above 400 r there was a marked decrease in the speed of 
synthesis of antibodies labeled with 14C-valine. Have you observed an effect of that 
sort? 
G. GERBER : Dr. Sassen and Dr. Reuter have studied incorporation of 3H-
phenylalanine into the globulins after exposure to 700 or 1000 r. They found that 
total radioactivity was slightly increased 4 days after exposure. However, due to 
the fact that the concentration of the globulins had decreased at this time, specific 
activity was considerably increased in comparison with normal mice. 
STUDIES ON THE COMPOSITION 
OF CHROMIUM­51­LABELLED HUMAN SERUM ALBUMIN 
R. HÖFER, H. SCHATZ and N. THUMB 
2"d Medical University Clinic, Vienna, Austria 
ABSTRACT 
Starting from observations on differences in metabolic behaviour of 131l­labelled 
human serum albumin and 51Cr­labelled human serum albumin or 131I­labelled 
polyvinylpyrrolidone (PVP) the composition of 5]Cr­labelled human serum albumin 
was studied. 
Gel filtration yielded three ultraviolet (uv) absorbing peaks and three radio­
activity peaks. Radioactivity peaks I and II and uv.­absorption peaks Τ and II were 
located in identical fractions and were identified immunologically as albumin. 
The findings suggest formation of (high specific activity) aggregates as a 
consequence of the labelling process. 
The possibility is discussed that radioactivity peak III consists of complex 
Cr salts. Excretion and turnover patterns of 51Cr­Iabelled human serum albumin are 
discussed in the light of these findings. 
INTRODUCTION 
Using 51Cr­labelled HSA for the study of protein loosing enteropathia we 
made in accordance with other authors l1· 6^  9> 10) a number of observations typical 
for the metabolic behaviour of this tracer substance : 
1) Fecal excretion values of 51Cr­labelled HSA in normals were lower than those 
obtained with 131I­labelled PVP. 
2) Fecal excretion values of 51Cr­labelled HSA in patients with gastrointestinal 
protein loss were higher than those obtained with 131I­labelled PVP. 
3) During the first 24 hours a relatively high percentage of the injected activity 
was excreted with the urine — the amount varied from preparation to preparation. 
4) Using whole­body counting techniques the half­life of the dose retained is extre­
mely long — 40 days and more, 
5) The half­life of 51Cr­labelled HSA in the plasma is shorter than that observed 
for iodinated albumin. It amounts to 8 days and less and varies with the prepa­
ration used. 
MATERIAL AND METHODS 
51Cr­labelled HSA was obtained from the Radiochemical Division of "Farb­
werke Hoechst", Frankfurt/Main, Germany. Commercial preparations as well 
as special preparations (varying specific activity with and without stabilizer) were 
investigated. 
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In addition to paper­ and microagargelelectrophoresis (11) Immunoelectropho­
resis <7) followed by autoradiography, and agar gel precipitation (4), a number of 
gel filtration experiments were performed : 
Sephadex G 25, G 150 and G 200 columns of varying size up to 750 ;■: 30 mm 
were used and eluated with Trisbuffer pH 7.3. ionic strength 0.1 or 0.2. Fractions 
of 3 ml were collected and protein concentration was measured at 280 ιτιμ using a 
Beckman DB­spectrophotometer. Radioactivity of the fractions was measured in 
a well type scintillation counter. 
For analytical ultracentifugation a Spinco Model E at a speed of 59780 RPM 
was used. 
RESULTS 
In paper­ and microagargelelectrophoresis the 51Cr­labelled HSA migrated 
in a single band in the albumin region. Using strip counting and autoradiography 
radioactivity could be detected in this band only. Immunoelectrophoresis (Figure 1) 
with antihuman serum of the preparation (upper well) gave a single precipitation 
line in the typical albumin region. There was, however, a slight but constant defor­
mation of the line suggesting that the line consists of two confluing bows. 51Cr human 
serum albumin incubated with normal human serum was placed in the lower well. 
Autoradiography showed that radioactivity was exclusively bound to albumin 
(Figure 2). 
Analytical ultracentrifugation of the native preparation showed a main peak 
with a sedimentation rate of 4.3 S and a small 6.1 S peak (85 % and 15% respec­
# 
t' 
■ 
FIGURE 1. — Immunoelectrophoresis : upper well : 31Cr­HSA, lower well : Normal human serum 
incubated with 51Cr­HSA for 30 min at 37" C. Antihuman serum was used. 
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FIGURE 2. — Autoradiography of figure 1. 
tively). Fractionation on Sephadex G 150 and G 200 yielded three protein peaks 
and three activity peaks (Figures 3, 4). The concentration·fraction curves for 
radioactivity and for uv.-absorption constantly showed peak I and peak II in 
corresponding positions. The relative concentration, however, of peak I : peak II 
was different for radioactivity and uv.-absorption, 
The ratio of peak I to peak II was 1 : 5 for uv.-absorption and 1 : 2 for radio-
activity. The third radioactivity peak appeared in earlier fractions than the third 
uv.-absorption peak. The third uv.-absorption peak corresponds to the PHB-ester 
which is added to the commercial preparation after the labelling procedure as could 
be shown by fractionation of PHB-free preparations under identical conditions. 
The third radioactivity peak appears during fractionation of PHB containing pre-
parations as well as in PHB free preparations. Radioactivity peak III is absent 
when peak 1 and/or II are refractionated. It is, therefore, not due to an unspecific 
elution effect of the Sephadex column. 
In the radioactivity peak III fractions of PHB free material no uv.-absorbing 
material can be defected. Furthermore, ninhydrin reaction was negative with these 
fractions, even when all fractions containing radioactivity peak 111 were concen-
trated up to 50 fold. Thus radioactivity peak 111 is neither labelled PHB nor labelled 
polypeptides nor labelled aminoacids. Further fractionation on Sephadex G 25 
showed that radioactivity peak III is also not composed of simple chromium salts 
like Chromate, since it appears in much earlier fractions than Chromate. The indi-
vidual protein peaks (uv.-absorption peaks I and II) were concentrated by vacuum 
dialysis and identified immunologically and by analytical ultracentrifugation. Peaks I 
and II were immunologically albumin and showed reaction of complete identity 
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FIGURE 3. — Fractionation of o lCr-albumin on Sephadex G 150 column 450 χ 25 mm, 
Trisbuffer pH 7.3; μ = 0.1; 3 ml fractions. 
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FIGURE 4. — Fractionation of 51Cr­albumin on Sephadex G 200 column 750 χ 30 mm, 
Trisbuffer pH 7.3; μ = 0.1; 3 ml fractions. 
in the Ouchterlony plate. Anti human serum and specific antiserum against albumin 
were used. In analytical ultracentrifugation peak I showed two components, one 
with a sedimentation rate of 6.2 S and a second with 4.1 S. Peak II was 4.0 S mate­
rial only. 
Radioactivity in urine (Figure 5) was not precipitable with all conventional 
protein précipitants. 
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FIGURE 5. ­ Plasma radioactivity and urinary excretion of radioactivity in a healthy subject after 
intravenous injection of 51Cr­HSA, 
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DISCUSSION 
It is relatively easy to explain the differences in fecal excretion values between 
51Cr-labelled HSA and 131I-labelled PVP. The lower normal values of 51Cr-labelled 
HSA are certainly due to the fact that the albumin molecules are much larger than 
the PVP molecules. 
The higher fecal excretion values on the other hand found for 51Cr-labelled 
albumin in pathological cases may sufficiently be explained by the longer half-life 
of chromium labelled HSA in the circulation as compared with radioiodine label-
led PVP. 
Schultze and Hughes (8) pointed out that the chromium label of slCr-HSA 
is readily transferred to other proteins of tissue cells at the site of albumin break-
down and they demonstrated this fact by autoradiographic studies. Such a label 
transfer must result in a prolonged apparent half-life of 5ICr-labelled HSA when 
whole body counting techniques are used and when results are compared with those 
obtained with radioiodine labelled HSA where the label is readily excreted after 
break-down of the albumin molecule. The shorter half-life of 51Cr-HSA in the plasma 
again in comparison with radioiodine labelled HSA must be attributed to some 
kind of denaturation of the albumin molecule which occurs in the course of the 
labelling procedure. 
Studies we carried out so far show in accordance with other reports <3,5) that 
chromium labelling leads to formation of albumin aggregates with higher specific 
activity than the monomere (8). We would suggest that these "polymere" fractions 
are more readily removed from circulation, thereby causing the observed shorte-
ning of plasma half-life of 51Cr-HSA. The removal of the high specific activity poly-
mere component from plasma would be followed by break-down and label transfer 
— this could explain the observation by Schultze and Hughes that chromated albu-
min polymeres show a longer half-life (in the whole-body) than monomeres. 
The high urinary excretion of radioactivity during the first 24 hours following 
intravenous injection of chromated HSA remains to be explained. It is very impro-
bable that it is due to a break-down of some parts of the chromated albumin since 
short period collections of urine after intravenous injection of 51Cr-HSA show that 
the excretion of radioactivity starts and is highest within the first hour after injection 
(Figure 5). Furthermore, as pointed out above, break-down of part of the chromated 
substance should lead to an increased label transfer rather than to an increased 
urinary label excretion. 
It can be seen from our fractionation experiments on Sephadex columns that 
the only non albumin fraction of our preparation is radioactivity-peak 111 which 
is, as already pointed out, not labelled protein, not labelled polypeptides, not label-
led aminoacids and not a simple chromium salt and we have not yet been able to 
identify this unknown chromium compound. We would suggest, however, that 
this unknown compound is the one that is excreted during the first 24 hours in the 
urine since the percentage of radioactivity found in peak 111 is of the same order 
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of magnitude than the percentage of radioactivity excreted within the first 24 hours 
after injection and it is interesting to point out here, that Cohen (2) found complex 
chromium salts in the urine after intravenous injection of chromium labelled albu­
min and it could well be that our radioactivity peak III is composed of such complex 
chromium salts. 
In summary, we would like to say that 51Cr­HSA cannot be used for albumin 
turnover studies because of the formation of highly labelled aggregates, and because 
of label transfer after albumin break­down. On the other hand 51Cr­HSA is a very 
valuable tracer substance for the study of gastrointestinal protein loss since it simu­
lates much better physiological conditions than 131I­labelled PVP. With the prepa­
ration on hand it is, however, not possible to obtain quantitative results since large 
aggregates of high specific activity are formed and since a portion of the tracer 
substance is present in an unknown form which is probably lost into the urine. 
Further in vivo experiments with the separated pure monomer fraction of chromated 
HSA going on now could possibly increase considerabely the value of studies of 
gastrointestinal protein loss with chromium labelled HSA. 
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DISCUSSION 
E. NIEMANN (Frankfurt) : In Ergänzung zu Dr. Höfers Ausführungen ist fol-
gendes zu sagen : 
1. Die in der Chromalbumin-Lösung enthaltene als Stabilisator bezeichnete 
Substanz dient nicht der Stabilisierung der Chromalbumins, sondern ist lediglich 
ein Bakteriostatikum. 
2. Es ist sehr unwahrscheinlich, dass es sich bei der über Sephadex abgetrennten 
niedermolekularen Verbindung um eine Chromaminosäure handelt. 
3. Versuche an Hunden haben gezeigt, dass ein geringer Prozentsatz der im Urin 
ausgeschiedenen 51Cr-markierten Substanz Chromat ist. 
Y. COHEN (Paris) : Le Dr. Höfer pourrait-il préciser la nature du stabilisateur 
qu'il emploie dans les préparations d'albumine humaine dites marquées au chrome-
51? 
E. NIEMANN : Es handelt sich um ein Gemisch von Methyl- und Propylester 
der p-Hydroxydbenzoesäure. 

THE ROLE OF PLASMA TRANSFERRIN 
IN IRON METABOLISM AS STUDIED WITH 131I-LABELLED 
TRANSFERRIN 
S. VENTURA, U. SENIN, R. PALUMBO, A. DEL FAVERO and L. COLI 
Istituto di Clinica medica generale e Terapia medica dell' Università di Perugia, Italy 
ABSTRACT 
The authors have investigated the rôle of plasma transferrin in iron metabo-
lism by studying the intraorganic movements of 59Fe-transferrin, 131I-transferrin 
and 59Fe-transferrin-131I in normal persons and in patients with iron deficiency 
anemia and aplastic anemia. 
The results of the investigations allow the authors to conclude that transferrin 
molecule does not show any attitude to direct the iron molecule in its intraorganic 
movements. 
Up to now we derived our knowledge on the behaviour of iron metabolism 
in normal and pathological conditions, by injecting intravenously radioactive iron 
bound to transferrin; only if linked to transferrin, the iron follows its normal intra-
organic pathway. 
Iron kinetic studies have shown that the quota of the metal released from the 
daily hemoglobin breakdown and carried to the marrow erythroblastic tissue is 
the main physiological path of iron metabolism. Secondary pathways are represented 
by the mineral storage and intestinal absorption. 
In all these intraorganic movements, the transferrin molecule plays a very 
important rôle, as iron can move inside the body and reach the cells where it is uti-
lized, only if linked with the transferrin molecule. 
This property of the transferrin depends upon its iron-binding capacity. 
As 80 % of plasma iron transferrin is carried, in normal conditions, to the 
erythropoietic marrow, the problem arises if such affinity is conditioned by a pecu-
liar property of transferrin to direct iron toward this tissue. 
Our researches try to reply to such a question. 
Crystalline transferrin was prepared from Cohn fraction IV-4 by the method 
of Inman and co-workers; physio-chemical analysis indicated that this protein 
was pure at a high degree (at least 95 %) . Transferrin was labelled with radioactive 
iodine. 
Radioactive transferrin, either free of iron or saturated with radioactive iron, 
was injected intravenously to normal and anemic subjects. 
A first study gave evidence, according to previous results of Katz and Away 
and Brown, that iodination does not produce any detectable alteration on the phy-
siological behaviour of the transferrin molecule. 
In fact in our experiments, 59Fe bound to iodinated transferrin and injected 
intravenously to normal subjects leaves the plasma, reaches the bone marrow and 
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then comes back to the blood as radioactive hemoglobin, in the same manner as 
does 59Fe bound to normal transferrin. The same result may be obtained in iron 
deficient patients, in which 59Fe linked to iodinated transferrin shows the same 
behaviour than 59Fe bound to normal transferrin. In conclusion, iodination does 
not modify the biological properties of the transferrin molecule. 
In a new series of experiments we investigated the transferrin metabolism in 
normal and anemic patients, examining its plasmatic behaviour, its intraorganic 
movements and, finally, its urinary excretion. This metabolic study of the trans-
ferrin molecule was always carried out together with an analysis of the behaviour 
of 59Fe bound to the iodinated transferrin. In the normal subject (Figure 1), the 
intravenous injection of transferrin labelled with 59Fe and 1311 is followed, during 
the first hours, by a linear disappearance of the radioactivity due to 59Fe and to 
iodinated transferrin. The initial exponential rate of decrease of radioactivity is 
much higher for iron (T/2 = 1.30 hours) than for transferrin (T/2 = 15.30 hours). 
loo 
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Figure 1 
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In the following days (Figure 2), the exponential rate of disappearance of radio­
activity undergoes a modification. The first exponential rate of 59Fe, which is related 
to the passage of plasma iron to the erythropoietic tissue, is followed by a second 
one, much slower, which, according to the iron­kinetic mathematical model of 
Pollycove and Mortimer, depends upon the re­entry of iron into plasma from the 
erythropoietic labile pool iron. 
On the other hand radioactive transferrin decreases in a curvilinear manner 
during the first days and such a behaviour may be related to equilibration of trans­
ferrin in various body compartments. Plasma disappearance rate of transferrin 
assumes, during the following days, a much slower and linear behaviour; this expo­
nential component of iodinated transferrin disappearance has a half­time of 8.7 
days and is probably related to the daily catabolic rate of transferrin. The urinary 
excretion of radioactive iodine, which is released from transferrin molecule and 
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excreted almost entirely in the urines, if uptake by the thyroid gland is blocked, has 
to be considered as an expression of the transferrin degradation. From such a beha­
viour it derives a proportionality between plasma and tissue transferrin. 
In iron deficient patients (Figure 3), the intravenous injection of 59Fe bound 
to iodinated transferrin, shows the following behaviour : 59Fe leaves the plasma 
more rapidly than normal, as it usually does in such an iron disease. Transferrin 
molecule, on the contrary, does not show any significant modification from its 
behaviour in normal subjects. 
In the opposite iron pathological condition : namely the aplastic anemia, 
59Fe is retained in the plasma, while iodinated transferrin follows its normal plas­
matic behaviour (Figure 4). We may so arrive to the conclusion that plasma disap­
pearance rate of iodinated transferrin is not affected by the state of iron metabolism. 
It is possible to get the same conclusion by studying the intraorganic movements 
of radioactive transferrin; this study is performed by detecting the gamma­ray 
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emission by body surface measurements over some organs directly related to iron 
metabolism : the sacrum (bone marrow), the liver (iron stores) and the spleen. 
Here we deal only with the radioactivity behaviour over the sacrum. Such a tissue, 
normally rich in bone marrow and erythroblasts, usually shows a selective accu-
mulation of iron which leaves the plasma. If we now take into consideration the 
sacrum behaviour of the radioactivity after intravenous injection in normal subjects 
of 59Fe bound to 131I-transferrin (Figure 5), we can see that 59Fe undergoes its nor-
mal selective accumulation followed in the subsequent days by a release into the 
blood as radioactive hemoglobin. On the contrary iodinated transferrin does not 
show any specific accumulation, but its initial radioactivity decreases gradually 
during the following days. 
In iron deficiency anemia (Figure 6), the hyperplasia of erythropoietic tissue 
induces a rapid accumulation of radio-iron in the marrow, but does not affect the 
transferrin behaviour. 
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In aplastic anemia the lack of erythropoietic tissue in the bone marrow gives 
reason of the very low passage of iron from plasma to sacrum while the iodinated 
transferrin behaves as in normal (Figure 7). 
The final conclusion is that the transferrin molecule does not show any sensi­
bility towards the intraorganic state of iron metabolism. This plasmatic protein 
behaves in a constant manner whatever may be the erythropoietic activity of the 
subject. So the transferrin molecule seems to possess only its iron binding capacity 
and our experiments have failed to show any attitude to direct the iron molecule in its 
intraorganic movements. 
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ABSTRACT 
An attempt has been made to interpret the time course of radioactivity in extra-
vascular space following injection of human serum albumin (RIHSA) and fibrinogen 
(RIHF), both labelled with131I, in normal tissues, inflammatory lesions and tumors. 
An'analog computer has been used to simulate the observed behaviour, on 
the basis of compartment models. Extravascular activity curves observed in any case 
with RIHSA and in normal and inflammatory tissues with RIHF can be simulated 
on the basis of compartmental model with constant exchange rates. On the contrary 
the extravascular activity curves observed with RIHF in tumors cannot be accounted 
for by such a model with all constant rates of exchange. The compatibility of simu-
lated curves with those in tumors has been achieved by decreasing feedback from 
extravascular spaces to plasma for a certain time after which it retained constant 
lower value. The relative implications are discussed. 
In recent years, using 131I-labelled preparation of plasma Cohn fraction 1, con-
taining about 65 % of radioactivity in fibrinogen and 35 % in albumin, and measu-
ring the time course of the radioactivity over inflammatory lesions tumors, Monas-
terio et al. have shown that the pattern of the curves representing the extravascular 
radioactivity in these two types of lesions present significant differences, which have 
been proved to be of diagnostic value (1> 2· 3). An example is shown in Figure 1. 
FEMUR METASTASIS TIBIA OSTEOMYELITIS 
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FIGURE 
50 100 150 200 250 hours 
— Calculated extravascular activity curves in a case of femur metastasis (A) and in a 
case of tibia osteomyelitis (B) after administration of 131I-labelled Cohn fraction 1 ; upper curves 
— lesion, lower curves — normal opposite side. 
(*) Work performed as part of the program of the Association Contract Euratom-ULB-
Università di Pisa No. 026-4-63 BIAC. 
194 Ν. R I C C I O N I , M. F. BECCHINI, F. VITEK AND L. DONATO 
All the measurements are performed by external counting under standardized 
conditions, and the curves over a healthy symmetrical region are regularly recorded 
for purpose of comparison : in the inflammatory process the EV radioactivity rises 
rapidly to a peak value higher than that over the healthy reference region and it 
starts then to decrease regularly with a pattern that simply resembles a magnification 
of the normal behaviour. On the other hand, over the tumors, after a similar ascending 
part, the counting rate tends to level off for variable length of time, after which it 
starts to drop regularly. This pattern seems to be due to the fibrinogen moiety of the 
preparation, since it has been shown to be prevented by heparin treatment (4). 
The aim of this communication is that of reporting on the attempts that we have 
made to interpret the extravascular activity curves in inflammatory processes and 
tumors using an analog computer for analysis and simulation of the curves obtained 
by successively injecting into the same subjects the Cohn fraction I, high purity 
albumin, or high purity fibrinogen, all labelled with 131I. 
CURVES EXAMINED 
The material for analysis and simulation was represented by the curves obtained 
in 5 subjects, four with bone tumors of various types and one with tarsus osteitis. 
The Cohn fraction 1 curves were obtained in each case and they all showed the 
typical pattern. In three tumor cases and in the case with the inflammatory process, 
131I-HSA labelled with the same technique was subsequently injected, and curves 
were recorded over the lesion and symmetrical healthy region. In the fourth tumor 
case, a high purity preparation of fibrinogen (95 % pure) labelled with 131I was 
injected. 
I 
TIME 
FIGURE 2. — Calculated extravascular activity curves after administration of RIHF. 
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The curves obtained with 131I-HSA were used to correct by subtraction the Cohn 
fraction 1 curves after suitable normalization for injected activity, and knowing the 
percentage of albumin in the preparation. 
Pure fibrinogen curves were thus obtained, and attempts were made to simulate 
them with an analog computer. 
Figure 2 shows the curves obtained : they have a peculiar pattern, particularly 
in tumors. All four fibrinogen curves show an obvious inversion in their trend after 
the peak concentration is reached, and decrease is started; the new rise varying from 
minimal to a new peak even overcoming the first one. 
In the examined case of inflammatory process this pattern is absent, but it is 
obvious that the radioactivity over the healthy side drops more rapidly. 
COMPUTER SIMULATION 
Intravascular activity curves, available in all cases, were submitted to multi-
exponential analysis so that they could be simulated on the computer : a sum of 
two exponentials was sufficient in every case. Intravascular activity was assumed to 
be the specific precursor of EV activity, and not to be influenced by feedback of 
activity from the lesion. 
The models with which the simulation attempts were made are shown in the 
next figures. 
The simplest model is that in which Kj and K2 are the fractional rates at which 
the activity is transferred from the intra- to an extravascular compartment and vice-
versa (see Figure 3). This simple model offered no difficulties in fitting the fibrinogen 
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FIGURE 3. — Calculated extravascular activity curves administration of RIHF in inflammatory 
process. Points : experimental values; continuous line : fitting by an analog computer. Simula­
tion of normal side is based on model I : simulation of inflammatory process on model 2. 
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curves over healthy region. It was not possible to simulate the curves of the inflamma­
tory process, neither (obviously) those of the tumors, by this simple model. 
In the next step it was assumed that from the first EV compartment a fraction 
of activity K3 were transferred to a second EV compartment, and that K4 were the 
rate at which activity from this latter compartment was fed back to blood. 
This model proved adequate to describe the time course of activity over inflamma­
tory process, but not in tumors. 
To simulate the curves in tumors, one had to device a model such that, at a 
time at which feedback from EV to blood already exceedes activity transfer in the 
opposite direction, an inversion of this trend could occur, resulting in a new rise, of 
more or less long duration and extent. 
In presence of a progressively decreasing plasma activity, one of the possible 
interpretations is that the new rise be due to a reduction of the activity fed back to 
blood from EV. On the other hand, this interpretation has to be in keeping with the 
assumption of steady state conditions. 
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FIGURE 4. — The effect of the value of the coefficient K4(r) on the shape of simulated curves. 
After various attempts it was shown that, with reference to the two EV com­
partments model, the possibility of fitting the tumor curves was that in which K4 was 
progressively reduced from its value at 0 time to a new lower value to be reached 
and maintained after a variable time. 
The effect of varying the extent of the reduction of K4, and its duration, is shown 
in the Figure 4. As one can see all the various patterns observed in tumors can be 
easily reproduced, and that in the inflammatory process as well. 
An example of the agreement of predicted with experimental curve is shown in 
the Figure 5.' ··'■ 
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FIGURE 5. — Comparison of measured RIHF — extravascular activity in Ankle sarcoma with the 
curve obtained from an analog computer. 
DISCUSSION 
The problem is now that of examining the possible physical justification of such 
a model, and its compatibility with steady state assumptions. 
An interpretation can be offered if one takes in mind that : a) more or less 
important amounts of fibrin are present in tumors tissue; b) heparin treatment 
prevents the occurrence of the typical tumor pattern after injection of the labelled 
protein. 
The model could be thought to result from a physical situation in which the 
second EV compartment is actually made up of fibrinogen and fibrin, and in which 
the gelification of fibrinogen into fibrin is not an instantaneous process, attaining 
equilibrium from 0 time. This could result both from the type of the reaction involved, 
or from the structures of the extravascular spaces in tumors, in which the contact 
between diffused fibrinogen and thrombin like enzymes may not be immediate. This 
latter assumption could be accounted for by uneven distribution of poor mixing of 
the indicator in this compartment. 
This hypothesis offers no difficulties in explaining the curves. Since the type of 
measurement performed here, the shape of the EV curve is determined by the 
balance between total input and total output to and from EV space, the time course 
of the activity in tumors could be explained assuming that activity can return from 
EV space to blood by true feedback of fibrinogen or lysis of fibrin. If this latter pro­
cess is slower in rate than the first one, which is quite acceptable, and the gelification 
of fibrinogen is not instantaneous, the overall rate of feedback of activity will initially 
be that due to exchange of fibrinogen, but it will then progressively decrease, as more 
and more131I-fibrinogen is converted into fibrin, to attain finally an equilibrium state 
in which the rate of feedback becomes constant because the indicator has attained 
equilibrium of distribution; the value of this final rate will actually and obviously 
198 N. RICCIONI, M. F. BECCHINI, F. VITEK AND L. DONATO 
depend on the fraction of fibrinogen in fibrin form in the compartment two and on 
the relative rates of feedback of fibrinogen and fibrinolysis. 
In this type of model the subdivision of the extravascular system into two com-
partments is unnecessary since exactly the same result with different constant could be 
obtained with a single EV compartment. 
At the light of this hypothesis which can explain the time course of EV activity 
in tumors and inflammatory tissues, the difference between the two types of process 
could be accounted for by : 
a) smaller amount of fibrin in inflammatory tissues in respect to tumors. 
b) rate of fibrinolysis in inflammatory tissues greater that in tumors, and therefore 
closer to the rate of feedback to blood of ungelified fibrinogen. 
c) faster diffusion of fibrinogen in the EV space of inflammatory tissues in compa-
rison to tumors, or better mixing conditions in the former in comparison with 
the latter. 
It is obvious that any combination of the above three conditions may be respon-
sible for the observed differences. 
The validity of common model capable to justify the behaviour observed both 
in tumors and inflammatory process is supported by some recent findings. The use of 
antifibrinolytic agents in inflammatory process tends to produce the typical tumor 
pattern (5). 
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DISCUSSION 
C. M. E. MATTHEWS (London) : Have you worked out the details of a model 
for the unlabeled fibrinogen in a steady state, which would lead to this kind of effect 
of variation of rate constant with time, or are you just saying qualitatively that a 
delay in this pool would give rise to such an effect ? 
F. VITEK : We do not study the model of fibrinogen kinetics under normal 
conditions. The model described enables only qualitative description of the system. 
Of course, if it would be possible to separate extravascular impulse-rate curve in 
two parts, one of which could describe the pure fibrinogen only, another mathema-
tical approach could be used and, for example, the determination of the life time 
of a new substance formed should be possible. But the separation of the impulse-
rate curve measured above the tumor region into these two parts is not possible. 
J. COURSAGET (Chairman) : If you allow me a last remark, I would like to 
say that one of the major conclusions we may draw from this session is that the fate 
of labeled plasma proteins is of a major interest to a great variety of scientists which 
belong to disciplines as different as chemistry, physiology, immunology, pathology, 
even radiobiology. It seems that further progresses will be largely dependent on 
the degree of cooperation which can be achieved between those who are preparing 
very pure reliable labeled plasma proteins and those who are using them for biolo-
gical or chemical investigations. 

LABELED PROTEIC HORMONES FOR METABOLIC STUDIES 
Chairman : E. F. PFEIFFER 
Abteilung für Klinische Endokrinologie, I. Medizinische Universitätsklinik, 
Frankfurt j Main, Deutschland 
PRELIMINARY REMARKS BY THE CHAIRMAN ON 
Lack of correlation between immunologic neutralization 
of biologic action and antigenic reactivity of certain proteic 
hormones (insulin, ACTH) 
I take it as a great honour and privilege to chair this symposium on « Labeled 
proteic hormones for metabolic studies" in the course of which so many eminent 
scientists from different countries will give their views on problems, of our mutual 
interest and concern. The first four papers should deal critically with the use of 
labeled proteic hormones in radioimmunoassays. Evidently, the general technical 
precepts as uniform binding to the protein without changing its physical, chemical, 
immunologic or biologic properties should be even better preserved in the labeling 
of hormones than with regard to other proteins. Many examples are known where 
alterations of a proteic hormone were ensued by diminishing and even abolishing 
its biologic activity without changing its immunologic reactivity and vice versa. 
Handling of ACTH containing solutions for more than 20 minutes already suffices 
FAT PAD DIAPHRAGM IMI 
Figure 1. — Effect of sera of normal Wjfà and Houssay I I dogs on isolated fat pads and 
diaphragm in comparison with immunologically measurable insulin (IMI). 
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for destroying its steroidogenic capacity. How sure can we be that denaturated or 
biologically inactive hormones are not included in immunoassay values? It is one 
of the purposes of the first and even more of the second part of our symposium 
to determine, as good as possible, the reasons for the discrepancies existing between 
bioassay and immunoassay values for certain hormones. I hope that speakers and 
discussors will come back on that point once and again. Fortunately, our main concern 
will be the 3 polypeptide hormones of small molecular size, ACTH, glucagon, and 
insulin, leading the more critical problems connected with the HGH and the para­
thormone to a special round table conference. 
ILA 
pE/ml 
400-
300-
200-
100-
22 22 
V.= 100 ¿.0,6 
lì lì 
100 ¿3.7 
I SEM 
ρ < 0,001 
Ν Ν +AS ' 
ρ<0,001 
Hou Hou+AS 
FIGURE 2. — Inhibition of ILA (fat pad) of sera from 22 normal and Houssay­dogs by guinea­pig 
anti­insulin serum 
You will permit me to briefly pick out one, I feel, hot point, i.e. the lack of corre­
lation between immunologic neutralization of biologic action and antigenetic reac­
tivity of certain polypeptide hormones. 
We were first confronted with that problem when studying serum insulin in 
Houssay­dogs in which both the pituitary and the pancreas were removed for pro­
viding survival without substitution with exogenous insulin. The studies were begun 
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in collaboration with Dr. and Mrs. Sirek from Toronto (1°' u · 1 3 ) , but were continued 
in our laboratory upon return of our associate Dr. Schöffling to Frankfurt <2' 12). 
I shall refer to these newer findings. 
In Figure 1 is shown that the two operations induced the diminishment but 
not the disappearance of plasma ILA on both fat pad and diaphragm until the end 
of the experiment, i.e. for more than 100 days, whereas the Immunologically Mea­
lurable Insulin (IMI) values promptly fell to zero upon removal of the pancreas. 
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FIGURE 3. — Inhibition of glucose uptake of rat diaphragm by guinea­pig anti­insulin serum in 
sera of normal and Houssay­dogs 
The persisting ILA still was immunologically suppressible on both the fat pad 
(Figure 2) and the diaphragm (Figure 3), and the same observation was made when 
the ILA was extracted from the serum. However the intravenous injection of the 
same antiserum in Houssay­dogs did not alter the blood glucose concentration, 
the hyperglycemia being confined to the controls (Figure 4). 
Hence, the biologic ILA of serum and serum extracts of Houssay­dogs were 
inhibited by an antiserum in vitro, whereas the same antiserum neither did neutralize 
ILA in vitro nor demonstrate any IMI in vitro. 
I shall desist from listing other examples of the said discrepancy, as amply 
provided by insulins from primitive species acting on mammalian tissues lL 3) or 
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insulins produced by malignant tissues (10> for discribing an analogous observation 
concerning ACTH. 
In contrast to insulin, ACTH values determined by immunoassay, in the stan­
dards as well as in normal serum or plasma, are higher than the ACTH activities 
measured on the basis of the steroidogenic capacity in hypophysectomized rats 
<4, 9). The same observation is made, in general, also in Cushing's Syndrome and 
Addison's disease where elevated values are measured. Therefore, it was a surprise 
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FIGURE 4. — Verhalten des Blutzuckers nach I.V.­Injektion von Meerschweinchen­anti­Insulin­
Serum (3 ml/kg) beim normalen und hypophysektomiert pankreatektomierten(Houssay) Hund. 
when in a case of Cushing's disease due to the so­called "ectopic ACTH­Syndrome", 
i.e. a carcinoma producing ACTH like susbstances <7), the elevated bioassay values 
in the serum constantly exceeded the immuno­ACTH concentrations which were 
found to be even lower than in normal subjects. 
We try to interpret these findings, in conformity with a recent remark of Felber 
(1965) with the pituitary inhibition due to secondary adenocortical overactivity; 
this inhibition should be reflected more precisely by the immuno­ACTH values, 
measuring mainly the endogenous pituitary ACTH in plasma, than by the biolo­
gically determined ACTH activity, perhaps being mostly of tumourous origin. If 
so, the ACTH extracted from the carcinoma or its metastases, must show high 
activity in the bioassay but react only weakly in the immunoassay. As shown in 
Table I, this assumption was confirmed by the experimental data, demonstrating 
the high steroidogenic and low immunologic activity of the ACTH which Dr. Stewart 
extracted from large amounts of metastatic tissue secured post mortem, pituitary 
ACTH being reduced to 1/4 to 1/10 of the normal content. 
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TABLE I. — Biological and immunological ACTH quantities in a patient with a metastatic carcinoma 
of the lung associated with Cushing's syndrom 
Plasma (mu/100 ml) 
Pituitary (mu/mg) 
methods of determination 
biological immunological 
2.0 
11.6 
10.0 
0.2 
0.1 
0.11 
However, this high steroidogenic activity was nearly completely neutralized 
by the simultaneous injection of the antiserum into the hypophysectomized rats, 
the same antiserum which, in vitro, did measure only a small quantity in the radio-
immunoassay (Table II). 
These results shed some doubts on recent speculations, derived from studies 
on synthetic ACTH and ACTH fragments, localizing the steroidogenic site of ACTH 
activity in the N-terminal portion and the immunologic site in the C-terminal por-
tion (6). 
TABLE II. — Neutralization of ACTH-like activity with specific ACTH antiserum in metastases 
of a carcinoma of the lung associated with Cushing's syndrom 
Metastases (mu/g) 
ACTH standard (0.5 mu/inj.) . . . . 
Liver extract control (mu/g) . . . . 
ACTH 
content 
10.0 
0.45 
> 0.03 
ACTH 
content + 
antiserum 
> 0.03 
> 0.02 
These hypotheses of a clear-cut molecular topography of ACTH activities are 
also difficult to reconcile with the immunologic neutralization of other biologic 
actions residing in the N-terminal portion, as the skin darkening or lipolytic effect 
(8· 14). Either the antibodies produced against the antigenic property residing in the 
C-terminal portion do also affect the N-terminal component, or the folding occu-
ring in the course of the formation of the antigen-antibody-complexes does prevent 
the biologic active site to fix to its cell receptors, etc. 
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Anybody seriously interested in this problem should profitably consult the work 
of the biochemists concerning the neutralization of enzyme action by specific anti-
sera. The heterogeneity and multiplicity of the mechanisms by which antibodies 
inhibit, do not inhibit, and even increase enzyme activities is impressive. The most 
recent data are given in a small volume by title "Immunchemie" which has been 
published by Springer in 1965. 
For the time being, we better defer from equating immunologic inhibition 
of hormone action with its immunologic reactivity. It would be gratefully acknow-
ledged if anybody willing to contribute to that point would participate, in the appro-
priate place, in the discussions of this morning's session. 
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ABSTRACT 
Two primary considerations in the use of labeled proteins in biomedical inves-
tigations are : I. — a labeled protein is a valid tracer for its parent unlabeled pro-
tein in a particular system, S, if, and only if, the labeled and unlabeled proteins 
exhibit identical behaviour in S, similarities or dissimilarities of behaviour in all 
other systems being irrelevant and II. — a labeled protein may be used other than 
as a tracer for the parent unlabeled protein, in which case identity of behaviour 
of labeled and unlabeled proteins may be irrelevant to the validity of application 
of the labeled protein. 
Radioimmunoassay is an illustration of II. Factors are considered in detail 
which affect the sensitivity and precision of immunoassay, namely, 1) selection 
of a suitable antiserum 2) labeling of hormone at high specific activity 3) puri-
fication from " preparation damage " 4) minimization of "incubation damage" 
5) distinction between bound and free labeled hormone. The significance of iodi-
nating at more than 1 atom per molecule protein in affecting the suitability of a 
tracer and a method for evaluating the extent of iodination of ¡odoinsulin are des-
cribed. 
We have earlier (1) emphasized two considerations for the use of labeled pro-
teins in biomedical investigations which may be stated in the form of theorems. 
Theorem I : a labeled protein is a valid tracer for its parent unlabeled protein in 
a particular system, S, if, and only if, the labeled and unlabeled proteins exhibit 
identical behaviour in S, similarities or dissimilarities of behaviour in all other 
systems being irrelevant. 
Theorem II : a labeled protein may be used other than as a tracer for the parent 
unlabeled protein, in which case identity of behaviour of labeled and unlabeled 
proteins may be irrelevant to the validity of application of the labeled protein. 
We present here a few obvious examples of the applicability of these theorems. 
Much of the early work on labeled proteins involved studies of the metabolic turn-
over of 131I-labeIed serum albumin in man < 2 · 3 ) . It was observed that some prepa-
rations of 131I-Iabeled albumin that are subject to an abnormally rapid metabolic 
degradation in vivo exhibit no abnormalities on ultracentrifugation l3). On the 
other hand, a detectable difference in electrophoretic mobilities of labeled and 
unlabeled albumin <4) (which might simply be the consequence of the presence of 
a tyrosyl iodine) certainly does not vitiate the use of I31I-Iabeled albumin in turnover 
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studies since some labeled preparations show the same turnover rate as unlabeled 
albumin :<2· 5). Similarly, for testing the validity of 131l-labeled hormone in turn-
over studies it is important to establish only that labeled and unlabeled hormones 
are turned over at the same rates and not that the labeled hormone maintains its 
hormonal potency. In general it has been difficult to ascertain the hormonal potency 
of a labeled preparation that is completely satisfactory for metabolic or other stu-
dies. Lightly iodinated insulin, for example, is turned over at the same rate as unla-
beled insulin in the rabbit ((i) but assay of the hormonal potency of a preparation 
containing 1 iodine atom per 20-40 insulin molecules hardly tests the iodinated 
component (6>. In order to test the biologic activity of iodoinsulin it is necessary 
that most of the insulin molecules be iodinated. Since Harington (7) has shown 
that highly iodinated insulin is virtually without hormonal activity, the question 
is reduced essentially to the activity of monoiodoinsulin. However, at an average 
of 1 1 atom/molecule insulin, a significant fraction of the insulin molecules have 
2 iodine atoms, some have 3 and a small percentage even more (8, n). Thus, even 
by choosing a stoichiometric ratio of iodine to insulin we are left with a hetero-
genous mixture of variously iodinated insulins. We shall describe later a method 
for selecting more homogeneous components from these mixtures. 
131I-labeled insulin can provide further examples of both theorems. In the study 
of the immunochemical reaction between insulin and insulin antibody, crystalline 
insulins from several different mammalian species were labeled and used as tracers 
for the unlabeled hormones (10· U). It was therefore necessary to establish that the 
labeled and unlabeled hormones reacted identically with the antibodies. This was 
found to be the case not only for insulin (9> but also for the reaction of 131I-labeled 
growth hormone with growth hormone antibodies (12). It cannot be too strongly 
emphasized that where Theorem I is to be applied, the condition of identity of 
behaviour must be specifically tested for the system S, not only in general but in 
particular. For example, an 131l-labeled hormone may react exactly as does the 
unlabeled hormone in a certain antiserum but quite differently in another, perhaps 
because the antibodies in the latter are directed principally against a site of the 
hormone near the substituted iodine atom. For this reason the behavior of one 
antiserum with labeled hormone, unlabeled hormone and hormone fragments cannot 
be transferred unreservedly to another antiserum. Moreover, a monoiodinated 
hormone may exhibit unimpaired immunochemical reactivity whereas the multiply 
iodinated hormone may react poorly. For instance, we have found that singly and 
doubly iodinated insulins show unaltered reactions with a guinea-pig antiinsulin 
serum but at 3 and more iodine atoms/insulin monomer progressive diminution 
in immunoreactivity becomes evident <9). 
The last comments bring us to an illustration of Theorem II. In the radio-
immunoassay of peptide hormones, labeled hormones are exploited in such a way 
that the validity of the method does not depend on the identity of reaction of label-
ed and unlabeled hormones in any system <13). The theoretical basis of the assay 
is expressed in the set of competing i mmunochemical reactions. 
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Free 131I-Hormone + Hormone Antibody ~ t Antibody-bound 1 3 ,I-Hormone 
(F) + (Β) 
Unlabeled hormone 
tv 
Antibody-bound unlabeled hormone 
The labeled hormone must be able to bind to antibody but there is no essential 
requirement that its binding be identical to the binding of unlabeled hormone. It 
is only necessary that endogenous plasma hormone and unlabeled hormone exhibit 
the same competitive inhibition of binding of the labeled hormone. Then, the concen­
tration of hormone in an unknown plasma is determined by comparing the inhi-
KNOWN STANDARDS OF HUMAN INSULIN 
riBODY 
DUO 
ULIN 
/ \ 0 m j^q/ml 
STANDARD CURVE 
ANTI FREE 
BOUND INSULIN 
INS
ANTIBODY FREE 
BOUND INSULIN 
INSULIN Λ 
0.3nyjg/ml / i 
GP 53817 
l'60.000 DILUTION 
OF ANTISERUM 
HUMAN INSULIN CONCENTRATION 
IN RA I HOUR SAMPLE IS .64 nvug/ml . 
160 juU/ml 
HUMAN INSULIN CONCENTRATION 
PLASMA SAMPLES 
ANTIBODY 
BOUND FREE 
INSUUN INSULIN 
RA.PLASMA CONTROL 
NO ANTISERUM 
« -
I 
FIGURE 1. — Chromatoelectrophoresis of '"I-insulin-antiserum mixtures containing known con­
centrations of human insulin (left) and unknown plasma (right). At the bottom of each set 
is a control mixture to which no antiserum had been added: migrating activity in control tubes 
represents damaged fractions. The standard curve (middle) is obtained from measurement 
of areas under each of the two peaks in the complete series of chromatograms of which 8 are 
shown. The insulin concentration in the 1 hour post-glucose specimen of patient RA is calcu­
lated as shown. (Reproduced from Ref. 22.) 
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bition it produces with that produced by the standards. The most direct way of 
doing this is to plot the ratio (B/F) of antibody-bound (B) to free (F) labeled hor-
mone as a function of hormone concentration in known standards and to match 
the B/F ratio in unknown samples to the standard curve (Figure 1). 
Having emphasized the application of Theorem II and the nonessentiality 
of establishing identity of reaction of labeled and unlabeled hormones in radio-
immunoassay, we wish to devote the remainder of this presentation to a consideration 
of factors determining sensitivity and precision of the assay. Five principal factors 
merit discussion : 1) selection of a suitable antiserum. 2) labeling of hormone at 
high specific activity. 3) purification of labeled hormone from labeled components 
damaged during preparation (« preparation damage »). 4) minimization of and 
correction for damage during incubation with plasma (« incubation damage »). 
5) separation of bound and free labeled hormone. 
1. SELECTION OF ANTISERUM 
The slope of the standard curve is dependent primarily on the interaction energy 
between antigen and antibody (10· 14· 15). It is a matter of experience that antisera 
obtained from different animals of the same species immunized on the same sche-
dule vary in their energy of reaction with antigen <12'16). Proper choice of antisera 
CLOSED SYMBOLS-GUINEA PIG ANTISERUMS 
OPEN SYMBOLS- RABBIT ANTISERUMS 
GUINEA PIG 60 
ANTI-PORCINE ACTH SERUMS 
.025 .25 5 10 rryjg/ml. 
HUMAN ACTH CONCENTRATION 
DOSED SYMBOLS-GUINEA PIG ANTI-BOV 
INSULIN SERUM-TRACER BOVINE INSULIN 
OPEN SYMBOLS-GUINEA PIG ANTI-PORC 
INSULIN SERUM-TRACER PORCINE INSULII 
02 05 5 IOm/jg/ml. 
HGH CONCENTRATION (m/ ig /ml . ) HUMAN INSULIN CONCENTRAT 
FIGURE 2. — Percent reduction in ratio (B/F) of bound (B) to free (F) 131I-labeled hormone as a 
function of the concentration of unlabeled hormone. Initial B/F ratios 0.6 : 1 to 3 : 1 ; antiserum 
dilutions 1 : 1000 — 1 : 2,000,000. 
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can result in a hundred fold or greater increase in sensitivity for detection of hor­
mone (Figure 2). Insulin and growth hormone commonly give excellent antisera, 
at least in guinea-pigs. Furthermore, these hormones are present at sufficiently 
high levels in human plasma that sensitivity is usually not a serious problem. Never­
theless, for reasons to be given, it is desirable to assay plasma at a dilution of 1 : 10 
to 1 : 20 or greater and therefore to aim for as great a sensitivity as can be obtained. 
For certain other hormones, parathyroid hormone and ACTH, for example, the 
plasma concentrations may be so low that the sensitivity must be more than 10 
fold greater than that which would be adequate for insulin and growth hormone. 
Since the yield of such good antisera is relatively low, successful assays for some 
hormones may require an extensive program of immunization and testing of antisera. 
2. — REQUIREMENTS FOR SPECIFIC ACTIVITY OF THE LABELED HORMONE 
From a brief consideration of the immunochemical reactions shown previously, 
it is evident that if the antibody is present in marked excess over the hormone to 
be assayed, the binding of the labeled hormone cannot be significantly inhibited 
by unlabeled hormone. Therefore, in practice, the antiserum is diluted sufficiently 
to reduce the concentration of antibody-combining sites to the same order of magni­
tude as the concentration of plasma hormone. Similarly, the concentration of 
labeled hormone should be kept within the same range. Indeed, more precise deter­
minations are obtained when the concentration of labeled hormone (« tracer ») 
is small compared to the concentration of hormone in plasma. The value of decreas­
ing the concentration of tracer depends on the antisera available. With an insen­
sitive antiserum little improvement is gained by decreasing the tracer beyond a 
certain level (Figure 3). The more sensitive the antiserum the greater is the reduc­
tion in B/F obtained with a given increment in hormone concentration (Figure 2). 
Since this holds true also for the tracer, the initial slope of the standard curve is 
sharper and the assay more sensitive, the lower the concentration of tracer02 '. 
For a given antiserum, therefore, the ability to measure low concentrations of hor­
mone will be increased by increases in the efficiency of the counting equipment, 
in the volume of the incubation mixture, or in the concentration of plasma contained 
therein or by a decrease in the concentration of the tracer. 
A decrease in the concentration of tracer with maintenance of suitable counting 
rates can be effected by an increase in specific activity of the labeled hormone. This 
certainly has a limit when both positions on all the tyrosyl residues have been occu­
pied; indeed for most hormones, the effective limit may be considerably lower 
since, as already noted for insulin, multiply iodinated hormone may lose immu­
nochemical reactivity. It seems generally desirable to keep the average iodination 
level to not more than 1 I atom/molecule although it may be useful to exceed this 
value for some hormones. In the case of ACTH, for example, the plasma concen­
tration in normal fasting subjects is frequently less than 20 μμg/ml. If we are to 
assay at I : 2 dilution of plasma in a volume of 0.5 ml and would accept a total of 
3000 counts/minute (after a 6 day incubation period) in a system with an efficiency 
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Effect of tracer concentrations of beef parathyroid hormone -I131 on initial ratios 
Γ 
Sensitive antiserum Insensitive antiseri m 
TRACE 
.05 rn^g/ml 
4 TRACE 
0.2 ni/ig/ml 
B F B F 
FIGURE 3. — Self-explanatory. (Reproduced from Ref. 19.) 
of IO6 c/m^Ci131I, we must have added 131I-ACTH in a concentration of 0.01 μ ο / 
ml initially. For this tracer not to exceed 10 μμg/ml in the 1 : 2 plasma, the specific 
activity of the 131I-ACTH must be 1 curie 131I/mg protein. For 131I contaminated 
with other isotopes to the extent of 70 % (the most nearly carrier-free material 
we have obtained) this means an average of about 1 I atom/molecule ACTH (MW 
= 4500). We have labeled at significantly higher levels, but a diminished immuno­
chemical reactivity seems to offset the advantage of the higher specific activity. 
As indicated earlier, the specific activity requirements of the labeled hormones 
are less stringent for hormones present at significantly higher concentrations than 
ACTH. Yet, since it is preferable to assay at plasma dilutions of 1:10 or greater 
in order to minimize "incubation damage" and since concentrations of hormone 
even lower than normal fasting levels may be of interest, it will often be desirable 
to exceed the minimum satisfactory specific activity. 
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A brief consideration of other radionuclides as potential labels for hormones 
in radioimmunoassay is pertinent. Under conditions for maximal sensitivity for 
measurement of plasma hormones, the concentrations of antigen and antibody 
are so low that the optimum time of incubation is generally about 3-5 days. Isotopes 
of iodine with shorter half-lives than 131I would offer no great advantage. The use 
of longer-lived isotopes such as 125I would result in a lower specific activity of the 
labeled hormone. When such lowering of the specific activity is acceptable and if 
the labeled hormone has a suitably long shelf-life, labeling with 125I may be useful. 
Even were multiple substitutions with 14C or 3H possible, it does not appear likely 
that hormones labeled with these nuclides are potentially useful for radioimmu­
noassay in view of the very much lower specific activities attainable. 
The method of iodination that we have used most extensively for the prepara­
tion of 131I-labeled hormones at very high specific activities is that of Hunter and 
Greenwood (17), which uses chloramine Τ as an oxidant to effect virtually instan­
taneous iodination with yields generally about 90 %. Immediately after completion 
of iodination, the reaction mixture always contains, in addition to the unreacted 
iodide, a variable fraction of damaged 131I-hormone which migrates with plasma 
proteins on paper chromatoelectrophoresis (1M. 
3. — PURIFICATION OF LABELED HORMONES 
To obtain labeled hormone free of damaged components and iodide, we have 
used a technique that exploits the ability of undamaged hormone to adsorb to 
cellulose (13). Immediately after iodination the reaction mixture is added to 10-20 
μΐ plasma and placed on a small column packed with .2-.4 ml cellulose powder. 
Undamaged hormone is adsorbed to the column; damaged fractions bound to 
plasma proteins and unreacted iodide 131I pass through with the plasma proteins. 
The column is then washed several times with buffer. For purification of labeled 
ACTH, parathyroid hormone and insulin, the adsorbed undamaged hormone is 
eluted rapidly with whole plasma into several test tubes containing several milliliters 
of an appropriate buffer. For HGH, since elution with plasma does not produce 
a satisfactory preparation, elution with 20 % acetone in veronal buffer has been 
used (19). 
131I-Insulin and 131I-ACTH, when labeled at specific activities of 1000 mCi131I/ 
mg, generally contain less than 3 % migrating components after purification. The 
bovine parathyroid hormone preparations we have employed (Aurbach, Rasmussen) 
have seldom been purified to less than 5 % migrating components even when label­
ed at low specific activity. The migrating components with various HGH prepa­
rations also average approximately 5 % (Figure 4). Since certain hormone prepa­
rations may contain significant amounts of contaminating proteins or altered hor­
mone molecules that adsorb to cellulose and still are immunochemically unreactive, 
it is often desirable to test the labeled preparation for ability to bind completely 
to antibody by incubating of a small amount of labeled hormone with a strong 
antiserum for an hour or so at room temperature and analyzing the incubation 
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mixture by chromatoelectrophoresis (Figure 4). However, it should be noted that 
ability to bind completely does not necessarily indicate immunochemical reactivity 
identical to that of unlabeled hormone. 
ACTH 
ORIGINAL 
ELUATE 2 
ELUATE 2 
ANTIBODY BOUND 
ORIGIN1 
PARATHORMONE 
ORIGINAL 
IODIDE 
JS^-Jl 
ELUATE 4 
ELUATE 4 ' 
ANTIBODY 
BOUND 
HGH 
ORIGINAL 
STARCH GEL 
: / 
.. 
ACETONE 
ELUATE 2 
STARCH .GEL 1 ACETONE ELUATE 2 
: V ANTIBODY . ' ANTIBODY 
/' \ BOUND / l BOUND 
ORIGIN' ORIGIN' 
FIGURE 4. — Scans of paper chromatoelectrophoretograms of labeled hormone preparations added 
to control (non-immune) plasma (Rows 1 and 2) and specific antisera (Row 3). Paper strips, 
showing the origin (vertical line at right) and stained migrating serum albumin, are shown 
below the scans of the original preparations prior to purification. In Row 2 are shown plasma 
eluates of labeled ACTH and parathyroid hormone purified by adsorption chromatography 
on cellulose columns and extract from starch gel and acetone eluate from cellulose column 
purification of 131I-HGH. (Reproduced from Ref. 19.) 
In earlier studies we regularly purified HGH using preparative starch gel elec-
trophoresis (20). Immediately following iodination the reaction mixture is added 
to an equal volume of non-immune plasma and subjected to starch gel electrophoresis 
according to the method of Smithies l21). After 10 hours at 150V. the gel is removed, 
radioautographs are obtained and used as a guide for the sectioning of the intense 
radioactive bands. The latter are cut out and separately frozen for 3-4 hours. When 
these sections are thawed, their fluid contents are readily extracted and placed in 
separate tubes. A sample from each tube is tested for damage and ability to bind to 
antibody. 1311-HGH prepared from several highly purified preparations of Wilhelmi 
(e.g. HS502B2, HS372B. etc.) migrates almost completely in the pre-albumin zone 
(Figure 5); several thin cuts from this region will show virtually complete binding 
to antibody (Figure 4). Different results have been obtained (l!" with a new highly 
purified preparation of Wilhelmi (HS612A). which is to be distributed as an inter-
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national standard for radioimmunoassay. When a freshly prepared solution is 
labeled with 131I, the radioactivity is concentrated principally in and just behind 
the albumin region (Figure 5). However, after repeated freezing and thawing of the 
same solution of HS612A, newly labeled preparations exhibit a more significant 
pre-albumin band of radioactivity and a loss of the more slowly migrating compo­
nents (Figure 5). Labeled HGH612A from all cuts, including the post albumin 
zones, binds well to antibody. 
612A PREPARED 2 / 1 7 / 6 5 
REPEATEDLY THAWED & REFROZEN 
612A PREPARED 9 / 2 3 / ' 6 5 
FROZEN & THAWED ONCE 
372Β PREPARED 9 / 2 3 / Ό 5 
FROZEN & THAWED ONCE 
I 
REGION OF 
ALBUMIN STAIN 
612A PREPARED 2/17/Έ5 
REPEATEDLY THAWED & REFROZEN f 
612A PREPARED 9 / 1 4 / 6 5 ! f 
USED IMMEDIATELY - NEVER FROZEN] | 
REGION OF 
ALBUMIN STAIN 
FIGURE 5. — All preparations of 1;"I-HS372B as well as several other highly purified Wilhelmi 
human growth hormone preparations have shown virtually all radioactivity in the pre-albumin 
region. In contrast, freshly prepared I31I-HS6I2A has reproducibly shown a major fraction 
with slower migration. After repeated thawing and refreezing of the unlabeled material, a 
significant fraction of freshly iodinated material migrates in the pre-albumin region. (Repro­
duced from Ref. 19.) 
When 1311-insulin of high specific activity is added to plasma and subjected 
to starch gel electrophoresis, the labeled insulin is found in a series of discrete spots 
(s· 9). In order to determine whether the multiple components represented inhomo-
geneity of the starting material or were produced during labeling, comparisons were 
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made between iodinated preparations with a ten-fold difference in specific activities. 
The most anodal components were absent in the low specific activity preparations 
(Figure 6). Studies with labeled insulin preparations of the same specific activities 
but with varying amounts of carrier 127I indicated that the individual bands corres­
ponded to insulin molecules with different numbers of iodine atoms (8, 9) (Figure 7). 
These observations have been exploited to estimate the specific activity of commer­
cially available 131I preparations <9). The estimation is made by comparing the starch 
gel electrophoresis patterns of insulins labeled with varying quantities of 131I (Figure 
8) with those obtained by labeling with small amounts of 131I and graded known 
amounts of 127I (Figure 7). 
HIGH SPECIFIC 
ACTIVITY PREPARATION • 
ORIGIN 
LOW SPECIFIC 
ACTIVITY PREPARATION 
ALBUMIN 
REGION 
FIGURE 6. — Beef insulin (Lilly lot#719106) was labeled with 131I and added to an equal volume 
of plasma for electrophoresis on starch gel. After electrophoresis the gel was removed from 
the mold, covered with Parafilm and placed in contact with x-ray film for radioautography. 
Bromphenol blue was added to the plasma prior to electrophoresis for ready identification 
of the serum albumin. High specific activity, --^ 520 mCi t31I/mg insulin. Low specific activity 
~ /50 mCi 131I/mg insulin. (Reproduced from Ref. 8.) 
40mc I / m g 
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AtBUMIN STAIN 
PER MOLECULE OF INSULIN ( M W 6 0 0 0 ) 
FIGURE 7. — Same experimental conditions as in Figure 5 except that the low specific activity pre. 
ration was 40 mCi131I/mgprotein and127Iwas added to 13II as indicated for 2 lower preparations-
In all three preparations, iodination was approximately 95 % complete so that final labeled 
products contained essentially the initial iodine : protein ratio. (Reproduced from Ref. 8.) 
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FIGURE 8. — Same experimental conditions as in Figures 6 and 7 except that another lot of 131I 
was used to prepare l31I -insulin at the indicated specific activities 
Since the 13I1 supplied for clinical purposes is often of low specific activity and 
is protected from oxidation by reducing agents, only 131I designated "for iodination" 
by isotope suppliers is suitable for the present purposes. However, uniform pro-
duction of satisfactory labeled hormones is not always possible even with these 
special preparations. On occasion, lots of 131I are unsatisfactory for iodination of 
hormones either because they result in low iodination yields or because the iodinated 
hormone fails to purify well. The identification of the noxious substance has not 
been made, but our studies with several such lots suggest that the difficulty does 
not always arise from low specific activity of the 131I. 
4. — MINIMIZATION OF INCUBATION DAMAGE 
After the initial purification of labeled hormone, increasing amounts of labeled 
products which migrate with or are bound to serum proteins appear during incuba-
tion of the labeled hormones in plasma (18). Such "incubation damage" occurs 
with all 131I-labeled hormones but the factors responsible may differ with the indi-
vidual hormones. However, virtually all plasmas become more damaging when 
stored for extended periods of time at room temperature or above, and minimally 
damaging plasmas are obtained when blood samples are taken with a heparinized 
syringe, immediately centrifuged and stored in a deep freeze. 
131I-lnsulin is protected from damage in plasma with 0.5 % iodoacetamide for 
20-30 min at 37° C (22). Whereas we earlier considered that this effect might be due 
to the blocking of -SH groups present in plasma (and thus reducing the potential 
for reductive splitting of disulfide groups), the possibility exists that iodoacetamide 
may act by inhibiting sulfhydryl-dependent proteolytic enzymes, especially since 
free 131I appears not infrequently to accompany incubation damage. Whereas -SH 
compounds, under appropriate conditions, damage insulin, mercaptoethanol in 
concentrations of 0.25-0.5 % has a strong protective effect on 131I-ACTH. Although 
mercaptoethanol protection of ACTH against biological inactivation has been 
attributed to prevention of oxidation of the methionine group, we are not certain 
that this is the sole mechanism for its protection of 131I-ACTH since mercaptoe-
thanol is not helpful in protecting against damage to 131I-parathyroid hormone, 
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which also is biologically inactivated by oxidation of the methionine group. It may 
well be that the protection of 131I­ACTH by mercaptoethanol can be attributed 
to inactivation of disulfide­dependent proteolytic enzymes. Evidence for the rôle 
of plasma proteolytic enzymes in incubation damage arises from the observed effec­
tiveness of trypsin inhibitors in protecting labeled hormones from damage in plasma 
(111) 
5. — SEPARATION OF BOUND AND FREE LABELED HORMONE 
Since free iodide 131 is not a part of the bound or free labeled hormone, it 
obviously must not be counted with either. Separation by paper chromato­
electrophoresis permits recognition of iodide 131 as a separate peak not included in 
the protein fractions. Test tube separations of bound and free hormones are generally 
blind to the appearance of free iodide 131 in the incubation mixtures and erroneous 
concentrations for immunoassayable hormone may be attributable to significant 
but variable deiodination in the incubation mixtures. 
For all separation systems, proper controls must be set up for detection of 
and correction for the presence of damaged hormone that is bound non­specifically 
to serum protein and thus prevented from participating in the antigen­antibody 
reaction. The appropriate control for paper chromatoelectrophoretic separation 
is an incubation mixture prepared identically with standard or unknown solutions 
but without antibody; the migrating material is identifiable as damage. When cumu­
lative damage due to preparation or incubation is small, adequate correction can 
be made but when it is greater than 20­25 % the determination of hormone concen­
tration is subject to great error. 
In the case of double antibody techniques for separation of bound and free 
hormone, damaged fractions bound to human plasma proteins are not available 
for binding to antibody and are therefore not precipitable with the second anti­
body. Proper controls in this procedure require a second precipitation with anti­
whole human plasma for determination of protein­bound damaged fractions (as 
previously recommended (22)). To our knowledge this has not been done by workers 
relying on the double antibody separation. 
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DISCUSSION 
K. BRUNFELDT (Gentofte) : With the modern counting systems 125I should not 
cause any difficulties, at least, when the double antibody method is used. If a method 
based on a scanning of paper strips or agar plates is used, 131I may be preferable. 
Regarding the separation of iodinated insulin preparations, I should like to ask 
whether you have been able to obtain this with all your insulin preparations, and 
under which conditions the electrophoresis was carried out ? I should also like to 
direct your attention to the fact that it is possible to separate crystallized insulin 
into two fractions by continuous paper electrophoresis, the fast migrating one con­
taining the major part of the Zn+ + content of the original sample. 
R. S. YALOW : Starch gel electrophoresis was carried out according to the 
method : Smithies, O. (Adv. Protein Chem. 14 : 65, 1959). Freshly dissolved crys­
talline beef and pork insulins from Lilly, and crystalline pork insulin from Novo 
behave identically in this system when iodinated. Prolonged storage at —15° C of 
these insulins in acid solutions (0.001 M HCl) results in bands with increased anodal 
mobility for both labeled and unlabeled preparations, probably because of loss of 
amide groups. 
F. C. GREENWOOD (London) : Concerning the intensive immunization schedule 
you mentioned, it would be useful to know exactly how many animals for example 
you require to immunize, to get a very good ACTH antiserum ? The other technical 
point is, how routine is the determination of specific activity of isotope samples ? 
I would like to congratulate yourself and Dr. Berson on this procedure since I under­
stand the producers of carrier free 131I have spent a long time trying to develop 
routine methods for specific activity. 
R. S. YALOW : The best ACTH antiserum we have is capable of detecting 
5 μμg/ml human ACTH. The animal was one of 18 immunized. In this group there 
was another animal whose antiserum had a sensitivity of 25-50 μ,ϋ /^πιΐ and a number 
of others had antibody detectable with antiserum dilutions of 1 : 104 or greater. 
It should be emphasized that a very small tracer must be used for testing these very 
sensitive antiserums or the tracer alone would occupy all the antibody-binding 
sites. 
With respect to the second question, we have been performing the specific 
activity determinations for almost each new lot of Isoserve iodine for the last month 
or two. We plan on doing it at monthly intervals for a while to intercompare Oak 
Ridge, Isoserve and" Amersham iodines. 
R. P. EKINS (London) : We have shown that the optimum amount of tracer 
to be employed in an immunoassay is 4/K (Mol/1) and the optimum amount of 
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antibody is 3/K. (Mol/1) where Κ is equal to the reaction constant (1/Mol) (Ekins, 
1963; Ekins and O'Riordan, 1966). The minimum detectable amount of hormone 
is given by 4 A / 2 / \ / K V S T where V = volume (in liters) of incubation mixture 
subjected to the separation procedure, S = specific activity of tracer (c.p.m./Mol) 
and Τ = the total counting time per free/bound pair (min.). These theoretical consi­
derations depend on the assumption that the error in the determination of the free 
to bound ratio comprises the counting error only, which I realise is invalid; however 
in certain assay procedure (I am thinking particularly of the assay of vitamin B12 
using the analogous saturation assay technique (Barakat and Ekins, 1961) the total 
error in the determination of Rflb (or Rblf) is indeed very close to the counting error 
(at the 1 % level). Under these circumstances, it may well be that better sensitivity 
is not obtained by reduction of the amount of tracer as Dr. Yalow has recommended 
without qualification. 
In the assay of vitamin B12, we have used activated charcoal to separate free 
and bound B12 and have found it a very useful reagent yielding an extremely simple 
technique. Dr. Herbert (Herbert et al., 1965) has recently employed activated charcoal 
to separate free and bound insulin and has suggested its use in the assay of HGH. 
I wonder if Dr. Yalow has any comments to make on the use of this reagent. Regard­
ing the point raised by Dr. Greenwood, Dr. Reith in our laboratory (Reith and 
Bown, 1964) has routinely measured the specific activity of 131I supplied by the 
R. C. C. Amersham by iodinating 14C-labeled tyrosine. Following chromatographic 
separation of the unreacted tyrosine it is a simple matter to calculate the specific 
activity on the 131I supplied by measuring the ratio of the 131I and U C activities in 
the iodotyrosines. Using this method, the proportions of 131I in the material sup­
plied was shown to be as low as approximatively 5 % though in recent preparations 
this proportion has somewhat improved. 
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R. S. YALOW : A number of techniques have been used to separate bound (B) 
and free (F) labeled hormones. If charcoal absorbs 95-100 % of free hormone and 
less than 5 % of antibody-bound hormone under the conditions employed, it should 
be satisfactory as another method for separation of Β and F. However, for each 
hormone and for each separation system the optimal conditions for separation 
must be evaluated. 
I have seen the publication by Reith and Brown (Nature, 201 : 621 [1964]) on 
the experimental estimation of the specific activities of 131I-iodotyrosines using 
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14C-tyrosines in the iodination procedure. In this paper they made no reference to 
the specific activity of 131I-iodide. Perhaps you could supply the exact reference for 
the study you have quoted. 
A. E. FREEDLENDER (Boston) : Using the Soeldner modification of the method 
of Morgan and Lazarow we have assayed sera at dilution between 1 : 2 and 1 : 20. 
When results are corrected for dilution, equivalent values for insulin were obtained, 
indicating an absence of degradation in this system even at low dilutions of sera. 
These results are in confirmation of the data recently published by Soeldner 
and Slone. 
R. S. YALOW : Degradation of labeled insulin by plasma is quite variable and 
dependent on the plasma and on the individual lot of 131l-insulin. On occasion 
131I-insulin added to plasma and stored for several weeks at 4° C has shown vir-
tually no detectable increase in damage. An occasional check, therefore, is not 
definitive evidence for absence of damage with other lots of insulin and other plasmas. 
Using chromatoelectrophoresis we have evaluated each lot of 131I-insulin and each 
patient's plasma for damage. By this time, evidence has accumulated that at 1 : 10 
or 1 : 20 dilutions only occasional plasmas are significantly damaged, but in undi-
luted plasma or plasmas at low dilution, significant damage occurs quite frequently. 
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ABSTRACT 
The effect of progressive iodination on the biological activity of labelled insulin 
has been investigated. Iodination up to 8 iodine atoms per insulin molecule has been 
performed under standardized and controlled conditions. Preparations were tested 
for their biological activity using the epididymal fat pad method. 
The distribution of iodine among the four tyrosine residues has been measured 
and tentatively correlated with the drop of biological activity occurring above a 
certain level of iodination, on one side, and the reduction in SS bridges reactivity 
towards sulphite on the other. 
Insulin iodination beyond a certain substitution degree has been reported by 
several authors to cause the inactivation of the hormone (1"3). Since the only occurring 
reaction is the conversion of tyrosine residues in the mono­ and di­iodinated deriva­
tives, inactivation must necessarily be correlated to this process. 
In Figure 1, the insulin activity is plotted versus the average iodination degree 
for a series of iodo­insulin preparations. Biological activity was measured by the 
epididymal fat pad assay (Table I). Insulin iodination was carried out at pH 7.6 using 
the previsouly described electrolytic technique, under standard conditions. The 
Table I shows that hormonal activity is apparently unchanged up to a substitution 
degree of the order of 2 iodine atoms per molecule and becomes negligible at a substi­
tution degree of the order of 5 iodine atoms per molecule. 
At a first sight, these results would seem to indicate that below an iodination 
degree of 2 iodine atoms per mole, labelled 131I­or 125I­insulin could be considered an 
adequate biological tracer. In fact, such a clearcut conclusion is not warranted on 
the basis of these data. The internal variability of the bioassay, the contribution of the 
unlabelled insulin to the measured biological activity and the probably not uniform 
distribution of the iodine atoms among the insulin molecules, only permit to identify 
the iodination degree of 2, as the level at which the amount of inactivated 
insulin is large enough to induce a detectable loss of hormonal activity. 
The question of the actual iodination level at which 131I­or 125I­labelled insulin 
can be considered an adequate biological tracer, is then still open. 
(*) Work performed under EURATOM contracts No. 053­63­10 RISI and No. 048­64­6 ΒΙΟΙ. 
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Relationship between hormonal activity and iodination degree. 
Some experiments reported by Fraenkel-Conrat suggest a way to interpret our 
results (1). 
The inhibition of the hormonal activity depends on the attainment of a critical 
intramolecular structure, which is probably related to the distribution of iodine among 
the tyrosine residues. 
A further step in the understanding of the inactivation process obviously requires 
a full knowledge of the relationship between the location of iodine in a iodinated 
insulin molecule and its hormonal activity. 
Following this line, we have undertaken, on insulins iodinated at increasing 
degrees, the study of the distribution of iodine among the four tyrosine residues, and 
its correlation with the biological activity. 
TABLE I. — Relationship between degree of iodination and biological activity of iodcinsulins. 
Iodination degree 
(I atoms per insulin 
molecule of M.W. 5734) 
0.5 
2.0 
2.2 
3.7 
3.9 
4.0 
4.6 
5.5 
7.3 
Hormonal activity in 
epididymal fat pad assay 
(% of activity 
of native insulin) 
94.4 ± 4 . 1 4 
90.1 ± 1.13 
82.1 ± 6.60 
16.5 ± 1.70 
19.9 ± 2.60 
22.0 ± 2.60 
21.9 ±4 .01 
7.0 ± 1.20 
< 5 ± 2.90 
Observations 
Not significant 
Not significant 
— 
— 
— 
— 
— 
— 
— 
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The procedure of fragmentation, which allowed the average iodine distribution 
to be evaluated, was the following (Figure 2) : 
— A and Β chains were separated by splitting the interchains ­S­S­ bonds, accord­
ing to the procedure described by Bailey (4). 
— the chains were separated by paper electrophoresis under the experimental condi­
tions given by De Zoeten ( 5 '6 ) and eluted in the pure form from the paper strip. 
— subsequent fragmentation of the chains was performed by enzymatic hydrolysis 
at a pH 8.4 with ß­chymotrypsin or trypsin for A and Β chains respectively. 
A chain Ρ ­Chymotrypsin 
^ S T - c ) i f e ^ ) - ^ a u / / Ä c ö Y S ^ 0 0 H Λ 
/ . / " Β chain b >o b ena in 
HlN/cYSTfH,sfGLu/^/cYSTf@RGTG¿Y//^COOH t 
Trypsin 
IODINATED INSULIN 
A chain 
ι — 
splitting of interchains ­S­S­bridges 
with Na2S03 and Na2S40„ 
Electrophoresis in 8M urea and 
20 % CFL COOH 
B chain 
ENZYMATIC HYDROLYSIS 
(ß­chymotrypsin) 
Electrophoresis in 
30 % acetic acid 
ENZYMATIC HYDROLYSIS 
(Trypsin) 
Electrophoresis in 
0.2M phosphate 
buffer in 8M urea 
A(l­14) 
_L_ 
A( 19­21) 
¿ _ 
ι— 
B(l­22) B(23­29) 
MIT and DIT residues are chromatographically determined on each sample after total hydro­
lysis with pancreatin followed by chromatographic separation. 
FIGURE 2. — Schematic representation of the fragmentation procedure. 
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— fragments separation was carried out by paper electrophoresis followed by selec­
tive elution with an appropriate solvent. 
— each group of fragments was submitted to total hydrolysis with pancreatin. Mono-
and di-iodinated tyrosine residues were separated by descending paper chromato­
graphy as MIT and DIT, and counted for125I activity. 
As result of such a fragmentation procedure, a set of experimental data was 
obtained for each preparation of iodinated insulin. 
These data concerned : 
a) the distribution of iodine between the two chains, expressed in percentage of the 
total iodine bound to the insulin. 
b) the distribution of the iodine bound to each chain between the two tyrosyl resi­
dues, expressed in percentage of the total iodine bound to the chain. 
c) the amount of iodine bound to the single tyrosine residues. 
The procedure employed for the calculations concerning the point c) requires 
a brief commentary. As a result of the fragmentation, the tyrosyl residues of a certain 
type (for example A 14 or A 19) are found, part as a mono-iodinated form, part as 
a di-iodinated form. By difference, the uniodinated tyrosines may be calculated. The 
results are expressed as percentage of the total tyrosines ofthat peculiar type. 
The iodine distribution between the two chains is represented in Figure 3. In 
agreement with the results of De Zoeten (5 ,6), the A chain shows a higher reactivity 
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- Distribution of iodine between A and Β insulin-chains. The percentages of total insulin-
iodine, found in A chain (#) and in Β chain ( A ) are plotted vs. iodination degree. 
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towards iodine. Up to an iodination degree of 4 iodine atoms per mole, about the 
70 % of the reacted iodine, is carried by the tyrosine residues of the A chain. As a 
consequence of this uneven distribution, the number of free tyrosine groups in the 
Β chain is still 70 % of the initial value, even for an iodination degree of 4 (Figure 4). 
The dotted lines, on the Figures 3 and 4, define the range of iodination degree, within 
which the hormonal activity falls from 80 % to about 20 %. The distribution of iodine 
between B­16 and B­26 positions was experimentally found of the same order. Con­
sequently, about 65­70 % of the tyrosine residues of each type were found to be not 
substituted, when the insulin was already highly inactivated. 
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FIGURE 4. — Percentage of tyrosine residues in uniodinated form found in A chain ( A ) and in Β 
chain (#) at different values of the iodination degree. 
Statistical considerations on these findings indicate that a critical rôle of the 
Β chain in the inactivation process is highly unlikely. 
In Figure 5 the number of uniodinated tyrosine residues in A 14 and A 19 
positions is plotted versus the degree of iodination. At an average iodination degree 
of 4, all the A 19 and about 75 % of A 14 tyrosines have been substituted. 
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Percentage of tyrosine residues A 14(A)and A 19(0)in uniodinated form at different 
values of the iodination degree. 
We have used these results in the attempt to identify the critical intramolecular 
combinations responsible for insulin inactivation. These analyses were performed with 
the aid of an IBM 7090 digital computer. Due to the limited number of available 
experimental data, the analysis was performed disregarding the Β chain. This 
restriction, on a first approach, may be considered of limited importance, following 
our previous considerations. When A chain only is considered, 9 combinations are 
possible, as shown in Table II. 
The probability for each combination was obtained as the product of the rela­
tive measured frequencies of its components; the fluctuation around the most pro­
bable distribution was disregarded in this first approach. 
The hypothesis was made that every intramolecular combination could be 
either inhibitory or not inhibitory on the biological activity, thus obtaining a series 
of 29 (512) hypothetical structures. The computer was programmed to test the 
efficiency of every hypothesis in predicting the biological activity of each preparation 
for which distribution data were available. 
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TABLE II. — Possible intramolecular combinations (I.C.), deriving from the distribution of the 
iodine between Tyrosine residues A 14 and A 19 
i.e. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
Position A 14 
TYR 
TYR 
TYR 
MIT 
MIT 
MIT 
DIT 
DIT 
DIT 
Position A 19 
TYR 
MIT 
DIT 
TYR 
MIT 
DIT 
TYR 
MIT 
DIT 
Cod 
0 
0 
0 
1 
1 
1 
2 
2 
2 
e(!) 
0 
1 
2 
0 
1 
2 
0 
1 
2 
TYR = Uniodinated Tyrosine residue. 
MIT = Mono-iodinated Tyrosine residue. 
DIT = Di-iodinated Tyrosine residue. 
(') Code symbol identifying each Combination, for the Analysis at Digital computer. 
The results of the analysis indicate that the hypothesis giving the best fit of our 
observations, about the correlation between biological activity and iodination degree, 
is that : inhibition is due to the intramolecular combinations 6, 8 and 9. 
In other words, the inhibition effect due to the progressive iodination starts 
when one of the tyrosine residues of A chain has been mono-substituted and the 
other residue di-substituted. The confidence limits of these results will be well defined 
when the study, now in progress, will be completed. 
We are fully aware of the limited significance of these data, due both to the 
various assumptions and restrictions introduced and to the limited number of experi­
mental data. 
However, from the practical point of view, it seems possible to conclude that in 
absence of di-iodinated tyrosines in the A chain, a preparation of iodinated insulin 
certainly retains its biological activity. In our preparative conditions, this requirement 
is met when insulin is iodinated below 0.5 iodine atoms per molecule. 
In which way the inhibitory structures affect the biological activity is purely a 
matter of speculation. 
However, it cannot be concluded without further investigations that one or more 
tyrosyl groups are directly involved in the hormonal activity. 
One of the possible hypotheses is that tyrosine groups iodination creates a steric 
hindrance in the reaction on which hormonal effect is based. Before ending this 
communication, I would like to report briefly the results of an experiment that may 
suggest some possible interpretations of this phenomenon. 
As it is well known, insulin contains three disulphide bridges per "monomer" 
unit, two connecting the A and Β chains, the third one forming a ring in the A chain. 
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Cecil (7) has found that, when insulin reacts with sodium sulphite at a pH of 
about 7, only the two interchain -S-S- bridges are splitted. 
When the Cecil's procedure was applied by us to study the reactivity of the 
sulphur bridges in a highly iodinated insulin, we found that only one -S-S- bond per 
insulin molecule was splitted. 
Measurements carried out on iodoinsulin preparations, having an iodination 
degree ranging from 0.5 to 6 iodine atoms per molecule, gave the results reported in 
Figure 6. 
° IODINATION DEGREE 
I atom s /molecule 
FIGURE 6. — Titratable S-S-/mole found in iodoinsulin preparations, having an iodination degree 
ranging from 1 to 8 iodine atoms per insulin molecule. 
As it can be seen, iodination of insulin up to a substitution degree of about 
2 iodine atoms per molecule, does not affect significantly the reactivity of the -S-S-
bonds towards the sulphite, since the correct value of 2 -S-S- bonds per mole was 
measured. Iodination beyond 3 iodine atoms per molecule causes a progressive 
decrease in the value of the titratable -S-S- bonds. Only one -S-S- bond per molecule 
is splitted when the iodination degree is 4-5 iodine atoms per molecule, or more. 
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FIGURE 7. — Biological activity (.A) and -S-S- reacted/mole (#) versus iodination degree. Titration 
results are expressed in %, taking as 100 % the value of 2 -S-S-/mole found in native-insulin, 
and 0 % the value of I -S-S-/mole found in fully iodinated insulin. 
This result appears to be an interesting example of how a substitution process, 
localized in the tyrosine groups, may interfere with the chemical behaviour of the 
other groups. 
When the biological activity and the number of-S-S- reacted per insulin molecule, 
are represented on the same graph, as a function of the degree of iodination, both 
phenomena show a very similar trend (Figure 7). This was confirmed, when the 
computer program was used to correlate iodine distribution with the behaviour of the 
-S-S- bonds. 
The same intramolecular distributions of iodine were found to account for both 
processes. 
An attractive working hypothesis could be that splitting of interchains -S-S-
bonds is an essential step in the insulin action. 
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DISCUSSION 
K. BRUNFELDT (Gentofte) : I should like to stress that by intravenous injection 
in rabbits we have found in our laboratory nearly same degree of inactivation as 
a function of the degree of iodination as has been demonstrated by Dr. Rosa. 
E. SAMOLS (London) : It would seem to be worthwhile to clarify what is meant 
by biological activity of hormones. Dr. Rosa has shown a decrease in biological 
activity of insulin with increasing iodination. This measurement of native insulin 
activity is different from the determination of biological activity of "insulin" in 
biological fluids and extracts. For example Prof. Pfeiffer described a decrease of 
insulin like activity on addition of anti-insulin serum to the serum of Houssay dogs 
but no changes in blood glucose when these dogs were infused with the same anti-
serum. 
The possibility that the antiserum is acting primarily on the diaphragm or 
epidydimal fat pad rather than neutralizing insulin like activity must be considered. 
It should also be appreciated that bio-assay of low concentrations of insulin is beset 
by problems, and some knowledge about the index of precision of the bio-assays 
used would be relevant to the assessment of Dr. Rosa's results. 
U. ROSA : Our results must be interpreted in the sense that they give a relation-
ship between a localized substitution process on the insulin molecule and the hor-
monal activity measured under reproducible conditions in a well defined system. 
When the native insulin and the substituted one are compared by means of a bio-
assay, I think that any difference we find must of course be attributed to the substitu-
tion process. On my opinion the example reported by Dr. Samols has nothing to 
do with this kind of experiments, although I quite agree that employing other kinds 
of bio-assays, one can possibly find a different relationship between iodination degree 
and biological activity. 
As far as the precision of our bio-assay procedure is concerned, it was evaluated, 
on the basis of standard experiments, to be of the order of 15-20 %. 
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ABSTRACT 
A double step, double tracer radioimmunoassay is presented which allowed 
us to study the immunologic behaviour of iodoinsulin. Iodination induces an impair­
ment of the immunologic properties of insulin, increasing with the degree of iodi­
nation. This effect, slowly progressive is different from the biologic one. 
In practice, this means that the degree of iodination should remain as low as 
possible. 
A non saturation of the antibody sites by iodinated insulin has been found 
which has possible inference in the interpretation of the radioimmunoassay. There­
fore every labelling methods should be evaluated, in order to use the best one. 
The same problem probably exists for the other labelled proteinic hormones. 
It has long been recognized that iodinated insulin preparations contain immu­
nologic "damaged" hormone. Therefore methods have been developped to purify 
these preparations. Procedures are described for minimizing damage to the labelled 
hormone during its preparation, purification and incubation with plasma <24). But 
the immunologic identity of these "purified" labelled insulin and non­labelled insulin 
has been much less questionned than the biological one, notwithstanding a lack of 
convincing experimental data. Only one indirect experimental argument is presented 
by two authors (4> 21); they found "at any particular insulin concentration, the same 
degree of binding of 131I­insulin whether the insulin present was derived entirely 
from the preparation of 131I­insulin or was primarily non­iodinated insulin with 
only a tracer amount of iodoinsulin". It was assumed consequently that "the immu­
nologic reactivity of insulin is not altered by the labelling procedure employed" (4). 
The first purpose of the work was to set up a device allowing us to compare 
properly the immunologic identity of labelled and unlabelled insulins when both 
are put simultaneously in competition, as is the case in the radioimmunoassay. The 
comparison to be valid, requires both forms of insulin to be measured in the same 
experiment, by two different methods : one based on the distribution of the radio­
active molecules (the radioimmunoassay itself); the second based on the direct eva­
luation of the unlabelled molecules, by transfer in a second system. 
(*) These studies were supported in part by United States Public Health Service Grant AMO 
6001 and the Association Contract Euratom­Universités de Pise et de Bruxelles (No. 026­63­4 BI AC). 
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In a second part the influence of various degrees of iodination is investigated. 
On the immunologic aspect of this problem, few data are found in the literature : 
Berson and Yalow <24) recommand the use of low iodination as probably advisable : 
"over­iodination appearing to have untoward effect on the stability and immu­
nologic reactivity of insulin". On the contrary Izzo et al. <13) conclude that varying 
degree of iodination (1 to 5 at. I/mol) has no demonstrable effect on the binding 
of radioactive insulin to the insulin antibodies. 
COMPARISON OF LABELLED AND NON­LABELLED INSULIN 
In the first part, we investigated the immunologic identity of labelled and non­
labelled insulin. 
Beef insulin has been used throughout the whole experiment to eliminate all 
problems of species specifity. 131I­ and 125I­insulin were prepared by two different 
methods : Iodine monochloride U6) and elementary iodine (I7). The iodination degree 
was evaluated to 1 atom of iodine per molecule of insulin (M. W. 6,000). 
Guinea­pig gammaglobulin was isolated from guinea­pig insulin antisera or 
normal serum by DEAE column chromatography (23). The purity of this prepara­
tion was demonstrated by Immunoelectrophoresis : it induced a single precipitating 
arc against rabbit anti­whole guinea­pig serum. This material was used for the pro­
duction of rabbit antiserum against guinea­pig gammaglobulin. 77;e antisera against 
beef insulin in the guinea­pig and against guinea­pig gammaglobulin in the rabbit 
were prepared according to Arquilla (1). The insulin immune hemolysis inhibition 
assay (H. L.) has been set up by Arquilla. The λ, index of precision (S. D. of points 
about the regression line divided by the slope of the regression line) was 0.08. As 
radioimmunoassay (R. I. A.) : the double antibody method of Hales and Rändle 
(10) was utilized slightly modified. The calculated λ was 0.05. Insulin biological 
assay : the rat epididymal fat pad method of Ball and Merril (2) was used to test 
the neutralizing biological capacity of the anti­insulin sera. The experimental design 
is summarized in Figure 1. 
Guinea­pigs immunized with crystallin insulin produce anti­insulin serum. 
Rabbits injected with pure guinea­pig gammaglobulin produce precipitating anti­
bodies directed against the guinea­pig gammaglobulin. The guinea­pig anti­insulin 
serum is mixed with the rabbit precipitating antiserum in adequate proportion to 
assure optimal precipitation; from the guinea­pig anti­serum, only the gammaglo­
bulin, containing the anti­insulin antibodies are precipitated and isolated. To this 
precipitate is added a mixture of radioactive insulin (always the same tracer amount) 
and 10 times crystallized non­labelled insulin, in increasing amount. 
Before use, the radioactive insulin has been purified on a Sephadex G. 75 or 
on cellulose column : 94 % of the radioactivity or more was able to bind to anti­
bodies. After incubation, the precipitate containing the antibody­bound insulin is 
separated from the supernatant containing the free insulin. The duration of all 
incubations were controlled to allow completion of the antibody­antigen reaction. 
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In the first method used, the radioimmunoassay (R. Ι. Α.), the results are based 
on the repartition of the radioactivity between the precipitate (or so­called anti­
body­bound insulin), and the supernatant (or so­called free insulin). The free insulin 
present in the supernatant is on the other hand directly measured by transfer in 
two different assays : 
a) immune hemolysis assay (H. L. assay) or 
b) another radioimmunoassay (2nd R. I. A.) using a different isotope of iodine as 
tracer for insulin (double tracer method) : in this second series of experiments 
different batchs of labelled insulin, other antisera, at other dilutions, were utilized. 
Also in one experiment, instead of mixing first the anti­insulin serum to the 
precipitating antibody to obtain a preformed precipitate (method Β of Hales 
and Rändle) the anti­insulin serum was first incubated with the insulins (labelled 
+ unlabelled) and precipitation was carried out afterwards (method A of Hales 
and Rändle). There was no difference in the result with pre­ or post­formed 
precipitate. 
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FIGURE 1. — Experimental design 
If antibodies combined with both iodoinsulins and crystallin insulin to the 
same degree, then the free (or bound) insulin assayed radioimmunologically should 
have equalled the free (or bound) unlabelled insulin assayed directly by transfer in 
the second system. 
Table I gives the result. At every concentration, in each experiment, less insulin 
is found free by the direct dosage, than is expected from the radioactive distribution. 
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The differences are statistically highly significant (p < 0.01). These results indicate 
that, when in competition with unlabelled insulin, iodinated insulin is preferentially 
displaced from the antibody complex and so demonstrates a significant impairment 
to combine with insulin antibodies. 
TABLE I. — Comparison of the amount of free unlabelled insulin (remaining in the supernatant) 
as deduced 
1° indirectly from the repartition of the radioactive insulin (1st R. Ι. Α.). 
2° directly measured by transfer in either an insulin immune hemolysis assay (H. L.) or a second 
radioimmunoassay (2nd R. Ι. Α.). 
Cryst. 
insulin 
added 
(μώ 
0.5 
1 
2 
4 
6 
(μυ) 
250 
500 
1000 
Free insulin by 
1st R. I. A. 
(in μ&) 
0.11 
0.39 
1.17 
2.89 
4.8 
1st R. I. A. 
(¡η μ υ ) 
33 
186 
668 
H. L. Assay 
(in μg) 
0.03 
0.016 
0.55 
1.9 
2.9 
2nd R. I. A. 
(in μ υ ) 
0 
86 
393 
But from these experiments, another characteristic must be pointed out, which 
is illustrated in Figure 2. 
Figure 2a represents the mean of 3 experiments obtained with free insulin 
dosed in the 2nd R. I. A. When 250 μΙΙ of insulin is added, no free insulin can be 
detected. This fits remarkably well the biological neutralizing capacity of the anti­
serum used; this concordance is an indirect proof of the validity of our results : 
in both conditions the titer of the antiserum was 1.5 U/ml. But, when no detectable 
insulin is found free, already 14 % of the radioactivity is displaced from the anti­
body into the supernatant. 
Figure 2b represents the mean of 3 experiments obtained with the free insulin 
measured in the immune hemolysis system. Same results : when 12.5m U crystallin 
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insulin is added, almost no free insulin is found : again in very good correlation 
with the biological neutralizing capacity : but again, at this insulin level, 20 % of 
the radioactivity is displaced from the antibody. 
RADIOACTIVITY AND FREE INSULIN IN 
THE SUPERNATANT OF A RADIOIMMUNOASSAY 
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FIGURE 2. — Evolution of the % radioactivity displaced (0 0) and the free insulin directly 
dosed ( · — · in the supernatant of a radioimmunoassay 
a) left figure : free insulin measured in the 2nd R. I. A. 
ft) right figure : free insulin dosed by H. L. Assay. 
How can this be explained ? At any level below 250 μΕΙ (Figure 2a) or 12.5 mU 
(Figure 2 b), addition of crystallin insulin begins to displace fraction of the labelled 
molecules from the antibody complex into the supernatant. But at these levels as 
indicated by the further binding of higher amount of crystallin insulin, there are 
still antibody sites free, for unlabelled insulin, but not for the labelled molecules 
which remain unbound in the supernatant. So, iodoinsulin (or part of it) appears 
unable to saturate all the antibodies present in an anti­serum. 
INFLUENCE OF THE DEGREE OF IODINATION ON THE IMMUNOLOGICAL PROPERTIES OF 
INSULIN 
Recently we have received from Dr. Rosa radioactive insulin iodinated to varying 
degrees with 131I or 125I by the same method <19). This allowed us to study the 
influence of the degree of iodination on the immunological properties of insulin. 
In each experiment two different iodoinsulins, one labelled with 131I, the other with 
123I ,were mixed in tracer amount and incorporated in a radioimmunoassay. Figure 3 
gives the curves obtained in experiments performed simultaneously with 3 diffe­
rent iodoinsulins; the more insulin is iodinated, the more it is preferentially displaced 
by equal amount of unlabelled insulin. 
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Figure 4 gives the results obtained with the different iodoinsulins prepared by 
Dr. Rosa's method in comparative R. I. A. performed on different days, these last 
2 months. As reference, one single point of the R. I. A. curve was choosen to repre­
sent the radioactivity displaced. 
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FIGURE 3. — Influence of the degree of iodination of insulin on its displacement by non­iodinated 
insulin 
R. I. A. performed the same day with the same reagents : in one set of experiments, iodoinsulins 
with 1 and 2 at. I/mol were mixed; in the second, iodoinsulins with 1 and 4 at. I/mol. were mixed. 
In abeissa, % radioactivity displaced; in ordinate log. of crystall. insulin added. 
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FIGURE 4. — Influence of the iodination degree of insulin on its displacement by unlabelled insulin. 
Experiments with various iodoinsulin batchs performed during a period of two months. As 
reference (for the % radioactivity displaced by unlabelled insulin) : the level 250 μ υ unlabelled 
insulin added was choosen. 
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It is quite obvious that the displacement of radioactive insulin by cristallin 
insulin from the antibody is influenced by the degree of iodination. This effect appears 
different from the biological one. The influence here, is progressive, without sudden 
break in the curve, as is the case with the biological activity (20>. 
But these results are in contradiction with Izzo's results <13). 
Therefore an experiment was set up, similar to that of Izzo. The binding of 
equal amount of two iodoinsulins 131I and 125I (1.1 and 3.8 at. I/mol insulin) is com­
pared in presence of increasing amount of guinea­pig anti­insulin serum (Figure 5). 
Izzo et al. did not find any differences in their work. We find a significant one. This 
contradiction can be due to the different methods of iodination used : Rosa's method 
is probably more gentle and progressive, the oxidation method used by Izzo more 
explosive ? 
100, 
80 
60 
= LO 
-o n cc 20 
1at. l/mol 
'¿at. I/mol 
FIGURE 5. 
1x10-5 1 x 1o-4 I X 10 -3 
ml. Guinea-Pig Anti-Insulin Serum 
Influence of the iodination degree of insulin on its ability to bind to increasing amount 
of anti­insulin antibodies 
CONCLUSIONS 
What conclusions to draw from these experiments : 
First point : iodinated insulins were tested, prepared by three different methods : 
monochloride iodine, elementary iodine and electrolysis. At least with these pre­
parations and the various antibodies used, these experiments demonstrate that 
iodination of insulin induces an impairment of its immunologic properties. This 
is consistent with different other data of the literature : indeed it has been shown that 
iodine binds preferentially to the tyrosine of the A chain (e>7) ; tyrosines are important 
antigenic determinant (11). Iodination of tyrosine is an important modification of 
a protein, as an antigen ( U · 1 4 ) . Finally A chain appears, following the work of Wilson 
et al. (22) more critical than Β chain in the neutralizing capacity of anti­insulin seras. 
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Second point : the impairment appears proportional to the degree of iodination 
(from 1 up to 4 at. I/mol). So increasing degree of iodination influences both the 
biologic and immunologic properties of insulin, but as shown, differently. This 
difference of the biologic and immunologic behaviour is in agreement with number 
of previous data. The results also confirm that the degree of iodination of insulin 
should remain as low as possible for R. I. A. use. 
Third point : the non saturation of the antibody sites by iodoinsulins can have 
some inference in the interpretation of the radioimmunoassay. Indeed there are 
increasing doubts concerning the immunologic identity of extracted (crystallin) 
and the endogenous hormone a5< 18). Endogenous hormone, if antigenically diffe­
rent, perhaps does not react with all the antibody sites directed against crystallin 
insulin. We show that iodoinsulin probably does not react with all the antibody 
sites. Both points together are a possible cause of error in the radioimmunoassay. 
The problem raised up by the iodination of insulin should be probably extended 
to the labelling of other proteinic hormones. Less is known of these hormones than 
of insulin. What is known appears or the same or less favorable (5' !'­ 12). And yet, 
as far as we know, in the works dedicated to the R. ï. Α., we are not aware of any 
proper experimental device investigating the immunologic identity of the iodinated 
hormones. 
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DISCUSSION 
R. S. YALOW (New York) : 1) Do you believe that lose of immunologic inte­
grity of the labeled hormone affects the validity of its use as tracer in immunoassay ? 
We have pointed out of course, that it is not. 
2) While your experiments may prove that the iodinated proteins you prepare 
do not retain full immunologic activity, it is not safe for you to generalize concern­
ing the immunologic behaviour of other preparations of iodinated hormone with 
other antisera. Obviously where labeled hormone is used as tracer for unlabeled 
hormone, the investigator is responsible for demonstrating that in his system labeled 
and unlabeled hormones react identically with antibody. 
H. A. OOMS : I do not know if the question of immunological identity between 
the labeled and non-labeled hormone can yet be answered. Three insulins are pre­
sent in a radioimmunoassay : endogenous insulin, extracted insulin and labeled 
extracted insulin. Should endogenous insulin be immunologically identical to the 
extracted hormone, then it would not be necessary for the radioactive hormone 
to be "identical" to the unlabeled one. But, as already told, if endogenous insulin 
is immunologically not identical to the extracted insulin, as suggested by recent 
works, then the use of a third form of hormone, also different, could lead to impre­
visible error. 
E. F. PFEIFFER (Chairman) : I should like to know Dr. Yalow's opinion about 
the many evidences (Fenton et al., 1963; Renold et al., 1963; Deckert, 1964) indi­
cating antibody formation to species identical, homologous pancreas-insulin. 
Does not that mean that, in the course of extraction, insulin must be somewhat 
denaturated ? 
R. S. YALOW : I am certain that the antigenicity of extracted hormone in homo­
logous species implies that at least some fraction of the administrated hormone 
was not identical with endogenous plasma hormone. We might extend Dr. Pfeiffer's 
remarks to include the evidence from our laboratory and from other groups that 
human growth hormone is antigenic in man and we might even refer to the earlier 
work of Milgrom and Witebsky (J.A.M.Α., Π/Χ : 56, 1960) who showed that precipi­
tated and frozen autologous rabbit γ-globulin is antigenic in the rabbit. Thus, subtle 
changes may occur which can account for the antigenicity of homologous or even 
autologous serum proteins and hormones. I might call attention to a less subtle 
change that raises some concern about the interpretation of immunization experi­
ments with supposedly "pure" beef or pork insulins. We have presented evidence 
(S. A. Berson and R. S. Yalow, Am. J. Med., to be published in 1966) that Lilly 
pork insulin Η 499667 contained a small, but significant contaminant of beef insulin. 
Dr. Otto Behrens of Lilly Laboratories several months ago confirmed that at the 
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time this lot of insulin was prepared (about 10 years ago), the facilities for prepa-
ration of beef and pork insulins were not completely separated and that contamination 
of pork insulin with beef and vice versa was not unexpected. 
However, I am certain that Dr. Pfeiffer's question is not concerned with whether, 
because of accidental contamination or minor alteration extracted hormone appears 
to be antigenic in the homologous species, but rather that it is meant to imply that 
this antigenicity suggests that extracted insulin does not behave identically in the 
radioimmunoassay system with the endogenous insulin for which it serves as stan-
dard. We have in the past documented in detail our experimental evidence for the 
validity of radioimmunoassay when properly performed. The fact is that this is the 
only assay system in which dilution of plasma shows a linear response with respect 
to measured insulin concentration (R. S. Yalow and S. A. Berson, J. Clin. Invest., 
1960) so that in this critical respect at least plasma insulin does behave as pancreatic 
insulin. 

SOURCES OF ERROR IN RADIOIMMUNOASSAY 
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ABSTRACT 
Errors may stem from faults and irregularities in the analytical performance 
of the assay or they may be of a more specific nature related to the use of immu­
nochemical reactions and labelled proteins. Some sources of error of the first kind 
are : adsorption of proteins to glassware, contamination of reagents with the com­
pound to be assayed for, and lack of control with reaction times, temperature, 
pH, and salt concentration. 
Sources of error in the second category include : (1) species difference. The 
standard antigen can be from another species than the antigen assayed, and then 
it should be carefully checked whether the reaction of the antigens from the two 
species towards the antibody is identical ; (2) structural difference. The structure 
and thereby the specific immunological activity of the antigen may be changed 
in the extraction process used for the preparation; (3) incomplete precipitation. 
One major problem is the separation of free and antibody-bound antigen, and 
several different methods have been developed for this purpose. In the double anti­
body method, which includes the use of an anti-guinea pig γ-globulin rabbit serum, 
errors may occur due to cross reactions between human γ-globulin and the second 
antibody; (4) presence of antibody in the sample. Falsely high or low results, depen­
ding on the method of separation chosen, may occur if the samples (e. g. serum) 
already contain antibodies capable of reacting with the labelled antigen; (5) inacti­
vation of immunological activity. Degradation of antigen or antibody, e.g. by enzymes, 
may give rise to falsely high values. 
All the antigen in a sample may not be detectable in the assay, but may be 
present in an immunologically inactive state. Thus still another kind of error is 
possible, which may be important in the biological research. 
The principle of the radioimmunoassay is simple. In constant volumes a known 
amount of antibody is mixed with a sample containing unlabelled antigen and a 
known amount of radioactively labelled antigen, and after a certain reaction time 
an equilibrium mixture of labelled and unlabelled antigen-antibody complexes 
has been formed. The amount of labelled complex formed will then be a function 
of the concentration of unlabelled antigen. A high concentration of unlabelled anti­
gen will give a relatively low amount of labelled complex and vice versa. 
As the amount of added labelled antigen is constant it is only necessary to 
determine the amount of either free or bound radioactivity, and a separation of 
these two components is the next step. The radioimmunoassay has first of all been 
used for determining hormones and unfortunately antibodies to hormones are in 
most cases incomplete, which means that they do not form a precipitate with their 
homologous antigen. Therefore, the separation of free and antibody-bound antigen 
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has to be done using special methods. Five different methods of separation have 
been used in the immunoassay : 
1) Separation by chromatography or electrophoreses (1 '2). 
2) Precipitation of the antibody-complex with an anti^-globulin antibody (3i 4' 5). 
3) Precipitation of the antibody-complex with sodium sulfite ((1) or ethanol (7). 
4) Binding of the free antigen to an anion exchange resin (8, 9), or dextran-coated 
charcoal (10). 
5) Separation by gel filtration on Sephadex G 75 (U). 
Before mentioning some of the more specific sources of error related to the 
use of immunochemical reactions and labelled proteins I should like to discuss 
some errors, which may occur in the analytical techniques. Any of these errors 
may completely spoil the analysis and give wrong results. 
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FIGURE 1. — Formation of insulin-antibody complex at different times 
It is well known that proteins adsorb to the surface of glassware. At concen­
trations of protein hormones as low as normally used in radioimmunoassay a high 
percent of adsorption will occur if the hormone is not protected against adsorption 
by addition of other proteins, e.g. albumin. A concentration of 0.1 percent albumin 
is sufficient to prevent adsorption of insulin. 
Another important source of error is contamination with the compound to 
be assayed for. When it is remembered that 1 mg of insulin is 25,000,000 μυ" of 
insulin and the amount of insulin in the sample may be 10 μϋ it can be understood 
that weighing and working with such or higher amounts in the laboratory presents 
a risk for contamination by air and glassware or other utensils. 
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When antigen­antibody­reactions take place a certain reaction time is needed 
before equilibrium is reached. Figure 1 shows a curve where the amount of formed 
antibody­bound insulin is plotted against varying reaction times. It takes several 
days to reach equilibrium in this system, and fortunately the analysis can be finished 
before this has occurred, but one has to choose a reaction time, which is so long 
that unavoidable accidental and systematic variations have no influence on the 
results. Variations in reaction time are not so easily controlled when the chromato­
graphic or electrophoretic methods are employed, whereas an ethanol precipitation 
of 100 samples can be done within a few minutes. 
The purity and the storage conditions of the antigen and the antiserum are 
very important. Radiation damage increases with the concentration of labelled 
antigen, which therefore must not be stored in too concentrated solutions. Normally 
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FIGURE 2. — Influence of different salts on the insulin­antibody reaction 
an I­isotope is used for labelling the antigen and the 125I­isotope is to be preferred 
to the 131I, since it has a much longer half life time. 131I has a half life of approxi­
mately 8 days which means that if a series of samples is counted over 20 hours the 
last sample will have lost 7 percent of the activity during the counting time, and the 
values must be corrected for this. 125Ihas a half life of 60 days, and it can be mentioned 
that if a 125I­insulin preparation with a specific activity of 10 mC/mg is stored at 
—30° C in the dilution used in the immunoassay, e.g. 300 ¡j.U/ml, the same solution 
can be used for more than six months without apparent loss of immunological 
activity. This can be checked by adding a surplus of antibody to the labelled antigen 
and determining how much becomes bound to the antibody. 
A loss of potency of the antiserum can be observed if the sera are frozen and 
thawed several times, and if antisera are exposed to evaporation even at —30° C 
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a loss of immunological activity can also be shown. As ordinary rubber stoppers 
shrink at low temperature it can often be observed that the stoppers become too 
small after a storage at —30° C, and therefore a tight fitting cap should be used. 
In the antigen-antibody-reaction pH must be under control. Morgan and 
Lazarow (5) have shown that the optimum pH is close to 7 for the insulin-antibody-
reaction, and that a deviation of more than one pH-unit to either side causes for-
mation of a smaller amount of antigen-antibody-complex. Variations of the pH 
will therefore give variations in the analytical estimates. Besides the pH the concen-
tration of certain ions is of great importance to the reaction. Figures 2 and 3 show 
the influence of a number of different ions on the reaction between insulin and anti-
body : to a mixture of 125I-pork insulin and insulin antiserum increasing amounts 
of different salts are added. It can be shown that only the monovalent anions 
influence the reaction and that the presence of one of these ions in a concentration 
above 20 mmol/1 is necessary to ensure a complete reaction. 
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FIGURE 3. — Influence of different salts on the insulin-antibody reaction 
If the concentration of necessary ions is too low or if the pH is wrong, too 
high estimates will result, and in general it can be said that most of the errors from 
the analytical techniques lead to falsely high values. 
Errors due to wrong pH and salt concentration will naturally not occur when 
serum or plasma — not diluted too much — is analysed, but if extracts of serum 
are assayed, pH must be checked and the buffer used for dilution must contain 
enough active ions. 
It is very important that the concentrations of antigen and antibody are adjusted 
such that the solution contains an excess of free antigen, when the first antibody-
reaction is finished. This must not erroneously be interpreted as if the antibody 
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is saturated with antigen, since it does not bind all the antigen available. Figure 4 
shows the amount of insulin bound at varying concentrations of free insulin; the 
antibody concentration is the same in all the determinations. When 180 μΙ_1 is added 
to 1 ml of antiserum only 140 μ ϋ is bound, or 80 percent, but if 6,000 μ υ is added 
to the same amount of antibody 3,000 μΙΙ, or 50 percent, becomes bound to anti­
body, and if more insulin is added even more becomes bound. 
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FIGURE 4. — Binding of insulin to antibody at different concentrations of insulin 
A number of important trivial errors has been mentioned, and furthermore 
a few sources of errors more specially related to labelled proteins and immunoassay 
shall briefly be discussed. 
Errors due to species differences of the antigen may occur because antibodies 
only react with the substance used to produce them and more or less with substances 
showing close chemical and structural relationship with the homologous antigen. 
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Apart from insulin it is very difficult to obtain pure preparations of the human 
hormones, and therefore one often has to use hormones from animals both for 
immunizing and as a standard for a human hormone. It is therefore very important 
to check that the hormones from the two species react identically with the antibody. 
Berson and Yalow(12) have shown that human and pork insulin could give different 
standard curves with several different antisera although the two hormones only 
differ in one amino acid. It is possible that this difference is dependent on other 
causes than the small variation in the chain sequence. However, in most cases insulin 
antisera react similary with pork and human insulin, whereas beef insulin often 
reacts differently. 
It has been stated that it is necessary that the labelled and unlabelled antigen 
should have the same binding affinity to the antibody, but this is not the case, when 
the conditions are the same in the standard which is made at every run and in the 
assay system. Of course it is of no advantage if the labelled antigen has a much 
greater affinity to the antibody, since this will decrease the sensitivity of the assay. 
It is incidentally a very difficult task to determine whether the specific affinity of 
the labelled and the unlabelled antigen to the antibody is different. 
It must be remembered that all the hormone preparations used to-day as stan­
dard have been extracted from animal tissue by a procedure which may involve 
treatment at low pH, extraction with an organic solvent, salting out, and so on. 
It cannot be excluded that these treatments may alter the hormones, e.g. in such 
a way that the chain conformation becomes different from the native structure, 
and hereby the immunological specificity can be changed. To-day one does not 
know whether the circulating hormones, measured with the immunoassay, are 
identical with the extracted hormones. 
Furthermore it can not excluded that some of the natural hormones in blood 
are bound and threrefore do not react with antibody, but retain the activity in biolo­
gical assays. This would explain differences between biological assays and immu­
noassays. 
It is well known that persons treated with insulin form antibodies against insu­
lin, and blood samples from persons containing antibodies against the antigen to 
be assayed therefore cannot be analysed directly. The assay will give either too high 
or too low estimates depending on the method of separation and the antiserum 
used. 
One of the major problems in the radioimmunoassay is the separation of free 
and antibody-bound antigen, and one of the methods most commonly used is the 
double antibody method, where the antigen-antibody-complex is separated by an 
immunoprecipitation with an anti-guinea-pig γ-globulin antibody : 
1) Ag-Ab + anti^-globulin -y Ag-Ab-anti^f-globulin 
soluble soluble insoluble precipitate 
2) Ab + anti^f-globulin -> Ab-anti^f-globulin 
soluble soluble insoluble precipitate 
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Unfortunately the anti­guinea­pig γ­globulin is able to cross react with human 
γ­globulin to a certain degree thereby causing a decrease in the amount of antibody 
capable of precipitating the antigen­antibody­complex (13). In some instances this 
may cause an incomplete precipitation, which gives falsely high levels. It is generally 
accepted that this error can be avoided if a co­precipitation of the two antibodies 
is used as shown. The first antibody does not lose its ability to bind the antigen 
after the precipitation has taken place. If one still prefers the first modification for 
technical reasons a surplus of anti^­globulin must be used, and it must be checked 
that the incomplete precipitation does not occur. 
The last source of error to be mentioned is inactivation of immunological 
activity due to degradation or denaturation of antigen and antibody. It is obvious 
that an enzymatic degradation of either antigen or antibody will disturb the results. 
Degradation or denaturation of the antibody in the samples will always give rise 
to erroneously high results, because the antibody will bind a smaller amount of 
labelled antigen. Degradation of both labelled and unlabelled antigen may give 
either too high or too low results (in most cases too high). 
Degradation of the antigen does normally only occur to a slight degree in 
serum and plasma samples, but after a fractionation of e.g. serum by electrophoresis 
it has been shown by Orskov (14) that the very high insulin values found in some 
of the fractions were false and due to degradation of the labelled insulin. Fortu­
nately it is easy to control whether the antigen is degraded by using the chromato­
graphic technique, whereas antibody degradation is more difficult to observe. 
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DISCUSSION 
H. A. OOMS (Bruxelles) : In the double antibody method, one of the causes of 
error reported by Dr. Heding consists in incomplete precipitation of the complex 
"antigen-first antibody" by the second antibody (anti-guinea-pig gammaglobulin 
antiserum). This is in several papers generally only attributed to cross-reaction 
between human gammaglobulin and guinea-pig globulin. I do not know if demons-
tration of this cross-reaction, by Immunoelectrophoresis has yet been published. 
But even if this is or can be the case, another cause we think more important in 
practice has to be taken into account : Morgan and Lazarow (Diabetes 13, 579, 
1964) have demonstrated the interference of complement in the inhibition of the 
first antibody-second antibody reaction. Another cause of error as pointed out 
by Dr. Yalow is to neglect to evaluate the incubation "damage". This can be easily 
performed in the double antibody method. After the normal incubation period of 
the antigen -first antibody reaction, an excess of the first antibody is added and 
after a second incubation period the complex antigen-excess first antibody is preci-
pitated by the second antibody. 
C. N. HALES (Cambridge) : Concerning the evidence of a cross-reaction between 
human gammaglobulin and an antiserum to guinea-pig gammaglobulin prepared 
in rabbits, Prof. Rändle and I have published such evidence (Hales C. N. and Rändle 
P. J. (1963) Biochem, J., 88, 137) and a photography of the precipitation reaction 
quoted is contained in my Thesis (Hales C. N., Ph. D. Thesis, Cambridge University). 
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ABSTRACT 
A radioimmunoassay of serum ACTH is presented. 131I­ACTH was prepared 
of specific activities of 300­500 mC/mg by the method of Hunter and Greenwood and 
purified free of components damaged by Sephadex G­50 column after incubation with 
normal serum. 131I­ACTH degradation products after two purifications are less than 
5 % of total radioactivity. To separate antibody bound 1311­ACTH we used an anion­
exchange resin (Amberlite CG 400 I), already employed for serum insulin assay. For 
the preparation of standard curves we used an anti­ACTH­rabbit­serum diluted 1:40,000, 
1:50,000. The sensitivity of the method is at level of 0.05­0.1 m μg|ml. The values of 
serum ACTH in normal subjects was found to range from 0­0.4 m μg|ml. Elevated 
ACTH­levels were also demonstrated in an Addison­patient and in two dishing patients 
after adrenalectomy. 
ZUSAMMENFASSUNG 
ES wird über eine radioimmunologische Bestimmung von ACTH­Serum berich­
tet. Nach der Methode von Hunter und Greenwood wurde 131J­ACTH mit spezi­
fischer Aktivität von 300­500 mCi/mg hergestellt und nach Inkubation mit normalem 
Serum über eine Sephadex­G­50­Säule von beschädigten Bestandteilen gereinigt. 
Nach zweimaliger Reinigung machen die 131J­ACTH Abbauprodukte weniger 
als 5 % der Gesamtradioaktivität aus. Zur Isolierung von antikörpergebundenem 
131J­ACTH verwendeten wir ein Anionenaustauschharz (Amberlit CG 400 I), das 
bereits zur Insulin­Serum­Bestimmung verwendet wurde. Zur Aufstellung der 
Standardkurven verwendenten wir ein Anti­ACTH­Kaninchen­Serum in einer 
Verdünnung von 1:40.000 und 1:50.000. Die Empfindlichkeit der Methode liegt 
im Bereich von 0,05­0,1 m μg/ml. Es wurde festgestellt daß bei Gesunden die Werte 
für ACTH­Serum zwischen 0 und 0,4 m μg/ml liegen. Hohe ACTH­Werte wurden 
bei einem Patienten mit Addisonscher Krankheit und bei zwei Patienten mit Cus­
hingscher Krankheit nach Adrenalektomie nachgewiesen. 
Die Messung von ACTH im Blut mit der radioimmunologischen Technik 
wurde dadurch möglich, daß einerseits hochgereinigte ACTH­Präparate zur Ver­
fügung gestellt, andererseits Antikörper gegen ACTH bei Tieren erzeugt wurden. 
Untersuchungen von McGarry und Mitarb.(6), Yalow und Mitarb. (12\ Himura und 
Mitarb.(4) über die biologischen und immunologischen Eigenschaften von natür­
lichen und synthetischen ACTH­Präparaten haben gezeigt : 
1. Die biologische Aktivität des ACTH liegt bei den ersten 20­26 Aminosäuren 
des Moleküls. Die vollsynthetischen Peptide, die die ersten 24 (al­24) oder 26 
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(al­26) Aminosäuren des adrenocorticotropen Hormons darstellen, besitzen 
die biologische, nicht aber die gleiche immunologische Aktivität der hochge­
reinigten Präparate. 
2. Die immunologische Aktivität ist besonders and den letzten Teil (20­39 Amino­
säuren) des Moleküls gebunden. 
3. Antikörper gegen Schaf­ACTH reagieren auch mit Schweine­ und Menschen­
ACTH; in Kreuzreaktionen zeigen Schaf­, Schweine­ und Menschen ­ACTH 
ähnliches immunologisches Verhalten, wobei Schweine­ und Menschen­ACTH 
sich nicht unterscheiden. 
Als erster benutzte Felber (1) für die Bestimmung von ACTH im Blut das von 
Yalow und Berson (13) für die Bestimmung von Insulin angegebene Prinzip. Bei 
Anwendung des Doppelantikörper­Systems von Haies und Rändle (3) fand Felber 
bei Stoffwechselgesunden sehr hohe Werte von 30­50 m^g/ml Plasma. 
Ebenso wie für Insulin, Wachstumshormon und Parathormon verwenden 
Yalow und Mitarb. (12) zur Trennung des gebundenen vom freien 131J­ACTH 
die Chromatographie und die Papierelektrophorese. Die Methode dieser Autoren 
ist sehr empfindlich; mit ihr können bis 0,06­0,12 mE ACTH/100 ml Plasma gemes­
sen werden. Bei Stoffwechselgesunden schwanken die Werte von Yalow und Mitarb. 
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zwischen 0,15 und 0,38 m μg/ml Plasma mit einem Mittelwert von 0,26 m μg/ml 
(0,6 mE/100 ml). Diese Werte entsprechen den Werten der biologischen Methoden. 
Um das freie und das antikörpergebundene 131J­ACTH zu trennen, haben wir 
Anionenaustauscher verwendet (Amberlite CG 400 I). Die Anionenaustauscher 
wurden schon von Meade und Klitgård (7) und von uns selbst (8> für die Bestimmung 
von Insulin im Serum benutzt. Die Trennung beruht auf der Eigenschaft des Kunst­
harzes freies 131J­Hormon zu binden (Free). Die nicht an den Anionenaustauscher 
gebundene Radioaktivität entspricht antikörpergebundenem 131J­Hormone (Bound). 
Das anti­ACTH­Serum wurde von Kaninchen gewonnen. Die Tiere wurden 
in Abständen von drei Wochen — über einen Zeitraum von sechs Monaten — 
mit 1 ml einer Emulsion immunisiert, die zu gleichen Teilen aus Schweine­ACTH­
Lösung und Bacto Adjuvant Complete (H 37 Ra, Difco Laboratories, Detroit, 
USA) bestand. 
ACTH wurde mit 131J nach der von Greenwood und Mitarb. (2) angegebenen 
Methode markiert. Diese Methode verwendet Na­131J (IBS 3 von Radiochemical 
Center Amersham, England) mit einer Gesamtaktivität von 2­4 mC und Chloramin 
Τ als Oxydationsmittel. Die spezifische Radioaktivität von 131J­markiertem 
ACTH lag bei unseren Versuchen zwischen 300 und 500 mC/mg (0.4­2 Atome 
Jod/mol ACTH). 
Bei der Markierung entstehen durch die Strahlung und andere chemische 
Alterationen des Hormonmoleküls radioaktive Degradationsprodukte, die sich an 
Serumproteine binden. Zur Vermeidung von Fehlern bei der radioimmunologischen 
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Bestimmung muß das verwendete 131Jod­Hormonpräparat von solcher unspezi­
fischen Radioaktivität befreit werden. Zur Reinigung wurde das 131Jod­ACTH 
nach der Markierung mit Bromphenolblau­gefärbtem Serum kurz inkubiert und 
dann auf einer Sephadex­G­50­Säule filtriert <9). In dem milliliterweise gesammelten 
Eluat findet man drei deutlich abgegrenzte Radioaktivitätsgipfel (Abbildung 1). 
Der erste entspricht der an die Serumproteine gebundenen unspezifischen Radioak­
tivität, der zweite dem 131J­ACTH, der dritte dem Jodid­131, das nicht an das Hor­
mon gekoppelt wurde. In der Papierelektrophorese wandert die unspezifische Radio­
aktivität mit allen Serumproteinen, während das intakte Horminmolekül, von der 
Zellulose des Papierstreifens adsorbiert, am Startpunkt bleibt (Abbildung 2). 
Nach ein oder zwei Reinigungen des 131J­ACTH in Sephadex G­50 findet 
man im Papierelektrophoretogramm nur einen scharfen Radioaktivitätsgipfel. 
Nach Inkubation mit normalem Serum liegt er am Startpunkt (Abbildung 3, oben), 
während er nach Inkubation mit anti­ACTH­Serum im Bereich der Gammaglo­
buline zu finden ist. (Abbildung 3, unten). 
Entsprechend sind die Ergebnisse mit Amberlite CG 400 I. Das Harz wurde 
vor Gebrauch aus der Chloridform in die Hydroxylform umgewandelt. In dieser 
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Form kann Amberlite CG 400 I das freie 131J­ACTH binden, nicht aber die an 
Albumin oder an Serumproteine adsorbierte unspezifische Radioaktivität und nicht 
das antikörpergebundene Hormon. 
Die Abbildung 4 zeigt die Adsorption des 131J­ACTH und der unspezifischen 
Radioaktivität an Amberlite in Abhängigkeit von der Konzentration des Albumins 
oder des Serums. 131J­ACTH wurde in 2 ml Veronal­Puffer (0,1 M, pH 8,6) verdünnt 
und 15 Minuten mit 200 mg Amberlite geschüttelt; danach wurde die Radioaktivität 
im Überstand gemessen. 
Die Verteilung der unspezifischen Radioaktivität auf Amberlite und Überstand 
ändert sich mit der Konzentration des Albumins oder der Serumproteine im Lösungs­
mittel. Bei Gebrauch eines Puffers ohne Albumin oder mit niedriger Albuminkon­
zentration (0,5 %) werden die Degradationsprodukte zum großen Teil von dem 
Harz adsorbiert (Abbildung 4). Steigt die Albuminkonzentration im Puffer, so 
steigt auch die Radioaktivität im Überstand. Mit Albuminkonzentrationen von 
2­5 % erreicht die Adsorption einen Grenzwert, der durch weitere Zugabe von 
Albumin nicht mehr deutlich überschritten wird. Wie mit 1:4 verdünntem Serum 
sind praktisch alle Spaltprodukte an Protein adsorbiert und können auf diese Art 
als konstanter Faktor im Überstand gehalten werden. Mit einem gut gereinigten 
131J­ACTH wird, wie die Abbildung 4 zeigt, das freie 131J­ACTH auch bei einer 
Albuminkonzentration von 20 % von Amberlite völlig adsorbiert. 
"/. Radioactivity 
in supernatant 
14-1 
BEEF ALBUMIN CONCENTRATION IN BUFFER 
I _.. ι 
NORMAL SERUM 
, 3 , I -ACTH after 1 s t pur i f icat ion 
• · ,3 ' I-ACTH after 2nd pur i f i ca t ion 
Radioactivity not adsorbed to amberlite CG­400 I 
ABBILDUNG 4. 
Die Voraussetzungen für die radioimmunologische Messung des ACTH sind 
in der Abbildung 5 dargestellt. Freies 131J­ACTH muß im Serum ebenso wie im 
Puffer von Amberlite adsorbiert werden. 
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Die Zugabe von Serum (1:2, 1:4 verdünnt) darf die Verteilung der Radio­
aktivität auf Amberlite und Überstand nicht beeinflussen. Das Antiserum muß 
so verdünnt werden, daß 70­80 % des 131J­ACTH an Antikörper gebunden sind. 
Radioactivity 
0,05-0,1 
Buffer-2 % alb. 
Serum 
1:2, 1:4, 1:8 
Di lu t ion o f 
antiserum 
1:40,000 
in supernatant 
Γημδ m I - A C T H 
3-5 % 
3-5 % 
70-80 % 
ABBILDUNG 5. 
Die Ansätze für die Standardkurve und für die Serumbestimmung enthalten : 
1 ml verdünntes Antiserum (1:40.000 — 1:60.000) mit 0,01 — 0.03 m μg/Jod131­
ACTH. 
1 ml unmarkiertes ACTH (2,5 bis 0,05 m μg) oder Serum (1:2; 1:4; 1:8 verdünnt). 
Für die Ansätze haben wir entweder Veronal­Natrium­Puffer (0,1 M, pH 
8,6) oder physiologische Kochsalzlösung mit Zusatz von Rinderalbumin (1­2 %, 
normalem Kaninchenserum (I %) und 0,01 % Merthiolat verwendet. 
Nach drei Tagen Inkubation wurden jedem Wassermannröhrchen 200 mg 
Amberlite zugesetzt. Nach 15 Min. Schütteln und kurzem Zentrifugieren wurde 
die Radioaktivität von 1 ml Überstand gemessen. Sie entspricht der Hälfte des 
antikörpergebundenen 131J­ACTH (1/2 B). 
Die Abbildung 6 zeigt eine typische Standardkurve. Ohne Zusatz von unmar­
kiertem ACTH sind 80 % der Radioaktivität an Antikörper gebunden. Schon mit 
nur 0,05­0,1 τημξ unmarkiertem ACTH hat man einen signifikanten Abfall der 
Radioaktivität im Überstand (gebundenes 13IJ­ACTH). Mit 2,5 nuj.g ACTH sind 
nur 36 % der Radioaktivität an die Antikörper gebunden. 
Mit verschiedenen Schweine­ACTH­Präparaten fanden wir bei der Aufstellung 
der Standardkurven keinen signifikanten Unterschied. 
Die Abbildung 7 zeigt, da der Verlauf der mit drei Schweine­ACTH­Präpara­
tionen (75­84,5­100 E/mg) gebildeten Standardkurven völlig identisch ist. ACTH, 
einem Serum zugesetzt, wurde bei verschiedenen Serumverdünnungen zu 80­100 % 
wiedergewonnen. 
Bei einer Serumverdünnung von 1:2, 1:4; 1:8 messen wir bei Stoffwechsel­
gesunden Werte im Bereich von 0 bis 0,4 n^g/ml (3,4 mE/ml). In Gewichtseinheiten 
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cpm-lO1 
7 -
6 -
5 -
4 -
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ABBILDUNG 6. 
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DILUTION OF ANTISERUM 1:40000 
( RABBIT-ANTI-PORCINE-ACTH-SERUM ) 
2.5 mug/ml 
UNLABELED ACTH 
ABBILDUNG 7. 
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angegeben, entsprechen unsere Werte denen von Yalow und Mitarb. (12). In biolo-
gischen Einheiten sind sie etwas höher. Bei StofTwechselgesunden werden in unserem 
Laboratorium mit der biologischen Methode <5, 10, u ) Werte im Bereich von 0,25-
1 mE/100 ml Plasma mit einem Mittelwert von 0,4 mE/100 ml gemessen. 
Erhöhte Werte von ACTH im Serum fanden wir bei einem Addison-Patienten 
(2 m^g/ml; 16,8 mE/100 ml Serum) und bei zwei operativ behandelten Cushing-
Patienten (2,2-2,6 n^g/ml; 18,5-21,8 mE/100 ml Serum). 
ZUSAMMENFASSEND : 
1. Die radioimmunologische Methode, die wir benutzt haben, ist sehr empfindlich 
und technisch einfach. 
2. Die Werte bei Stoffwechselgesunden entsprechen in n ^ g berechnet denen von 
Yalow und Mitarb. 
3. Die kleinen Unterschiede, die bei der Umrechnung in biologische Einheiten 
auftreten, liegen wahrscheinlich in der nicht einheitlichen Standardisierung der 
verschiedenen ACTH-Präparationen. 
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DISCUSSION 
J. P. FELBER (Lausanne) : Dr. Melani's method seems very interesting, being 
simple and precise. The plasma values obtained are similar to the ones published 
by Yalow et al. (J. Clin. Endocrinol., 24 : 1219, 1964) and slightly lower than ours 
since we have started using precipitation in the double antibody system. 
What seems striking in this paper is that Dr. Melani's method does not seem 
to suffer from the difficulties due to ACTH degradation in plasma. The ACTH 
estimations are done in serum instead of plasma. Would it be possible that the 
degradation of ACTH which certainly does occur during the period of coagulation 
would affect the biological activity without affecting the immunological activity ? 
It is also of interest that this method does not seem to suffer from incubation 
damage, which obliged other autors (Yalow et al.) as well as ourselves, to use mer­
captoethanol to prevent this degradation. 
R. S. YALOW (New York) : I have been asked to comment on the potential 
interference of ACTH fragments in the immunoassay. 
In our first report on the immunoassay of ACTH in plasma we noted that 
synthetic and highly purified a­MSH and hormonally active synthetic tricosapeptide 
inhibited the binding of labeled synthetic pork ACTH to antipork ACTH serum 
(Figure 1) (R. S. Yalow, S. N. Glick, J. Roth, S. A. Berson, J. Clin. Endocrin. and 
Metab., 24 : 1219, 1964). But at least a thousand to ten thousand fold higher quan­
tities are required to produce the same effect as intact ACTH. The higher reactivity 
of native ß­MSH may be related to contamination with ACTH since the prepara­
tion used was not highly purified. Since that time Imura, Grodsky et al. have report­
ed that, with their antiserums, hormonally inactive peptide fragments reacted more 
GP 50-12-18 
1-10,000 DILUTION OF ANTISERUM 
1 
* ft ■ ■ 
* ■ ■ * ■ ■ ■ 
\ 
*. 
^NATIVE (ÛVS-I8-32) 
* . <K-MSH 
K SYNTHETIC 
SYNTHETIC 
- - + _ .r TRICOSAPEPTIDE-ACTH 
—_. 
^-pMSH 
1 . 1 1 1 
* 
* 
GQ|U_ 
01 I 2 3 4 5 6 7 8 
CONCENTRATION-yug/ml. 
FIGURE 1. —B/F ratios for 131I­Iabeled synthetic porcine ACTH (Schwyzer) as a function of concen­
tration of ACTH (left), various MSH's and ACTH tricosapeptide (Hofmann) (right). The 
synthetic a­MSH was prepared by Dr. K. Hofmann. The heavy vertical line adjacent to the 
ordinate axis of the right­hand graph shows the entire concentration range of the left­hand 
graph (Reproduced from J. Clin. Endocrin. and Metab., 24 : 1219 (1964)). 
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strongly that intact ACTH. As I emphasized earlier, this must be tested individually 
for each hormone and with each antiserum. 
With the antiserum we now employ for the assay of ACTH, both hormonally 
active (1­23 and 1­24) and inactive (11­24 and 25­39) ACTH fragments reacted hun­
dred to thousand fold less strongly than intact ACTH; so that these fragments would 
have had to be present in very high concentration to be of significance. Furthermore, 
no constant factor will tansform the cross­reactivity curves of the fragments to 
that of the intact preparation. For the latter reason, when there is present in plasma 
a substance which cross­reacts in the immune system, but which is not identical 
PLASMA FROM 
UMBILICAL VEIN OF / 
NEWBORN INFANTS / 
/ 
/ 
1200 1100 I'SO Γ20 
E-i · 
ε-2 * 
E-S ■ 
I 200 I 100 I 50 
DILUTION OF PLASMA DILUTION OF PLASMA 
FIGURE 2. — Effect of dilution of plasma on apparent HGH plasma concentration. Values should 
fall along the diagonal line if reacting material is immunochemically identical with pituitary 
HGH used as standard. Plasma from normal adults and from acromegalic subjects behaves 
like plasma from umbilical veins of newborn infants. Plasma from pregnant women does not 
behave properly on dilution. (Reproduced from Ree Prog, in Hormone Res., XXI : 241 (1965)). 
Dilution of Plasmo 
J MeaniS.E.M. 
MOO i:so 1:23 1:20 
Dilution of Plasma 
FIGURE 3. — Effect of dilution of plasma on measured concentration of endogenous plasma insu­
lin. For replicate determinations were made for each point in the experiment on the right. 
(Reproduction from J. of Clin. Invest., 39 : 1157, I960)). 
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with the hormone used as the standard, dilution of the plasma does not produce 
a proportionate decrease in the apparent concentration of hormone. For instance, 
plasma from the umbilical cord blood of the new born, from acromegalic subjects 
or from normal subjects stimulated to secrete high levels of growth hormone all 
show proportionate decrease in hormone concentration on dilution (S. M. Glick, 
R. S. Yalow, J. Roth, S. A. Berson, Nature, 199 : 784, 1963). But plasma from 
pregnant women does not behave properly on dilution because of the presence of 
placental lactogen, a substance which cross-reacts with, but is not identical with, 
human growth hormone (Figure 2) (S. M. Glick, J. Roth, R. S. Yalow, S. A. Berson, 
Ree. Prog. In Hormone Res., XXI : 241, 1965). 
In the case of insulin, we earlier demonstrated proportional decrease in endo­
genous hormone concentration on dilution (Figure 3) (R. S. Yalow and S. A. Berson, 
J. Clin. Invest., 39 : 1157, 1960). With ACTH also, dilution of plasma from 1 : 2.5 
to 1 : 100 results in proportionate decrease in hormone concentration. 
It would appear as if a dilution experiment similar to those described above 
would provide the most useful direct demonstration of immunologic identity of 
reactive material in plasma with the hormone used in the preparation of the stan­
dard curve. 
E. F. PFEIFFER (Chairman) : I should take the opportunity for commenting on 
the comparisons between the ACTH values measured by immuno- and by bio­
assay. We are familiar with the bioassay, based on corticosterone production of 
the dexamethasone (pituitary) blocked and hypophysectomized rat, measuring the 
corticosterone increase either in the peripheral or in the adrenal venous blood since 
several years (Pfeiffer et al., 1960; Retiene et al., 1962; Pfeiffer et al., 1963). As a 
matter of fact, it has turned out to be our best assay, running with an index of pre­
cision of λ = 0.18 over 4 years. This was due to the fact that we cannulated the 
adrenal vein of the hypophysectomized rat from the femoral vein, drawing the 
blood before and after injection of the standard and the serum, each animal serving 
as its own control. One of my associates, Dr. Retiene was invited by Dr. Lipscomb 
to join him for one year time, running the Lipscomb and Nelson procedure and 
our own, without having any differences. Hence, I feel any differences observed 
cannot be attributed to the method but rather to the different ACTH content on 
a weight basis of the various ACTH preparations used as standards. Moreover it 
seems to us that the immunoassay per se always gives a little bit higher values, and 
this can be due to the fact that the 1-39 aminoacid residues containing molecule is 
measured immunologically, whereas the bioassay (steroidogenic capacity taken as 
parameter of ACTH activity) mostly evaluates the N-terminal portion. 
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ABSTRACT 
A short review is given of the method for radioimmunoassay of glucagon, 
which was first described by Unger and co­workers. Glucagon antibodies have 
been demonstrated in rabbit, guinea­pig and goat. Various immunization techniques 
have been tested. The immunization with P. V. P. or C. D. I. conjugated glucagon 
mixtures given weekly seems to be most successful and reliable. Like insulin anti­
bodies, glucagon antibodies are of the nonprecipitating type and can, therfore, 
be detected only by such method as the paper chromato­electrophoretic, precipi­
tation or ionic exchanger techniques. 
The preincubation of nonradioactive glucagon with glucagon antiserum reduces 
binding of 131I­glucagon to a degree related to the quantity preincubated, thereeby 
providing the basis of a radioimmunoassay for glucagon. 
Other peptide hormones do not influence 131I­glucagon binding, implying a 
high degree of specificity for the assay. Cross reaction between human or canine 
glucagon and antibodies to beef­pore glucagon has been proved. 
Therefore the radioimmunoassay for glucagon is highly specific and exqui­
sitely sensitive and facilitates the measurement of circulating glucagon in concentra­
tions as little as 150­200 μμg/ml. Glucagon levels have been determined in the 
plasma of dog and man in different metabolic situations to study the physioiogic 
rôle of this hormone. 
The labelling of proteo­hormones with 131I has been discussed competently. 
The procedures employed for radio­iodination of glucagon are a modification of 
the Pressman­Eisen technique (1' 2), the method of Hunter and Greenwood (3>, 
and the one described by Niemann (**). 
These techniques provide a high specific activity without undue damage to 
the glucagon molecule. Biologic assays of 131I­glucagon failed to demonstrate a 
greater loss of biologic activities despite weeks of storage in frozen state. 
The specific activities used are in a range between 10 and 600 mCi/mg. The 
degree of specific activity has to be considered when different techniques of sepa­
ration between free and antibody­bound hormone are applied. 
The main problem of the glucagon­assay is the production of specific anti­
serum, probably due to the relatively low molecular weight of 3483. 
Various procedures of immunization with different adjuvants, precipitations 
and the conjugation with larger molecules, as well as different injection techniques 
and various animals have been used. They are summarized in Figure 1 (4,7). 
(*) The own investigations were supported by Deutsche Forschungsgemeinschaft. 
(**) These' Proceedings, p. 43. 
Antigens Animals (No.) Method of Inject. No. of Inject. Cases with Antibodies (Authors) 
Beef-pork glucagon in complete Freund's 
adjuvant (1 mg/2 ml) 
(emulsified or alum-precipitated) 
Recrystallized porcine glucagon suspended in 
Bayrol-Alarcel or Freund's adjuvant 
or conjugated to ovalbumin with bis-diazo 
benzidin suspended in adj. 
Beef-pork glucagon alum-precipitated in 
Freund's adjuvant. 
Beef-pork glucagon + Freund's adj. (emul­
sified or alum-precipitated). 
Beef-pork glucagon 4 Freund's adjuvant. 
Beef-pork glucagon (10 mg/2 ml Η20) 
+ polivinyl pyrrolidone (3 ml; 25 %) 
+ Freund's adjuvant (5 ml) 
Conjugated beef-pork glucagon (10 mg) rabbit 
or guineapig serum albumin ( 100 mg in 0.5 ml 
H20) with carbodiimide (100 nig). 
white female 
rabbits (29) 
male albino 
rabbits (4) 
female goat ( 1 ) 
rabbits 
chickens 
rabbits 
chickens 
guineapigs 
gumcapigs 
rabbits 
guineapigs 
(S) 
(5) 
(3) 
(2) 
(5) 
(5) 
(4) 
(D 
0.2 ml foot pad 
1.8 ml subcutaneously 
(hindquarter) 
subcutaneous 
3-10 mg 
subcutaneous 
(neck) 10 mg 
subcutaneous 
1 or 2 mg 
subcutaneous + 
foot pad 1 or 2 mg 
subcutaneous + 
foot pad I or 2 mg 
subcutaneous 
subcutaneous + 
foot pad 1 or 2 mg 
monthly for 
3 months 
varying intervals 
over a 2-year 
I inj. every 
two weeks 
27 (Fig. 2) 
(Unger, R. H. et al. : J. Clin. Invest. 
(1961) 40 : 1280) 
4 (after 1-3 months) (Grodsky et al 
Proc. Soc. Exp. Biol. (1961) 107 : 
491). 
1 (after 3 months) 
(Weinges et al. : Verb. Dtsch. Ges. 
Inn. Med., Bd. 71 (1965) 713). 
0 (7) (Assa, R. et al. : 
0 (3) Lancet 1965 II, 590) 
I (3) 
0 (2) 
4 (4)* 
3 (4)* 
3 (3) 
I (I) 
( ) No. of animals tested 
* one animal died — anaphylactic shock 
Ζ 
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The demonstration of antibodies after immunization with emulsified or preci­
pitated glucagon with or without Freund's adjuvant remains inconstant. The immu­
nization with conjugated glucagon, however, seems to be more successful and 
reliable, as described by Assam The antigenicity of glucagon seems to increase 
by association (conjugation or adsorption) with larger molecules, proteinic or not. 
This may be related to the greater stability of the molecule and to the well-known 
fact that insoluble antigens are more immunogenic than soluble antigens. Prepa­
rations of long-acting glucagon are shown in Figure 2 (alium-precipitated) and 
Figure 3 (conjugated with CD1). 
Solutions (sterile) : 
1. 0.35 g borax in 25 ml water (stock solution). 
2. 10.0 g KAI (SOj)2.12 HX> in 100 ml water. 
3. 5 n sodiumhydroxide (NaOH). 
Preparation : (mixed in a 100 ml glass tube, work under sterile conditions). 
1. 0.8 g of eggalbumin in 12.0 ml normal saline. 
2. 70 mg glucagon dissolved in 30 ml solution of (16 g (ml) glycerol, 2.27 (ml) phenol, 
981.73 g (ml) Η.,Ο, titrated to pH 2.85 with HCl). 
3. add. a mag 131I-glucagon in 0.1 ml (in order to determine the loss of glucagon). 
4. add. 45 ml 10 % KA1 ( S O ^ — solution 2. 
5. titration to pH 6.5 with 5 η NaOH — solution 3. 
6. spin at 2000 RPM 5 min, discard supernatant. 
7. wash twice with 50 ml borax solution — 1.0 ml of stock solution 1. in 99.0 ml normal 
saline. 
8. dissolve again with an adequate volume of normal saline. 
9. count glucagon-disappearance rate — recovery of 80 per cent is sufficient. 
10. prepare for injection the suspension (1-2 mg glucagon in 1 ml) can be injected to animals 
with or without Freund's adjuvant. 
FIGURE 2. — Preparation of long-acting glucagon (Unger et al.) 
1. rabbit or guineapig serum albumin 100 mg in 0.5 ml of water. 
2. beef-pork recrystallized glucagon 10 mg (powder). 
3. carbodiimide ("Morpho CDI", Aldrich Chemical) 100 mg (powder). 
(work sterile, mix, conjugation mixture must be dialysed before injection to prevent the death 
of the animals). 
Linkage was checked using labelled glucagon. Fractionation by "Sephadex G-75", by paper 
electrophoresis, and by immuno-precipitation with an anti-albumin serum proved that 40-
70 % of radioactivity was bound to albumin. 
Guinea-pigs received 1 or 2 mg glucagon weekly. The animals were bled 14 days after the third 
injection. 
FIGURE 3. — Preparation of long-acting glucagon (Assan et al.) 
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Like insulin antibodies, glucagon antibodies are of the nonprecipitating type 
and can, therefore, be detected only by such methods, which permit separation 
of free 13II-glucagon from antibody-bound 13Il-glucagon. 
Detection and study of antibodies can be carried out by the Berson, Yalow 
and Volk technique adapted for mI-glucagon (8) (Figure 4). This method is based 
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FIGURE 4 (Unger et al.) 
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upon the observation that 131I­glucagon, when incubated in normal serum and then 
applied to a filter­paper strip, is adsorbed to the paper at the point of its application 
(origin) and will not, under these circumstances, migrate either chromatographi­
cally or electrophoretically, thereby permitting its separation from the serum pro­
teins. In the presence of glucagon antibodies, however, 131I­glucagon is expected 
to bind to and migrate with globulin in a manner similar to that described for 131I­
insulin and insulin antibodies (9). Whereas the insulin­binding antibodies of humans 
and guinea pigs are in the inter­yß­zone, the glucagon­binding antibodies of rabbits 
and guinea pigs appear to migrate electrophoretically as a γ­globulin. 
Berson, Yalow and Volk have shown that a small fraction of 131I­glucagon 
damaged by irradiation or other factors, during or after the iodination procedure, 
migrates non specifically with serum proteins. Therefore, parallel control runs with 
undiluted serum from unimmunized rabbits are necessary. The damaged moity 
ranges from 4.0 to 20 per cent, but is almost always less than 10 per cent. 
The antiserum also can be tested by salt precipitation (Na2S04) or by ionic 
exchanger (Amberlite). 
Protein 
content 
.014 
.001 
.001 
.002 
.018 
Curve 
1.0 ml albumin free buffer 
0.2 ml 7 % albumin (pH 7.6) 
0.1 ml antiserum (1:20) 
in 1 % albumin­glycine 
buffer dilution 
0.1 ml standard 
in 1 % albumin­glycine 
buffer dilution 
one ho 
0.2 ml mI­glucagon 
in 1 % albumen­glycine 
buffer dilution 
1.6 ml 
incul 
Protein 
content 
— 
.002 
.014 
Samples 
1.0 ml albumin free buffer 
0.2 ml antiserum (1:40) 
in 1 % albumin­glycine 
buffer dilution 
0.2 ml sample (unknown serum) 
ur preincubation 
.002 
.018 
0.2 ml 131I­glucagon 
in 1 % albumen­glycine 
buffer dilution 
1.6 ml 
)ation 4 days at 4° C 
FIGURE 5. — Preparation of spot­curve and samples for radioimmunoassay of glucagon 
(0.2 m glycine buffer, pH 8.8) 
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A dilution of antiserum able to bind 60-80 per cent of the iodine-labelled glu-
cagon permits the measurement of as little as 150-200 ¡j.[j.g/ml of glucagon with con-
fidence and with a reproducibility approaching 2 per cent. 
The preparation technique carried out for the radioimmunoassay of glucagon 
is demonstrated in Figure 5. 
An identical protein content in both, samples of standards and samples of 
unkonwn serum, is very important. 
The mixture is incubated at 4° C for at least 24 hours, better even for 2 to 4 
days. 
Free and antibody-bound glucagon can be separated with different techniques 
similar to the method to separate free and antibody-bound insulin : 
I. paper chromato-electrophoretic method of Berson and co-workers (9, 1()· n > , 
II. Na2S04-precipitation <12· 13), 
III. ionic exchanger <(i). 
The preparation of specimens for salt precipitation is shown in Figure 6. The 
procedure is simple, but there is the disadvantage of co-precipitation of free glucagon 
in amounts of approximately 6 to 10 per cent. 
We are using the ionic exchanger Amberlite CG 400 I. A sufficiënt amount 
of Amberlite is added to the antibody-glucagon mixture samples after the incubation, 
shaken at room temperature for 1 hour and then centrifuged. Free glucagon will 
be adsorbed to the ionic exchanger (F) and the antibody-bound glucagon remains 
in the supernatant (B). The activity of aliquots of the supernatant is counted. 
Specimens 
1 
2 
3 
4 
5 
6 
7 
Curve 
1.6 ml (0.2 ml 7 % albumin) 
add : mixture of "carrier protein' 
0.2 ml EDTA plasma 
1.0 ml human plasma 
1.0 ml glycine buffer 
3.8 ml final volume 
Sample 
1.6 ml (0.2 ml plasma) 
0.2 ml 7 % albumin 
1.0 ml human plasma 
1.0 ml glycine buffer 
3.8 ml 
mix and stir well; allow to set at room temperature for 1 hour 
spin at 2,000 RPM for 30 min. 
remove supernatant carefully with 
wash with 6 ml of 15 % Na2SOj, 
spin again, remove supernatant 
a capillary pipette. 
stir well 
count radioactivity of precipitation. 
FIGURE 6. — Preparation of samples for Na : S0 4 precipitation (separation between free and anti-
body-bound glucagon) 
After incubation the mixtures were allowed to reach room temperature. Place 8-12 samples in 
waterbath at 30° C 
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Good Separation can be achieved as compared with the paper­chromato­elec­
trophoretic method. The advantage is the possibility to use a mI­glucagon with 
the relatively low activity of 10 to 20 mCi/mg. 
Standard curves of salt precipitation and separation by means of ionic exchanger 
are given in Figure 7. 
1 3 4 6 B 10 2 
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FIGURE 8 (Unger et al.) 
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Studies of kinetics were done (10). Similarities between insulin-binding and 
glucagon-binding reactions were observed. First, the reaction of glucagon and its 
antibody was found to be reversible. Second, like insulin-binding, glucagon binding 
is governed by the law of mass action; at a constant antibody concentration the 
amount of 131I-glucagon bound increases with the concentration of 131I-gIucagon, 
although the percentage of 131I-glucagon bound decreases progressively (Figure 8). 
There is no evidence of cross reactivity between insulin and glucagon, the 
binding of 131I-insulin to globulins in anti-glucagon serum and of 131I-glucagon 
in anti-insulin serum being no greater than in non-irnmune sera. The ability of 
other peptide hormones to lower the B/F ratio of 131I-glucagon was tested and 
compared with that of glucagon. Only glucagon causes a significant decline in the 
B/F ratio of 131I-glucagon, suggesting a high degree of specifity for the assay method 
(10) _ 
Curves made with different lots of 131I-glucagon and different lots of diluted 
antiserum differ from each other to a varying degree. Excellent reproducibility 
can be noted when the same standards and other materials are set up in duplicate 
on the same day. Under these circumstances Unger (10) found in 35 consecutive 
duplicate B/F ratios of glucagon standard solutions r mean standard deviation 
of ± 0.-0436. 
In order to test the ability of the immunoassay to measure exogenous beef-
pork glucagon in vivo, 3 mg unlabelled glucagon were injected intravenously and 
blood specimens were drawn at intervals for one hour thereafter. Measurements 
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FIGURE 9 (Unger et al.) 
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of glucagon concentration by means of the immunoassay gave a disappearance 
curve for exogenous glucagon quite similar to that obtained by radioactivity mea-
surements after radioglucagon administration (Figure 9). 
A higher plateau of trichloroacetic acid-recipitable radioactivity is attributed 
to the altered 131I-glucagon which binds to serum proteins and disappears less rapidly 
than undamaged 131I-glucagon. 
The high glucagon concentrations, measurable in extracts of human and canine 
pancreas, indicate a cross reaction between the glucagon of these species and anti-
bodies to beef-pork glucagon. 
These results of Unger and co-workers are the bases for the study of circulation 
endogenous human glucagon in health and disease. 
100 
GLUCOSE 
(mg.%) 
GLUCAGON 
(*i>ig eq /ml ) 
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-1200 
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FIGURE 10 (Unger et al.) 
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By means of the exquisitely sensitive and highly specific radioimmunoassay, 
glucagon has been measured in the plasma of dogs and man for the first time. The 
glucagon concentration in dogs ranges from 0 to 800 μμg/ml mean 496 μμ^/ηι]) 
and in man from 0 to 650 μμg/ml (mean 292 μμg/ml) (*). 
Dogs made acutely hypoglycaemic by a rapid administration of glucagon­
free insulin, generally show a gradual rise in glucagon secretion. Severe chronic 
hypoglycaemia in dogs induced by the administration of phloridzin is accompanied 
by a more striking and consistent rise in glucagon secretion. The mean pancreati­
coduodenal venous glucagon level in the hypoglycaemic dog is approximately 4 
times that of the control group (14). 
In man the chronic glucose need induced by total starvation is associated with 
a 3­fold rise in mean peripheral venous glucagon concentration after 72 hours of 
fasting (Figure 10) ,15). 
These findings reveal the presence of endogenous glucagon in pancreatic venous 
blood, and indicate that glucagon secretion is enhanced during glucose need, irres­
pective of cause, and that sudden glucose replenishment abruptly abolishes this 
hyperglucagonaemia (16). 
Glucagon mobilizes not only glucose from liver glycogen but also non­esterfied 
fatty acids in adipose tissue and provides the organism with two most important 
substrates with high energy potentials (17). 
In its physiologic rôle glucagon seems to be a "starvation hormone". Epine­
phrin, in comparison, which has very similar metabolic effects could be called a 
"stress hormone". 
More studies on glucagon secretion are necessary to gain further knowledge 
of its physiologic significance (**). Roger Unger wrote in his last letter that he has 
found a patient with a glucagon producing tumor with the extremely high peri­
pheral glucagon level of 50 n^g/ml. 
I think he will report on the metabolic stiuation of this patient later on this 
year. 
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DISCUSSION 
E. SAMOLS (London) : Dr. Weinges is to be congratulated on his presentation, 
at short notice, of the admirable work of Dr. Unger. The availability of an anti-
glucagon antiserum with a suitable binding energy for endogenous glucagon is of 
course a critical requirement for the radioimmunoassay of plasma endogenous 
glucagon levels in man. In the absence of a human glucagon preparation, it is impor­
tant that serial dilution of plasma should give a proportional decrease in glucagon 
concentration, to show that human endogenous glucagon cross-reacts perfectly 
with the beef pork glucagon used as a reference standard. Neither Dr. Weinges nor 
Dr. Unger have, to the best of my knowledge, presented information on plasma 
dilution curves. We have recently reported (E. Samols, J. Tyler, G. Marri and V. 
Marks, Lancet ii, 1257, 1965) mean overnight fasting endogenous glucagon con­
centrations in man of 2 n^g/ml, almost ten times greater than the mean level of 
0.29 n^g/ml mentioned by Dr. Weinges. We were therefore concerned about the 
validity of our assay values, but our results have been supported by plasma dilution 
studies. Over a range of plasma dilutions from 1 : 2 to 1 : 50 the decrease in endo­
genous glucagon is almost proportional. Dilution curves enable us to construct 
standard curves for endogenous glucagon which show, with our antiserum, a vir­
tually identical cross-reaction between human endogenous glucagon and beef pork 
glucagon. It is possible that our fasting glucagon levels are higher that those of 
Dr. Unger in part because the cross-reaction between endogenous and exogenous 
glucagon is better in our antiserum. Dr. A. M. Lawrence from Chicago has also 
recently reported fasting endogenous glucagon concentrations in agreement with 
our results. 
On the other hand the lower fasting glucagon levels reported by Dr. Unger 
are, in one respect, more plausible to me than our own fasting assay values. I shall 
be presenting data to show the potent insulinogenic effect of constant infusions of 
relatively small amounts of glucagon (1-5 μg/min). It is difficult to understand how 
glucagon infusions promote such hyperinsulinaemia with a rise in circulating glu­
cagon levels (by immunoassay or by calculation) which is relatively small compared 
with our fasting values, so that the lower fasting glucagon values reported by Dr. 
Unger might be more appropriate. 
The immunoassay is complicated by the damaging effect of human plasma 
on glucagon 131I. We obtained our higher fasting glucagon values and dilution 
curves only after reducing incubation damage. At present correct absolute values of 
circulating glucagon remains an open question, but relative changes (i.e. increase 
or decrease) in endogenous glucagon after provocative tests are detectable with 
confidence by our immunoassay. We have recently reported (Samols et ai, 1965, 
Lancet, ii, 1257) the new observation that endogenous glucagon levels rise after 
100-200 g glucose by mouth. We have suggested that the alimentary absorption 
of glucose stimulates glucagon secretion by the gut or the pancreas, thereby pro­
moting insulin secretion. 
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K. F. WEINGES : For the present I have no real comment on Dr. Samols results. 
We have to compare our glucagon antiserum, the separation technique of free 
and antibody bound 131I-glucagon and we have to discuss the possibility of labeled 
glucagon damage in human plasma during the incubation. Unger and we found a 
cross-reaction between extracted human's pancreas glucagon and beef pork glu-
cagon antiserum. There was no possibility to test cristallized and purified human 
glucagon because we could not get one. I was listening with great interest Dr. Samol's 
communication. There are a lot of problems. It is very hard to believe that glucagon 
stimulates the secretion of endogenous insulin directly. 
As you know Dr. Pfeiffer and coworkers found a stimulation of insulin secre-
tion by STH and secretin. We found a considerable increase of Cortisol in plasma 
after glucagon administration and there is correlation between Cortisol and insulin 
levels in plasma. 
The most remarkable effect of glucagon is its effect on the liver. May be the 
changing of the liver metabolism (increase of glucose concentration in the liver cells) 
has an inactivation influence on endogenous insulin. 
E. SAMOLS : I doubt that Dr. Weinges would observe a rise in plasma Cortisol, 
1-2 minutes after the start of the injection of glucagon, nor have we observed dra-
matic changes in plasma control after constant infusions of smaller amounts of 
glucagon. We have previously shown (E. Samols, J. Ryder, J. Clin. Invest., 1961) 
that, in subjects with porta-caval anastomoses, the hepatic uptake of insulin is rela-
tively constant even when insulin levels are increased by infusing exogenous insulin, 
so that the insulin response to a rapid injection of glucagon represents a spur of 
insulin secretion. 
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ABSTRACT 
Insulin radioimmunoassay permits precise reproducible estimations of endo­
genous plasma insulin in man, and is valuable clinically in the differential diagnosis 
of spontaneous hypoglycaemia. 
Compared with control subjects, excessive inappropriate insulin secretion 
was demonstrated in all of 28 patients with fasting hypoglycaemia. Insulin levels 
were normal, or more often low, in most other diseases causing spontaneous hypo­
glycaemia, including 11 patients with non-islet cell tumours (unless the tumours 
were invading the pancreas). Overnight fasting hyperinsulinism, demonstrable in 
simple obesity, diabetes mellitus and hepatic cirrhosis, did not occur in conjunction 
with hypoglycaemia in obesity and diabetes. 
The insulin responses to tolbutamide, L-leucine and glucagon were frequently 
exaggerated in patients with insulinomas but the response to intravenous glucose 
was usually normal or subnormal. This led to the discovery that glucagon nor­
mally stimulates insulin secretion, independently of its effect on arterial blood glu­
cose. With constant infusions of relatively small amounts of glucagon the insuli-
nogenic effect, usually apparent only when the blood glucose was raised, was greater 
than that induced by simple hyperglycaemia. The insulinogenic action of glucagon 
was enhanced by hyperglycaemia. Evidence is presented to suggest that the insu­
linogenic effect of glucagon may be physiological. 
In a series of outstanding reports dating from 1956, Berson and Yalow (1"3) 
pioneered the principles, development and application of a radioimmunoassay 
technique for insulin. Its value in elucidating homeostatic mechanisms and in cli­
nical diagnosis has been attested to in numerous publications <4"6), including a recent 
review <5). It is our intention in this communication to demonstrate the usefulness 
of insulin immunoassay in (a) the differential diagnosis of spontaneous hypogly­
caemia in man, and — arising from these studies — (b) establishing the insulino­
genic property of glucagon. 
In compiling this report we have relied largely upon our own experience. 
METHODS 
It was requested that this report should not discuss the technical features of 
immunoassay. According to the principles of radioimmunoassay, the amount of 
labelled insulin which can be bound by a constant quantity of antibody is decreased 
by additional unlabelled insulin in a standard or a plasma sample. Beef or pork 
131I-insulin with a specific activity of 150-600 μC/μg was prepared by the method 
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of Greenwood and Hunter (7), which is vastly superior to the method of Samols 
and Williams (8), used before 1963. Insulin was bound by guinea­pig anti­beef or 
anti­pork insulin antibodies with high equilibrium constants, and the soluble anti­
body­bound insulin complex precipitated with a rabbit anti­globulin serum by the 
immunoprecipitation method of Samols and Bilkus <n). We still use the original 
chromatographic separation of Yalow and Berson (1) as the final arbiter in doubtful 
assays, and extensive tests have shown the precise agreement between the two 
techniques. 
Because of the variable species specificity of the antigen antibody reaction, 
human insulins — prepared (9) by Dr. Fisher, Connaught Laboratories, Toronto, 
and by the Wellcome Laboratories, Beckenham — were used as reference standards 
until 1964, after which Novo twice crystallised human insulin (23.6 U/mg) was 
used. 
95 % confidence limits of 3.0­7.8 % were obtained for concentrations of human 
insulin between 1.0­30.0 μυ/ml and were + 10% for plasma insulin values measured 
in duplicate in the range 5­400 μυ/ml. The reproducibility of the assay is shown 
when each plasma sample was assayed only once on two different occasions (Table I). 
Blood glucose was measured by glucose­oxidase and plasma glucagon by radio­
immunoassay. 
TABLE I. — Comparison of Single Plasma Insulin Estimations on Different Occasions 
Fresh plasma before 
freezing 
μυ/ml 
33 
40 
90 
121 
130 
130 
140 
121 
200 
Stored frozen plasma 
4 weeks later 
μυ/ml 
31 
40 
91 
120 
119 
III 
97 
120 
190 
FASTING PLASMA INSULIN LEVELS. 
a) Control Subjects. 
In 1963 we reported U) the range for overnight fasting plasma insulin in 100 
■control subjects as 2­63 μυ/ml, with a mean value of 19 + SD 7.5 μυ/ml. Subsequent 
recognition that obesity alone may lead to elevation of the overnight fasting plasma 
insulin concentration, led to a re­evaluation of the normal range. After an overnight 
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fast, the mean plasma insulin level in 350 venous blood samples from 150 non­
diabetic, non­obese normoglycaemic men and women in the U. K. and U. S. A. 
was 18 ¿ S D 5.7 μυ/ml in 1963­64<5). In 1965 mean overnight fasting plasma insulin 
12 16 20 2¡, 26 32 
PLASMA INSULIN (μυ/ml.) 
36 
FIGURE 1. — Overnight fasting plasma insulin levels in control subjects, 1963­64 and 1965 
was 17 ¿ S D 4.1 μυ/ml in 189 venous samples from 75 control subjects in the U.K. 
(Figure 1). The histogram of these results approximates normal distribution, and 
in both series the vast majority of levels fall in the range 8­31 μυ/ml. The small 
shift to the left in the second series — which may have been accounted for by the 
use of a fresh standard, or by minor changes in technique — is not clinically signi­
ficant. In contrast to non­obese control subjects, the fasting plasma insulin concen­
tration is — despite normoglycaemia — more than 30 μυ/ml (usually 30­50 μυ/ml) 
in over 30 % of subjects who are more than 20 % above their ideal weight. This is 
important clinically because patients with spontaneous hypoglycaemia may also 
be obese. 
h) Modification of Plasma Insulin Concentration by Hypoglycaemia. 
When the blood or plasma glucose concentration is depressed in normal indi­
viduals — either by severe carbohydrate restriction or prolonged fasting —■ there 
is a parallel fall (Figure 2) in plasma insulin (r = 0.89; ρ = <0.001). Similar paral­
lelism between blood glucose and plasma insulin is observed in obese subjects under 
the same conditions. These observations suggest that insulin levels would be lower 
than normal in "spontaneous hypoglycaemia" unless endogenous hyperinsulinism 
was responsible for, or contributing to, the hypoglycaemia. Thus, it can be shown 
that the hypoglycaemia resulting in susceptible subjects from the ingestion of sali­
cylates, fructose, galactose or alcohol is not insulin mediated (10"13', plasma insulin 
levels being invariably low under these circumstances. 
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FIGURE 2. — Plasma glucose and insulin concentration before and during prolonged fasting. 
Each symbol represents one subject. (Reproduced from On the Nature and Treatment of Dia­
betes, Ed. B. S. Liebel and G. S. Wrenshall, by permission of the publishers). 
c) Insulinoma. 
Our results of fasting plasma insulin assays in patients with insulinoma and 
those of others (3' 6), show that inappropriate excessive insulin secretion is the cause 
of hypoglycaemia in this condition. With realisation that the upper limit of normal 
for fasting plasma insulin is lower than formerly believed, and that hypoglycaemia 
per se lowers the concentration still further, we have reviewed all of our data and 
INSULINOMAS (2Bcascs| 
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FIGURE 3. — Plasma insulin concentrations during spontaneous fasting hypoglycaemia in 28 
patients with insulinomas (above) and 11 patients with non­islet cell tumours (below). 
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find clear-cut evidence of fasting hyperinsulinism, i.e. plasma insulin levels of 40 
μυ/ml or more, in every one of the 28 cases (Figure 3) of proven insulinoma we 
have examined. This high detection rate is attributed to our practice of taking mul­
tiple samples on several different days, as we previously reported (4) that occasio­
nally, despite hypoglycaemia, the plasma insulin level may be completely normal. 
This apparent contradiction to the view expressed above that inappropriate insulin 
secretion is the cause of hypoglycaemia in insulinoma, is at least partially explained 
by the demonstration ,4) that in some, though not all cases of insulinoma, large 
spontaneous fluctuations in plasma insulin levels occur within periods of 10-120 
minutes. Another explanation is that insulin concentrations in portal blood may 
be elevated without a corresponding elevation of peripheral insulin concentration 
(4). In many of the patients with insulinoma, the plasma insulin level remains cons­
tant (±15 %) for several hours, and it is not uncommon to obtain similar elevated 
values from day to day in the same subject. Thus, it seems that while all tumours 
secrete insulin inappropriately, some secrete it in spurts and others — particularly 
malignant ones — secrete it more or less constantly. 
d) Other Conditions Associated with Spontaneous Fasting Hypoglycaemia. 
Plasma insulin levels are normal or, more commonly, low in patients with 
non-islet cell tumours causing hypoglycaemia (14· 15) showing that hyperinsulinism 
is not the cause of hypoglycaemia (Figure 3). Nevertheless, in two of 11 personal 
cases, plasma insulin levels were high during hypoglycaemia. In each of these, the 
tumour — a retroperitoneal mesenchymal fibrosarcoma in one case and a pancreatic 
acinar carcinoma in the other — involved the pancreas itself, suggesting that under 
these circumstances there may be true "inappropriate" insulin secretion. 
We have invariably found fasting plasma insulin levels to be normal or low 
during hypoglycaemia in patients with essential reactive hypoglycaemia, Addison's 
disease (4 cases), hypopituitarism (5 cases), and various types of glycogen storage 
disease (5 cases). High fasting plasma insulin levels occasionally occur with normal 
blood glucose levels in mild, and particularly, obese, diabetics who at other times 
may also have spontaneous hypoglycaemia. Hypoglycaemia and high plasma insulin 
levels do not coincide however, i. e.there is not inappropriate insulin secretion. In 
patients with cirrhosis of the liver, particularly those with porto-caval shunts, plasma 
insulin levels in excess of 40 μυ/ml are occasionally encountered, suggesting that 
hyperinsulinism may contribute to the production of hypoglycaemia in this condition. 
Our experience with children with idiopathic hypoglycaemia of childhood (IHC) 
is limited, but like that of Yalow and Berson ,3), suggests that hyperinsulinaemia 
is uncommon, but does occur. 
INTRAVENOUS TOLBUTAMIDE TEST. 
In normal individuals, the rapid intravenous injection of 1 g sodium tobulta-
mide causes a moderate increase in plasma insulin and a fall in blood glucose (5). 
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In patients with insulinomas, the insulin response to tolbutamide is often exag­
gerated and was diagnostically useful in 14 out of 16 patients. In most the plasma 
insulin rose excessively within ten minutes of the tolbutamide injection and fell 
thereafter, but frequently failed to return to normal levels (Figure 4). In two cases, 
the rise in plasma insulin following intravenous tolbutamide was less pronounced 
and slower to appear but persisted for up to 180 minutes. In three of the cases the 
abnormal plasma insulin response was unaccompanied (Figure 4) by the charac­
teristic fall in blood glucose concentration (lu) and in two patients, neither the glucose 
nor insulin response was typical of insulinoma. An exaggerated plasma insulin 
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FIGURE 4. — Plasma insulin and glucose values during a tolbutamide test in a patient with insu­
linoma. 
response to tolbutamide cannot be considered pathognomonic of insulinoma how­
ever, as a similar response occurs in a small percentage of patients with cirrhosis 
and paradoxically, some obese maturity­onset diabetics <5). 
Despite encouraging earlier reports <16' 17) abnormal glucose responses to intra­
venous tolbutamide are common in other varieties of spontaneous hypoglycaemia, 
being encountered in patients with hypoglycaemia due to cirrhosis, adrenal and 
pituitary insufficiency, non­islet cell tumours, IHC, and in those with alcohol­ indu­
ced hypoglycaemia. The insulin response, on the other hand, is generally normal 
except in cirrhotics, in whom it may be excessive. 
L­LEUCINE. 
L­leucine is normally a stimulus to insulin secretion, but with a standard oral 
dose (150 mg/kg body weight) the mean normal rise in plasma insulin is only 9 
μυ/ml. In half the patients with insulinoma tested, the same dose of L­leucine causes 
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a rapid rise in plasma insulin of 40 μυ/ml or more, and an acute fall in blood glu­
cose concentration. Both responses are restored to normal by removing the tumour. 
Increased sensitivity to L-leucine, judged by its effect on plasma insulin, does not 
occur in other types of "spontaneous" hypoglycaemia, apart from that due to the 
leucine sensitive variety of IHC and factitious hypoglycaemia due to sulphonylurea 
ingestion. 
ORAL AND INTRAVENOUS GLUCOSE TOLERANCE TESTS. 
The typical insulin response to provocative tests, summarised in Table II, 
shows that the insulinomas behave like an exaggerated caricature of normal cells 
when stimulated by tolbutamide, L-leucine and glucagon. It is therefore of interest 
that hyperglycaemia, the best known stimulus to insulin secretion, rarely provokes 
TABLE II. — Characteristic Insulin Responses to Provocative Tests in Insulinomas and Non-islet 
Cell Tumours 
Tolbutamide 1 g I.V 
L-leucine 
Glucagon 
I.V. Glucose 
Insulinomas 
Exaggerated 
Exaggerated (50 %) 
Exaggerated 
Exaggerated or normal 
Sub-normal or normal 
(rarely exaggerated) 
Non-islet cell tumours 
Sub-normal or normal 
Sub-normal or normal 
Sub-normal or normal 
Sub-normal or normal 
Sub-normal or normal 
an excessive insulin response, as is shown by the typically normal or sub-normal 
insulin response to intravenous glucose. The insulin response to oral glucose does 
not reflect the insulinogenic effect of hyperglycaemia alone, as insulin secretion is 
normally augmented by other factors after the ingestion of glucose. 
These results explain why blood glucose studies during oral or intravenous 
glucose tolerance tests do not provide useful information in the diagnosis of insu­
linoma. While a normal or sub-normal insulin response helps to exclude generalised 
islet cell hyperactivity, an excessive insulin response to glucose is compatible with 
either generalised islet cell hyperactivity or localised islet cell tumour(s). 
THE GLUCAGON TEST. 
The insulin response to intravenous glucagon was excessive in 10 out of 12 
patients with insulinoma, as shown by the example in Figure 5. This provides a 
rational explanation for the report by Marks <18) and our further observations that 
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in patients with insulinoma, the injection of glucagon typically provokes reactive 
hypoglycaemia after 90-180 minutes. 
20 30 ¿0 50 60 
M I N U T E S 
FIGURE 5. — Plasma insulin and glucose values during a glucagon test in a patient with insulinoma. 
STIMULATION OF INSULIN SECRETION BY GLUCAGON IN NORMAL PEOPLE. 
The possibility that the excessive rise in plasma insulin we observed in patients 
with insulinoma resulted from a direct effect of glucagon on the abnormal islet 
cells was considered, and led to the discovery (19) that in man glucagon is a potent 
stimulus to insulin secretion by normal as well as by tumorous ß-cells, and has a 
previously unsuspected rôle in glucose homeostasis (2Ü). 
The second part of this report describes how the insulinogenic effect of glucagon 
was clearly established and separated from its hyperglycaemic effect. Although it 
was known with the advent of radioimmunoassay that glucagon caused a rise in 
insulin levels, this response was, until recently <19), considered to be secondary to 
arterial hyperglycaemia resulting from accelerated hepatic glucose release. Arterial 
blood (brachial) was sampled in these studies as there may be large arterio-venous 
blood glucose differences during hyperglycaemia, and it is conventionally thought 
that it is the arterial blood glucose perfusing the pancreas that determines the rate 
of insulin secretion. 
It is apparent from Figure 5, that the maximum insulin response to 1 mg glu-
cagon given by rapid intravenous injection normally precedes maximal hyper-
glycaemia, in contrast to the situation when hyperglycaemia was induced by admi-
nistering glucose (5). The time relations of glucagon administration and the rise 
in blood glucose and plasma insulin occasioned by it, were amplified in 7 healthy 
volunteers by frequent arterial sampling during and after the administration, at 
a constant rate over a 2 minute period, of 1 mg glucagon intravenously. 
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FIGURE 6. — Changes in arterial glucose, insulin and glucagon concentrations in a normal subject 
given glucagon 1 mg intravenously (Reproduced by permission of the Editors, Minerva Med. 
Marri, Tyler, Marks and Samols. To be published). 
In a representative subject (Figure 6) there was a striking and highly signifi-
cant rise in arterial insulin at 1, 1.5, 2 and 2.5 minutes after the start of the glucagon 
injection, even though arterial blood glucose levels did not change during this period. 
The maximum insulin response occurred during the first ten minutes, in contrast 
to the maximum rise in blood glucose which was observed after 15-30 minutes. 
Thus, glucagon was directly responsible for the earlier larger rise in plasma insulin 
which reflects a spurt in insulin secretion. This early insulinaemic response was so 
rapid and so large that it could have been due neither to a reduction in the rate of 
insulin degradation, nor to a decrease in its rate of disappearance from the blood. 
There is also conclusive evidence that insulin contamination of the glucagon pre-
paration used U9) was not responsible for the rise in plasma insulin. 
These results clearly show that glucagon in relatively large amounts — i.e. 
1 mg — stimulates insulin secretion directly and independently of its effect upon 
the arterial blood glucose concentration. That the insulin so released is also biolo-
gically active was intimated by the observations in patients with islet cell tumours, 
and confirmed by the demonstration that in normal subjects the rate constant (K) 
for glucose disappearance during the intravenous glucose tolerance is significantly 
increased by concommitant administration of glucagon (19). 
During the phase of maximal hyperglycaemia, 15-30 minutes after glucagon 
injection (Figure 6), insulin levels were still two to three times the fasting level. 
This later, smaller insulin rise was secondary to hyperglycaemia as it did not occur 
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in certain patients — including diabetics — who were known, from previous expe­
rience, to have a negligible insulin response to glucose. 
The pattern of change of glucagon levels after injection of 1 mg of glucagon 
intravenously was similar in four subjects. Plasma glucagon rose immediately at 
0.5 minute, and increased further to peak values of 45-70 μη^/ιηΐ at the end of 
the two minute injection. Thereafter, glucagon levels fell rapidly to reach basal 
values after 10 to 20 minutes. The half-life of exogenous glucagon was 5-10 minutes, 
but these figures, although derived from an exponential slope, may reflect disap­
pearance of glucagon before it reached its volume of distribution. 
A second intravenous injection of 1 mg of glucagon, 40 minutes after the first 
and while the arterial blood glucose concentration was still raised, caused a greater 
rise in plasma insulin despite a similar elevation of the plasma glucagon level. This 
finding is consistent with other evidence that the insulinogenic effect of glucagon 
is enhanced by hyperglycaemia and suggests that during the hyperglycaemic phase 
following glucagon injection, there is no obvious inhibition of insulin secretion, 
e.g. by catecholamine release (21>. 
During constant infusions of glucagon in doses of 1, 2, 10 or 20 μ£/ηιϊη plasma 
insulin levels rise and fall pani passu with the arterial glucose concentration. This 
correlation between glucose and insulin levels contrasts with the effect produced 
by a rapid injection of large (i.e. 0.25-1 mg) amounts of glucagon, when the highest 
plasma insulin levels precede maximal hyperglycaemia. 
In order to compare the hyperinsulinaemic effect of smaller amounts of glu­
cagon with glucose, it is necessary to obtain similar arterial blood glucose concentra­
tions. This was achieved in several ways. Successive infusions of glucagon (10 μg/ 
min), glucose (500 mg/min) and a mixture of glucose and glucagon in half the pre­
vious strengths, were given to six healthy volunteers. Representative results in one 
subject, shown in Figure 7, clearly indicate that the insulin response to the glucagon 
or glucose-glucagon infusion, was at least twice as large as the insulin response 
to the glucose infusion alone, even though the arterial blood glucose levels were 
similar. When, in the same subject, the order of infusion was reversed and glucose 
given before the glucagon, the hyperinsulinaemic effect of glucagon (Figure 8) 
was much more rapid and much greater (Figure 7). This agrees with other evi­
dence (19' 20) that raising the blood glucose either with intravenous glucose or glu­
cagon enhances the insulinogenic effect of glucagon. The greater insulin response 
during the glucagon infusion caused enlargement of the arterio-venous (A-V) 
blood glucose difference in the forearm (Figure 8). 
The possibility that the insulinogenic effect of glucagon represents a pharma­
cological, rather than a physiological effect of glucagon was considered but dis­
counted for the following reasons. The amount of glucagon infused was progres­
sively reduced and-the smallest amount of glucagon (0.2μg/min) that we have infu­
sed, produced a 40 % mean rise in arterial insulin (Figure 9) and a 10 % mean 
rise in arterial blood glucose in four healthy subjects. As the increases in blood 
glucose and insulin were very small in individual subjects, the insulinogenic effect 
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FIGURE 7. — Comparison of the effects of glucagon and glucose infusions on arterial blood glucose 
and insulin concentrations in a healthy subject. 
2 50 
FIGURE 8. — Comparison of the effects of glucose and glucagon infusions on arterial blood glu­
cose and insulin concentrations in the same subject as Figure 7. 
of glucagon was not clearly demonstrable with a very small rise in circulating glu­
cagon. Because of the relatively small or negligible effect of glucagon 0.2 μ£/πιίη, 
it is plausible that physiological increases in glucagon concentrations were similar 
to those produced by infusions of glucagon 0.5-5 μg/min (20). With 1-5 μg/min glu­
cagon infusion, the insulinaemic effect was two to three times greater than during 
similar hyperglycaemia produced by an intravenous glucose infusion (Figure 10). 
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FIGURE 9. — Mean percentage rise above arterial fasting values of glucose and insulin in four 
subjects during a constant intravenous infusion of glucagon 0.2 μg/min. 
These doses of glucagon are "physiological" since they raise the blood glucagon 
level to values no higher than those observed after oral glucose, which we have 
recently shown <20) increases endogenous glucagon levels. 
In any one subject (Figure 10) glucose 100 g by mouth also produced a greater 
rise in plasma insulin than does intravenous glucose at similar arterial glucose con­
centrations. It should be noted (Figure 10) that there is a correlation between blood 
glucose and plasma insulin levels after oral or intravenous glucose and glucagon 
in the same subject, but that insulin secretion is augmented both by intravenous 
glucagon and when glucose is taken by mouth. 
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FIGURE 10. — Comparison and correlation ot arterial blood glucose and insulin concentrations 
in the same individual given intravenous glucose, intravenous glucagon and oral glucose on 
different occasions. 
Thus, the ingestion of glucose in man stimulates the secretion of endogenous 
glucagon in amounts sufficient to augment insulin secretion, and may explain why 
glucose by mouth, compared with intravenous glucose, causes a large rise in plasma 
insulin for similar blood glucose levels. The physiological and pathophysiological 
implications of the insulinogenic effect of glucagon are of some interest and may 
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be relevant not only to certain types of diabetes mellitus (glucagon deficiency?) 
and reactive hypoglycaemia — particularly after gastrectomy — ( glucagon excess?) 
but also to the fundamental control of insulin secretion. Elsewhere, evidence has 
been summarised to suggest (22) that the first step in the promotion of insulin secre­
tion by glucagon is stimulation of glycogenosis within the ß­cell. 
Finally, the present report has presented two aspects of the use of the radio­
immunoassay of insulin in metabolic studies. The diagnostic value of the assay in 
hypoglycaemic states has been illustrated. Prompted by results in these diagnostic 
studies, insulin assay was used to show that glucagon directly stimulates or augments 
insulin secretion. 
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DISCUSSION 
H. DITSCHUNEIT (Frankfurt) : I was really impressed by your data but they 
give rise to some questions. If you stop the glucagon infusion then the immuno-
insulin will decrease very quickly and this means that the half time of the measurable 
insulin will be only of a few minutes. When you inject crystallized insulin you will 
find a much longer half time of about 30 minutes. How would you explain this 
discrepancy ? 
E. SAMOLS : We have conclusively shown that insulin contamination of the 
glucagon preparations used could not have caused the insulinogenic effect of glu­
cagon for a number of reasons. Firstly with an insulin contamination of 0.2 mU 
insulin per mg Lilly beef pork glucagon, the injection of 1 mg of glucagon would 
not increase the plasma insulin level by more than 0.6 μ/ml, by simple calculation, 
and we have proved this experimental by injection of 0.3 mU pork insulin in human 
subjects (E. Samols, G. Marri, V. Marks, Lancet, ii, 415 /1965/), by the same tech­
nique used for the rapid injection of glucagon. Secondly a rapid injection of insulin 
would cause a peak insulin value at the end of the injection followed by a rapid 
fall in insulin levels, unlike the insulin response to the injection of glucagon. Thirdly 
there is no insulin response to glucagon in some diabetics with very high fasty blood 
glucose values, but when these same diabetics are controlled with chlopropamide 
and diet, an insulin response to glucagon becomes apparent. The rapidity of the 
fall in insulin levels on cessation of the glucagon infusion is quite compatible with 
a half life of about 10 minutes that we obtain for endogenous insulin. After stopping 
constant I. V. infusions of glucose the rate of fall of endogenous insulin is frequently 
very similar to that observed after glucagon infusions are ended. 
F. C. GREENWOOD (London) : As Dr. Yalow has pointed out the labeled hor­
mone did not react in an identical manner of the unlabeled hormone or plasma 
hormone (Yalow, Berson, 1960, J. Clin. Invest., 39, 1157). Dr. Samols figures illus­
trate the validity of this concept and show that a slight loss of precision and sensi­
tivity has to be accepted but that specificity is not impaired. 
E. F. PFEIFFER (Chairman) : The findings of Dr. Samols pointing at the capacity 
of glucagon to stimulate insulin secretion, are particularly fascinating. I wonder 
whether these results might have been obtained also in the in vitro preparation. 
When we, last week and without knowing that Dr. Samols is going to bring up 
that point, were adding glucagon to slices of pancreatic tissue from rabbits and 
dogs, no increase in insulin labeled activity and immunoinsulin secretion was obtai­
ned. On the other hand, in the same preparation, secretin for example was fully 
active in inducing insulin release in amounts comparable to those mobilized follow-
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ing 200 mg glucose concentration in the medium (Pfeiffer et al., Dtsch. Med. 
Wscht. 1965). 
E. SAMOLS : I think that the observation of Prof. Pfeiffer of the insulinogenic 
effect of glucagon in vitro with rabbit pancreas may have been due to the absence 
of glucose in the medium. The human being, even when hypoglycaemic, always 
has some glucose perfusing the pancreas. Prof. Pfeiffer's observations are consistent 
with our hypothesis that glucagon promotes insulin secretion by stimulating intra­
p­cell glycogenosis, and that glucose entering the ß­cell is not metabolised until 
it has passed through glycogen (i.e. 2 pools of glucose­6­phosphate). For this reason 
raising the blood glucose enhances the insulinogenic effect of glucagon. Also during 
prolonged starvation the intra­ß­cell glycogen stores are depleted and the insulin 
response to glucagon is diminished or abolished. Thus during prolonged starvation 
glucagon levels may rise, but insulin levels fall parallel with blood glucose levels. 
E. F. PFEIFFER : If glucagon is active on ß­cell tissue only in presence of a certain 
glucose concentration whereas secretion is working also in the glucose free medium, 
then we should be justified in concluding that the two effects are different. This 
seems to be an important point. 
A. LUYCKX (Liège) : J'aimerais signaler ici les résultats d'une étude réalisée à 
l'Institut de Biochimie Clinique de Genève (Prof. A. Renold) par Mlle D. Vecchio 
et moi­même. Nous avons utilisé le pancréas de rat foetal, prélevé le 17e jour de 
gestation, cultivé 4 jours puis incubé dans un tampon bicarbonate pendant deux 
heures. Dans un tel système, nous avons observé une nette augmentation de la quan­
tité d'insuline libérée dans le milieu, mesurée par méthode radioimmunologique, en 
présence de glucagon. Nous avons étudié des doses de 0,2 à 0,3 μπι/gl et avons 
constaté l'existence d'une relation dose­effet entre ces valeurs. 
LABELLED PROTEIC HORMONES 
FOR METABOLIC STUDIES 
Chairman : C. A. ROSSI 
Istituto Chimica Biologica, University of Pisa, Italy 
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ABSTRACT 
A radioimmunoassay of ihe follicle stimulating hormone (FSH) and of the cho­
rionic and pituitary luteinizing hormone is now proposed. 
1. The follicle stimulating hormone extracted from human pituitaries is labelled by 
131I using Greenwood and Hunter method. The specific activity is around 100 and 
350 μC/μg. This labelled preparation of FSH is purified and the contaminants 
discarded by chromatography and often by horizontal starch gel electrophoresis. 
So, a pure preparation of 131I­labelled FSH was obtained which in radio­immu­
noelectrophoresis shows only one line. 
Antiserum against FSH is treated by serum proteins from hypophysectomised 
subjects to discard aspecific antibodies. This treated antiserum shows only one 
precipiting line in Immunoelectrophoresis and neutralizes completely the biolo­
gical effect of FSH. 
To separate free 131I­FSH from complex 131I­FSH­antibodies the chromai o 
electrophoresis on paper and the chemical reaction with ions exchangers are not 
available. We use a good separating method based on starch gel electrophoresis. 
With this technique, free FSH migrates in the postalbumine zone and the complex 
FSH­antibodies in the fraction of starch gel between the origin and the slow a2­
globulins. 
2. Purified chorionic luteinizing hormone is obtained. This hormone is labelled by 
the Greenwood and Hunter method. Controls of purity were made by chromato­
graphy and radio­immunoelectrophoresis. The antiserum against this pure prepa­
ration of HCG contains only one type of antibodies which neutralizes the biolo­
gical activity of the hormone. 
Starch gel electrophoresis can separate free 131I­labelled HCG from 131I­labelled 
HCG­Antibodies. 
In this condition, we may appreciate the human chorionic gonadotrophs in 
serum and urines from pregnant women. The radioimmunoassay of HCG can be 
used to test the human luteinizing pituitary hormone (LH). Indeed, there is a cross 
reaction between HCG and LH. 
Some results are reported in this communication. 
RÉSUMÉ 
Une méthode radio­immunologique de dosage de l'hormone folliculo­stimu­
lante et des hormones lutéinisantes chorionique et hypophysäre est proposée. 
1. L'hormone folliculo­stimulante extraite d'hypophyse est marquée par 131I en 
utilisant la technique de Greenwood et Hunter. Cette préparation de 131I­FSH 
(*) Chercheur Qualifié du Fonds National de la Recherche Scientifique. 
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est purifiée et les contaminants écartés par Chromatographie sur DEAE-celluIose 
puis par électrophorèse horizontale en amidon. Nous obtenons ainsi une pré-
paration pure de 131I-FSH. 
Le sérum anti-FSH est incubé préalablement par des protéines sériques de 
sujets hypophysectomisés afin d'écarter les anticorps aspécifiques. 
Pour séparer la FSH* libre de la FSH*-Ac nous utilisons l'électrophorèse 
en amidon. Avec cette technique la FSH libre migre dans la zone des postalbumines 
tandis que le complexe FSH-Anticorps se situe du côté cathodique des a.,- glo-
bulines lentes. 
2. L'hormone chorionique gonadotrope lutéinisante peut être obtenue à l'état 
pur. Le marquage de cette hormone par 131I s'effectue en utilisant la méthode 
de Greenwood et Hunter. Les contrôles de pureté ont été réalisés par Chroma-
tographie sur Séphadex G 200 et par radio-immuno-électrophorèse. L'anti-
sérum anti-HCG contient un seul type d'anticorps qui neutralise l'activité biolo-
gique de l'hormone. 
L'électrophorèse en amidon permet de séparer 131I-HCG libre de 131I-HCG 
fixé aux anticorps. 
Dans ces conditions nous pouvons apprécier le taux de l'hormone chorio-
nique gonadotrope dans le sérum et les urines de femmes enceintes. 
Le dosage radio-immunologique de l'HCG peut être utilisé pour apprécier 
le taux de l'hormone lutéinisante hypophysäre (LH) dans le sérum ou les urines 
car il existe une parenté antigénique entre HCG et LH. 
Les premiers résultats obtenus à l'aide de notre technique sont ici rapportés. 
Depuis quelques années, l'étude de la sécrétion des hormones protidiques s'est 
considérablement développée grâce à l'introduction des techniques immunologiques 
dans les méthodes de dosage de ces hormones. La méthode radio-immunologique 
est la meilleure car dans les conditions idéales, elle associe à la spécificité rigoureuse 
de la réaction antigène-anticorps l'exquise sensibilité des techniques isotopiqties. 
Ces méthodes radio-immunologiques sont actuellement utilisées pour explorer la 
sécrétion de l'insuline (Yalow et Berson, 1959), de l'hormone de croissance 
(Utiger et al., 1962. Greenwood, 1962), de l'ACTH (Felber. 1963; Yalow et ai. 
1964). du glucagon (Unger et al., 1961) et de la parathormone (Berson et ai. 1963). 
L'application de ces techniques radio-immunologiques aux gonadotrophines 
est rendue difficile par l'absence de préparations parfaitement putifiées de ces sti-
mulines hypophysaires et du fait de l'ignorance de la structure chimique des gona-
dotrophines physiologiques. 
Depuis plusieurs années, nous nous sommes attachés au problème du dosage 
des gonadotrophines. Nous avons proposé, en 1962, une technique immunologique 
reposant sur l'hémagglutination (Franchimont. 1962). En 1965, nous avons mis 
au point une méthode de dosage radio-immunologique de l'hormone folliculo-
stimulante (Franchimont et Van Cauwenberge, 1965; Van Cauwenberge et Fran-
chimont, 1965) et de l'hormone lutéinisante chorionique et hypophysäre (Fran-
chimont, 1965). 
Dans cette communication, nous désirons prouver la valeur des techniques 
radio-immunologiques que nous avons proposées pour le dosage des hormones 
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folliculo-stimulante (FSH) et lutéinisante (LH). Nous nous attacherons en parti-
culier à démontrer le respect dans ces cas particuliers, des conditions indispensables 
à la réalisation de tout dosage radio-immunologique, à savoir : 
— l'obtention d'un antiserum spécifiquement dirigé contre la seule hormone à 
doser; 
— l'utilisation d'une préparation d'hormone marquée à l'état pur; 
— l'emploi d'une méthode valable de séparation de l'hormone marquée libre et 
de l'hormone marquée fixée aux anticorps. 
Nous avons en outre vérifié l'identité immunochimique de l'hormone étalon 
et de cette même hormone présente dans les milieux biologiques. 
I. DOSAGE RADIO-IMMUNOLOGIQUE DE L'HORMONE FOLLICULO-STIMULANTE 
A. O B T E N T I O N D ' U N A N T I S E R U M SPÉCIFIQUEMENT D I R I G E C O N T R E LA SEULE H O R M O N E 
FOLLICULO-STIMULANTE. 
La préparation d'hormone folliculo-stimulante utilisée, a été extraite d'hypo-
physes humaines par la méthode de Steelman et al., (1959). Son activité FSH est 
de 2.250 unités HMG24 et LH de moins de 25 U.I. HCG par mg. Elle a servi à induire 
la formation d'anticorps chez le lapin. 
L'étude immuno-électrophorétique de cette préparation et des antiserums 
correspondants a montré qu'il existe, dans ces derniers, trois types d'anticorps 
« - " 
FIGURE 1. — Diagramme immuno-électrophorétique obtenu lors de la réaction entre la prépara-
tion d'hormone folliculo-stimulante déposée dans les logettes et soumise à l'électrophorèse 
et l'antisérum correspondant, seit non traité (se trouvant dans les rigoles supérieure et moyenne) 
soit incubé avec des protéines sériques de sujet hypophysectomisé (déposé dans la rigole infé-
rieure). 
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dirigés contre des protéines migrant respectivement dans la zone des albumines, 
des cLy­ globulines et des a2­ globulines (Figure 1). 
Les albumines et les αχ­ globulines sont des contaminants aspécifiques. En 
effet, lorsque ces antiserums sont épuisés par les protéines sériques de sujets hypo­
physectomisés suivant une technique précédemment décrite (Franchimont, 1964), 
puis mis en contact avec notre nouvelle préparation purifiée de gonadotrophines 
hypophysaires (*) nous n'obtenons plus qu'un seul trait de précipitation en a2­ glo­
bulines (Figure 1). L'antisérum ainsi épuisé ne donne plus aucune réaction soit en 
immuno­électrophorèse, soit par la technique d'Ouchterlony, soit par l'hémagglu­
tination, ni avec les albumines humaines purifiées ni avec l'ensemble des protéines 
sériques. Par ailleurs, la préparation gonadotrope purifiée mise en contact avec un 
sérum antisérum humain fait apparaître deux traits de précipitation en albumines 
et en a1­ globulines. Les albumines et les v.x­ globulines sont donc des contaminants 
aspécifiques tandis que les a2­ globulines ne sont pas des constituants majeurs du 
sérum. 
Biologiquement, l'antisérum ainsi épuisé inhibe l'activité tant FSH (test de 
Steelman et Pohley, 1953) que LH (accroissement de poids de la prostate ventrale 
et depletion de la vitamine C et du cholestérol ovarien) d'une préparation de gona­
de 
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15 V HPG 15 Ϋ HPG + 
S.a. FSH 
L.P. 15 V 15 Í HPG 
HPG + 
S.a. FSH 
L.P. 15 ï 
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FIGURE 2. — Etude des tests biologiques appréciant l'activité folliculo­stimulante (Modifications 
pondérales des ovaires de rates saturées par de l'hormone chorionique gonadotrope : HCG) 
et lutéinisante (Augmentation du poids de la prostate ventrale du rat immature et variations 
de la concentration du cholestérol ovarien) sous l'action de 15 μg d'une préparation d'hormone 
gonadotrope hypophysaire (HPG) et de cette même quantité de HPG préalablement incubée 
avec 0,25 ml de sérum anti FSH épuisé par des protéines sériques d'un sujet hypophysecto­
misé (S.a.FSH). L'incubation avec l'antisérum inhibe toutes les activités biologiques de la 
préparation de HPG manifestes lorsqu'elle est injectée seule. 
* marque les variations statistiquement différentes par rapport aux valeurs témoins. 
(*) Préparation gracieusement mise à notre disposition par les laboratoires de Recherches 
Organon que nous remercions très vivement. 
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dotrophines hypophysaires humaines (HPG) moins pure dont l'activité FSH est 
égale à 400 unités HMG24 et LH de 66 U.I.HCG/mg et utilisée afin d'épargner 
notre préparation hautement purifiée (Figure 2). 
L'antisérum épuisé par les protéines sériques d'un sujet hypophysectomisé 
ne donne donc plus qu'un seul trait de précipitation en a2­ globulines. Celui­ci 
correspond à la réaction gonadotrophines­anticorps antigonadotrophines, car il 
inhibe l'activité FSH et LH d'une préparation de gonadotrophines hypophysaires. 
Il importe de voir s'il existe des anticorps spécifiquement dirigés contre des groupe­
ments antigéniques déterminants propres à l'hormone folliculo­stimulante et s'il 
est possible d'écarter les anticorps anti­LH. 
Wide et Gemzell (1961) puis nous­mêmes avons démontré qu'il existe une com­
munauté antigénique entre la LH hypophysaire et l'hormone chorionique extraite 
d'urine de femmes enceintes (HCG). En effet, le sérum anti­HPG inhibe l'action 
biologique de HCG, ce qui permet d'envisager la neutralisation, par l'hormone 
chorionique, des anticorps anti LH de notre immun­sérum déjà traité par des pro­
téines sériques de sujets hypophysectomisés. Dans ce but nous avons recherché la 
quantité de HCG capable de neutraliser les anticorps dirigés contre l'hormone 
lutéinisante en déterminant l'effet de quantités identiques de HCG non traitées et 
préalablement incubées avec le sérum anti­FSH sur la depletion de cholestérol ova­
rien (Van Cauwenberge, Franchimont, 1965). 
A partir de 200 unités, le HCG retrouve sa propriété spécifique de diminuer 
le taux de cholestérol ovarien en dépit de son incubation préalable avec 1 ml de 
°/c 
200Λ 
1004 
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SI eelman e t Pohley 
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cholestérol ovarien 
HCG HCG HCG 
+■ + 
15 % HPG 15 y HPG 
L.P. is y 
HPG 
15yHPG L.P. « y 
+ , , HPG S.a. FSH.épuise 
15 YHPG 
+ S.a. FSH .épuise 
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FIGURE'3 . — Etude des mêmes tests biologiques que dans la figure 2 sous l'action de 15 μg de HPG 
seul puis de cette même quantité d'hormone préalablement incubée avec 0,25 ml de sérum 
anti­FSH traité à la fois par les protéines sériques de sujet hypophysectomisé et par 5000 U.I. 
de HCG; seule l'activité folliculo­stimulante est inhibée par l'incubation de la préparation 
avec l'antisérum ainsi traité. 
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sérum anti­FSH qui inhibe l'activité biologique spécifique du principe lutéinisant 
pour les doses inférieures utilisées. 
Désirant assurer à cette réaction d'épuisement des anticorps anti­LH la plus 
grande sécurité, nous avons ajouté par ml 5.000 U.I. de HCG. 1,'antiserum ainsi 
traité fait encore apparaître en immuno­électrophorèse le trait de précipitation 
décelé avant la mise en contact avec l'HCG et conserve la propriété d'inhiber l'ac­
tivité FSH des préparations de HPG. Par contre, il ne modifie pas l'activité LH de 
ces préparations (Figure 3). 
Ainsi donc nous avons obtenu un antisérum spécifique, dirigé uniquement 
contre la seule hormone folliculo­stimulante. La première condition pour la réali­
sation d'un dosage radio­immunologique de l'hormone folliculo­stimulante est 
ainsi obtenue. 
B. OBTENTION DE L'HORMONE FOLLICULO­STIMULANTE MARQUÉE A L'ÉTAT PUR. 
La préparation d'hormone folliculo­stimulante en notre possession contient 
au moins trois types d'antigènes générateurs d'anticorps après injections aux lapins. 
Les albumines et les α­χ globulines sont des contaminants tandis que les a.,­gIobuIines 
correspondent bien à l'hormone folliculo­stimulante. Il importe donc de marquer 
la préparation par l'iode radioactif puis d'écarter les contaminants marqués en 
même temps que l'hormone folliculo­stimulante. 
SEPARATION DE LA FSH* SUR SEPHADEX G 50 
15 
ml d'élution 
0 1 5 10 
FIGURE 4. — Filtration sur Séphadex G 50 de la préparation de FSH immédiatement après marquage 
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1. Marquage de la préparation d'hormone folliculo-stimulante par 131I. 
Nous avons utilisé la méthode de Greenwood et al. (1963). L'hormone marquée 
est séparée des sels iodés radioactifs par filtration sur Séphadex G 50. L'hormone 
gonadotrope qui n'est pas retenue dans les mailles du gel passe dans le premie 
pic tandis que les sels radioactifs se retrouvent dans le second (Figure 4). 
Nous avons déterminé la récupération de la préparation d'hormone folliculo­
stimulante utilisée après les opérations de marquage. Des 5 μg de départ, la quantité 
moyenne récupérée varie entre 1,64 et 0,97 μg avec une valeur moyenne de 1,27 μg. 
L'activité spécifique des préparations d'hormone folliculo­stimulante marquée 
(FSH*) oscille entre 100 et 350 μ€/μ& 
2. Purification de la préparation d'hormone folliculo-stimulante marquée. 
Pour écarter les contaminants albuminiques et KJ­ globuliniques marqués en 
même temps que l'hormone, nous pratiquons en deux temps : 
Une Chromatographie sur DEAE cellulose (colonne de 10 cm de hauteur­dia­
mètre 1 cm) équilibrée par K2 HP04 0,01 M est réalisée en premier lieu. Le volume 
recueilli après marquage est porté au sommet de cette colonne et l'élution s'effectue 
par 20 ml de K2 HP04 0,01 M puis 0,05 M. Comme l'illustre la figure 5, nous obser­
vons un pic de radioactivité au cours de l'élution par K2HP04 0,01 M et une éli­
mination plus importante de radioactivité lors de l'élution par K2 HP0 4 0,05 M. 
L'activité biologique se localise uniquement au niveau du second pic. En effet, après 
Chromatographie, dans des conditions rigoureusement identiques, de 0,2 mg d'une 
préparation moins purifiée de FSH, nous avons injecté à l'animal saturé en HCG 
(Test de Steelman et Pohley, 1953) les volumes d'élution compris entre les flèches 
et correspondant à ces deux pics. Les volumes d'élution du premier pic ne provoquent 
pas d'accroissement du poids de l'ovaire tandis que ceux du second pic provoquent 
une augmentation pondérale de ces ovaires de l'ordre de 194 %. 
Poids 
ovaires 
V.IStEELMAH 
FIGURE 5. — Chromatographie de la préparation de FSH* sur DEAE cellulose. Elution par 
Ko HPOj 0,01 M puis 0,05 M 
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Les deux ml correspondant au sommet du second pic d'élution sont alors 
soumis à l'électrophorèse en amidon selon la technique de Ferguson et Wallace 
(1961). La durée de l'électrophorèse est de 5 heures et la différence de potentiel 
de 220 volts. La région des postalbumines où se localise l'hormone folliculo­stimu­
lante après électrophorèse (Franchimont, 1966) est prélevée et les protéines qui s'y 
trouvent sont récupérées soit par filtration­congelation soit par électro­dialyse 
(Moretti et al., 1958). 
La préparation ainsi obtenue peut être utilisée pour le dosage radio­immu­
nologique de l'hormone folliculo­stimulante car elle nous donne des garanties de 
pureté suffisante pour aborder cette technique. En effet, lorsque la préparation de 
FSH* obtenue après marquage, mélangée avec de la FSH non marquée, réagit 
en immunoélectrophorèse avec le sérum anti­FSH non encore neutralisé par les 
protéines sériques de sujets hypophysectomisés, trois traits de précipitation appa­
raissent. Cette immunoélectrophorèse, mise en contact avec une plaque photogra­
phique impressionne celle­ci suivant ces trois mêmes traits de précipitation. Si l'hor­
mone folliculo­stimulante marquée, puis purifiée, réagit en même temps que la 
FSH non marquée, avec le même sérum anti­FSH, la plaque photographique est 
ν _ + 
FIGURE 6. — Diagramme auto­radio­immunoélectrophorétique obtenu en présence de la FSH* 
marquée non purifiée et l'antisérum anti­FSH non traité ('). On note 3 traits d'impression 
de la plaque photographique correspondant aux traits de précipitation en albumines, en ax­
et en a,­ globulines obtenus en immunoélectrophorèse. Le diagramme inférieur (2) est celui 
de l'auto­radio­immunoélectrophorèse obtenu lors de la réaction de la FSH marquée et puri­
fiée en présence du même antisérum. II n'existe plus qu'un seul trait d'impression correspon­
dant à la précipitation de l'hormone folliculo­stimulante dans la zone des a,­ globulines. 
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impressionnée selon un trait unique correspondant aux traits de précipitation situés 
dans la zone des oc2­ globulines (Figure 6). 
Ainsi nous possédons une préparation de FSH* à l'état suffisamment pur 
pour ne plus impressionner la plaque photographique que suivant le seul trait de 
précipitation de l 'hormone folliculo­stimulante. La seconde condition est réalisée. 
C. MÉTHODE DE SEPARATION DE L'HORMONE FOLLICULO­STIMULANTE MARQUEE (FSH*) 
ET DU COMPLEXE HORMONE FOLLICULO­STIMULANTE MARQUEE­ANTICORPS ( F S H * ­
Ac). 
Dans le but de réaliser la séparation de la FSH* libre et de la FSH*­Ac, nous 
avons tenté d'appliquer l'électrophorèse sur papier comme Yalow et Berson l 'ont 
réalisé pour le dosage de l'insuline (1959) et la fixation chimique de l 'hormone 
libre sur un échangeur d'ions à l'instar de Melani et al., pour l 'hormone de crois­
sance (1964). 
La séparation par électrophorèse sur papier 3 MM nous paraît insuffisante 
pour assurer une séparation valable de la FSH* libre et de la FSH*­Ac. En effet, 
le principe de la séparation est en défaut. Celui­ci postule que l 'hormone marquée 
libre doit subsister au point d'origine tandis que, seuls les complexes «hormones­
anticorps » vont migrer avec les γ­globulines. En fait, l 'hormone folliculo­stimu­
lante marquée libre ne persiste que partiellement au point d'origine lors de l'utili­
sation du papier 3 MM Whatman. Avec le papier de D. E. 81 la migration existe 
mais est beaucoup moins importante. 
Par ailleurs, la présence de protéines sériques humaines dans le milieu accroît 
encore la migration de l 'hormone folliculo­stimulante marquée à partir de la région 
de départ. Ces éléments sont illustrés par la figure 7 où l'on constate une diminu­
tion de la radioactivité dans la zone de départ, en l'absence de tout anticorps, au 
% 
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FIGURE 7. — Influence des protéines sériques humaines (S. H.) sur la persistance de la radio­
activité au point d'origine au cours de l'électrophorèse sur papier 
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fur et à mesure que la concentration en protéines sériques humaines est accrue : 
0,1 ml et 0,2 ml de sérum humain (S. H.) dans 0,5 ml d'incubation. Le reste du volume 
est constitué par du tampon phosphate de Sorensen pH 7,5 0,05 M contenant 5 g 
%0 d'albumines bovines. Cette méthode de séparation n'a donc pas été retenue. 
Par ailleurs, aucune réaction chimique entre l'hormone folliculo-stimulante 
libre et un échangeur soit d'anions soit de cations n'a pu être exploitée comme méthode 
de séparation de la FSH* libre et de la FSH*-Ac. Il n'est donc pas possible d'utiliser 
semblables techniques. 
Seule l'électrophorèse en amidon permet une migration propre de la FSH* 
libre dans la zone des postalbumines et du complexe FSH*-Ac dans la région 
située entre les a2- globulines lentes et le point de départ. Il est très important 
d'effectuer cette électrophorèse pendant 5 heures sous une différence potentielle 
de 220 volts. A la fin de cette migration, il suffit de réaliser une coupure dans la 
bande d'amidon au niveau des a2- globulines lentes. La radioactivité du fragment 
anodique provient de l'hormone folliculo-stimulante marquée libre et correspond à 
98,4 % de la radioactivité totale en l'absence d'anticorps anti-FSH. Celle de 
la fraction cathodique provient du complexe FSH*-Anticorps. En utilisant l'élec-
trophorèse en amidon nous réalisons la troisième condition. 
FSH*-Ac 
D. VARIATION DU RAPPORT sous L'ACTION DE DOSE CROISSANTE DE 
FSH*LIBRE 
F S H N O N M A R Q U E E . 
FSH*-Ac 
Pour établir la courbe standard de décroissance du rapport sous 
FSH* libre 
l'action de quantités connues de FSH non marquée nous mettons incuber pendant 
90 heures à 4°, 0,25 n^g de FSH*, l'antisérum à la dilution finale de 1/25.000 et 
des doses croissantes de FSH non marquée : 0, 0,1; 0,5; 1 ; 2 et 5 n^g. Le liquide 
de dilution est constitué par le tampon phosphate pH 7,5-0,05 M contenant 5 g %0 
d'albumines bovines. Lorsque le délai d'incubation est écoulé, chaque tube reçoit 
immédiatement avant d'être soumis à l'électrophorèse en amidon 0.1 ml de sérum 
de cheval de façon à réduire à moins de 1 % la quantité de FSH libre adsorbée 
au point d'origine. L'électrophorèse est alors réalisée pendant 5 heures. Après colo-
ration des bandes d'amidon, celles-ci sont coupées en un endroit bien précis et la 
FSH*-Ac 
radioactivité des deux fragments appréciée. Pour obtenir le rapport 
FSH* libre 
. , „ , , , . , la radioactivité du fragment cathodique 
il suffit d établir le rapport entre— - . 
la radioactivité de fragment anodique 
La sensibilité de la technique permet encore de doser 0,5 m¡j.g de FSH soit 
1,17 m. U HMG24. 
IL DOSAGE RADIO-IMMUNOLOGIQUE DE L'HORMONE LUTÉINISANTE CHORIONIQUE ET 
HYPOPHYSAIRE. 
L'hormone lutéinisante hypophysäre (LH) n'est pas disponible, à l'heure 
actuelle, à l'état suffisamment pur pour permettre un dosage radio-immunologique. 
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Par contre depuis les travaux de Got et Bourillon (1959-2 et 11) il est possible d'ob-
tenir l'hormone chorionique gonadotrope lutéinisante (HCG) à l'état chimiquement 
pur. Par ailleurs, on connaît, à la suite des travaux de Wide et Gemzell (1961) la 
communauté antigénique qui existe entre l'hormone lutéinisante hypophysaire et 
l'hormone chorionique gonadotrope lutéinisante. 
Au cours de cette seconde partie du travail nous voudrions vérifier les conditions 
indispensables à la réalisation du dosage radio-immunologique de l'hormone cho-
rionique gonadotrope et démontrer que ce dosage radio-immunologique de l'HCG 
permet d'apprécier la concentration de l'hormone lutéinisante hypophysaire dans 
le sérum de sujets normaux ou atteints d'affections diverses. 
A. OBTENTION D'UN ANTI-SERUM SPÉCIFIQUEMENT DIRIGE CONTRE L\ SEULE HORMONE 
CHORIONIQUE LUTÉINISANTE. 
Les laboratoires Organon nous ont fourni des préparations chimiquement 
pures de HCG dont l'activité biologique est de 12.500 à 14.000 U.I./mg. Ce sont 
ces préparations qui ont servi à induire la formation d'antisérum chez le lapin. 
L'analyse de la composition en anticorps des antiserums obtenus a été réalisée 
par les techniques immunologiques classiques : la double diffusion en gélose, l'hé-
magglutination et l'immunoélectrophorèse. 
De cette étude il ressort que nos antiserums ne contiennent qu'un seul type 
d'anticorps. En effet, en immuno-électrophorèse, lorsque la préparation pure de 
HCG réagit avec l'antisérum correspondant, nous n'observons qu'un seul trait 
de précipitation dans la zone de migration des a2- globulines (Figure 8). Le sérum 
de femmes enceintes et un extrait placentaire donnent un trait de précipitation 
identique en présence de ce même antisérum. Ce trait de précipitation correspond 
FIGURE 8. — Diagramme immuno-électrophorétique obtenu lors de la réaction de l'hormone 
chorionique gonadotrope et du sérum anti-hormone chorionique gonadotrope 
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bien à la réaction HCG-Anticorps anti-HCG, car les effets biologiques lutéinisants 
normalement obtenus avec l 'HCG seule sont inhibés par l'incubation préalable de 
l 'hormone pure avec le sérum anti-HCG (S. a. HCG) (Figure 9). Notre antisérum 
est spécifique et la première condition d'un dosage radio-immunologique est ainsi 
réalisée. 
150. 
100. 
50. 
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rattes immatures en 
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FIGURE 9. — Modification du poids de la prostate ventrale du rat immature et de la teneur des 
ovaires en acide ascorbique et en cholestérol, sous l'action de 30 U. I. d'hormone chorionique 
(HCG) et de cette même quantité de HCG préalablement incubée avec 0,25 ml de sérum anti 
HCG (S.a.HCG). 
* marque les variations significativement différentes par rapport à la valeur témoin (rats rece-
vant L. P. = NaCl 9 %0). 
B. UTILISATION DE L'HORMONE CHORIONIQUE MARQUEE A L'ÉTAT PUR. 
La préparation purifiée de H C G a été marquée par 131I en utilisant la technique 
de Greenwood et al. (1963). L'activité spécifique obtenue est de 150 à 300 u.C^j.g. 
En chromatographiant cette préparation de HCG marquée (HCG*) sur Sepha-
dex G 200 nous obtenons un pic unique de radioactivité. Nous conservons les tubes 
d'élution correspondant à l'élimination maximale de la radioactivité : du 19e au 
22e ml (Figure 10). Il s'agit bien de l 'hormone chorionique gonadotrope, car l'in-
jection de ces éluats provoque, chez le rat, les manifestations lutéinisantes classiques. 
Un argument en faveur de la pureté de la préparation marquée et de la conser-
vation de ses propriétés immunologiques après marquage est fourni par l 'auto-
radio-immunoélectrophorèse. Lorsque l'immunoélectrophorèse. obtenue en pré-
sence de l 'hormone chorionique marquée et de l'antisérum correspondant, est 
mise en contact avec une plaque radiographique, nous n'obtenons, en effet, qu 'un 
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CPM 
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Chromatographie de HCG* 
sur sephadex G 200 (1g2) 
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FIGURE 10. — Chromatographie de HCG* sur Séphadex G 200. Les volumes d'élutions compris 
entre les deux flèches sont conservés et serviront au dosage radio-immunologique 
FIGURE 11. — Diagramme radio-immunoélectrophorétique obtenu en présence de HCG* et du 
sérum anti-HCG 
seul trait d'impression correspondant à la ligne de précipitation relevée en immuno-
électrophorèse (Figure 11). 
La préparation de HCG marquée puis filtrée sur Séphadex G 200 est pure puisque 
l'impression de la plaque photographique s'effectue uniquement suivant le trait 
de précipitation de l'hormone en immuno-électrophorèse. Par ailleurs elle paraît 
bien conserver ses propriétés antigéniques lui permettant de réagir avec son anti-
sérum. La seconde conditions est réalisée. 
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C. METHODE DE SEPARATION DE L ' H C G * LIBRE ET DE L ' H C G * FIXÉE AUX ANTICORPS. 
Différentes techniques de séparation ont été tentées. Nous n'avons pas pu 
obtenir de bons résultats avec l'électrophorèse sur papier ni avec les échangeurs 
d'ions du type Amberlite 500, 50 ou DEAE cellulose (Franchimont, 1965). 
Par contre, l'électrophorèse en amidon constitue une bonne technique de sépa-
ration. En effet, l 'hormone chorionique marquée libre migre dans la zone des <x2-
globulines rapides comme l'indiquent les expériences biologiques et radio-immuno-
logiques, tandis que, en présence d'anticorps, la radioactivité de HCG* se situe 
au point d'origine et dans la zone comprise entre les a2- globulines lentes et le point 
d'origine (Figure 12). 
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FIGURE 12. — Répartition de la radioactivité, après électrophorèse en amidon, de 
traitée ou préalablement incubée avec l'antisérum correspondant. 
'HCG* non 
Pour réaliser une séparation de l 'hormone marquée libre et combinée aux anti-
corps il suffit de faire une électrophorèse en amidon à 220 V pendant 5 h 30, de 
colorer et fixer la plaque, puis de la couper au niveau du trait des a2- globulines 
lentes. La radioactivité de la fraction anodique provient de l 'HCG* libre et celle 
de la fraction cathodique dépend du complexe HCG*-Anticorps. 
En l'absence d'anticorps, la radioactivité au point d'origine et entre celui-ci 
et les a2-globulines lentes ne dépasse pas 3 %. C'est cette technique de séparation 
que nous utilisons. 
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D. IDENTITÉ ANTIGENIQUE ENTRE L'HORMONE CHORIONIQUE ÉTALON PURIFIÉE ET 
L'HORMONE CHORIONIQUE PRESENTE DANS LE SERUM OU LES URINES DE FEMMES 
ENCEINTES. 
Lorsque nous recherchons les courbes de décroissance du rapport 
HCG* fixée aux anticorps . . . . . . . . , , . , „ „ 
X 100 sous 1 action soit de la preparation purifiée d HCG 
HCG* totale 
non marquée soit d'urines (U$E) soit encore de sérum (S$E) de femmes enceintes, 
nous notons un parallélisme de ces courbes. Ce dernier signe un comportement 
immunologique identique de l'hormone chorionique gonadotrope, qu'elle soit 
purifiée ou présente dans les milieux biologiques, urines ou sérum (Figure 13). 
0,001 0p05 
mpg de HCG · -
ml de SQE x_ 
rnl d'UÇE °~ 
FIGURE 13. — Etude du rapport 
HCG* fixée aux anticorps 
χ 100 sous l'action de quantités crois­HCG* totale 
santés de HCG non marquée et de volumes différents de sérum (S$E) ou d'urine de femme 
enceinte (UÇ E). 
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E . COMMUNAUTE ANTIGENIQUE ENTRE L'HORMONE LUTEINISANTE HYPOPHYSAIRE ET 
L'HORMONE CHORIONIQUE GONADOTROPE. 
Peut-on utiliser la méthode de dosage radio-immunologique que nous pro-
posons pour apprécier le taux de l'hormone lutéinisante hypophysaire chez des 
sujets non gravides ? La réponse sera affirmative pour autant qu'il existe une commu-
nauté antigénique entre l'hormone chorionique gonadotrope (HCG) et l'hormone 
hypophysaire lutéinisante (LH) et que tous les anticorps présents dans le sérum 
anti-HCG réagissent avec des groupements antigéniques déterminants communs 
à ces deux hormones. 
La communauté antigénique entre HCG et LH a été découverte par Wide 
et Gemzell (1961). 
Pour notre part, nous avons montré que le sérum anti-HCG agglutine les héma-
ties de moutons recouvertes d'une préparation de gonadotrophines extraites d'hy-
pophyses et contenant de l'hormone lutéinisante. Par ailleurs, ce sérum anti-HCG 
inhibe l'activité biologique lutéinisante de cette même préparation de gonadotro-
phines hypophysaires (Figure 14). 
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FIGURE 14. — Modification du poids de la prostate ventrale du rat sous l'action de 30 y.g de gona-
dotrophines extraites d'hypophyse humaine (HPG) non traités puis préalablement incubés avec 
le sérum anti HCG (S. a. HCG). 
* Marque les variations significatives par rapport à la valeur témoin. 
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HCG*­Ac 
Enfin, les courbes de décroissance du rapport X 100 sont parallèles 
HCG totale 
en présence soit de HCG non marquée soit de gonadotrophines extraites d'urine 
de femmes ménopausées (Human menopausal gonadotrophs : HMG) soit de 
gonadotrophines extraites d'hypophyses humaines (Human pituitary gonadotro­
p i n : HPG), préparations contenant l'hormone lutéinisante d'origine pituitaire 
(Figure 15). La valeur la plus basse de ce rapport est identique lorsque l'on utilise 
des quantités importantes de HCG, de HMG et de HPG. Aussi, pouvons­nous 
confirmer la communauté antigénique entre l'hormone lutéinisante chorionique et 
l'hormone hypophysaire lutéinisante et démontrer que, dans nos conditions expé­
rimentales, les groupements antigéniques déterminants de l'hormone chorionique 
qui ont donné naissance aux anticorps de l'antisérum, sont communs à l'hormone 
lutéinisante hypophysaire. 
S.o. HCG=_ 
20000 
HCG*= 0,25 mpg 
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FIGURE 15. — Etude du rapport HCG* fixée aux anticorps χ 100 sous l'action de quantité crois­HCG* totale 
sante de HCG non marquée, de gonadotrophines extraites d'hypophyses (HPG) et de gonado­
trophines extraites d'urines de femmes ménopausées (HMG). 
En utilisant l'hormone chorionique purifiée marquée et l'antisérum corres­
pondant, nous pouvons donc réaliser un dosage radio­immunologique des hormones 
Iutéinisantes chorionique et hypophysaire. 
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I I I . R E S U L T A T S O B T E N U S P A R LES METHODES R A D I O ­ I M M U N O L O G I Q U E S 
Les exp lo ra t i ons réal isées à ce j o u r c o n c e r n e n t p r i n c i p a l e m e n t des f emmes 
j e u n e s en b o n n e san té . Le t a u x sé r ique de l ' h o r m o n e fol l iculo­s t imulante est t rès 
élevé d a n s les p r e m i e r s j o u r s d u cycle m e n s t r u e l . C ' e s t ainsi q u e n o u s re levons une 
c o n c e n t r a t i o n t rès i m p o r t a n t e les 2 e , 3 e e t 4 e j o u r s d u cycle. L a va leur m o y e n n e 
calculée lo r s d e ce p r emie r p ic est de 42,2 n ^ g / m l . P a r la sui te , elle d i m i n u e , p u i s 
VAR!ATtONS DES CONCENTRATIONS SERIQUES DE FSHfLH ET STH 
AU COURS DU CYCLE MENSTRUEL 
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FIGURE 16. — Evolution du taux de l'hormone folliculo­stimulante (A— A ) , de l'hormone 
lutéinisante ( © 0 ) et de la somatotrophine ( · — · ) au cours d'un cycle menstruel de 
quatre jeunes femmes 
(La flèche marque le décrochement thermique). 
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augmente à nouveau immédiatement avant ou au moment de l'élévation thermique. 
La valeur sérique de cette hormone rediminue alors pour s'accroître une fois encore 
dans la seconde partie du cycle, aux environs du 24e jour (Figure 16). 
Par ailleurs il existe deux pics de sécrétion de l'hormone lutéinisante, le pre-
mier suivant de peu celui de la FSH et l'autre se situant entre le 13e et le 18e jour 
du cycle. 
La figure 16 donne les taux de FSH et de LH présents dans le sérum au cours 
d'un cycle menstruel chez quatre jeunes femmes. 
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DISCUSSION 
F. C. GREENWOOD (London) : Dr. Franchimont have you carried out parallel 
inhibition curves between your standards and a crude pituitary extract ? Similarly 
have you compared your standard curve in your FSH assay with the inhibition 
effect of plasma ? 
P. FRANCHIMONT : La préparation d'hormone lutéinisante hypophysaire que 
nous possédons est très impure puisqu'elle possède une activité FSH de 970 U. HMG24 
(appréciée par le test de Steelman et Pohley) et une activité LH de 172 U. I. HCG. 
La difficulté d'obtenir une préparation pure de LH hypophysaire nous a obligés 
d'entreprendre le dosage de cette hormone en utilisant le système hormone gona-
dotrope chorionique-anticorps antihormone gonadotrope chorionique. La prépa-
ration hypophysaire dont l'activité biologique vient d'être signalée provoque une 
wij HCG — Ac 
courbe de réduction du rapport parallèle à celle produite par l'hor-
P F 131I HCG l ibre v v F 
mone chorionique non marquée. C'est un des arguments qui nous paraît établir 
la similitude immunologique de l'hormone lutéinisante hypophysaire et chorionique. 
En ce qui concerne la FSH, nous n'avons pas encore tous les résultats de l'étude 
relative à la variation du rapport B/F. Les expériences qui sont en cours utilisent 
soit la préparation purifiée de FSH soit les milieux biologiques riches en FSH comme 
le sérum ou les urines de femmes ménopausées physiologiquement ou chirurgica-
lement. 
RADIOIMMUNOASSAY OF HCG 
P. G. CROSIGNANI and F. POLVANI 
Clinica Ostetrica e Ginecologica, 
Università di Milano, Centro di Endocrinologia Ginecologica, C. N. R., Milano, Italy 
ABSTRACT 
A simplified HCG radioimmunoassay method is described. 
A preparation of HCG labelled with 125I by means of electrolysis was used. 
Rabbit anti­sera against HCG were obtained. They have been found capable 
of agglutining HCG coated red cells and of reacting with 125I labelled HCG. The 
complex during the latter reaction is soluble, furthermore antibodies carefully 
precipitated (coagulated) with organic solvents are capable of binding 125I­HCG, and 
bound radioactivity can be separated by centrifugation. When 125I­HCG and unla­
belled hormone are mixed, the specific activity of the former is decreased. By adding 
to the above mixture a given amount of coagulated anti­HCG γ­globulin, this will 
bind an aliquot of the 125I­HCG and unlabelled HCG. The radioactivity bound 
to the coagulum is directly related to the specific activity of the mixture, and the 
unknown amount of hormone can be measured. 
This method was applied to radioimmunoassay of human chorionic gonado­
trophin in pure solution, and it would also appear suitable for assay in biological 
fluids. 
The following immunological methods are currently in use for the determi­
nation of HCG in biological fluids : haemagglutination inhibition u ' , inhibition 
of "latex particle agglutination" (2), and complement deviation (3). 
The first two methods are more widely employed, but are only semiquan­
titative. The third method is quantitative, although the various parameters of the 
haemolitic system which acts as index of the reaction have to be constantly controlled. 
Wilde and co­workers (4) have recently applied to the determination of HCG 
the radioimmunological method developed for insulin by Hales (5). 
The method consists of addition of anti­HCG antibodies to a mixture of unla­
belled and labelled HCG and measurement of the specific activity in the superna­
tant after precipitation of the antigen­antibody complex; the amount of unlabelled 
HCG in the system is calculated from this specific activity. 
The complex HCG­rabbit antibodies is completely soluble at low concentra­
tion; it can be separated from the unbound hormone either by adding a second 
antibody, an anti­rabbit γ­globulin serum, as proposed by Hales, or by making 
the complex insoluble. With the latter method the time required is much shorter, 
and the possibility of incomplete precipitation of the antigen­antibody complex 
by the second antibody is avoided. In fact, γ­globulin can be coagulated by means 
of various agents without destruction of the combining sites. A coagulum obtained 
in this way has already been employed in microbiology as specific antigen adsor­
bent (6). 
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Owing to the advantages afforded by the use of coagulated antibodies, we 
decided to use this method. 
MATERIAL AND METHOD 
ANTISERA HCG. 
Antisera to HCG were prepared by injecting into rabbits a crude preparation 
of the hormone (Lot No. 51 M. ISEC) containing 5,300 LU./mg, together with 
Freund's complete adjuvant. The sera so obtained were pooled and adsorbed with 
an extract of urine of a child, in the proportion of 1 ml of antiserum to an extract 
corresponding to 100 ml of urine, as suggested by Goss (7>. The hemagglutination 
title of the antiserum was 1/5,120. 
The antiserum γ-globulin was separated by salting with Na2SO.,, and then 
redissolved in a volume of water twice the original volume of serum. 
The γ-globulin was coagulated by addition of 90 % aq. ethanol at pH 7, lea­
ving 30 min at 34° C, as described by Sutherland (6). The coagulum so formed was 
washed three times with buffered saline (*), suspended in a volume of buffered 
saline two-four the volume of the γ-globulin solution and merthiolate added. 
HUMAN CHORIONIC GONADOTROPHIN (HCG). 
A commercial preparation containing 2,000 LU./mg (Pregnyl Organon), was 
labelled with iodine 125I by Dr. Rosa (Sorin, Saluggia, Italy) using an electrolytic 
method <8). The specific activity was 5 mC/mg. The labelled hormone was lyophi-
lized and kept in the dry state. 
PROCEDURE 
Preliminary experiments were performed to establish the amount of coagulated 
anti-HCG globulin sufficient to remove approximately half the total radioactivity 
of a fixed aliquot of 125I-labelled HCG. Immediately prior to use, the solution con­
taining the coagulated antibodies was thoroughly shaken to insure homogeneous 
suspension, and then let to stand for 2 min. 0,1 ml aliquots were distributed in 
two series of conical bottom test tubes. The tubes were centrifuged at 4,000 rpm 
for 5 min and the supernatant discarded. The coagulated antibodies were incubated 
for 60 min at room temperature with 0,1 ml of standard or unknown solution of 
unlabelled HCG in duplicate. 
Subsequently, 0.05 ml of a solution containing 100 n^g 125I-HCG per ml, 
equal to 500 μμg, was added, the test tubes shaken one by one and left at room 
temperature for 60 min. After this, they were centrifuged at 4,000 rpm for 5 min 
and the supernatant transferred to another test tube; the precipitate was washed 
(*) Solution containing 0.15 M NaCl and 0.11 M Phosphate Buffer, pH 7.4. 
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with 0.5 ml buffered saline, again centrifuged and the supernatant added to that 
obtained after the previous centrifugation. The radioactivity was measured in both 
the precipitate and the supernatant by means of a crystal scintillation counter. 
RESULTS 
With coagulated anti­HCG γ­globulin in excess only 65­70 % of the radio­
activity was recovered in the precipitate in each experiment; the radioactivity in 
the supernatant is not attributable to free 12δΙ, since this accounts for less than 1 % 
of the total radioactivity. The linkage of labelled HCG to coagulated anti­HCG 
globulin took place very rapidly and was practically complete within 30 min 
(Figure I). The effect of varying amounts of unlabelled hormone on the adsorption 
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FIGURE 1. — Binding of '"I­HCG with anti­HCG coagulated γ­globulin in relation to incubation 
time 
of labelled HCG to the antibodies is illustrated in Figure 2. Within a certain range, 
there was a linear relationship between log amounts of unlabelled hormone pre­
incubated with the antibody and the percentage of radioactivity present in the pre­
cipitate. By comparing with a standard scale the ratio bound/unbound radioactivity 
in the sample, i.e. the radioactivity in the precipitate and in the supernatant res­
pectively, it is possible to calculate the amount of unlabelled hormone present in 
the sample. 
We prefer to measure the radioactivity present in both supernatant and preci­
pitate and not only in the supernatant as in other methods, because the bound/ 
unbound radioactivity ratio is also dependent upon the specific activity of the hormone 
in the sample, and in addition has the advantage of decreasing technical errors 
which may occur in the procedure. 
The method described above is simple and rapid. A series of determinations 
can be accomplished within 4­6 hours. The sensitivity and precision of the method 
depend upon the specific activity of the labelled HCG — reliable results cannot 
be obtained with a specific activity less than 2­3 mC/mg —, and upon the relative 
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proportions of antibody and antigen incubated together; an excess of antibodies 
reduces both the precision and the sensitivity of the method. The sensitivity of the 
method would appear to be greater than that of the haemagglutination inhibition 
reaction which is generally considered satisfactory for clinical purposes. 
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FIGURE 2. — Standard assay curve for HCG. Effect of preincubated unlabelled HCG on the 
binding of 12,,I­HCG to anti­HCG coagulated γ­globulin 
It must be noted, however, that when HCG is assayed in urine containing 
less than 300­400 I.U. HCG/liter, the presence of LH, which can cross­react with 
anti­serum HCG(1) could interfere with the assay. 
Results of duplicate radioimmunoassays performed on pregnancy urine showed 
good agreement; the values were comparable with those obtained on the same 
samples by means of the hemagglutination method (i,). 
However, these results in urine must be considered only preliminary and further 
work is needed in order to confirm the validity of the method. 
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DISCUSSION 
P. FRANCHIMONT (Liège) : Je voudrais faire trois remarques : 
1) L'antisérum obtenu par le Dr. Crosignani en utilisant une préparation de 
HCG d'une activité biologique de 5.000 U. I./mg n'est certainement pas spécifique. 
En effet, nous avons déterminé que semblable préparation contient au moins 4 types 
d'antigènes dont un correspond à l'hormone gonadotrope chorionique et les 3 autres 
à des contaminants aspécifiques. Il faut donc nécessairement effectuer un épuisement. 
2) Le Dr. Crosignani marque par 131I une préparation de HCG ayant une 
activité de 2.000 U. I./mg. Nous avons fait l'étude de la composition antigénétique 
de ces préparations et avons montré qu'elle contient 7 à 8 substances antigénétiques 
différentes dont une seule est l'hormone chorionique. Ces protéines aspécifiques 
seront donc marquées également par 131I et perturberont le dosage. En effet, avec 
131I HCG liée 
un antisérum spécifique, le rapport doit rester très bas par suite de 
131I HCG libre 
la présence de ces contaminants marqués qui ne réagissent plus avec l'antisérum 
épuisé. L'auteur envisage­t­il une purification consécutive au marquage'? 
3) Le pourcentage de l'hormone chorionique marquée, fixée aux anticorps 
serait, selon le Dr. Crosignani, modifié pour 0,05 U. I. HCG. Nous avons observé 
dans nos expériences une modification significative de ce pourcentage pour 0.1 m μg 
d'une HCG dont l'activité biologique est de 12.500 U. I./mg, soit pour 0,00125 
U. I. de HCG. La sensibilité que nous obtenons est donc meilleure. 
P. G. CROSIGNANI : Rispondo nell'ordine alle tre domande : 
1) L'antisiero utilizzato presentava 6­7 contaminanti specifiche e si è infatti 
provveduto alla loro eliminazione mediante assorbimento con "Peduex" in accordo 
con Goss (J. Clin. Endocrinol., 24 : 408, 1964). 
2) Concordo pienamente con il Dr. Franchimont sull' utilità di una purifi­
cazione della gonadotropina marcata, tuttavia le elevate quote di ormoni presenti 
nelle urine della donna gravida permettono una valutazione quantitativa della 
HCG anche nelle condizioni descritte. 
3) La sensibilità del sistema rivelatore utilizzato dal Dr. Franchimont appare 
indubbiamente molto più elevata della nostra. Il suo problema però è quello di 
misurare l'LH ipofisario (poche decine di unità internazionali per litro di urina); 
il nostro è quello di determinare l'HCG in gravidanza (alcune migliaia di unità 
internazionali per litro di urina). 
i25I­INSULIN AS A TRACER OF INSULIN 
IN DIFFERENT CHEMICAL PROCESSES 
K. JØRGENSEN and C. BINDER 
Novo Research Institute, Copenhagen, Denmark 
ABSTRACT 
A method for the preparation of 12äI­insuiia is briefly described. 
The radioactivity of the 125I­insulin almost completely followed carrier insulin 
in the crystallization process. Nearly 100 percent of the radioactivity could also 
be bound to antibodies against insulin. 
However, the radioactivity did not follow carrier insulin in all experiments 
of electrophoresis. Furthermore, in a certain partition chromatography about 
half of the radioactivity followed the single peak of carrier insulin, while the other 
half of the radioactivity appeared as «trailing». 
The radioactivity of ,25I­insulin, prepared by an other method, also followed 
carrier insulin in the crystallization process and could also be bound to antibodies 
against insulin. However, in the partition chromatography this labelled insulin 
behaved quite differently from both insulin and 125I­insulin prepared by the pre­
sent method. 
The results demonstrate the need of investigating the behaviour of radioio­
dinated insulin in comparison with that of insulin in the specific process, for which 
the labelled insulin is intended as a tracer of insulin. 
A description of such an investigation is given, which shows the reliability 
of using 125I­insulin prepared by the present method for studies of the absorption 
of some subcutaneously injected pharmaceutical insulins. 
For use in the present study insulin was radioiodinated by mixing carrier free 
125I~ and insulin in acid solution, and subsequently adding an excess of iodate. Puri­
fication was performed by precipitation with zinc acetate, filtration, and washing. 
The specific radioactivity of the final product was between 10 and 15 mC/mg insulin 
corresponding to a degree of iodination of about 5 atoms of iodine per 100 insulin 
monomers. The yield of radioactivity was about 70 percent. 
With fresh preparations it was found that nearly 100 percent of the radioac­
tivity followed carrier insulin of the same species as the labelled insulin through 
at least four crystallizations. With preparations stored for two months at ­25° C 
in a solution containing 0.1 percent albumin, having a pH of 3, and with an initial 
radioactivity concentration of about 10 μΟ/ηιΙ, 95 percent or more of the radioac­
tivity still followed added insulin through the crystallizations. 
Nearly 100 percent of the radioactivity could also be bound to antibodies 
against insulin. 
However, the radioactivity did not follow carrier insulin in certain experi­
ments of electrophoresis, while it did follow in other experiments of electrophoresis. 
Furthermore, discrepancies appeared when a mixture of the 12sI­insulin and carrier 
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insulin was submitted to a reversed­phase partition chromatography performed 
according to a modification of the method described by Andersen (1). 
The chromatogram A in Figure 1 shows how one part of the radioactivity 
curve followed the insulin curve while the rest appeared as trailing. 
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FIGURE 1. — Reversed­phase partition chromatography of pork insulin + pork 125I­insulin pre­
pared by the present method (A) and the method of Greenwood et al. (Β). Degree of iodination 
for both 12SI­insulin preparations : 5 percent. Optical Density at 276 ιτιμ in percent of max. 
value : Radioactivity in percent of max. value : System : 500 ml 0.04 M tri­
chloroacetic acid and 200 ml 2­butanol. Stationary phase : 4 ml organic phase supported by 
6g si lane­treated kieselguhr(2) in a column (13 χ 1.2 cm). Fractions of 2 ml, diluted with 1 ml 
water before measurements. Flow rate : 0.5 ml/min. Temperature thermostatically maintain­
ed at 21° C. Application : 10 mg pork insulin + 125I­insulin (trace amount) in 1 ml aqueous 
phase. 
For the sake of comparison, 125I­insulin was prepared according to the method 
of Greenwood, Hunter and Glover (3) using chloramine Τ as the oxidizing agent 
at pH 7­8 and gel filtration on Sephadex for purification. Nearly 100 percent of 
the radioactivity of this preparation also followed carrier insulin through four 
crystallizations and could also be bound to antibodies against insulin. However, 
as seen in the chromatogram Β in Figure 1 the radioactivity curve was quite diffe­
rent both from the insulin curve and from the radioactivity curve in the chroma­
togram A. 
These results demonstrate that it is possible to prepare radioiodinated insulin 
.vhich follows insulin in the crystallization process and which is immunologically 
active. However, on this basis alone no predictions can be stated as to the pro­
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perties of the labelled insulin as a tracer of insulin in other chemical processes. 
Therefore, the reliability of using a given kind of radioiodinated insulin as a tracer 
of insulin must be investigated for each intended kind of application. 
In the following a description will be given of such an investigation which 
shows the reliability of using 125I-insulin prepared by the present method for studies 
of the absorption of subcutaneously injected pharmaceutical insulins. 
The point was to inject 125I-insulin containing preparations and to follow the 
absorption by measuring the radioactivity above the site of injection by means of 
a scintillation detector. 
In order to investigate whether the externally measured count rates truly reflect-
ed the absorption of insulin, experiments were carried out in animals. 
Pork and beef 125I-insulin were prepared separately by the present method. 
The preparations were diluted with carrier pork and beef insulin, respectively. 
The mixtures were then treated in the prescribed ways for the preparation of five 
different, pharmaceutical insulins as given in Table I. 
TABLE I. — Results of sheep experiments 
SI = Soluble Insulin, an acid solution of pork insulin. 
A = Actrapid, a neutral solution of pork insulin with a low content of zinc. 
SL = Semilente, a neutral suspension of amorphously precipitated pork insulin with a high content 
of zinc. 
CII = Crystal II, a neutral suspension of beef insulin crystals with a low content of zinc. 
UL = Ultralente, a neutral suspension of beef insulin crystals with a high content of zinc. 
Kind of insulin injected 
(1 m l ~ 4 0 i . u . ) 
Percent rest-radioactivity at the time 
of excision, externally measured 
Percent rest-radioactivity in excised 
tissue, measured in well-defined 
geometry 
Percent 
insulin-bound 
radioactivity 
In preparation . . 
In extract . . . . 
Specific radioactivity 
of extracted insulin 
Specific radioactivity 
of injected insulin 
SI 
a 
49 
98 
98 
1.02 
A 
34 
28 
97 
105 
0.85 
SL 
46 
46 
96 
98 
0.91 
CII 
37 
33 
100 
98 
0.92 
UL 
49 
47 
99 
99 
0.92 
" The determination failed. 
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I ml of each preparation was injected subcutaneously in five different sheep. 
The radioactivity was measured by a scintillation counter above the skin. When 
the apparent radioactivity had fallen to about 50 percent of the initial value the 
injected tissue was excised and extracted with acid aqueous ethanol. The radio­
activity of the extract plus the small amount of un­extracted radioactivity was deter­
mined in percent of the injected radioactivity on the basis of measurements in well­
defined geometry. From Table I it appears that the externally measured rest­radio­
activities at the time of excision are in fairly good accordance with the measurements 
performed in well­defined geometry after excision. 
The relative insulin­bound radioactivities were determined in the insulin pre­
parations and in the extracts as the percentages of radioactivity following added 
insulin of the corresponding species through four crystallizations. It appears that 
all the percentages are close to 100. 
Finally the specific radioactivities were determined in the preparations and in 
the purified extracts. The single specific radioactivity was computed as the ratio 
between the concentration of insulin­bound radioactivity and the concentration 
of insulin determined by immunoassay, performed as a modification of the method 
of Heding l4). In Table I the ratios between the specific radioactivity of the extracted 
and of the correspondingly injected insulin are given. As all of the ratios are close 
to one, it is concluded that if there are differences in the rates of absorption for the 
labelled and the unlabelled insulin such differences must be very small. 
These animal experiments thus show that the externally measured count rate 
is proportional to the amount of residual radioactivity. This is equal to the amount 
of insulin­bound radioactivity, which is again proportional to the amount of resi­
dual insulin. Thus the externally measured count rate is proportional to the amount 
of residual, unabsorbed insulin. 
In summary, the results of the present work demonstrate how radioiodinated 
insulin can fail as a tracer of insulin in some processes and still be an excellent tracer 
of insulin in other processes. 
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DISCUSSION 
K. BRUNFELDT (Gentofte) : 1 should like to ask whether you can give an expla-
nation of the different behaviour of the 2 iodinated preparations. As our know-
ledge of the fate of the insulin in the organism is restricted, experiments, as reported 
by you. demonstrating differences in the chemical behaviour between labeled and 
non labeled insulins are very useful. Thus the distribution of the insulin in the orga-
nism may be heavily influenced by changes due to the labeling of the insulin molecule. 
K.. JØRGENSEN : 1 must answer that I have not investigated that point, but since 
it seems that the radioiodine is really protein-bound in both preparations the chro-
matographical differences may be due to different distributions of iodine in the 
insulin molecule. I can only say that in the 125I-insulin prepared by the present 
method nearly all of the radioactivity is present in the A-chain. 
R. S. YALOW (New York) : Can labeled pork insulin be used as tracer for beef 
insulin or vice versa in crystallization experiments — i.e. can you crystallize to 
constant specific activity with the heterologous species ? 
K. JØRGENSEN : I must answer that I have only performed some few experiments 
of the mentioned kind, but it seems like mixtures of labeled insulin of one species 
and carrier insulin of an other species do not crystallize with constant specific radio-
activities. Therefore, when I check my 125I-insulin preparations I always use carrier 
insulin of the same species as the labeled insulin in the crystallization process. 

VERGLEICH ZWISCHEN BIOLOGISCHER 
UND RADIO-IMMUNOLOGISCHER INSULINBESTIMMUNG 
H. DITSCHUNEIT, J. BEYER, F. MELANI, K. SCHÖFFLING, M. TELIB und E. F. PFEIFFER 
Abteilung für Klinische Endokrinologie, l. Med. Univ. Klinik 
Johann Wolfgang Goethe-Universität, Frankfurt!Main, Deutschland 
ABSTRACT 
From the results of comparative insulin assays in normal and pancreatectomized 
dogs deprived of their hypophyses, as well as in small pancreas portions incubated 
"in vitro" and stemming from rabbits, and in human adults and newly born, such com-
parisons being made with isolated fat tissue, rat diaphragm and by the radioimmu-
nological method, the following conclusions were arrived at : 
1) The different insulin values obtained by the biological and the radioimmunological 
methods cannot be explained only by a different specificity of those methods. Pro-
bably they must for a large part have originated in qualitatively different proper-
ties of endogeneous insulin. 
2) It will probably be immunologically impossible to measure all of the insulin pre-
sent in the serum, while in case of application of biological methods still other 
substances having an insulin-synergistic effect on metabolism must be taken into 
consideration. 
3) It will not be possible to achieve clarification of problems of insulin metabolism 
by the highly sensitive, very accurate and rather simple radioimmunoassay alone. 
For the time being, it is still unavoidable to have recourse to biological methods 
too, among which the fat tissue method offers a maximum of advantages. 
ZUSAMMENFASSUNG 
Aus den Resultaten vergleichender Insulinbestimmungen an normalen und 
pankreatektomierten hypophysenlosen Hunden sowie an in vitro inkubierten Pan-
kreasstückchen von Kaninchen und an erwachsenen Menschen und Neugeborenen 
mit dem isolierten Fettgewebe, Rattendiaphragma und radioimmunologischem 
Verfahren ergeben sich folgende Schlußfolgerungen : 
1) Die unterschiedlichen mit biologischen und radioimmunologischen Methoden 
gemessenen Insulinwerte sind nicht allein mit einer unterschiedlichen Spezifizität 
der Methoden zu erklären. Sie werden zu einem großen Anteil wahrscheinlich 
auf qualitativ differente Eigenschaften des endogenen Insulins zurückzuführen 
sein. 
2) Immunologisch läßt sich wahrscheinlich nicht das gesamte im Serum vorhandene 
Insulin messen, während bei Anwendung biologischer Methoden noch andere, 
auf den Stoffwechsel insulinsynergistisch wirksame Substanzen in Erwägung 
gezogen werden müssen. 
3) Aufklärungen von Problemen des Insulinstoffwechsels werden nicht mit den 
hochempfindlichen, äußerst genauen und technisch sehr einfachen radioimmu-
nologischen Insulinbestimmungsverfahren allein zu erreichen sein. Auch bio-
logische Verfahren müssen z.Zt. noch eingesetzt werden, von denen die Fettge-
websmethode die größten Vorteile bietet. 
336 H. DITSCHUNEIT, J. BEYER. F. MELANI. K. SCHÖFFLING, M. TEL1B UND E. F. PFEIFFER 
Insulinbestimmungen mit biologischen Methoden führen bei Verwendung 
des isolierten Fettgewebes und Diaphragmas von Ratten zu unterschiedlichen 
Resultaten. Diese wiederum unterscheiden sich sehr wesentlich von den mit radio-
immunologischer Methodik gewonnenen Ergebnissen. Die Ursache für diese Diskre-
panzen könnte in einer unterschiedlichen Spezifität der einzelnen Methoden, aber 
auch in differcnten Eigenschaften des im Blut zirkulierenden Insulins im Vergleich 
zu kristallisierten Insulinpräparationen begründet sein. Um näheren Aufschluß 
über diese Probleme zu erhalten, wurden vergleichende Untersuchungen mit dem 
isolierten Rattendiaphragma und Fettgewebe sowie dem radioimmunologischen 
Verfahren durchgeführt. 
Die Bestimmungen erfolgten an normalen und pankreatektomierten Hunden, 
ferner an in vitro inkubierten Pankreasstückchen von Kaninchen sowie an erwach-
senen Menschen und Säuglingen. 
METHODIK 
Die Sera und Inkubationslösungen der isolierten Pankreasstückchen wurden 
unmittelbar nach der Gewinnung eingefroren und bis zur Insulinbestimmung 
bei —20° C aufbewahrt. 
Die Insulinbestimmung mit dem isolierten Rattendiaphragma erfolgte exakt 
nach der zur Zeit von Vallance-Owen (I) angewendeten Arbeitsvorschrift. 
Die Bestimmung am isolierten Rattenfettgewebe führten wir nach dem von 
Martin, Renold und Dagenais l2) angegebenen Prinzip in einer technisch leicht 
modifizierten Weise durch (3). 
Die radioimmunologiselle Insulinbestimmung erfolgte nach dem von Yalow 
und Berson (41 entwickelten Prinzip in einer kürzlich von Melani und M. <5) beschrie-
benen Modifikation. 
Bei den Untersuchungen an Hunden konnte nur ein Teil der mit dem Fettge-
webe bestimmten Sera auch gleichzeitig mit dem Diaphragma und radioimmuno-
logisch gemessen werden. 
Die Anordnung der Versuche und der Houssaypräparationen sowie die Serum-
extraktionen erfolgten entsprechend den bereits früher von uns mitgeteilten Ver-
fahren |6· 12). 
Die Meerschweinchen-Anti-Insulin-Sera wurden in der früher von uns angege-
benen Weise gewonnen (5). 
Bei den in vitro-Versuchen über die Insulinfreisetzung isolierter Pankreasstück-
chen erfolgten die Insulinbestimmungen immer gleichzeitig mit der Fettgewebs-
methode und dem radioimmunologischen Verfahren. Die verwandte Technik 
entsprach unserer früheren Mitteilung U3). 
Bei den Versuchen am erwachsenen Menschen über den Einfluß intravenöser 
Glukosebelastungen (0,33 g/kg) auf den Seruminsulingehalt wurde die ILA nur 
am Fettgewebe und nicht am Diaphragma gemessen. Gleichzeitig erfolgte die Be-
stimmung aber auch in allen Serumproben mit dem radioimmunologischen Ver-
fahren. Die Messungen wurden unmittelbar vor sowie 15 und 30 Minuten nach der 
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Glucoseinjektion vorgenommen. Zum 45­Minutenzeitpunkt bestimmten wir nur 
das Immunoinsulin. 
Bei 104 Säuglingen stoffwechselgesunder Mütter, die nach dem Geburtsgewicht 
von weniger und mehr als 4.000 Gramm in zwei Gruppen unterteilt wurden und 
ferner bei 6 Säuglingen von diabetischen und prädiabetischen Müttern führten 
wir ebenfalls Insulinbestimmungen mit dem Fettgewebe und gleichzeitig auch mit 
dem radioimmunologischen Verfahren durch. Die Bestimmungen erfolgten im 
Nabelschnurvenenblut. das unmittelbar nach der Entbindung gewonnen wurde. 
ERGEBNISSE UND DISKUSSION 
Im Blut von 34 Hunden, das an mindestens zwei verschiedenen Tagen inner­
halb einer Woche entnommen wurde, ergab sich für insgesamt 98 Einzelproben 
mit dem Fettgewebe ein mittlerer Wert für 1: 2 verdünnte Sera von 236 + 18 μΕ/ml. 
Bei 21 dieser Hunde wurde in den gleichen Proben auch das Immunoinsulin 
bestimmt. Für 37 Proben errechnete sich für konz. Serum ein Mittelwert von 
21,6 + 2,4 μΕ/ml. der damit weniger als 1/10 des ILA­Meßwertes beträgt. 
Am Diaphragma steigern 33 unverdünnte Sera der gleichen 21 Hunde die 
Glukoseaufnahme um 8,1 + 0,7 mg %/10 mg Trockengewicht. Dieser Effekt läßt 
sich wegen des erheblichen methodischen Fehlers der Diaphragma­Methode nur 
grob mit dem Effekt von krist. Insulin vergleichen. Die in jedem Versuchsansatz 
zur Kontrolle gleichzeitig bestimmte Wirkung von 1.000 μΕ/ml Insulin auf die 
Glukoseaufnahme von 3 Zwerchfellhälften betrug 12 bis 15 mg %/10 mg Trocken­
gewicht, so daß unter Zugrundelegung der von Vallance­Owen et al. t l4) für die 
Dosis­Wirkungsbeziehung am Zwerchfell gefundenen Gesetzmäßigkeiten dieser 
Serumeffekt schätzungsweise im Bereich von 500 μΕ/ml krist. Insulin liegt und 
damit ungefähr der Wirkung von unverdünntem Serum am Fettgewebe gleichkommen 
könnte. In Relation zu dem gemessenen Immunoinsulin liegt dieser Meßwert am 
Muskelgewebe aber bei den Versuchen am Fettgewebe wie um ein Vielfaches höher. 
Nach Entfernung der Hypophyse und des Pankreas fallen die mit allen drei 
Methoden meßbaren Insulinaktivitäten ab. Aber während das Immunoinsulin 
praktisch vollständig verschwindet, persistiert ein großer Teil der ILA am Fettge­
webe und auch am Diaphragma während der gesamten bis auf über 4 Monate 
ausgedehnten Beobachtungszeit. Dieser Anteil der ILA, ebenso wie die Differenz 
zwischen Immunoinsulin und ILA am Fett­ und Muskelgewebe von normalen 
Hundesera, kann aber nicht allein einem unspezifischen Serumeffekt zugeschrieben 
werden. Diese Annahme wird durch die folgenden z. T. von Professor Pfeiffer gestern 
bereits genannten Untersuchungsresultate unterstützt . 
1. Mit Insulin­Antiserum läßt sich die ILA von normalen Hunden am Diaphragma 
und auch am Fettgewebe um einen weit größeren Betrag hemmen, als immu­
nologisch zu messen ¡st. 
2. Die ILA des Serums von pankreatektomierten Hunden, in denen kein Immu­
noinsulin zu finden ist, kann durch Antiserumzusatz weiter vermindert werden. 
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3. Mit Insulinextraktionsverfahren (Salzsäure-Alkohol) kann ebenso wie aus Nor-
malserum auch aus dem Serum von Houssay-Hunden ILA extrahiert werden, die 
nahezu komplett mit AS hemmbar ist. 
4. Die ILA des Houssayserums läßt sich durch Cystein komplett inaktivieren (vgl. 
auch Steinke et al., 1963 <15)). 
Bei vergleichenden Untersuchungen mit dem Fettgewebe und der radioimmu-
nologischen Methode über die Beeinflussung der Insulinaktivitäten durch Glukose-, 
Tolbutamid- und Wachstumshormonbelastungen ergeben sich bezüglich der zu 
beobachtenden Maxima Unterschiede (Abbildung 1). Nach Injektion von Glukose 
erreicht sowohl die ILA als auch das Immunoinsulin nach 15 Minuten das Maximum. 
min 0 15 30 45 50 mmO 15 30 45 60 75 90 60 120 180 240 300 360 
ABBILDUNG 1. — ILA and IMI values in peripheral venous blood of normal dogs following injec-
tion of glucose (1 g/kgi.v.) [A], tolbutamide (100 mg/kg i.v.) [B], and human growth hormone 
(5 mg i.v.) [C], n = number of dogs. 
Nach Tolbutamidgabe liegt das Maximum der ILA dagegen bei 30 Minuten, wäh-
rend das des Immunoinsulins bereits nach 15 Minuten erreicht wird. Weit größere 
Differenzen treten nach STH-Belastung auf. Der höchste ILA-Wert ist dabei erst 
nach ungefähr 4 Stunden der höchste Weit für das Immunoinsulin dagegen bereits 
nach 2 Stunden zu messen. 
Diese Differenzen sind nach den Untersuchungsresultaten an Houssay-Hunden 
wahrscheinlich nicht einer unzureichenden Spezifität der biologischen oder radio-
immunologischen Methoden, sondern irgendwie verschieden gearteter Insulinakti-
vitäten zuzuschreiben. Für diese Annahme sprechen auch unsere Resultate an in 
vitro in Pufferlösung inkubiertem Pankreasgewebe (Abbildung 2). 
Das von dem Gewebe an das Inkubationsmedium abgegebene Insulin ergibt 
am Fettgewebe einen 6-fach höheren Wert als immunologisch zu erfassen ist. Nach 
Stimulation der Insulinabgabe durch Zusatz von Glukose steigt das Immunoinsu-
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lin in 18 Versuchen im Mittel um 270 μΕ/ml an, während die ILA eine Steigerung 
um 1.000 μΕ/ml erfährt. Dennoch lässt sich durch Zusatz von Insulin­Antiserum 
die gesamte ILA hemmen, so dass die immunologischen Eigenschaften des aus 
dem isolierten Pankreasgewebe abgegebenen Faktors erwartungsgemäss kristalli­
siertem Insulin gleichen. Bezüglich der Reaktionsenergie mit dem Antikörper scheint 
aber gegenüber krist. Insulin ein wesentlicher Unterschied zu bestehen, da ande­
renfalls die biologischen und radioimmunologischen Messwerte identisch sein 
müssten. 
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ABBILDUNG 2. — IMI and ILA of the incubation medium of isolated pieces of rabbit pancreatic 
gland and the effect of guinea-pig anti-insulin (AS) on ILA. η = number of experiments. 
Für die sehr unterschiedlichen absoluten biologischen und radioimmunolo­
gischen Messwerte beim Menschen haben verschiedene Insulinaktivitäten wahr­
scheinlich ebenfalls grösste Bedeutung. Im Nüchternserum von 98 Personen, bei 
denen es sich um Stoffwechselgesunde, Adipöse und Prädiabetiker handelt, ergab 
sich für die ILA am Fettgewebe ein Mittelwert von 237 μΕ/ml (Abbildung 3). Für 
das Immunoinsulin beträgt der Mittelwert dagegen nur 15 μΕ/ml. Nach intra­
venöser Glukosebelastung mit 0,33 g/kg steigt das Immunoinsulin innerhalb von 
15 min. bedeutend stärker an als die ILA. Bei Aufteilung des Gesamtkollektivs 
nach dem aus der Glukosebelastung berechneten Assimilationskoefli.zien.ten in 
zwei Gruppen finden wir bei 38 Probanden mit einem k­Wert unter 1,3 eine pro­
longierte, über den gesamten Beobachtungszeitraum von 45 Minuten anhaltende 
Steigerung des Immunoinulins, die aber gleichfalls auch bei der ILA zu erkennen 
ist. Bei der Gruppe mit k­Werten über 1,3 ist der Anstieg beider Messwerte nur 
kurzdauernd. Auf die Bedeutung dieser Befunde für den Zusammenhang zwischen 
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ABBILDUNG 3. — IMI and ILA following glucose injection (0.33 g/kg B. W., i.v.) in persons 
divided in two groups with k­values below (A) and above (B) 1.3. η = number of persons. 
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ABBILDUNG 4. — Insulin im Nabelschnurvenenblut bei Neugeborenen Bestimmung mit isoliertem 
Fettgewebe (oben) u. immunolog. (unten). 
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gestörter Blutzuckerregulation und erhöhtem Insulinspiegel bei Prädiabetikern 
soll hier nicht näher eingegangen werden. 
Die Ergebnisse der vergleichenden Untersuchungen an Säuglingen sind in der 
Abbildung 4 wiedergegeben. Das Immunoinsulin beträgt auch in diesen Versuchen 
bei den verschiedenen Gruppen nur etwa 1/10 der gemessenen ILA. Bei Neuge-
borenen mit einem Geburtsgewicht über 4.000 g ergeben sich mit beiden Verfahren 
etwa zweifach höhere Werte als bei der Kontrollgruppe. Die Kinder von diabe-
tischen und prädiabetischen Müttern weisen dagegen relativ höhere ILA-Werte 
als immunologisch messbare Werte auf. 
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DISCUSSION 
J. R. M. FRANCKSON (Bruxelles) : Je voudrais demander au Dr. Ditschuneit 
s'il a eu l'occasion d'étudier les modifications du taux sanguin de l'insuline immu-
nologiquement dosable dans les heures qui suivent immédiatement la pancréa-
tectomie. D'après les résultats fragmentaires que nous avons obtenus, il nous semble 
que la demi-vie que nous avons observée dans le sang portai est nettement supérieure 
aux valeurs usuellement signalées dans le sang périphérique. 
H. DITSCHUNEIT : Die ersten Messungen des Insulinspiegels mit der immu-
nologischen Methode ergfolgten erst 24 Stunden nach der Operation, und zu diesem 
Zeitpunkt konnten wir kein Insulin mehr nachweisen. Über die Halbwertszeit des 
Immunoinsulins lässt sich daher aus unseren Versuchen kein Anhaltspunkt gewinnen. 
K. BRUNFELDT (Gentofte) : Haben Sie ein Kontrollversuch mit Extrakten von 
Pankreas ohne Inselgewebe ausgeführt ? Denn es muss kontrolliert werden, ob 
die Werte, die man mit der Fatpad-Methode erreicht, nicht von anderen Substanzen 
als Insulin bedingt sind. 
H. DITSCHUNEIT : Kontrollversuche mit Pankreasgewebe, das keine Inseln 
enthält, haben wir nicht durchgeführt. Wir sind aber sicher, dass aus dem inku-
bierten Pankreasgewebe keine insulinpotenzierenden Substanzen abgegeben wurden. 

A SIMPLIFIED INSULIN RADIOIMMUNOASSAY METHOD 
L. G. HEDING 
Novo Research Institute. Copenhagen, Denmark 
ABSTRACT 
Insulin-antibody-complex is separated from free dissolved insulin by preci-
pitation with 80 percent ethanol. With this technique the sources of error found 
with the double antibody reaction are avoided and the procedure is rapid and easy. 
With the simplified method it was found that any of the ions Cl~, N03~, HCOO~, 
CHgCOO-, and I~ increases the insulin-antibody reaction rate and the amount 
of antibody-bound insulin. The following ions were found inactive : Na+, K+, NH4+, 
S04—, HP04—, BO3 , citrate, and oxalate. 
The insulin content of serum and plasma from normal persons has been deter-
mined and the influence on the insulin content of different anticoagulants used for 
the preparation of plasma investigated. 
The separation of free and antibody-bound insulin in the immunochemical 
determination of insulin has been performed in five different ways : 
1) Electrophoretic and chromatographic separation, the original method introduced 
by Berson and Yalow (1, 2). 
2) By means of the second antibody reaction between insulin-antibody-complex 
and anti-y-globulin (3, 4 · 5). 
3) Sodium-sulfite precipitation of insulin-antibody-complex in the presence of 
15 percent urea and carrier protein <6). 
4) Separation of the free insulin from the antibody-bound insulin by means of 
an anion-exchange resin (7' 8) or dextran-coated charcoal (9). 
5) Separation by a gel-filtration, using Sephadex G 75 <10). 
Besides these five methods of separation, which have been used in the immu-
noassay, a few other separation methods have been described. 
Moloney and Aprile (11) have reported a semi-quantitative precipitation of 
the insulin-antibody-complex by 25 percent ethanol at —5° C. The insulin concen-
tration was approximately I unit/ml. 
Gordis (12) has used 79 percent ethanol containing salt and potassium hydroxid 
and a temperature of—10° C for the precipitation. 
The obvious simplicity of an ethanol precipitation in the immunoassay pro-
cedure motivated our present study. 
As a reference we used an immunoassay method based upon the double-anti-
body principle. 
All reaction-media contained albumin and 0.04 M sodium phosphate at a 
pH of 7.4 in the reference assay as well as in the experimental study. 
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First the solubility of free labelled insulin was examined using various concen­
trations of ethanol. The curve below in Figure 1 shows that the insulin (approxi­
mately 120 μυ/ml) was completely soluble at concentrations of ethanol as high 
as 84 percent. The amount of precipitated antibody­bound insulin was then mea­
sured in another series with the results shown by the two other curves. The upper 
curve was obtained with anti­insulin serum diluted 1:400. The middle curve corres­
ponds to the usual dilution 1:6,000. Precipitation was considered complete at con­
centrations above 79 percent ethanol since the upper limit reached at this concen­
tration is identical with the amount of precipitated insulin found with the double­
antibody method used as a check. The values obtained with the double­antibody 
method are plotted at the ordinate. Furthermore it was shown that the chromato­
graphic method gave the same results as obtained with the ethanol method. A con­
centration of 81 percent ethanol was chosen for the separation of free and anti­
body­bound insulin. Other solvents, methanol, propanol, dioxan, and acetone 
have been tried, but none of them could be used for the separation. 
84 * ethanol 
í.ci ml 
FIGURE 1. — Solubility of '­"'I­insulin and '­'I­insulin­antibody­complex at various ethanol con­
centrations. 
It is essential that the ethanol is added after the reaction of insulin with anti­
body has taken place since this reaction is immediately stopped by the addition 
of ethanol. Actually the course and rate of reaction can be studied by adding the 
ethanol at different times. 
It could be suspected that the precipitated insulin­antibody­complex would 
break down releasing free insulin into solution, and this process was found to occur 
to some degree, but not within the first two hours. 
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In the experiments with standard solutions of insulin it was observed that the 
insulin antibody reaction was contigent upon the presence of specific ions. 
As the anti-serum which was used in the reactions was diluted 1.6,000 with 
buffer it practically did not contain any of the ions from the serum, and as the pro-
cedure did not involve any addition of serum or plasma the reaction could be carried 
out in a pure buffer medium where all concentrations of ions could be controlled. 
In this way it was possible to investigate the influence of certain ions of the anti-
body reaction. 
cpm 125 I in precipitate 
m.eqv./l 
FIGURE 2. — Effect of KCl and K : S0 4 on the insulin-antibody reaction 
Figure 2 shows the effect of the addition of KCl and K2S04 in equivalent 
amounts. It is seen that only the KCl increased the amount of antibody-bound 
insulin. There was a sharp increase in the interval 0-20 m. eq./l, and a déconcentra-
tion above 20 m. eq./I gave no further rise in the amount of antibody-bound insulin. 
Figure 3 shows the effect of NaCl and Na2HP04 in equimolar concentrations. 
It is seen that Cl~, but neither phosphate nor Na+-ions were effective. It was found 
that other monovalent anions such as nitrate, formate, acetate and iodide had the 
same effect as chloride, whereas sulphate, phosphate, borate, citrate, oxalate, ammo-
nium, sodium and potassium had none or very little effect. All the active ions men-
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tioned gave the same maximum amount of antibody-bound insulin when the concen-
tration of any of the ions was 20 mmol./l or higher. 
It is therefore concluded that a certain minimum concentration of some spe-
cific ions is necessary for the completion of the reaction under the conditions of 
the assay. 
Errors in the immunoassay are likely to occur if the concentration of active 
ions in the standard solutions is not sufficiently high. 
1 i n prec ip i ta t e 
NaCl 
NaJIPO, 2 4 
0 2 o **<> m.eqv./l 
FIGURE 3. — Effect of NaCl and Na2HP04 on the insulin-antibody reaction 
If ethanol is used in the immunoassay procedure it is possible to determine 
the amount of free as well as antibody-bound insulin very easily. When plasma 
or serum is analysed a voluminous precipitate of plasma protein is formed after 
addition of ethanol, and some of the free insulin will naturally be present in the 
precipitate containing appreciable amounts of solution. Therefore, it is preferable 
to measure the activity in the supernatant liquid instead of in the precipitate. 
Some of the free insulin might be adsorbed to the ethanol protein precipitate. 
This possibility therefore was checked. Known amounts of 125I-insulin were added 
to buffer in one series and to serum and plasma in another. Ethanol was then added 
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and 125I-insulin measured in the supernatant liquids after centrifugaron. The re­
sults were identical in the two series, and the amounts of adsorbed 125I-insulin were 
small and insignificant. However, adsorption should be remembered as a possible 
source of error under other conditions than those already checked. 
With the ethanol precipitation it is possible to avoid errors which are due to 
an incomplete second antibody reaction. Especially in serum samples it can be very 
difficult to obtain complete precipitation of the antibody complex even with a high 
concentration of precipitating anti-serum. 
Figure 4 shows a standardcurve based upon counting of supernatant aliquots. 
The straight line relationship illustrates that the amount of antibody-bound 125I-
insulin is proportional to the amount of antibody not blocked by the standard 
insulin added in the first step. 
i k cpm in supernatant 
3ooo 
20GO" 
15ο μ\] insulin/ml 
FIGURE 4. — Standardcurve 
A number of serum and heparinized plasma samples from fasting normal 
persons have been analyzed after storage at —30°C. The values found were between 
0 and 35 μ υ per ml. 
Increasing amounts of different anticoagulants were then added to serum 
and standard-solutions of insulin in order to see if any of the added anticoagulants 
would interfere, e.g. by disturbing the antigen-antibody reaction. No influence 
on the immunological activity of the samples or on the antibody reaction could 
be shown as a result of the addition of heparin, citrate, oxalate and EDTA. The 
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maximum concentration of anticoagulant added was approximately 5 times the 
concentration normally used. 
The conclusion is that in the immunoassay procedure insulin­antibody­com­
plex can be separated from free insulin by precipitation with ethanol. The results 
found with this method were identical with the results obtained with the double 
antibody reaction and the chromatographic method. 
It was found that monovalent anions in a concentration of 20 mmol./l or higher 
were necessary for the completion of the insulin­antibody reaction. 
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DISCUSSION 
C. N. HALES (Cambridge) : Did I understand you to say that if you are carrying 
out a methanol precipitation in the presence of plasma, some of the insulin was 
carried down with the plasma proteins and the error due to this was avoided by 
counting the supernatant ? 
L. HEDING : The carried down free 125I-insuIin is a consequence of a certain 
amount of solvent present in the precipitate and not of a degradation or binding. 
But since the amount of labeled insulin in aliquotes of the supernatants, when 125-I 
insulin and plasma in one series and buffer in another series are added, is identical, 
no unspecific binding of 125I-insulin to the plasma proteins can be shown to occur. 
K. BRUNFELDT (Gentofte) : I cannot understand your troubles with the two 
antibody-methods which have now been in use for two years in our institution. 
The reliability allows the calculation of the results to be carried out automatically, 
by conversion of the scaler decimal output to decimal binary code on punched 
tape for later computer treatment, also comprising statistical calculations based 
on the double determinations. 

BINDING OF RADIOIODINATED INSULINS WITH THE RAT 
DIAPHRAGM IN VITRO (*) 
W. MALAISSE and J. R. M. FRANCKSON 
Laboratoire de Médecine Expérimentale, Université de Bruxelles, Belgium 
ABSTRACT 
In vitro studies of the rat diaphragm show that the fixation of different radio-
iodinated insulins can be divided into two stages : a rapid and reversible binding 
occurring in the early minutes of incubation and a slow process easily isolated from 
the 10th minute onwards. The results of numerous experiments are compatible with 
the hypothesis that the first phenomenon is an adsorption process, poorly specific. 
Incubation or pretreatment of insulin with guinea-pig anti-insulin antibodies 
inhibits the tissue fixation of the labeled compounds, revealing an identical immuno-
logical behaviour of cristalline insulin and of the radioactive fraction which binds 
to the muscle. 
On the contrary, cristalline insulin, whatever the concentration or the incubation 
conditions, does not reduce the fixation of labeled material on the diaphragm. This 
lack of competition between the hormone and the radioisotopes is discussed. 
Previous studies in vitro carried out with labeled insulins, were intended either 
to detect their subcellular distribution (1·3·4» or to compare tissue binding with 
metabolic activities ϋ2·13·14>. On the contrary, our aim was to characterize the rate 
of binding of iodo-insulins on muscle in a simplified model. 
The experiments were performed on hemidiaphragms of fasted rats weighing 
150-250 g, incubated at 37.6° C in Krebs-Ringer bicarbonate buffer in a Dubnoff 
metabolic shaker <δ). At the end of incubation, the diaphragms were rapidly dried 
between filter papers, washed twice for 10 seconds in buffer and dried again in order 
to avoid contamination due to the diffusion of the radioactive materials in the tissues 
interstial water (7). The diaphragms were then put into glass tubes and the radio­
activity directly counted in a crystal scintillator, well type (6). 
The 131I-insulins added to the incubation medium had a specific activity ranging 
from 2.5 to 10 mC/mg, a mean iodination degree of 1 atom per mole (M.W. 6,000), 
an immunological purity of 90-92 %, a biological activity always superior to 80 % 
of the original crystalline lot (diaphragm and fat pad bioassays). They were generally 
prepared by elementary iodine oxydation (10) (**) and sometimes by catalytic oxy­
dation l u ) (***). The 125I-insulins were obtained by the catalytic procedure (***); 
(*) Work performed under Association Contract EURATOM-ULB-University of Pisa, 
No. 026-63-4 BIAC. 
(**) Farbwerke Hoechst, Frankfurt, Germany. 
(***) Sorin, Torino, Italy. 
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their mean iodination degree was superior to 3 atoms per mole, their biological 
activity practically abolished and their immunological properties markedly impaired. 
The tedious problem of measuring the surface of the diaphragms was ruled out 
according to data obtained in a preliminary work (5) where in a relationship of direct 
proportionality was found between the surface area of the diaphragms (S, expressed 
in mm2) and a function of their fresh weight (P, expressed in mg) : 
S = 1.24 X P2/3 
The characteristics of the binding of131I-insulin to the diaphragm may be summa­
rized as follows : 
1. Binding is proportional to the duration of dipping of the diaphragm in the 
insulin medium (Figure 1), but the rate of binding decreases progressively and, for 
instance, between the 15th and the 90th minute represents only 1 % of the rate 
recorded during the first minute of dipping. 
0 1 5 10 
minutes 
FIGURE 1. — Relationship between tissue binding of I31I-insuIin (expressed in cpm per hemidiaphragm 
and duration of dipping (min). Figures given are the mean and the extreme values. 
2. Whatever the duration of the dipping, the binding is directly proportional to 
the surface area of the diaphragms, as estimated by the function P2'3. Figure 2 illus­
trates the results observed for 2 different periods of dipping. 
3. A straight line relationship between the amount of 131I-insulin bound to the 
muscle and its concentration in the incubation medium can be demonstrated for a 
range of concentrations from 10 μυ/ml up to 20 U/ml and for periods of dipping 
lasting from 30 seconds to 90 minutes (Figure 3). 
4. The amount of bound radioactivity is very small : less than 5 % of the medium 
concentration being bound by surface unit. However this bound fraction comes 
mainly from 131I-insuIin and not from the accompanying impurities since an excess 
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FIGURE 2. — Relationship between 131I­insulin binding (cpm) and the surface area of the diaphragms 
(P2'3). Lower regression : after 30 sec dipping; upper regression, 90 min. 
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μ υ / ml 
FIGURE 3. — Relationship between 131I­insulin binding (expressed incpm/surface unit) and I31I­insulin 
concentration in the incubation medium (¡iU/ml). Clear circles correspond to 30 sec dipping; 
black circles, to 30 min). 
356 W. MALAISSE AND J. R. M. FRANCKSON 
of guinea-pig anti-insulin serum added to the medium prior to the dipping of the 
diaphragms, prevents the binding of the radioactivity up to 85 % of the control 
value (6). 
5. The analysis of the curve expressing the binding of 131I-insulin in respect to 
dipping time allows to define 2 exponential components (Figure 4) : the first one 
corresponding to a rapid association of the radioisotope with the tissue, only influences 
the curve during the 10 first minutes; the second one beginning with a delay of about 
10 minutes represents a slow association process which tends to saturation around the 
3rd hour of dipping <7). None of these processes is the expression of diffusion as 
recently claimed (2), since the rapid washing and drying systematically performed 
before counting can clear the tissues interstitial fluids of the radioactive materials(7). 
03 
1 5 10 15 30 t min 90 
FIGURE 4. — 13II-insulin binding (F in cpm/P2 '3) in respect to dipping time (min). In the upper part 
of the graph are indicated the evolution of the rapid (A') and the slow (F-A') association pro-
cesses. In the lower part of the graph are plotted the semilogarithmic lines representative of 
these inverse exponential processes. Given figures are the mean and S.E.M. 
The removal of the bound radioactivity can be achieved by washing diaphragms 
in buffer for prolonged periods. Figure 5 illustrates the decrease of the bound radio-
activity in relation to the duration of the washing for a large number of diaphragms 
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FIGURE 5. — Study of the removal of the 131I-insulin bound to the diaphragm : relationship between 
the bound radioactivity (cpm) and the duration of the washing in buffer. Figures given are the 
mean and S.E.M. 
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Simultaneous binding of different iodo-insulins to the rat diaphragm (mean and 
extreme values). 
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pretreated with 13,I­insulin in identical conditions. As easily noticed, this curve is the 
reversed image of the binding curve shown in Figure 1 ; it can also be split up in 
2 exponential components whose slopes come very near to those extracted from the 
binding curves. 
6. The association rate of the iodoinsulins with the muscle does not run parallelly 
to their biological properties : incubation of diaphragms in buffer containing equal 
concentrations (in μgN) of 131I­insulin (1 at./mol.) and 125I­insulin (3 at./mol.) 
reveals that the binding of the heavy­iodinated compound is at any time the more 
marked one (Figure 6). 
The poor specificity of these processes is also emphasized by its possible inhibition 
by non specific agents such as albumin added to the incubation medium (9) or by 
inert substrates <8·ιβ>. 
These data support the working hypothesis that the binding of iodoinsulins to 
muscle could be accounted by adsorption. All the characteristics required for this 
unspecific phenomenon are present : rapidity, reversibility (equal rates of adsorption 
and elution); direct proportionality to the surface (even for long periods of contact), 
stability of the ratio between the fraction bound to tissue and the medium concen­
tration (equivalent to an actual partition constant), low value of this ratio (quan­
tity bound to the interphase being negligible), possible inhibition by non specific 
competition. According to this hypothesis, in vitro association of I­insulin with 
muscle might be represented by a simple model : the membrane surface, locus of the 
rapid adsorption and desorption phenomena, would separate the incubation medium 
from a deeper membrane pool, where the exchanges of I­insulin or its catabolites 
and their entry inside the cell would proceed at lower rates. This concept is in con­
cordance with autoradiographic studies <151 and with analysis of the intracellular 
distribution of iodoinsulins (1). 
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ANALYSIS OF PLASMA DISAPPEARANCE 
CURVES OF CRYSTALLINE 
AND RADIOIODINATED INSULINS (*) 
Y. ARNOULD, C. DELCROIX, E. RASIO, Η. A. OOMS and J. R. M. FRANCKSON 
Laboratoire de Médecine Expérimentale et Laboratoire de Médecine Nucléaire, 
Université de Bruxelles, Belgium 
ABSTRACT 
Different amounts of cristalline insulin (0.1 to 100 U/kg) or of radioiodinated 
insulins (0.4 to 8 mC) have been rapidly injected by the venous route to normal 
anesthetized dogs, maintained in normoglycaemia by glucose compensation. Blood 
samples were collected from the 2nd minute to the 6th hour following injection. 
Plasma insulin was estimated by radioimmunoassay and by bioassays; plasma insu­
linic radioactivity, by paper chromatography and immunochromatography. The blood 
disappearance curves have been submitted to mathematical analysis (digital computer). 
The disappearance curves of cristalline insulin (radioimmunoassay) can be 
expressed by a sum of exponentials, variable according to the injected amounts. The 
shape of the radioinsulin curves are different, they tend to an assymptote differing 
from zero and can only be expressed by a sum of exponentials and of one constant. 
Simultaneous injections of a same tracer of radioinsulin with graded loads of 
cristalline insulin, only produce a small change in the disappearance rate of the 
labelled compound. Several hypotheses can be forwarded to explain the poor compe­
tition between both types of insulins. 
The kinetics of the blood disappearance of radioiodinated insulins following 
rapid intravenous injection has been but little studied. Most of the workers isolated 
one segment of the disappearance curve generally corresponding to the 2 first hours : 
they assumed it was a simple exponential and compared its characteristics in normal 
and diabetic subjects α · 2· 3· 4· 5·10· Π) . 
This procedure is rather arbitrary. Indeed, in semi­logarithmic coordinates, 
isolation of one segment in a fall­off curve may easily simulate a straight line whatever 
the equation of the whole curve. Moreover, no one is authorized to draw directly 
by graphical procedure an exponential out of a complex curve if the phenomenon 
has not been studied long enough to allow isolation of the final slope. 
The aim of the work we present was to study the plasma disappearance of both 
crystalline and radioiodinated insulins for a long period of time in order to obtain 
a valid mathematical analysis of the curve. This was achieved by injecting in 10 sec 
into the femoral vein of healthy anaesthetized dogs (20­30 kg) 0.4 to 0.8 mC of iodi­
nated insulin and by sampling arterial blood specimen from the 2nd up to the 240th 
(*) Work performed under the Association Contract EURATOM­ULB­University of Pisa 
No. 026­63­4 BIAC. 
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or to the 420th minutes following injection. In most of the experiments, the131I-insulin, 
prepared by elementary iodine oxydation, had a mean specific activity of 10 mC/mg, 
a mean iodination degree of 1 atom per mole (assumed M.W. : 6,000), an immuno-
logical purity of about 90-92 % and a biological activity generally ranging from 80 to 
90 % of the crystallin lot, as tested on the rat fat pad. Graded loads of crystalline 
insulin were simultaneously injected with the radioisotope in several groups of dogs 
so that the total amount of biologically active insulin ranged from 0.1 to 100 U/kg 
body weight. In every case normoglycaemia was maintained throughout the experi-
ment by appropiate glucose infusions. 
Plasma 131I-insulin was isolated by classical paper chromatography t2) (Whatman 
3 MC) in veronal buffer (0.2 M) ; the chromatography was allowed to run horizontally 
for about 4 hours at 12-16° C; the strips were cut in 0.5 cm parts and counted by 
crystal scintillation. The purity of the insulin spots isolated at the different times 
were cheked by chromatography with an excess of guinea-pig anti-insulin serum. 
The shape of the disappearance curves of 131I-insulin is illustrated by Figure 1. 
In cartesian coordinates these curves seemed to tend asymptotically to both axes, 
suggesting an hyperbola. This possibility was ruled out by a digital computer using 
the least squares method and successive iterations. Despite a satisfactory mean square 
240 MIN 
FIGURE 1. — Disappearance curve of plasma I31I-insuIin in cartesian coordinates. I3lI-insulin levels 
are expressed as percentage of ratio between injected amount of 131I-insulin (R) and plasmatic 
volume (Vp). 
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deviation from the hyperbolic curve, this adjustment provoked a consistent distor-
tion of the experimental curve as shown on Figure 2. This forced us to reject the 
hyperbolic function. 
15%. 
10%. 
5% 
^ EXPERIMENTAL CURVE 
.ADJUSTED HYPERBOLIC CURVE 
60 120 180 240 300 360 min. 
FIGURE 2. — Tail part of a plasma 131I-insulin disappearance curve showing the distortion caused 
by the hyperbolic adjustment. 
Therefore, another approach of the formula ruling these curves was attempted 
by the multiexponential analysis. After gross estimation of the different components 
by manual peeling off, a curve fitting was realized with the assistance of a digital 
computer IBM 7040 : a first estimate of the characteristics of each term was obtained 
by a subtraction-type method and the values were finally adjusted by the least squares 
method with a mean precision superior to 0.2 % of initial value (*>. From these cal-
(*) Sample standard error of estimate .v 
. / S C v - y ) 2 / r where y are the experimental 
n — 1 
values (expressed as percentage of initial value), y the corresponding values on the curvilinear regres-
sion, n the number of values. 
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culations, the plasma disappearance of 131I-insulin (y) in respect to time (t) might be 
represented by a sum of 1 constant and 3 exponentials (Figure 3) : 
y = C„ + Cje-K·* -|- C2e~Klt + C3e-Kl« 
DISAPPEARANCE CURVE OF PLASMA I 131 - INSULIN 
( SEMI - LOS. COORD. ) 
_l .79x10-2 t 
2 4 0 MIN 
FIGURE 3. — Semi-logarithmic representation of a disappearance curve of plasma 131I-insulin 
(Figure 1). Results of the multiexponential analysis are indicated in the lower part of the 
graph. 
The final constant (C0) has a small value; it approximated zero in 1/4 of the 
cases (from —0.1 to 0.1 % of initial value) and never exceeded 1.3 %. The first 
exponential removed by peeling off or computer subtraction (CjC-1 ' '), is dominant 
from about the 100th minute up to the end of measurements (240-420 min); it 
can be adjusted with a precision of 0.016% of initial value. The 3rd exponential 
(Cse~K3t), corresponding to a rapid plasma disappearance rate mainly influences the 
curve during the first 15 min following injection. In the middle part of the curve 
(from 15th to about 100th min), the 2 exponentials Cxe~Klt and C2e~K:i are summing 
their effects. 
This multiexponential equation is not compatible with the simple generally 
accepted model in which, after mixing within the extracellular space, radioiodinated 
insulin would undergo irreversible disappearance by renal excretion, hepatic destruc-
tion and tissue uptake. 
Indeed, in such a compartmental model, beyond the mixing period, the plasma 
disappearance should be ruled by a simple exponential whose intercept with the y 
axis should allow an estimate of the extracellular fluids. On the contrary, the multi-
exponential equation implicates feed back to the plasmatic compartment; conse-
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quently each exponential is not a direct expression of an unique physiological process 
but represents the result of the different moves of the radioisotope from and to the 
plasmatic compartment. These implications are supported by the fact that the inter­
cepts with the y axis of the 1st exponential and of the sum of the 1st and 2nd ones 
provide volumes of distribution which do not correspond to a physiological fluid 
compartment. Only from the sum of all intercepts one can approach the plasmatic 
volume, indicating early mixing within the plasma (Table I). 
TABLE I. — Ratio between the injected amount of ,3ll-insulin (R) and the various intercepts 
C,„ C,, C2, C3. In the last column is given the plasma volume (Evans blue). 
R R 
C, C„ + C, A C, C„ i C , + C + CD 
Vp 
Volume 73 + 11 13.6 ± 1.3 5.6 ± 0.4 5.0 ± 0.2 
( % bodyweight) 
The constants (K.,, K2, KL;i) of the exponentials representing the different exchange 
rates of the radioisotope between its pools are rather stable from one animal to 
another and are poorly influenced by the amount of crystalline insulin injected toge­
ther with the labelled compound : the slopes of the regressions of the constants in 
relation to the dose of crystalline insulin are not statistically different from zero 
(Figure 4). Their mean values calculated for the whole group average : 
Kj = 1.36 x IO"2 ±0 .12 χ IO-2 
K, =6 .0 χ IO"2 ± 0 . 8 χ IO"2 
Κ3 = 2 9 χ ΙΟ-2 ± 3 χ ΙΟ"2. 
This lack of influence of large amounts of crystalline insulin upon the exchange 
rates of labelled insulin can be interpreted in different ways : there might either be 
no competition between the 2 compounds, labelled insulin being not a valid tracer 
for in vivo metabolic studies, or no relationship between the size of the pool and the 
exchange rate constants, both crystalline and labelled insulins being assumed identical. 
These hypothesis were checked by studying the plasma disappearance rates of unla­
belled insulin in conditions of administration, doses and time comparable to the first 
experiments. 
Four groups of 3 dogs were injected with graded amounts of crystalline insulin 
ranging from 0.1 to 100 U/kg; plasma insulin was estimated by radioimmunoassay 
using a double antibody system (7). The mean disappearance curves are illustrated 
in Figure 5. 
Curve fitting was performed on all individual curves, except on those correspond­
ing to the smallest dose (0.1 U/kg) owing to the early fall of plasma insulin level to 
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> — 6 . 
_Δ 
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CRYST. INS.: 0.1 1 10 100 U/KG 
FIGURE 4. — Relationship between the amounts of crystalline insulin simultaneously injected with 
131I-insulin and the slopes of the different exponentials (K„ K,, K.,) obtained from the analysis 
of plasma 131I-insulin curves. 
10' 
^U/ML 
10' 
10l 
io-
10' 
io 
60 120 160 2 - 0 300 360 4 2 0 MIN 
FIGURE 5. — Mean disappearance curves of plasma unlabelled insulin (radioimmunoassay) after 
rapid intravenous injection of different loads of crystalline insulin. 
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basal values and hence, to an insufficient number of available experimental points. 
In 7 out of 9 cases, the disappearance curves could be represented by a sum of 3 expo­
nentials but without the constant term C0 (Figure 6). The characteristics of these 
exponentials (intercepts and constants) come very near to those found for labelled 
insulin : 
Kx = 1.65 X 10" 2±0.17 χ IO"2 
K2 = 5.6 X IO"2 ± 0.43 X IO"2 
K 3 = 2 6 . 5 χ 10" 2 ±3.1 X IO"2. 
Here too the volumes determined by the intercepts do not correspond to phy­
siological fluid compartments and, from one animal to another, there is no relation 
between the amount of injected insulin and the constants of the exponentials. The 
major influence of the dose upon the disappearance rate of plasma insulin lays in the 
period during which the curve is the only expression of the slow exponential decay 
(C1e-K,i) : the larger the dose, the longer the simple exponential return to basal 
level (Figure 5). 
1.0C0.000 
^U/ML 
1 00.000 
10.000' 
1.000-
ANALYSIS OF PLASMA I.R.I. CURVE 
(EXP. 205 - CRYST. INSULIN 20 U/KG ) 
o EXPERIMENTAL VALUES 
ADJUSTED CURVE ACCORDING TO : 
^ ί ^ Y ± Sy =12.950 ± 1.150 μ M / M L 
0 30 60 90 120 240 MIN 
FIGURE 6. — Multiexponential analysis of a disppearance curve of unlabelled insulin after intra­
venous injection of crystalline insulin. 
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Thus, as far as the disappearance curve of crystalline insulin has a duration of at 
least 4 hours (injected amount superior to 1 U/kg), its mathematical analysis provides 
a multiexponential function similar to the one obtained from the decay of 131I­insulin, 
with the exception of the constant term C0. However, this type of disappearance curve 
is not specific to insulins still possessing the biological properties of the crystalline 
hormone. Indeed, works presently going on in our laboratory show that a similar 
sum of 3 exponentials and 1 constant can be drawn from the plasma decay of labelled 
insulins with a mean iodination degree superior to 3 atoms per mole, although those 
compounds exhibit practically no in vitro biological activity on the diaphragm (!)) 
or epididymal fat pad and a marked impairment of their immunological properties (8). 
To conclude : studied for periods lasting from 4 to 7 hours, the plasma dis­
appearance of 131I­insulin in relation to time can be represented by a multiexponential 
equation. Save for a constant term of small magnitude, this type of equation is similar 
to the one obtained with crystalline insulin. It is not specific of undegraded insulins. 
The characteristics of these exponentials are poorly influenced by the size of the 
insulin pool. 
The results of our analysis are not compatible with a simple model comprising 
an extracellular mixing pool with irreversible losses; they implicate at least a 3 com­
partments mamillary model with feed back to the central compartment. These com­
partments more probably represent differing metabolic pools than physiological 
spaces. 
These results are in concordance with in vitro data showing that the binding and 
the removal of the labelled insulins to and from the isolated muscle possess the 
characteristics of a non specific adsorption phenomenon (6). 
The physiological significance of the mathematical terms is yet unknown. 
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DISCUSSION 
K. BRUNFELDT (Gentofte) : Quels sont les calculs que vous avez employés pour 
justifier les deux lignes droites tirées sur la figure montrant l'adsorption sur le 
diaphragme de l'insuline marquée ? 
J. R. M. FRANCKSON : L'impression que vous avez provient de ce que les résul-
tats de l'expérience individuelle qui a été projetée sont représentés en graphique 
semi-logarithmique, ce qui donne une importance exagérée aux écarts entre valeurs 
extrêmes enregistrées aux faibles concentrations. Il ne nous a pas été possible par 
la méthode des différences finies de faire passer une seule courbe par tous nos points 
expérimentaux. Par contre, les 2 droites semi-logaritmiques représentées sont dans 
tous les cas comprises dans la zone fiduciaire 95 %. 11 est bien entendu possible 
qu'une analyse poussée du phénomène puisse donner une équation différente. 
PRELIMINARY DATA ON THE IN VIVO MEASUREMENT 
OF THE RATE OF DEGRADATION OF <3iI-INSULIN 
IN HUMANS (*> 
R. BIANCHI, G. FEDERIGHI, F. VITEK and L. DONATO 
Clinica Medica Generale dell' Università di Pisa, Italy 
ABSTRACT 
Using an original method which permits to measure in man the rate at which 
labeling iodine is liberated from rapidly degraded iodinated molecules, the rate of 
deiodination of 131I labeled insulin has been measured in humans. 
The method demands the simultaneous injection of 131I labeled insulin and 
Na 125I, and the continuous recording of thyroid uptake or urinary excretion of the 
two radioisotopes for two hours. 
The results obtained with preparations at different degrees of iodination and the 
possibility of using the technique for physiological investigation are discussed. 
Present methods for studying the metabolic degradation of iodoinsulin prepa-
rations are based on the estimate of the final slope of the plasma disappearance 
curve of the iodinated hormone after its intravenous injection (1· 2). 
It is well known that the final slope method yields correct results only when 
the residual activity is uniformly distributed throughout the hormone pool in 
the body. To approach such a situation the metabolic degradation of the protein 
should take place at a rate much slower than the rate at which exchange between 
plasma and extravascular compartments occurs. Due to its degradation, in the 
case of insulin the final plasma slope is probably not representative of the catabolic 
rate of the hormone, and the actual relationship between slope value and rate of 
catabolism cannot be easily formulated. 
In this paper we intend to illustrate the application of a new approach to the 
direct study of the in vivo degradation of iodinated insulin. 
PRINCIPLE OF THE METHOD 
The foundations of the method will be published in detail elsewhere (3). In 
essence the method assumes that the kinetics of elimination of iodide derived from 
insulin breakdown is the same as the kinetics of iodide injected intravenously, except 
for the difference that the input to the iodide pool is represented in one case by the 
rate at which insulin is degraded, and in the other case by a single injection. 
(*) Work supported by Euratom Association Contracts No. 026-4-63 BIAC and 
No. 48.65.1 BIOL 
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From these assumptions, the method proceeds as follows : 
131I-insulin and 125I-iodide are injected into the same patient; 
the cumulative excretion of both isotopes is followed; 
the cumulative excretion 131I is a convolution integral of the function expressing 
the rate at which iodide comes out of 131I-insulin and is fed to the iodide pool, 
and of the function expressing the excretion of iodine from the iodide pool, 
the latter is directly given from the cumulative excretion of 125I; 
after expressing both excretion curves as fractions of the respective doses, decon-
volution of 131I excretion into 125I excretion curves directly gives the function 
representing the cumulative amount of iodine derived from iodoinsulin at 
any time, hence permitting the direct measurement of its rate of degradation. 
The method can be used both measuring thyroid uptake or collecting urines 
in presence of a blocked thyroid uptake, and calculations can be made using an 
analog computer, or by direct analysis of the curve ,3). 
PRELIMINARY RESULTS 
The applicability of the method has been tested on iodo-insulin preparations, 
specially prepared by Rosa et al. <4), as a part of a study on the adequacy of iodoin-
sulin as a metabolic tracer. Studies so performed have indicated the feasibility of 
the method for direct measurement of the degradation rate of iodinsulin prepara-
tions in man. The results so far obtained can be summarized as follows : 
Five iodoinsulin preparations having an average iodine content of less than 
1 at I/mol were tested in normal subjects, and gave an average degradation rate 
of 2.61 ± 0.26(SD)% min-1 over the first two hours. At that time from 90 to 100 % 
of the preparation had already been degraded. 
Six iodoinsulin preparations, having an average iodine content above 4 at 
I/mol were tested in normal subjects. Their average degradation rate was 
0.98 ± 0.40 (SD) % min-1 over the first two hours, after which from 60 to 84 % 
of the preparation had been degraded. 
When a second injection of a low-iodinated insulin preparation was made in 
a young normal subject, during i.v. glucose infusion, the mean rate of degradation 
increased from 2.91 to 7.28 % min-1. 
When the same experiment was made with a highly iodinated preparation, 
a modest increase took place from 1.48 to 1.73 % min-1. 
CONCLUSIONS 
Too little experience has been collected to draw any conclusions concerning 
the practical value of the present method. The first results, however, seem to us 
very encouraging : the lower rates of degradation measured with high iodinated 
preparations, which are known to have suffered a loss of biological activity (4), 
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and the response to physiological stimuli, such as increase of blood glucose level, 
may all be suggestive of the practical value of the method as a simple and direct 
approach to the study of insulin metabolism in vivo. 
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DISCUSSION 
R. S. YALOW (New York) : The method descrbed should prove a valuable 
tool for solving a problem that would otherwise be quite difficult, i.e. providing 
direct means for demonstrating that the terminal phase of the plasma disappearance 
curve of the labeled insulin is the insulin degradation rate as well as making it pos-
sible to calculate changes in degradation rates. Would it be possible now to combine 
your data with the plasma disappearance curve and see whether the increased rate 
of degradation after glucose infusion is related to change in space of distribution ? 
L. DONATO : I will take it as an extremely interesting suggestion. It would cer-
tainly be worth to do such a sort of calculation. Something interesting could come 
out of it. Thank you. 
ROUND TABLE ON APPLICATIONS OF TRACER THEORY 
TO PROTEIN TURNOVER STUDIES 
Chairman : L. DONATO, Medical Clinic, University of Pisa, Pisa, Italy 
Participants : 
C. M. E. MATTHEWS, M. R. C. Cyclotron 
Unit, Hammersmith Hospital, London 
B. NOSSLIN, Malmoe Alhmanna Sjukhus, 
Malmoe 
G. SEGRE, Institute of Pharmacology, Came­
rino 
F. ViTEK, Institute of Biophysics, Praha 
S. B. ANDERSEN, Dept., Clin. Physiol., Glos­
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A. S. MCFARLANE, National Institute for 
Medical Research, Mill Hill, London 
P. PAVONI, Institute of Medical Pathology, 
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York 
L. DONATO : It is quite clear to everyone that no matter how good the experi­
mental data are, there is always a good possibility that they will be spoiled by erro­
neous analysis. It is, therefore, critical to establish the information content of an 
experiment in a correct way. 
This Round Table is an attempt to clarify this matter somewhat for the benefit 
of the investigators using labeled proteins for metabolic studies. We will first attempt 
to define what we would like to get out of the analysis of tracer studies with proteins. 
Let us first look at the experimental situation. 
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FIGURE 1. — Plasma proteins turnover studies. 
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In Figure 1, I have made an attempt to picture the system in purely descriptive 
terms. What we know is that after injection of the 131l labeled protein, iodine is 
released and body radioactivity decreases because of its excretion. 
We can measure the radioactivity remaining in the body either directly or by 
substracting the cumulative excretion of the tracer from the amount of tracer inject­
ed. As shown in Table I (Definition of terms) there are several synonimous terms 
for whole body activity. 
We may add information by sampling blood and measuring the activity con­
centration in it. 
We usually suppose that the mass of the protein that we want to study is in 
steady state conditions which are maintained by the balance between newly-syn-
thetised protein and degradation rate. Our aim is that of measuring the protein 
mass and its rate of turnover, but to achieve this goal several requirements have 
to be met. First, our labelled protein has to mix with all the protein which is in the 
box. The second requirement is that iodine be released from the labelled protein 
TABLE I. — Definition of terms 
1. 
2. 
3. 
4. 
5. 
6. 
Pool = Space = compartment = 
= a part of the protein mass in which mixing occurs so rapidly that uniform specific 
activity can be assumed at any time. 
— a part of the protein mass in which all molecules have equal probability of 
transfer to other compartments (If no feed back to the pool exists, activity directly 
introduced in it would decay as a single exponential function). 
"Turnover" generally indicates the process by which the substance is renewed through 
continuing synthesis and catabolism. Used with various meanings (iate, time). 
Mass of unlabeled protein in pool M,, = mass in plasma 
ME = mass in extravascular pool. 
Rates of transfer : a) fractional : fraction of pool transferred per unit time out of the pool. 
b) absolute : mass of substance transferred per unit time (in or out of 
the pool) = fractional rate χ pool mass 
Kinds of rates : 1. Synthesis. 
2. Exchange (Distribution). 
3. Catabolism ( = Synthesis in steady state). 
(Fractional catabolic rate = FCR). 
Whole body activity = Retained activity (retention curve) = 
— injected activity = cumulative excretion = 
= 1 — jVdt = Ρ + E. 
where U = fraction of dose excreted per day. 
Ρ = fraction of dose in plasma. 
E = fraction of dose in extravascular pool = 
= whole body activity — plasma activity. 
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only in connection with the degradation of the labeled protein. This requirement is 
pictured in Figure 1 showing the iodine released coming out from the pipe of the 
degradation products. 
If we were dealing with a single big box in which the label could easily mix 
with all the protein content, it is quite obvious that just measuring the fractional 
amount of iodine coming out of the box per unit time we could estimate the fraction 
of the protein degraded. In these conditions it is easy to show that both blood and 
body radioactivity would decay as a nice single exponential function. However, 
even in such simple case, complications may arise because of the excretion of iodine. 
It is obvious from Figure 1 that the size of the iodide pool and the conditions of 
renal function will influence the way in which iodine is excreted. 
All these points will be considered in this morning's discussion. But there is 
another point which I would like to consider briefly. 
FIGURE 2. — Partition in sub-units of the plasma protein pool. 
Sofar we have assumed that the activity could easily mix within the whole 
box : in fact this is not true, and instead of being a nice single big box if we could 
"open" the protein pool, we would find it more similar to the one which I have 
pictured in Figure 2. It is quite obvious that, if the pool is made up of several sub-
units, just changing the sub-unit in which we actually inject the tracer will pro-
duce different effects on the rate at which the tracer will be eliminated from the box. 
Even if we assume that eventually the tracer will spread to the whole of the box, 
it is obvious, for instance, that if we inject it close to the outflow pipe, a greater 
amount of tracer will leave the system before all the boxes have been reached by 
it than in the case that it had been injected further away. It is also obvious that 
uniform concentration throughout the system will never be attained. 
Even it we could think of starting out with uniform concentration in every 
sub-unit of the box, it is quite evident that the situation would be rapidly unbalanced 
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"because the concentration in the sub-units closer to the input would be continu-
ously lower than elsewhere, since the amount of tracer in them would be continu-
ously diluted by new unlabeled protein coming in. 
Fortunately we have some reasons to make some assumptions about the rela-
tionship between the location of the inflow and outflow pipe. We can assume that 
catabolism or degradation takes place in very close connection with the plasmatic 
space. The current assumptions in plasma protein studies are summarized in Table II. 
In Figure 3, I have pictured both catabolism and synthesis taking place close to 
the plasma pool; this simplifies our task of calculating the mass of the protein and 
its rate of turnover. 
INJECTION OF / '3 ' PROTEIN 
EXCRETION OF IODIDE 
FIGURE 3. — Favourable conditions for tracer studies. 
Unfortunately the process of protein degradation and label excretion is super-
imposed on the exchange processes that determine the transfer of the tracer between 
compartments or sub-units of the box. Our task would be much easier if we could 
split the exchange process, tending towards the attainment of an uniform concen-
tration of the tracer throughout the box, from the turnover process, tending to 
eliminate the tracer from the box. All our efforts are directed to overcome the dif-
TABLE II. — Assumptions in plasma proteins tracer studies. 
General assumptions : tracer behaves as mother substance, 
newly synthetised protein enters the intravascular compartment 
before mixing with the main extravascular compartment. 
Most models assume also : Catabolism takes place in a compartment which exchanges rapidly 
with the intravascular pool (3 ). 
rapid excretion of iodide. 
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Acuities arising from the fact that the two processes are in fact simultaneous and 
have to be dealt with together. 
I think we should now proceed and I will ask Dr. Nosslin to start presenting 
to you the discussion on the first methods that have beendivised to analyse protein 
tracer studies and that we have defined « approximation methods ». 
B. NOSSLIN : The use of the word "approximation" for one of the groups may 
seem difficult to understand and I will admit that the word "approximation" in a 
way could be used for every method which we use since we all know, and we have 
just seen, that the true model in the body is always much more complicated compared 
to the technique we use in analyzing our results. However, those calculation methods 
which we have assembled in the first group — under the name "approximation 
methods" — have some special assumptions which are not necessary in the methods 
of the other two groups, as I think it will be made clear later on in this discussion. 
Concerning calculation of the fractional catabolic rate, I will present three 
different methods often used. The first one is the well known use of the half life 
time, that is the half life of the final straight part of the curve when it is plotted on 
a semilog paper. I think you are all familiar with how to take it out graphically 
from the curve, and of course it has the dimension of time : in order to get a frac-
tional catabolic rate from it you have to use the well-known expression that the 
fractional catabolic rate equals the natural logarithm of 2 over T,,- that is 0.693/T,, 
The obtained fractional rate refers to the total pool. This estimation of the fractional 
rate is always an under-estimate of the true rate : that means that these half life times 
are always too long compared with the true half life of the protein. Unfortunately 
these half lives are often called the "biological half time" but since it is not identical 
with the true half life time of the protein I think the use of the word "biological" 
is not very good. 
If you also have excretion values you can calculate two further expressions for 
fractional catabolic rate as the ratio of urine excretion over total radioactivity retai-
ned — U/(P + E) — or the content of activity in the plasma — the U/P ratio. This 
latter fractional rate refers to plasma pool and it is a correct estimate if the cata-
bolism is intra-vascular. 
The expression U/(P + E) or excreted amount per day over retained activity 
will, under steady state conditions, reach, sooner or later, a final constant value 
and this has been used as an expression for fractional catabolic rate. Of course it 
refers now to the total pool (that is a point that came up in the discussion two days 
ago) : there are then two different types of fractional rates calculated from urine 
excretion, one is referring to plasma pool, the other to the total pool. It can be 
shown that U/(P + E) always leads to an under estimation of the fractional rate 
of the mother substance, the protein. 
I will now go over to the use of these methods for estimating the size of the total 
pool. The first, and the oldest one, I think, is the well-known "Sterling technique" (1) 
where the final straight line on the semilog paper is extrapolated back to zero 
Methods 
Α. — Approximation ι 
1. Final slope 
2. Distribution func­
tion (or retained 
activity) 
3. U/P clearance 
4. Equilibrium time 
Assumptions 
tethods 
Uniform specific acti­
vity throughout the 
protein pool 
Uniform specific acti­
vity throughout the 
protein pool when 
U/(P + E) is constant 
Intravascular catabo­
lism 
Rapid excretion of 
iodide 
Uniform extra­vascular 
pool 
TABLE III. — Vlethods of analysis 
Results and errors 
Pool masses 
Total pool mass from 
intercept of final slope 
overesti mation 
Total exchangeable pro­
tein (albumin) TEA = 
Retained activity 
Plasma sp. act. 
P + E , 
= P/MP ( a t e q u l 1 ­
brium 
overestimation 
— 
Extravascular pool 
mass from extravascular 
activity at peak time 
indeterminate 
Fractional 
catabolic rate 
As fraction of total 
pool from T + of final 
slope 
underestimation 
As fraction of totalpool 
Daily urine excr. 
Retained act. 
= U/(P + E) (at equi­
librium) 
= FCR final slope 
underestimation 
As fraction of i.v. pool 
U % dose/day 
Ρ % dose 
Usually correct; overe­
stimation (except first 
days) if iodide excretion 
slow 
Absolute 
catabolic rate 
From intercept and 
Τ J of final slope 
overestimation 
From TEA and FCR 
P + E U U 
P / M P X P + Ë _ P / M p 
Correct (if i.v. cata­
bolism) since errors 
cancel out 
U Urinedailyexcr. 
P/M,. plasma sp. act. 
usually correct overe­
stimation as for FCR 
References 
Sterling, 1951 ( l ) 
Berson and Yalow, 1953 <a) 
Campbell et al., 1956 (3) 
Berson and Yalow, 1957 <4> 
Campbell et al., 1956 (l» 
Β. — Specific models 
5. Multiexponential 
analysis of plasma 
curves 
I.v. catabolism 
Albumin pool divided 
in definite number of 
mixing compartments 
All pool masses from 
slopes and intercepts 
correct (specific com­
partment masses not 
necessarily meaningful) 
From slopes and inter­
cepts 
correct 
Fom fractional catabo­
lic rate and pool masses 
correct 
Berman and Schcenfeld, 1956 
(5) 
Matthews, 1957 (o) 
6. Multiexponential 
analysis of plasma 
and whole body 
curves 
Albumin pool divided 
in definite number of 
mixing compartments 
All pool masses from 
slopes and intercepts 
correct (specific com­
partment masses not 
necessarily meaningful) 
From slopes and inter­
cepts 
correct 
From fractional catabo­
lic rate and pool masses 
correct 
Berman and Schcenfeld, 1956 
(5) 
Lewallen et al., 1959 <»> 
Reeve and Roberts, 1959 (s) 
7. Pipe model Plasma and extravascu­
lar pool masses from 
slopes and intercepts 
correct 
From slopes and inter­
cepts 
conect 
From fractional catabo­
lic rate and pool masses 
correct 
Reeve and Bailey, 1962 (o) 
C. — General methods 
8. Multiexponential analysis of plasma and whole body curves Berman and Schcenfeld, 1956 
(5) 
9. Plasma curve integral Nosslin, 1964 <">> 
10. Plasma and retention curves integrals Nosslin, 1964 <lll) 
Matthews, 1965 ( l l ) 
II. Deconvolution techniques Vitek et al., 1966 (l2> 
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time and the intercept is read : this gives a kind of dilution value from which the 
total pool can be calculated, knowing the size of the plasma pool. It can be shown 
that this approach always leads to an over-estimation of the true pool, sometimes 
a large over-estimation. 
The next method in this group is the estimation of total exchanging albumin 
by dividing the retained activity by the plasma specific activity — a method used 
first by Berson and Yalow in 1953 (2). It can be shown that this method also leads 
to an over-estimation, although in general, not as large as the Sterling technique. 
A third method for estimating total pool is the so-called equilibrium time 
method (3) where the retained activity at peak time of extra-vascular activity is 
divided by the plasma specific activity at the corresponding time. This may lead 
to a correct estimation but that depends upon conditions in the extra-vascular space 
— whether the specific activity in the extra-vascular space is uniform or not. 
So now we have three different methods of estimating fractional rate and three 
different methods of estimating total pool : in order to get the absolute rate, we 
now have to multiply the fractional rate with the corresponding estimate of the 
total pool. 
L. DONATO : Thank you Dr. Nosslin. Dr. Matthews, would you like to comment 
on the approximation methods ? 
C. M. E. MATTHEWS : These approximate methods may certainly give the 
right result under some conditions, but in other circumstances there may be a consi-
derable error and so they must be used with caution. Taking the first method for 
the fractional catabolic rate, that is the half life method, this will always give an 
under-estimation and the reason can be shown by considering Figure 4. 
Initially the intra-vascular specific activity falls and the extra-vascular specific 
activity rises and crosses it at the maximum point of extra-vascular specific activity, 
i.e. at the equilibrium time. After this time the specific activity in the extra-vascular 
pool is always greater than in the intra-vascular pool. Hence there is a net transfer 
of radioactivity from the extra-vascular to the intra-vascular pool, the specific acti-
vity in the extra-vascular pool being always higher than in the intra-vascular pool 
after this time. Thus there is a net transfer of radioactivity from the extra-vascular 
to the intra-vascular pool which reduces the slope of the intra-vascular specific 
activify curve. Therefore this slope does not correspond to the slope which would 
be obtained simply due to catabolism and if the slope is taken as a measure of 
catabolism it is an under-estimate. 
When the fractional catabolic rate is low compared with the exchange rate 
between extra- and intra-vascular pools, the method may give approximately the 
right result, as for example with normal human albumin in normal humans, but 
when the catabolic rate is increased or total loss of protein from the intra-vascular 
pool is increased, as for example in nephrotic patients, the method does not give 
the right result. The method assumes in fact, a single pool, or that in all pools the 
fractional catabolic rate and the synthesis rate are the same : as we know this is not 
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FIGURE 4.— Intra- and extravascular specific activities in a two compartment system with intra­
vascular catabolism. 
the case, the method, in general, is incorrect. For the same reasons method I will 
always give an over estimate of pool mass and of absolute catabolic rate. Method 2 
also depends on the specific activity being uniform throughout the protein pool 
when the final slope :s reached and so involves similar errors. However for the 
absolute catabolic rate these errors cancel out and the same result is obtained as 
in method 3. 
Passing on now to the U/P ratio for fractional catabolic rate, this method 
is correct if the catabolism is in the intra-vascular pool or in a pool in rapid exchange 
with the intra-vascular pool, but there may be some error due to the effect of the 
iodide pool. If the iodide excretion is not sufficiently rapid compared with the cata­
bolic rate, activity will build up in the iodide pool and the radioactivity excreted 
will not give a true measure of the radioactivity produced by breakdown. I have 
plotted some curves with an analogue computer to illustrate this and Figure 5 shows 
the kind of errors you may expect. A rather low iodide excretion rate of 
80 %/day in assumed and the catabolic rate is varied from 7 to 100 %/day. 
The production of radioactivity due to catabolism is shown and the excretion 
of radioactivity which would be obtained if the iodide was excreted very rapidly 
indeed. The actual excretion of the radioactivity is also shown. The ratio of the 
actual excretion to the iodide produced due to catabolism, is also included and the 
ratio of the measured catabolic rate to the true catabolic rate. As you see in the 
case where excretion rate is much higher than catabolic rate the ratio becomes 
almost one and so the error is small here except in the first few days (left of Figure 5). 
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With an increased catabolic rate (middle of Figure 5) the ratio of the two curves 
again rises to an approximately constant value but in this case the constant value 
is greater than one — about 1.5. 
RATE OF PRODUCTION OF 
IODIDE RADIOACTIVITY 
OUE TO CATABOLISM 
CATABOLIC RATE 7*/ . /DAV 
IODIDE EXCRETION θθ"/ο / DAY 
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FIGURE 5.— Error in measured catabolic rate (U/P method) due to a constant slow iodide excretion 
for increasing albumin catabolic rates. 
To the right of Figure 5 curves are shown for an even greater catabolic rate, 
this time 100 % per day and here the ratio reaches a constant value which is greater 
than 2. Therefore the error, as one might expect, depends on the values of the iodide 
excretion rate and the catabolic rate and with high catabolic rates and low excretion 
rates this error may be considerable. Even though the catabolic rate is constant it 
may still not be correct. 
Figure 6 shows the effect on the whole body curve, with the curve which would 
be obtained without the iodide pool and also the total activity including the iodide 
pool. Again results are shown for three different catabolic rates with the same iodide 
excretion rate. 
Figure 7 shows the effect of varying the excretion rate for a constant catabolic 
rate. To the left curves are shown for a catabolic rate of 7 % per day and increasing 
values of the excretion rate in per cent per day. The lower the excretion rate the 
longer the excretion curve takes to reach its maximum value. Hence the ratio of 
radioactivity excretion to radioactivity production takes longer to reach 1 when 
the iodide excretion rate is lower. 
To the right of Figure 7 are shown curves for a very rapid catabolic rate of 
200 % per day and in this case the error is very considerable for low excretion rates, 
for instance, for an excretion rate of 80 % per day, or 40 % per day the curves 
never become parallel and the activity tends to build up in the iodide pool. For an 
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FIGURE 6.— Effect of slow iodide excretion on whole body curve for increasing albumin catabolic 
rates and constant iodide excretion rate. 
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FIGURE 7.— Effect of slow iodide excretion on radioactivity excreted for varying iodide excretion 
rates with a constant catabolic rate. 
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excretion rate of 200 % per day the curves do, in fact, become parallel after a time 
and the error is only about 25 %. 
Figure 8 shows the effect on total body activity, again for two different cata­
bolic rates and for different values of the excretion rate. Here the effect is very large 
and could tend to make the whole body curve diverge from the intra-vascular curve. 
TOTAL BODY ACTIVITY 
CATABOLIC RATE 77o/DAY 
IODIDE EXCRETION 
RATE (% /DAY) 
WITHOUT IODIDE POOL' 
2 3 4 5 6 7 β 9 IO II 12 13 14 IS 
d a p s 
TOTAL BODY ACTIVITY 
FIGURE 8.— Effect of slow iodide excretion on whole body curve for varying iodide excretion rates. 
and constant catabolic rate. 
The equilibrium time method depends on having only one extra-vascular pool, 
and if, in fact, there are two extra-vascular pools exchanging at different rates with 
the intra-vascular pool there will be some error, the extent of which is difficult to 
estimate as it will depend on the relative exchange rates between the two extra­
vascular pools and the intra-vascular pool. Another disadvantage of this method 
is that the extra-vascular radioactivity curve may have rather a flat top and so it is 
difficult to determine the exact point of the maximum. 
L. DONATO : Thank you Dr. Matthews. I would like to move now to the consi­
deration of methods in which a specific number of compartments is assumed and 
analysis of the curves is performed on the basis of these assumptions. So I will then 
again ask Dr. Matthews to discuss the subject of specific compartment models. 
C. M. E. MATTHEWS : I think you are probably all familiar with these models, 
1 will only mention them rather briefly. These are all based on the analysis of the 
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curves into exponentials — I am sure you are all familiar with the method by which 
this is done by successive subtractions of the final slopes to obtain the slopes and 
intercepts of the component exponentials. From these slopes and intercepts the 
exchange rates between the pools and the catabolic rate can be calculated if a spe-
cific model is assumed. 
The model assumed is usually the one in which the extra-vascular pools all 
exchange with a central intra-vascular pool with catabolism and synthesis in connec-
tion with the intra-vascular pool. Sometimes two extra-vascular pools and sometimes 
one extra-vascular pool are used. If the curve can be analysed into two exponentials, 
usually the simplest possible model is taken which would contain only one extra-
vascular pool; for three exponentials one takes two extra-vascular pools. 
It is important to emphasize that each of the slopes and intercepts depend on 
all the rate constants in the system and one cannot say that the fast exponential 
corresponds to the rapidly exchanging pool or the slow exponential corresponds 
to a slow pool. Each one of these exponential components depends on all the rate 
constants in the system, all the exchange rates and the catabolic rate. 
Reeve and Roberts <8) have extended the two or three pool model to include 
the iodide pool and extra-vascular catabolism, and because the model is more com-
plex they also have to use the total body radioactivity in order to have enough infor-
mation to solve the equations and to obtain all the rate constants. With the simpler 
model it is only necessary to use the intra-vascular radioactivity curve, and the whole 
body curve, if it is available, can be used to check the results. With Reeve and 
Robert's method it is essential to have both of these curves, and from these curves 
one can calculate the exchange rates and both intra-vascular and extra-vascular 
catabolism if the iodide excretion rate is knwon. 
Then another model is that of Reeve and Bailey l!l) in which the extra-vascular 
pool consists of a series of pipes, that is the protein leaves the intra-vascular pool 
through a series of pipes which then return it to the intra-vascular pool so that the 
effect is one of a delay. The specific activity is not altered in travelling through the 
pipes but the protein of that specific activity returns to the intra-vascular pool after 
a delay and the series of pipes have a distribution of lengths. This is an extravascular 
pool in which there is no mixing. However, in fact rather fortunately the results 
by this method turn out to be much the same as by the compartment analysis that 
is if the intra-vascular radioactivity curve can be represented by a sum of exponential 
functions then Reeve and Bailey have to assume an exponential distribution of 
passage times through the pipes and this leads to exactly the same equations as 
one finds in a pool with complete mixing. 
There is also the more general method of Berman and Schoenfeld l5) but we 
will be discussing that in the next section. 
1 will just make a small comment on these methods : sometimes the question 
is raised of what these pools mean and whether there is any point in finding these 
two extra-vascular pools. Perhaps they have no meaning and there is not much 
point in this calculation? Well I would like to show you that one can sometimes 
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find a meaning for these pools, fn animals I have found a slow and a fast extra-
vascular pool<13). Figure 9 shows results for albumin in rabbits and the analysis into 
pools. There is a large slowly exchanging extravascular pool and a small rapidly 
exchanging one two extra-vascular pools and this gives curves like this for the radio-
activity in the plasma in the slowly exchanging large extra-vascular pool and in 
the rapidly exchanging small extra-vascular pool are shown. The curve for the small 
extravascular pool reaches its maximum very rapidly and then comes down parallel 
to the intra-vascular pool. 
TheoreUcol distribution of I albumin in rabbits 
(Calculated from plasma activities only Exp.222A; 
% dose 
IOO 
I O -
4 0 8 0 I20 I60 2 0 0 Hours 
FIGURE 9. — Results of analysis of experimental plasma curve for 13II rabbit albumin ('3) 
Theoretical curves also shown for extravascular pools 3 and 4. 
Figure 10 shows experimental measurements of extra-vascular radioactivity 
in the pools in rabbits. The blood was labeled with 132I and the intra-vascular 
radioactivity subtracted to obtain extravascular radioactivity. The muscle skin 
and bone pool (mainly muscle and skin) gives a curve rather similar to the theo-
retical curve which you saw on the previous slide for the large slowly exchanging 
pool and the gastro-intestinal tract gives a curve rather similar to that for the small 
IO 
I 
ROUND TABLE ON TRACER THEORY 
Distribution of I albumin in rabbits. 
Exp. 23CT 
Ratio I 0 6 
389 
; Muscle, skin ι bone 
Blood 
Ratio O i l 
Gastrointestinal tract. 
1 1 ι 
BO 120 
FIGURE 10. 
O 4 0 80 I60 2 0 0 Hours 
Experimental measurements of extravascular radioactivity in rabbits ('3) 
rapidly exchanging pool. The other organs contained very small amounts of radio­
activity and had a negligible effect on the intra-vascular curve. 
L. DONATO : Thank you Dr. Matthews. Certainly the most elaborate step in 
dealing with compartment models is the Berman and Schoenfeld approach (5). 
I would like Dr. Segre to make a comment about the Berman and Schoenfeld 
technique. 
G. SEGRE : First of all I would like to set forth some probably obvious consi­
derations about compartmental analysis because the method of Schoenfeld and 
Berman is connected to them. The multi-exponential analysis is usually a pheno-
menological description of complex phenomena; by carrying out compartmental 
analysis a homomorphism is performed between some part of the complex expe­
rimental structure and a mathematical model. Moreover every experimental design 
is endowed by a given "resolving power" : within a given experimental design it 
is possible to "see" only a given structure. For instance if 2n equally spaced points 
have been sampled from a given compartment then no more than η compartments 
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can be seen; in this case the resolving power of the experimental design corresponds 
to n compartments. In compartmental analysis however the most interesting problem 
is the determination of the transfer constants of the model; now for a system of n 
compartments n2 transfer constants are possible and this number stops very soon 
the possibility of the analysis. The method of Schoenfeld and Berman represents 
a way to circumvent in a certain degree this impasse. 
The experimental outcome of a given experiment is given by one or more mul­
tiexponential functions. 
Xt(t) = Σ Aye­V 
j = l 
The transfer constants (Árs) of the model can be calculated through the matri­
cial equation 
|*| = |A| Η IA) - 1 
where 
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(Ki = Σ kir; i > r) 
r = 0 
When the Ay are not known, it is possible to substitute them by unknowns 
(.Y, y, z, etc.) and to solve the matricial equation; the matrix \k\ in this case will 
contain these unknowns, so that, by remembering that krs > 0 and that 
Κ,· — Σ kir = kio (kio indicates the transfer constant from compartment / to 
the exterior), one can write a system of η inequalities. 
For instance let us suppose that for compartment 1 one has 
XJxo = d)e­ (i)e­ iì)e ι 
(where .v0 is the dose introduced into the system), and for the sum of compartment 
2 and compartment 3 one has 
(X2 + X3)/.v0 = ­Q)er» + (J)<r'. 
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If one introduces two arbitrary parameters, χ and y, then the system becomes 
Xjxo = | e ­ 3 i + \e­°­t + \e­t 
XJx0 = — xe­u + ye~» + (x — y)e~ 
Χ3/λ'ο = (·ν — s)e i\p­3t ­ye -2Í 4_ f i (I + J — -vie-
Then one has 
| A | = 
f 3 0 0 
Λ:— y \, \a\= 0 2 0 
.γ — f — ƒ f — x + j | 0 0 
1/2 5 1\ 1/2 5 
y \3 3 4!. y \3 3 
1 / 3\ 1 1 - ¡-2x+y-r--) -(-2x+y) y\ 41 y 
1/2 1\ 1 ¡2 
1 yk' + '-j ; I'-ll· 
K| = 
—1 —1 
C-2x+j) |—^(|*—^)(^+^—|) W ^ - ^ - r - , 
The two parameters χ and y must satisfy to the following simultaneous ine­
qualities : 
(I) 
(ID 
2.V— y > 0 
3 • 2x + y + ­ > 0 4 
( n S(-^ + '+4)(2* + ' - í ) > ° 
(IV) 
(V) 
VI) 
I / 5 3\ 
­(2x + y)^x­
-* + -2y)>o 
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The above inequalities can be represented in a plane by the Figure 11, in which 
a straight line or a couple of straight lines delimitate the focus where the coordinates 
χ and y satisfy the above inequalities. The hatched areas correspond to the points 
where all the six inequalities are satisfied; these areas correspond therefore to the 
physically possible models. 
FIGURE 11. — See text (Segre) <22> 
It is clear that this approach has great limitations : too many calculations are 
required and the method appears of practical use when the unknowns are only 
two, because in that case the representation requires a plane, as in the example 
given above. When the unknowns are three, a tridimensional representation is 
required. 
L. DONATO : Thank you Dr. Segre. 1 know that Dr. Matthews has very precise 
opinions about the Berman and Schoenfeld approach and I would like to have her 
comments on this. 
C. M. E. MATTHEWS : 1 think this method is very useful when the pool model 
is not known and the total body activity and the intra-vascular activity have been 
measured. For example the method can be used to show that from results of plasma 
protein analysis the catenary model is inconsistent with the data. The experimental 
results cannot be fitted by a catenary model, that is one in which the extra-vascular 
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pools are connected in series. Using Berman and Schoenfeld's method, one can work 
out all possible values of the exchange rates and the catabolic rates in all pools for 
this general three-pool model, with interconnections between each of the pools. 
This gives a series of models which would fit the experimental results. This may 
sound as though one was obtaining too much information which it would be dif­
ficult to deal with but. in practice, one may find for example that certain rates may 
only have very small values, so that there is a limited range of values for this rate 
for the model to be consistent with the experimental results. A particular rate may 
also turn out to be very small, for example the catabolism may be nearly all in the 
rapidly exchanging extra-vascular pool with very little actually in the intra-vascular 
pool. Hence one may find quite a narrow range for the different exchange rates 
and 1 think this method is useful because it is a more general analysis than merely 
assuming that certain rates must be zero, and it shows that there is only a limited 
range of models which will fit the experimental results. 
L. DONATO : Thank you. We will certainly come back to multicompartment 
analysis during the discussion, but now 1 would like to move to the consideration 
of methods that seem to be less dependent on initial assumptions concerning the 
distribution of the mass in various compartments. We have called them "general 
methods" and L will ask Dr. Nosslin to start discussing this subject. 
B. NOSSLIN : Figure 12 gives a description of a general technique of calculating 
the more important parameters of a system when you have access to the plasma 
curve only. It works with a minimum of assumptions and it can be shown, 
mathematically, with a rigorous proof, that these solutions are exact. The assump­
tions are, as usual, that synthesis is in the intra-vascular pool and in the case when 
we have only the plasma curve we also have to assume the site of the catabolism. 
The solutions given here refer to intra-vascular catabolism but it is possible to give 
comparable general solutions for other sites of catabolism. The information you 
need is the common one, the plasma curve described in a series of exponential func­
tions; it does not matter how many, two or three or four or five or any number, 
since they are just used to describe the plasma curve completely, and after having 
done that graphically, with a common peeling-off technique, you have the information 
collected in a number of slopes and a number of intercepts, from which you can 
calculate three general magnitudes which are Α, Β and C under the picture. They 
are very easy to calculate, you divide each intercept by its slope, or by the square 
of its slope, or-you just multiply the intercept and slope and then sum them for each 
term. 
From these three expressions you can calculate the correct values for fractional 
and total catabolism and for the total pool and for the total exchange rate between 
plasma pool and all other pools in a way which is given in the legend of the figure. 
It is also possible to calculate a true value for the half time of the protein, the bio­
logical half time ; if this value is compared with the T,, of the final slope you will 
see that they will not come out equal. 
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CALCULATE A= Σ "5 (area under ρ curve) 
days 
C= XcbGni t ia l slope of Ρ curve) 
FIGURE 12. — A general method for analysis of a plasma disappearance curve (l0). Assumptions : 
synthesis and catabolism in (or in close connection with) the plasma pool (P pool). No assump­
tions about number and arrangement of the extravascular pools. The plasma curve (P) must 
be followed until it has reached a final constant slope. 
Calculations : 
Fraction of Ρ pool per day 
grams per day 
Total body pool Ρ pool x B/A2 grams 
Total exchange rate C — 1/A fraction of Ρ pool per day 
Half-life time 0.693 χ B/A days 
This method should be used when only the plasma curve has been measured. The expressions 
for fractional catabolic rate and synthesis are independent of site of catabolism, while the total 
body pool, half-life and turnover time are correct only under the assumption of no extravascular 
catabolism. 
Fractional catabolic rate 1/A 
Rate of synthesis Ρ pool/A 
I think that this general method should be used when you are interested only 
in the general properties of the system — total pool size, total catabolism, total 
rate of exchange. You do not need any more information in order to do this than you 
have in the other techniques discussed earlier. 
If you have access to two curves, that means plasma curve and whole body 
curve — or retention curve — then it is possible to do the corresponding calculations, 
but now we do not have to assume the site of catabolism : this is then a real mini­
mum of assumptions you need now and it is now possible to make correct estimates 
of the same parameters as earlier, just knowing the areas under the plasma curve 
and the retention curve (AP and AR in the figure). Also it is now possible to correct 
for the influence of the dead space between the system and the collection space, 
that is the iodide space. The area under these two curves can be measured or cal­
culated in several ways : for example, by exponential analysis (and then it is easy 
to calculate the whole area under the curve) or by planimetry, adding an estimate 
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of the final part in the usual way with the use of the final slope. The two areas exactly 
define rate of catabolism and total pool size in the simple way shown in the legend 
of Figure 13. 
(sum of all 
extravascular 
spaces) 
(iodide space) 
(cumulative 
excretion) 
FIGURE 13. — A general method for analysis of simultaneous plasma and retention (or whole body) 
curves (10). Assumption : synthesis to plasma pool. Measure (or calculate) area under Ρ curve 
(AP) and area under retention or whole body curve (AR). Area under the iodide space curve 
(A,) is = i¡k¡ ( = 0.50 days in man). 
Calculations : 
Fractional catabolic rate 1/AP Fraction of Ρ pool per day 
Rate of synthesis Ρ pool/AP grams 
Total body pool Ρ pool χ (AR­A,)/AP grams 
Half­life time 0.693 χ (AR­A,) days 
Corrections can also be made for sampling losses and for free iodide in plasma (not shown 
here). 
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These techniques, both of them, work with any number of extra­vascular com­
partments, and do not require any assumption about equal specific activity. The 
solutions must be equal to those in other techniques and they can be used as a check : 
for example, in the Berman and Schoenfeld technique, every other solution must 
come out with the same result as far as total size and total catabolism are concerned. 
As I said, there are proofs for this. These methods have been developed by several 
authors : Dr. Bergner in Sweden made it some years ago, I have done some work 
on it. Dr. Matthews has done it, and I think we can recommend them for more 
general use. They are not so well known today, because they haven 't been published 
in an easy form but 1 think we would like to recommend them for more common 
use. Thank you. 
C. M. E. MATTHEWS : I would just like to express the same thing as Dr. Nosslin 
has said, but in terms of compartment analysis. The compartment analysis as 
Dr. Nosslin has said, will in fact, give you the same results as his method but these 
particular results are independent of the arrangement of pools. 
Table IV shows some of the equations which are independent of the poo' 
arrangement, these two equations are also independent of the site of synthesis or 
of catabolism. The last two equations are to indicate the notation; the intra­vascular 
radioactivity is expressed as three exponential components with coefficients A n . 
A12 and A13 and slopes b,, b2 and b3. The total body radioactivity curve has the same 
slopes with intercepts A v A2 and A3. The last two equations are just included tc 
show the meaning of the symbols used. 
TABLE IV. — Equations for protein studies, based on compartment analysis, but independent from 
pool arrangements, and site of synthesis and catabolism. 
I.v. catabolism as fraction of i.v. protein mass = A ^ + A262 + A3¿>3 
Total rate of loss i.v. pool to e.v. pools = ( A n — A1)61 + (A12 — A2)Z>2 + (A13 — A3)63 
I.v. radioactivity as fraction of dose = A n e ~ & l i + A1 2e_ 63í + Α1Άε~ι'-ίΙ 
Total body radioactivity as fraction of dose = A 1 e _ í ' l í + A 0 e _ í ' - Í + A -bat 
The first equation states that the intra-vascular catabolism — that is the part 
of the catabolism which takes place from the intra-vascular pool only (even if there 
is extravascular catabolism) can be found from the initial slope of the whole body 
curve. This equation is independent of the pool arrangement. The second equation 
shows that the total rate of loss from the intra-vascular pool to all the extra-vas-
cular pools is the difference between the slope of the intra-vascular specific activity 
curve at time 0 and the slope of the total body activity curve at time 0. 
Table V shows some equations which are also independent of pool arrange-
ment but which do assume that the newly synthetised protein enters the intra-vas-
cular pool. The first equation gives the total catabolism expressed as a fraction of 
the intra-vascular mass and this is just the usual equation for the catabolic rate by 
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the compartment analysis. If there are more than three pools more terms are added 
corresponding to the number of exponentials. 
TABLE V. — Equations for protein studies based on compartment analysis but independent of 
pool arrangement. Assumption required : newly stynthetised protein enters intravascular 
pool. 
1 
Total catabolism as fraction of i.v. mass 
A,l 
A, 
, Aj2 , Aj3 
b2 b3 
b0 6g 
12 13 
bi ba 
Total protein mass as fraction of i.v. mass = 
I.v. radioactivity as fraction of dose = A n e *>' + A12e bît + A l g e *a' 
Total body radioactivity as fraction of dose = A · ^ - * 1 ' + A2e~l>'t + A3e~bd 
The second equation is for the total protein mass as a fraction of the intra-
vascular protein mass, and this is obtained from the whole body radioactivity curve 
and the intra-vascular radioactivity curve and again is independent of the arrangement 
of pools. 
L. DONATO : Thank you Dr. Matthews. There is a point that I would like to 
stress. Dr. Nosslin has discussed methods for measuring total mass of protein 
and catabolic rate which are independent of compartmental assumptions. But 
Dr. Matthews has just shown that total protein mass and catabolic rate can be derived 
just as accurately using multiexponential analysis. This is something that is very 
important to stress : some of the constants that may be calculated from labeled 
protein studies, such as size of individual extra-vascular compartments and indi-
vidual exchange rates, strictly depend on the model assumed and do not necessarily 
have physical meanings. On the other hand, constants like total protein mass or 
catabolic rate, are not model-dependent, and can be obtained by various approaches. 
Dr. Nosslin has indicated how the significant constants can be obtained from the 
integrals of the curves. The same integrals enter in Dr. Matthews's equations, in 
term of intercepts and slopes of the exponentials in which the curves have been 
resolved. The problem is then whether a good fit of the experimental curve can be 
obtained using a sum of exponentials. If it so, then it is immaterial how the integrals 
are obtained. Do you agree on this Dr. Nosslin ? 
B. NOSSLIN : Yes. 
G. SEGRE : I would like to add a comment on compartmental versus non-
compartmental analysis. If one fits a curve for instance by three exponentials, then 
one could obtain some information in addition to that deduced when the assumption 
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of compartmentalization is dropped. This information refers to the transfer constants 
of the model; by means of these transfer constants one might, for example, compare 
the clinical abnormal cases to the normal ones. The compartmental analysis in 
this case affords numbers which may be of value diagnostically. If one avoids the 
assumption of compartmentalization, then some information that might be of 
significance also from a practical point of view is lost. 
L. DONATO : Thank you Dr. Segre. I am sure we will come back to this point. 
The methods that Dr. Nosslin has discussed, and on which Dr. Matthews 
has commented are independent of assumptions on the system characteristics. 
They still require that the curves be entirely described since one has to calculate 
integrals from zero to infinity. This demands, in turns, experiments of long duration 
so that the final slopes of these curves are sufficiently well-defined to permit carrying 
out the extrapolation with minimal error. I would like Dr. Vitek to present us briefly 
another possible approach that might have the advantage of shortening the duration 
of the experiment. 
F. VITEK : There is a possibility of arriving at the complete definition of the 
system (total extra-vascular pool, total intra-vascular pool and total transfer rates) 
under steady state conditions, in a time shorter than that necessary when analysis 
is based on the direct observation of the time course of activity. This possibility 
arises when one considers that the extra-vascular activity which can be calculated 
with the usual method can be treated as the convolution integral of the plasma acti­
vity and the transfer function which can be defined as net activity transfer function 
from plasma to extra-vascular space ll2). 
InTable VI, Mp and Mn denote total plasma and extravascular albumin, S the 
rate of albumin transfer from one to the other and viceversa, P(/) and E(/) are acti­
vity in plasma and extravascular space. The transfer function G(/) is obtained by 
an analogue computer and it contains all the information required for the defini­
tion of the system except those concerning the degradation rate. 
The method is valid whatever the arrangement of pools. The obtained transfer 
function obviously depends of the exchange constants and also of the initial conditions 
and initial distribution of the tracer. If at zero time no activity is present in the 
extra-vascular space the transier function has some very important properties. 
Its initial value equals the overall fractional efflux from plasma to the extra­
vascular space, as it is seen in equation 2. The value of its integral from zero to 
TABLE VI. — Deconvolution analysis of plasma protein turnover studies. 
E(0 = f p ( - . ) G ( r - - > / T (I) 
•Ό 
G(o) = S/M„ (2) 
(•00 
M,./M„ = G(t)dt (3) 
•o 
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infinity equals the ratio of the extra-vascular to plasma albumina pool. Considering 
that the rate of degradation is obtained by a different approach the system is then, 
in our meaning, completely defined. 
Xp (t) 
ACTIVITY TRANSFER FUNCTION 
PLASMA-^. EXTRAVASCULAR 
G (t) 
io 
TIME (days) 
15 
FIGURE 14. — Transfer function of radioactivity from plasma to extravascular space as determined 
by deconvolution 
Figure 14 compares the time course of activity in plasma Xp(t) and the calcu-
lated transfer function supposing two extra-vascular compartments. It is quite evi-
dent that the transfer function attains a constant rate of change much earlier than 
plasma activity. This is obvious because the effect of degradation does not come into 
play here. I would like to state that the case shown in this slide is a patient with 
nephrosis in which, due to the loss of plasma albumin and increased degradation 
rate, a constant rate of change of plasma activity is attained relatively soon. The dif-
ference between the time course of the transfer function and that of the plasma 
curve will be greater in a normal person. Supposing intra-vascular breakdown of 
serum albumin, the catabolic rate can be determined from the transfer function 
from the blood plasma into the urine. It is also possible to determine this value 
after repeated injections of the same tracer. 
L. DONATO : I think it is time we stop for a moment the discussion between 
ourselves, and then I will ask Dr. McFarlane to come here and speak. 
A. S. MCFARLANE : First of all Dr. Donato, I want to congratulate you on the 
organisation of this symposium, it has been quite delightful to listen, but I did get 
a little alarmed that time was getting on and we would not be allowed to ask questions. 
What I wanted to ask about was in relation to the relative merits of compart-
mental analysis and the methods of Nosslin. In the first of Nosslin's methods, it is 
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apparently critically important that the curve must be followed until a final constant 
slope is reached. Now I think in practice this imposes too stringent a condition 
on the preparation of the labelled protein and on other matters. Once the retained 
dose in the plasma falls below 20 % of the injected dose — this is a matter of prac-
tical experience — the slope often becomes unreliable. It may be due to traces of 
other labelled proteins, it may be due to the thyroid beginning to put out labelled 
substances. But if that is a limiting condition, in your method, 1 think it is too 
stringent. 
It is my impression, but this is a point I would like to be corrected on if 1 am 
wrong, that all methods of compartmental analysis also depend on a reliable ter-
minal slope and therefore just at the moment 1 am immensely attracted to your 
last method in which the determination of the total body pool, which 1 think is 
one of the most critical measurements, is made from the ratio of the areas of the 
retention and plasma curve. Now if we measure those areas say up to a time of 20 % 
retention in the body, would that be, from your point of view, a satisfactory pro-
cedure and would we be free of the kind of errors that I have mentioned, which 
arise in the later stages ? 
B. NOSSLIN : Concerning the first question about the importance of the final 
straight line, I think you have given the answer yourself. It is quite correct that this 
method depends upon a complete description of the curve to time infinity which 
means that one has to do an extrapolation using the final straight line. So far this 
technique depends on it just as much as all other techniques using final slopes, or 
slopes at all. That means the Sterling technique, all other techniques based on final 
constant rates, and so on, and also the compartmental analysis. All techniques 
requiring extrapolation are on an equal base and the error will be exactly the same. 
In other words there is no further critical dependence on extrapolation in my tech-
nique; I agree with you that in cases where for some reason the final straight line 
is not attained, then one has to choose other methods such as the equilibrium time 
method, the U/P or the U/(P + E) ratios which also give the visual impression 
from day to day on what is actually going on. 
Concerning the second question about the other technique using areas under 
whole body curve and plasma curve, my answer to your question is, unfortunately, 
no — from a strict mathematical point of view — but in practice of course, the 
more you know the better is your estimate. So the longer the time you can go on 
measuring the more you come near to the correct value, but from a strict math-
ematical point of view it is the same situation as with a plasma curve, since you need 
to do extrapolation from the final slope. 
L. DONATO : I know that Dr. Matthews would like to add a comment to 
Dr. McFarlane's question. 
C. M. E. MATTHEWS : I only just wanted to say I agree with Dr. Nosslin, I 
think this is a basic difficulty in all methods of analysis. If you have only the first 
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part of the curve, you just have not got enough information to distinguish between 
different results and the longer you go on, as Dr. Nosslin says, the more information 
you have and the more accurate will be the results. 
I think Dr. Vitek's method is interesting. I have not studied this method yet 
but it apparently does not seem to require quite such a long experiment as the other 
methods. 
L. DONATO : ljust want to add one further comment that might be of interest. 
These methods are very similar to those that have been used for a very long time 
in circulation studies. The mass of the protein is obtained actually multiplying the 
mean flow of the substance — in this case the rate of synthesis or breakdown of 
the protein times the mean circulation time — through the entire protein mass; 
and what Dr. Nosslin is deriving with his equation is exactly the mean circulation 
time through the whole system. 
R. YALOW : Whether or not estimates from the intercept of the final slope of 
labeled protein disappearance curve represents an over- or an under-estimation 
depends on whether or not the degrading compartment is in rapid or slow equili­
brium with the plasma pool(4). In the former case the proper extrapolation should 
have been one with a curve concave upwards as it approached its ordinate, in the 
latter the extrapolation should have flattened as it approached the ordinate. 
Actually although the general assumptions did not state this, the mathematical 
analysis presented today has assumed that degradation takes place in a compart­
ment in rapid equilibrium with the plasma compartment, an assumption validated 
by previous experimental information U4). It should be emphasized that the 
degrading compartment need not be and, almost certainly, is not the plasma pool 
itself. 
A second comment concerns Dr. Matthews presentation concerning the signi­
ficance of equilibration in the iodide pool. Her work shows very nicely the value 
of computer techniques in performing the often difficult calculations introduced 
by sophisticated mathematical analysis. However, we should not let this ease of 
mathematical manipulation blind us to some pertinent physiologic facts. In the 
normal subject, where catabolic rates average about 3 '/2 %/day and iodide excre­
tion rates average almost 200 %/day, the renal excretion curve becomes virtually 
identical with the iodioalbumin degradation curve after the first day or so and the 
error introduced by equating the two is generally insignificant <2). 
Next I do want to remind those concerned with compartmental analysis of 
the debt we all owe to Sheppard and Householder ί15) whose elegant analysis is 
basic to many of the problems still under consideration. Furthermore 1 am sure 
that Dr. Matthews did not mean to imply that her work in 1957 was the first general 
analysis of 2-3 compartment models in the context of protein turnover. I should 
like to refer her to some earlier publications in which a number of these problems 
were analyzed and experimental studies validating the analyses were described in 
detail <14- !6· 17>. 
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L. DONATO : Thank you Dr. Yalow for your very interesting remarks. I would 
like to take just one for myself, that is the historical one. 
I entirely agree with what you said about Sheppard and Householder but I 
would like to make another historical reference — even further away. Most of the 
methods that were covered today could be easily derived from the Stewart-Hamilton 
principles currently used in circulation studies for the determination of blood flow 
and circulating blood volumes from the integrals of indicator curves. 
Dr. Yalow has posed a series of questions, and I think that Dr. Matthews 
should comment on them. 
C. M. E. MATTHEWS : I think I agree with most of Dr. Yalow's remarks. How-
ver, we did not intend to give a historical review, and the references are intended 
only to identify specific methods of analysis. 
As regards the iodide curves which I gave to show the effect of the iodide excre-
tion, I quite agree that under normal circumstances with normal catabolism of 
human albumin the error is very small. However, these curves were intended to 
show that the error could be large in certain circumstances, either with proteins 
where the catabolic rate is very much higher than that of albumin or where the 
total loss from the plasma pool is greater or where the iodide excretion rate is reduced 
for example due to impaired kidney function. 
I think I agree with most of the other remarks for cases where the catabolism 
is in the slowly equilibrating pool, but in fact all the evidence seems to indicate 
that this in fact is not so therefore we have not considered models in which the 
catabolism might be in the slowly exchanging pool for plasma proteins. On the 
other hand catabolism in a rapidly exchanging extra-vascular pool would give 
almost the same results as catabolism actually in the plasma pool. 
L. DONATO : I would like to add a brief comment of clarification concerning 
the values that have been reported for the catabolic rates. I think that Dr. Yalow 
refers to the catabolic rate as a fraction of the total protein mass, while the values 
reported by Dr. Matthews refer to the intra-vascular mass only. This explains the 
numerical differences. I will call now on Dr. Pavoni. 
P. PAVONI : AU the methods that have been discussed here assume the attai-
nement of a final straight line. However, the problem is not only that of continuing 
the experiment until the straight line is attained, but also that of obtaining values 
actually describing a straight line. Since during the last part of the experiment the 
radioactivity is very low, random errors play an important rôle : as a consequence, 
one is confronted with the problem of interpolating, and not simply of connecting 
the last points. Doubts may arise as to which points and how many of them should 
be considered in order to draw the straight line. 
1 would like to pose the following question : if the number of compartments 
and the biological behaviour of the system is unknown, which are the criteria and 
the methods followed by Dr. Donato and the other members of this panel in the 
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choice of the points for interpolation of the straight line, as well as in the choice 
of the type of model and of the number of compartments which are obviously influen-
ced by the selected straight line. I would like to known if other mathematical pro-
cedures are available besides those that we published in 1962 <18). Thank you. 
L. DONATO : The problem posed by Dr. Pavoni is a technical one. strictly con-
nected with the error of the experimental points. The interpolation is always some-
what arbitrary, whence the importance, for the methods based on the calculation 
of the integrals, of carrying on the experiment as long as possible, in order to mini-
mize the contribution of the extrapolated part of the curve. As to methods for inter-
polation, I can only recall the classical techniques for best fitting, like the least 
square method. As it has been already pointed out, most of the methods depend 
on the description of the final course of the curves; it is obvious that no result will 
be better than the data from which it has been calculated. 
The method discussed by Dr. Vitek may perhaps overcome some of these 
difficulties, since the calculation is based on the first part of the curve : the practical 
value of the method, however, is still to be demonstrated. 
G. SEGRE : May I add some comment on the question of Dr. Pavoni ? Parti-
cularly when highly scattered experimental points are obtained there is a need for 
a criteria to evaluate the precision of the calculated parameters of the model. First 
of all every point ought to be weighted in the fitting process; this cannot be prac-
tically done by hand computation, or even by the analog computers, but only by 
digital computers. The scattering of the point from the theoretical curve gives high 
standard deviations of the calculated transfer constants of the system. These consi-
derations are also of some relevance with respect to the problem raised by Prof. 
McFarlane : every truncated curve introduces an error into every value computed 
by means of that curve, either by using the method of Nosslin or by using the com-
partmental method. It is therefore necessary in any case to use a computing method 
that affords the standard deviations of each calculated parameter. 
L. DONATO : Thank you Dr. Segre. Dr. Nosslin. 
B. NOSSLIN : This is a very important question and it is often asked and I would 
like to summarise my view on it in the following way. 
If you have two curves, both the plasma curve and the total body curve then 
there are methods which give correct, or almost correct, estimates of total size and 
total catabolism which are not very dependent on the final straight line : the de-
convolution or other methods as we have discussed. But if you have only the plasma 
curve then there is no, and will never be, any method giving these correct estimates 
unless you know also the final slope; since we require the total area under the curve, 
the total form of the curve, then it is obvious that we will always need to know the 
final slope, and it will never be possible to calculate these parameters from just 
part of the plasma curve only. If the curve does not show a straight line then we 
have to use the final tangent and then we also have to be aware that we may be 
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under-estimating the area with a consequent influence on the values which we obtain. 
Another way of saying this is that it is very important, whenever you can, to measure 
not only plasma disappearance curve but also whole body or excretion. Thank 
you. 
L. DONATO : Thank you Dr. Nosslin. Unfortunately we are running short of 
time, but before we have some more discussion I would like Dr. Segre amplify 
his statements concerning the use of computers in this sort of studies. 
G. SEGRE : It is impossible even to summarize the topic in few minutes. The 
applications of the digital computers to the problems discussed in this round table 
will undoubtedly increase in the near future; the method of hand computation will 
be superseded because it is time consuming, does not give indications of the sta­
tistics of the parameters and it is expensive. 
Programmes for digital computers are now available; the most versatile pro­
gramme is that of Berman(19,20); the fitting of a multi-exponential curve to a compart­
mental model, by using this programme and an IBM 7094 costs abouts 2 $. 1 think 
that every university in the next few years will have a computing center to which 
the biologists and the clinicians will have access; a good example of this trend is 
given by the Medical Clinics of the University of Pisa which works in connection 
with the computing center recently opened in Pisa. 
The most important task for a research worker, before to procede to fitting 
the data to the model, is that of model building and of its validation. 
In this respect there are three general approaches : the first is the multiexpo­
nential analysis, which would afford the number of compartments. The second 
is the determination of the transfer (or the weighting) function between two sub­
systems of the system, by calculating the deconvolution between them; the third 
method is given by the analysis of the precursor's order between two points of the 
system. All these preliminary steps are carried out by hand computation, but for 
the deconvolution there are programmes for digital computers (Phillips, of the 
Argonne National Laboratories).(2I) The third method gives a quick indication on 
the number of arms which connect two compartments of the system(22). If there is 
one arm only, then the weighting function between the two compartments is equal 
to 
G(/) = A e~at 
and 
limG(r) = Α φ<ο; 
f - > 0 
in this case the two compartments are adjacent. 
When 
lim G(/) = 0, 
1^0 
then the two compartments are not adjacent and at least one other compartment 
is placed between them. 
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If the above limit is equal to zero and 
lim dG/dt φ 0 
then the number of arms which connects the two compartments is equal to two,. 
and so forth. 
Also the analog computers can be of great help in this stage of model building. 
After this stage has been performed, the approximate values of the parameters 
one is looking for are calculated; these values together with the experimental data 
are given to the computer. The Berman's programme includes many options and a 
great number of subroutines, and among the other problems, the following which 
are of interest for compartmental analysis may be processed : 
curve fitting to a multiexponential function; the programme provides the standard 
deviations of the computed parameters (the exponents and the coefficients of 
the exponential terms), as well as the differences and the ratio of the observed and 
the calculated values, their plot and the sum of the squares of the differences 
between the observed and the calculated values; 
the mapping, that is the solution of the previously discussed matricial equation 
|Jfc| = | A | \a\ I A ] - 1 ; 
the direct solution of the model, that is the computation of the transfer constants 
(with their standard deviation) directly from the experimental data. 
All these subroutines employ a least squares method and an iterative proce­
dure; a correlation matrix of the computed parameters is also provided by the 
programme. 
L. DONATO : Thank you Dr. Segre. Before concluding I would like to ask the 
audience if there are more questions on the subjects that have been discussed. 
Dr. Andersen. 
S. B. ANDERSEN : It would be interesting to hear a few words about which factors 
influence the error in the Berson and Yalow method of determining the total pool 
in comparison with the factors that determine the magnitude of the error in the 
Sterling method. 
C. M. E. MATTHEWS : The factors are similar to the factors in the Sterling 
method: both methods basically assume that the specific activity is the same in the 
extra-vascular and in the intra-vascular pool and therefore they will only give the 
correct result when the exchange rate between the pools is very rapid compared 
with the catabolic rate, but not where this ratio is smaller. 
L. DONATO : Would you like to comment on this Dr. Yalow ? 
R. YALOW: The metabolic clearance method^) [metabolic clearance rate = urinary 
excretion rate/mean plasma sp. activity (16)] is generally applicable when degradation 
t.1) Method 3 of Table III (No. E). 
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takes place in a compartment in rapid equilibrium with the plasma — the real phy-
siologic situation in all experimental cases so far studied — and when the system 
is in what one can call quasi-static equilibrium i.e. when changes in the steady state 
conditions are slow. It would not be applicable if the specific activity in the degra-
ding compartment were significantly different from that of plasma. The power 
of the metabolic clearance method is that it does not require long term sampling; 
for example, in the case of iodoalbumin it is sufficient to take, at 8-10 days, two 
plasma samples, 24 hours apart, and a single complete urine collection during this 
interval to get a reasonably good estimate of absolute catabolic rate. Absolute 
catabolic rates for iodoalbumin obtained using the metabolic clearance method 
do not differ significantly from that obtained by method 2, the one we used in our 
earlier work. 
B. NOSSLIN : I would like to say that as far as absolute catabolic rate is concern-
ed, the estimate with the Berson and Yalow technique is correct if there is intra-
vascular catabolism or the catabolism is in a compartment in close connection with 
the intra-vascular compartment. It is not the same with the Sterling absolute rate 
because that is always giving an overe-estimate. Therefore the error is greater in the 
Sterling method. As far as fractional values are concerned, I can only repeat that 
the fractional catabolic rate is an under-estimate and the total exchangeable pool 
is an over-estimate but when you multiply the two, the errors exactly cancel in the 
Berson and Yalow method. 
The total pool is always over-estimated as soon as there is a higher spe-
cific activity in the extra-vascular compartment. That is a question depending on 
the site of synthesis but if we assume that synthesis is intra-vascular there will always 
be higher specific activity in the extra-vascular space. This exchangeable mass is 
correct as far as the tracer is concerned, but unfortunately the distribution of the 
tracer and that of the mother substance are not the same because the mother sub-
stance is given as a continuous infusion while a tracer is given as a single shot and 
they do not end up with the same distribution ratio. 
L. DONATO : Thank you. 
I think we have to conclude this discussion, it could profitably go on for hours. 
I would like to make a few remarks and I will start from Dr. Yalow's consi-
deration that she rather likes methods that do not involve complex mathematical 
elaboration. I am sure that we all fully agree with her. I think it has been shown 
by this discussion that in fact there are reliable methods that do not involve too 
much mathematical elaboration of the data to provide useful data. 
I think that we should make a strict separation between the constants that 
are inherent in the system (absolute catabolic rate of the system and total system 
mass) and those constants that strictly depend on the type of model assumed. 
Exchange rates between compartments and number of compartments will obviously 
depend of the type of model assumed, although Dr. Matthews has shown us an 
interesting correspondence between a given compartment and some parts of the body. 
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I would like to point out that as far as the fractional catabolic rate measurement 
is concerned the U/P ratio seems to stand quite strong. Of course there are limitations 
and possible sources of error, and I would like to emphasize once more the impor-
tance of the iodide kinetics, which should be looked at from two points of view : 
one is the size of the iodide pool and the other are the conditions of the kidneys, 
because an impairment of renal function will delay the excretion of iodine from 
the body thus resulting in possible important errors. As far as the evaluation of 
the protein mass is concerned it is quite evident that adequate methods are available, 
be they based on the direct computation of the areas cf the curves as such, or on 
a preliminary multi-exponential fitting. They can provide us with the information 
we want, provided we can accurately describe the entire area : their limitation in 
fact is the accuracy with which we can obtain the full area and particularly the 
final slope. This, of course, bears directly on the duration of the experiment and on 
the accuracy of multi-exponential fitting. From the former point of view, I would 
like to point out that, if practical verification will be successfull, the method that 
has been described here by Dr. Vitek could be an interesting one on clinical grounds. 
From the point of view of multi-exponentail fitting of curves we have heard from 
Dr. Segre that computers can provide a much more rapid and efficient tool than 
simple peeling- off exponentials. 
I think we can conclude feeling fairly relieved about the availability of rela-
tively simple techniques to handle our problems. The possibility of measuring the 
catabolic rate and the total mass is probably the maximum that we should expect 
from present analytical techniques, since any additional information that we would 
like to derive from our experiments probably demands too many assumptions to 
be warranted on the basis of the available knowledge. 
Although I regret it, I think that we have to conclude at this time, and I would 
like to thank all the members of this panel for the effort they have made to simplify 
their way of reasoning, and with them I would also like to thank the audience for 
its patience and contribution to the discussion. 
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G. MILHAUD : To open the discussions at this round table on radioimmunoassay 
of growth hormone and parathormone, I should like to try to place the problem 
on a wider perspective. 
In the early days of endocrinology the existence of the chemical messengers 
— what hormones are — was revealed by a particular physiological effect. A suita-
bly chosen physiological effect was used to follow the purification of the hormone, 
which is the necessary step in the establishment of the chemical composition. As 
soon as the hormone was obtained in a pure or relatively purified state, the bioche-
mical mechanisms responsible for hormone action were investigated. In the era 
of classical enzymology, detailed descriptions were given of the variations in the 
activity of numerous enzymatic systems under the influence of insulin, of growth 
hormone, of adrenalin and more recently, of parathormone. In the days of messen-
ger RNA it was logical to attempt to relate hormone activity with the synthesis 
of enzymatic proteins. Consequently, in the case of growth hormone, parathormone 
and insulin, actinomycin D was used to see wether or not such particular bioche-
mical effects were or not dependent on a synthesis or activation of enzymatic sys-
tems. In the case of parathormone the increase in calcemia is suppressed by the 
administration of actinomycin D. Furthermore, we can attempt to investigate the 
mechanism by which serum calcium drops after parathormone-induced hypercal-
cemia. In thyroparathyroidectomized animals it could be assumed that at a given 
threshold, hypercalcemia initiates the induction or activation of a calcemia-decrea-
sing system, this being antagonistic to the calcemia-increasing system. In this case 
the administration of actinomycin D at the moment of the drop in hypercalcemia 
ought to inhibit the activity of the hypocalcemia-producing system, and the hyper-
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calcemia should either be higher or longer. But this is not so, and actinomycin D 
depresses always the hypercalcémie response to parathormone. The hypercalcemia 
is neither intensified nor prolonged, and this leads to the assumption that the pro-
gressive lowering of the hypercalcemia is due to inactivation or elimination of para-
thormone itself(1). 
However it may be advisable to consider the problem from another point 
of view, namely the relation between the hormone and the tissue receptor. Now 
if it is not at present possible to study the behaviour of the hormonal tissue receptor 
or receptors, we can at least study the variations in circulating hormone levels. 
This initial step can be accomplished either by means of biological assays or radio-
immunoassays. The former are frequently less sensitive than the latter, which from 
the technical point of view, however, are often rather difficult to perform properly. 
Therefore I thought it desirable today to compare the experience of those who are 
mastering radioimmunoassays of two bone-acting hormones, namely parathor-
mone and growth hormone, with the difficulties encountered by certain scientists, 
with the intention of promoting the development of radioimmunological techniques 
in Europe. I believe that this development has been delayed because very few bio-
chemists can carry out radioimmunoassays by using only the published techniques : 
certain reagents are difficult to find and it is necessary to know certain tricks which 
are essential to the success of one step or another of the assay. These difficulties 
must consequently be overcome, and this round-table conference will have achieved 
its purpose if it makes possible a transfusion of technical know-how from highly 
qualified donors to recipients who are greatly desirous of becoming donors in what 
we hope will be the near future. The following four main subjects will be discussed : 
1) Availability of highly purified growth hormone and parathormone, 
2) Preparation of 131I-labelled hormone of high specific radioactivity, 
3) Preparation of antisera, 
4) Assays techniques. 
First I would like to ask Dr. Stewart to tell us something about the prepara-
tion of human growth hormone. 
U. STEWART : For metabolic purposes and for the treatment of pituitary dwarfs 
we need large amounts of human pituitary growth hormone. We were thus forced 
to fractionate our own postmortem collected glands. Of all the procedures offered 
we most favoured and most successfully applied the one described by Gemzell 
et al(2). The fresh frozen glands are extracted under physiological conditons with 
phosphate buffer. The active principle is then precipitated by the addition of ammo-
nium sulphate and purified on Sephadex G 100 columns. From 100 g of fresh glands 
we obtain between 4 to 5 g of highly purified human growth hormone which contains 
neither serum protein impurities nor heme degradation products. The hormone was 
assayed in the laboratory of Dr. Li in Berkeley and had high biological activity in the 
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tibia test. With rabbit-antiserum against HGH we obtained a single antigen/antibody 
precipiting band. In starchgel electrophoresis, both in the conventional system of 
Smithies and in the modified system of Ferguson and Wallace, we have some hetero-
geneity. One major band is preceeded by a very faint more anodal band, both fractions 
migrate in the postalbumin region. On cellulose acetate as well as in disc-electropho-
resis we observe a similar pattern. For the purpose of labelling with 131I, we removed, 
about 8 to 10 % of aggregated protein by the procedure recently suggested by 
Hunter (3), namely filtration on Sephadex G 200 in alkaline buffer. The eluted active 
fraction is immediately employed for radioiodination without dialysis or freeze-
drying. We obtained growth hormone with a specific activity of 150-300 mC/ing. 
A small sample of this iodinated hormone reapplied on Sephadex G 200 under 
the conditions of Hunter, élûtes as a very symmetrical peak. Nervertheless, this 
material still shows unspecific binding to normal human serum. This problem will 
be dealt with in this panel. 
G MILHAUD : Thank you. There is also the good news which consist in the fact 
that you may not need to go through all the procedures described and 1 think that 
Dr. Cotes can tell us something about availability of highly purified growth 
hormone. 
P. M. COTES : It has already been emphasised that the reference standard is an 
important reagent in any radioimmunoassay system. Ideally, this standard is derived 
from the same species as the hormone being estimated and after extraction and 
purification it should behave in the same way as the native hormone in the assay 
system. The ideal standard is not always easy to make and extensive testing is fre-
quently necessary to establish the suitability of any one preparation to serve as a 
reference standard. The World Health Organization already provides a service by 
preparation and distribution of international standards of many hormones for 
bioassay purposes. It is proposed that this service should be extended by provision 
of international reference preparations, suitable to serve as radioimmunoassay 
standards, for some hormones which until recently could only be estimated by 
bioassay procedures. By international use of these services : 
— Bioassay results can be expressed in international units which are identical 
from one laboratory to another. Radioimmunoassay results can be expressed in 
terms of (mass of), a single internationally accepted preparation. The suitability 
of each of these preparations for use as a standard or reference preparation is deter-
mined by international collaborative studies. 
— When scarcity of certain biological reagents means that they must be used 
with the utmost economy, characterisation of these materials can be carried out 
in a few expert laboratories. Material needs not be wasted by replication of process-
ing and testing in many centers. 
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—■ Continuity of units is established since, on replacement of an international 
standard or reference preparation, the new standard is calibrated in terms of the 
old by international collaborative assay. 
The primary purpose of WHO international standards is for calibration of 
national and laboratory working standards. Certain international reference pre­
parations may be available in limited amounts for use as laboratory working stan­
dards. 
Batches of human growth hormone and human insulin have already been 
set aside by WHO for provision of international reference preparations for radio­
immunoassay purposes. 
The human growth hormone consists of highly purified hormone extracted 
from pituitaries collected by the British Medical Research Council and purified 
as part of a larger batch by Prof. A. E. Wilhelmi in the United States. Its suitability 
to serve as a standard has been studied in several laboratories including that of 
Dr. Yalow and Dr. Berson. Dr. Yalow is going to report some characteristics of 
a sample from the same batch of growth hormone from Prof. Wilhelmi. Tests on 
the final preparation will include studies of its long­term stability. 
It is expected that by the end of the year the International Reference Prepa­
rations of Human Growth Hormone and Human Insulin will be available as ampou­
les containing approximately 200 micrograms of hormone, with 5 milligrams of 
sucrose, freeze­dried and filled with nitrogen. Ampoules may be obtained by wri­
ting to : The Director — Division of Biological Standards — National Institute 
for Medical Research — The Ridgeway — Mill Hill — London, N. W. 7. 
It is hoped that these particular International Reference Preparations will be 
suitable to provide material for use as radioimmunoassay standards and for iodi­
nation. They will not be available for immunisation purposes. 
F. C. GREENWOOD : In 1961 we developed a method for the routine preparation 
of high specific activity labelled hormones for use in in vitro radioimmunoassays. 
A preliminary note was published in 1962 (4) and a full publication in 1963 (5). In 
the method some 2 mC of carrier­free 131I are reacted with 5 μg of protein in the 
presence of excess chloramine Τ (50­150 μg). The reason for the excess chloramine 
Τ is not known. Then chloramine Τ is added to the mixture of isotope ­f­ protein. 
Metabisulphite is added to stop the reaction and should be added rapidly since 
Drs. Yalow and Berson have obtained evidence that delayed addition causes 
increased damage. Carrier potassium iodide was then added to insure complete 
recovery of unreacted iodine from a subsequent dextran column. This addition 
is not necessary if the reaction mixture is to be purified on starch gel. 
We have carried out routine iodinations since 1961 and the method has been 
applied to a large number of hormones. The method was reliable until 1964 but 
we have subsequently obtained lower yields (30­50 % with an occasional 70 %) 
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using isotope samples from Amersham. Drs. Yalow and Berson, however,obtain 
yields from 80-90 % using isotope samples from Isoserve. In our experience damage 
to the hormone is more often present than not. 
In our experience we feel that the cause of low yield and damage is due to un-
known variations in the isotope samples. Dr. Yalow has indicated a correlation bet-
ween percentage yield and the specific activity of the isotope samples. The develop-
ment of a method to routinely measure the percent atoms excess of 131I in the iso-
tope samples by Drs. Yalow and Berson is extremely important. However, I would 
also agree with Dr. Yalow that there is still an additional factor responsible for 
damage which was not present in isotope samples from Amersham in the period 
from 1961-1964. 
At the present time, therefore, purification of the labelled hormone must be 
considered essential although we feel that labelled hormone purified from a damaged 
sample is less satisfactory than a labelled hormone obtained undamaged. 
Purifications of labelled hormones have been described using starch gel, Sepha-
dex G 200 and 100 with or without added plasma and cellulose columns. We have 
found the cellulose columns of Yalow and Berson extremely effective for the puri-
fication of ACTH and we will certainly try their method for growth hormone using 
cellulose columns and elution with 20 % acetone in buffer. 
A corollary of purification is that screening for damage is essential. In our 
opinion only the chromatoelectrophoretic method is available for this and this has 
predisposed us to use chromatoelectrophoresis for the subsequent assay. Cellulose 
acetate electrophoresis is less satisfactory for the detection of damage but we have 
retained it for routine growth hormone assays. Subsequent radioimmunoassays for 
ACTH, human prolactin, human placental lactogen and rat prolactin in our labo-
ratories have used the Berson and Yalow chromatoelectrophoretic system. It must 
be pointed out that different hormones differ in the ease with which they may be 
radioiodinated and in their susceptibility to damage. Dr. Hughes has pointed out 
that the chemistry of iodine is not fully understood and it seems unreasonable, 
therefore, to expect the radiochemists to be fully aware of what is happening with 
radioactive iodine. 
I would personally be delighted if a better method were available but in the 
meantime we willingly accept the difficulties involved for the output of 50-100 
plasma determinations each week. In conclusion I would say that I would be very 
delighted if a more adjusted method were available, if we except the present diffi-
culties, for the productivity of 50 to 100 plasma determinations each week with 
several hormones ? 
G. MILHAUD : Thank you. I think that Prof. Michel, who is now in the happy 
state of having succeeded in getting some growth hormone of high specific radio-
activity will tell us something about the time and the experience necessary to come 
to this point. 
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R. MICHEL : To iodinate growth hormone we use, with Job and Sizonenko, 
the method of Hunter-Greenwood after some minor modifications : in particular, 
we use a more dilute medium by adding two times more phosphate buffer and we 
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FIGURE 1. — Radioelectrophoretogram of iodination products of a human growth horomone 
preparation 
Abscissa : length in cm; Ordinate : number of counts pei minute of m I ; '-"STH (labelled hormone); 
X : (damaged protein); I - : (iodide). 
Whatman 3 MM, 400 V, Ι 'Λ hour, 0.1 M sodium veronal buffer, pH 8.4, yield 43 %, specific acti­
vity of the hormone, 182 uC/|j.g. 
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FIGURE 2. — Radioelectrophoretogram of iodination products of a human growth hormone pre­
paration (Same conditions as in Figure 1). 
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operate at 2° C. As soon as the labelling is performed, a paper electrophoresis 
is carried out on an aliquot to establish the yield. The results obtained are of two 
types. 
FIGURE 3. — Recordings of two radioelectrophoretograms indicating a preparation of undamaged 
growth hormone. 
A. Immediately after preparation; B. After three weeks of storage at —20 "C (Same conditions 
as in Figure I). 
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In Figure 1 three radioactive peaks are present; one at the origin, which is 
the labelled hormone, another corresponding to the damaged hormone and a third 
consisting of iodide. 
4wn ι 1 
AO 
"ímp jmn 
ÎOO0 
•Ίοοο 
Λα 0 
FIGURE 4. — Recordings of two radioelectrophoretograms of a growth hormone preparation indi­
cating partial damage. 
A. Immediately after preparation; B. After three weeks of storage at — 20 "C (Same conditions 
as in Figure 1). 
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In Figure 2, two peaks are left : one remaining at the origin, which is the radio­
active hormone and the other corresponding to the iodide. 
As the two preparations have been made in exactly the same conditions, the 
damage may be attributed to two different radioiodine preparations. 
After a G 50 Sephadex column the most radioactive eluate is subjected to 
electrophoresis. The homogeneous preparation stays at the origin. When stored 
in the frozen state at —20° C this pure preparation is unchanged three weeks later 
(Figure 3 and other samples of this preparation could be stored without damage 
for over 40 days). 
If. on the other hand, a tube containing a minor amount of damaged hormone 
(Figure 4 A) was kept under the same conditions for 3 weeks, the damage became 
very important (Figure 4 B). A kind of autocatalytic decomposition must have 
occurred. These facts must be kept in mind by the preparation and storage of 125I 
labelled hormone. 
A. S. MCFARLANE : In spite of the fact that it is not necessary that the labelled 
hormone should retain its biological activity for radioimmunoassay, 1 am sure 
that everyone here should like to obtain preparations that were less damaged. I 
think some of the damage which is attributable to chloramine Τ may in fact come 
from peroxides in the iodine shipment. I am surprised that the excellent procedure 
of Bale and his collaborators in Rochester (6) for getting rid of these peroxides, 
is not used more often. This is relatively simple and is based on the use of sulphite. 
If one wants to avoid chloramine Τ and at the same time to make use of iodate 
activity which is normally non-productive in labelling procedures then it is quite 
easy to convert the radioiodine into iodine monochloride, simply by adding hydro­
chloric acid. To do this quantitatively both for iodide and iodate it will be necessary 
to add a controlled amount of one or the other in inactive form which of course 
will produce a slight reduction in specific activity. It seems to me that a radioactive 
shipment treated in this way should be usable quantitatively for labelling purposes, 
but it will still be necessary to preoxidise any sulphydryl or other easily oxidisable 
groups in the hormone. Our procedure for doing this is one that Springell used <?) 
very nicely with insulin, which is to preoxidise with inactive iodine at an acid pH 
— at which the rate of substitution in tyrosine is very low. If the various hormone 
experts here are willing to permit this liberty being taken with the hormone then 
Γ think it should be possible to get less damaged preparations and more reprodu­
cible iodinations than at present. 
P. FRANCHIMONT : The purity of the labelled growth-hormone preparation 
and the preservation of its antigenic properties are suggested by the following obser­
vation. On radioautography of Immunoelectrophoresis of labelled growth-hor­
mone purified on Sephadex G 200 and the corresponding antiserum a single line 
is observed. This is an argument in our opinion that labelled growth-hormone 
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contains only a single type of antigen reacting always with the corresponding anti­
serum (Figure 5). Furthermore this labelled growth-hormone does not react with a 
horse serum anti-human serum : no serum contaminants seem to exist. 
+ 
FIGURE 5. Radioautography of Immunoelectrophoresis of labelled growth-hormone 
A. E. FREEDLENDER : Fortunately we, along with Dr. Yalow, have been using 
iodine from Isoserve. We have been iodinating for the past 8 months, with yields 
between 70 to 80 %. Stability studies on the final labelled preparation done by the 
method of Hunter and Greenwood have indicated that the preparation seems to 
be directly proportional to the amount of contamination in the protein used for 
stabilising. We have had our best results with the crystalline albumin. The material 
has maintened integrity of 95 % for periods of 3 weeks. 
F. C. GREENWOOD : I thank Dr. McFarlane for his comments. Certainly the 
Springell technique has been shown to be suitable for low specific activity 131I-
labelled insulin required for the double antibody method <8). We considered the 
addition of sulphite to decompose any hydrogen peroxide formed in iodine-131 
samples. We couldn't follow the Bale method of sulphite addition followed by 
aeration since our isotope samples are only 0.075 ml. We did add metabisulphite 
and then a calculated amount of extra chloramine Τ during radioiodination. We 
got no detectable effect on yield or on percentage damage. If I remember correctly 
it is quite difficult to remove traces of hydrogen peroxide completely by any chemical 
method. 
G. MILHAUD : Now we can come to the availability of antisera. Antisera can 
be obtained from two sources. The first one is William Latimer at Johns Hopkins 
at the National Pituitary Agency and he has rather large supply; antisera are also 
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commercially available at Mann. Furthermore we have some hope to get some 
Medical Research Council standards and I think Dr. Cotes could say a word on 
this. 
P. M. COTES : The British Medical Research Council holds a small stock of 
rabbit antihuman growth hormone serum. This is a high titre serum with good avi-
dity but, by mischance, the rabbit which provided it died after collection of only 
a small amount. This serum will be diluted and made available to users in the United 
Kingdom. Unfortunately, there is not enough of this reagent for it to be distributed 
internationally. 
R. S. YALOW : Our laboratory has supplied Dr. William E. Latimer, National 
Pituitary Agency, 1900 McElderry Street, Baltimore Maryland 21205, with a high 
energy anti-HGH antiserum in quantity sufficient to assay 1-2 millions of unknown 
plasma samples. Supplies of this antiserum and directions for its use can now be 
obtained from Dr. Latimer. When the antiserum supplied to Dr. Latimer is exhausted, 
we will replenish the supply. However, these antisera are specially selected for high 
sensitivity for immunoassay and are not in unlimited supply. A suitable rabbit 
anti-HGH serum can be obtained from Mann Laboratories (136 Liberty Street, 
New York, New York 10006, Cat 1435 Price S 15 per ml) for general laboratory 
purposes, such as testing 131I-HGH for complete binding to antibody or practice 
in setting up the immunoassay. The sensitivity of the Mann anti-HGH serum is 
probably five- to tenfold less than the best available rabbit or guinea-pig antiserum 
but it has been used to study dynamic changes in HGH concentration in human 
subjects. Let me emphasize that the antiserum being distributed by Dr. Latimer 
is available in amounts sufficient only for immunoassay. 
G MILHAUD : This policy seems very reasonable. Now if we go to the procedure 
of immunoassay 1 think that Dr. Franchimont has a few words to say. 
P. FRANCHIMONT : To separate free labelled growth hormone (STH*) from 
antibody bound STH* the following methods were used : chromatoelectrophoresis, 
fixation on an anion-exchanger (Amberlite 400) starch-electrophoresis. 
1) Chromatoelectrophoresis was done with two types of Whatman paper 
(3MC and DE 21) containing DEAE-cellulose. Studies were performed to determine 
the influence of serum protein (SP) concentration and of migration time, on the 
persistance at the origin of free labelled growth hormone (in the absence of any 
antibody). 
Figure 6 shows a reduction in the radioactivity at the origin when the concen-
tration of SP increases and also for the same SP concentration, when the migration 
time rises. The question is raised whether this is due to a degradation of STH* 
during the incubation or to a combined migration with human SP. 
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The two types of paper were used simultaneously (Figure 7). The reduction 
of the amount of free STH at the origin is observed only with 3MC paper. This 
difference may be attributed to a better quality of the batch 3 MC paper, which 
does not retain the labelled growth-hormone at its point of deposition. Further 
more when an excess of antibody is added the amount of antibody-bound STH is 
influenced by the concentration of human SP. It therefore appears that the concen-
tration of SP in the medium changes the electrophoretic behaviour of both free 
STH and antibody-bound STH. 
2) Amberlite 400 retains free STH* whereas antibody-bound STH goes 
through (9). This is a good method of separation. It must be stated, however, that 
in the absence of antibody the resin fixation of growth hormone is influenced by 
the presence of human SP added, long before (three days) or immediately before 
the separation (Figure 8). 
When 0.1 ml or less of human serum is added to the incubation medium, diffe-
rence in the amount of hormone retained is less than 5 %. A check is always carried 
out by studying the fixation of STH* on Amberlite 400 in the absence of antibodies 
and in the presence of the same volume of each serum used for the assay; a correc-
tion coefficient is thus calculated. 
3) Finally, the method which we recommend consists of starch electrophoresis. 
In well-defined conditions free STH* migrates in the pre-albumin area, the STH*-
antibody complex in the area situated between the slow a2-globuIin and the origin 
(Figure 9). Less than 6 % of free STH* migrates in STH-antibody complex area. 
STH*=0,2Smjjg 
Q2 0,6 0,4 0,5 ml. 
Volume de sérum humain dans 4-ml.d'incubation 
Figure 8 
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DISTRIBUTION DE LA RADIOACTIVITE DE LA STH* APRES ELECTROPHORÈSE 
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H. J. QUABBE : The difference between various methods for the radioimmu-
noassay of proteic hormones in plasma lies mainly in the technique by which anti-
body-bound and free hormone are separated after the completion of the antigen/ 
antibody reaction. Immunoprecipitation with an anti-gammaglobulin serum offers 
a possibility of separation which combines easiness with the possibility to use a 
hormone of relatively low specific activity. For the assay of human growth hormone 
(HGH) it was first used by Utiger el al.mi. Use of immunoprecipitation will some-
times yield falsely high serum values of the hormone, due mainly to incomplete 
precipitation of the first antibody. This may occur when some of the antigammaglo-
bulin serum is lost from the reaction with its specific antigen by crossreaction 
with human gammaglobulin. Such a crossreaction has been described by several 
authors (8,io,ii); wh¡ie others failed to find it(12). Figure 10 shows that the antigamma-
globulin serum used in our laboratory (directed against rabbit gammaglobulin) 
crossreacts with human gammaglobulin. Titration of the antigammaglobulin 
serum should therefore be done in the presence of human serum. 
For some sera the existence of an "inhibitor" of the immunoprecipitation 
has been postulated and Morgan et al. provided evidence that complement may 
be this inhibitor. When trying to apply their methods for elimination of the inhi-
bitor to our sera it was found, that heat treatment indeed was effective, but treatment 
with EDTA in a final concentration up to 0.02 M never had an influence on the 
inhibition. The cause of this difference in our results and those of Morgan et al. 
is not known. The antigammaglobulin serum itself, when used in relatively high 
concentration (1/10 final concentration) seemed to supply enough complement 
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for some inhibition, since precipitation was further improved, when this serum 
was treated as well (Figure 11). Addition of guinea­pig serum rich in complement 
to treated serum restored the inhibition to pretreatment levels. 
If proteic hormones are diluted to very low concentrations (in the order of 
micrograms or nanograms per ml) their nonspecific adsorption to the glass surface 
becomes relatively important. Since no data are available on this binding for HGH, 
its possible influence on the radioimmunoassay of this hormone was studied using 
131l­labelled HGH in the concentration which was used in the assay of the hormone 
(1 ng/ml). The labelled hormone was left in test tubes for 2 hours at ­j­ 4° C in the 
presence of different concentrations of protein. The tubes were then washed three 
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times with different solutions which were designed to study the reversibility of the 
binding by different protein concentrations in the washing fluid. Table I shows 
that at higher protein concentrations in the tubes the binding to the glass surface 
is less important and also, that the binding is at least partially reversible by increasing 
the concentration of protein in the washing fluid. 
TABLE I 
Influence of protein concentration in incubation medium and washing fluid on binding of 
1 3 1I-HGH to the glass surface and its reversibility. 
Incubation medium 
1. CBSA 50 mg % in buffer 
2. CBSA 50 mg % in buffer + undi­
luted serum 
3. CBSA 1 g % in buffer 
4. CBSA 1 g % in buffer + undi­
luted serum 
5. CBSA 1 g % in buffer 
6. CBSA 1 g % in buffer + undilu­
ted serum 
Washing fluid 
NaCl 0.9 % 
NaCl 0.9 % 
CBSA 50 mg % in buffer 
CBSA 50 mg % in buffer 
CBSA 1 g % in buffer 
CBSA 1 g % in buffer 
% Radioactivity remaining 
after three washings 
5.9 
2.2 
3.9 
2.4 
3.3 
1.8 
C. B. S. A. : crystalline bovine serum albumin. 
Significance : 1 : 2 ρ <0.001 3 : 4 ρ < 0 . 1 5 : 6 ρ < 0 . 1 3 : 6 ρ <0 .01 
In a small test series, not shown in the table, there was no decrease in the binding 
when siliconized tubes were used instead of normal glass tubes. The importance 
of these findings for the radioimmunoassay of HGH lies in the fact that usually 
the protein concentrations in the tubes of the standard curve and in the unknowns 
are different. The former are usually incubated in the absence of serum and a cer­
tain concentration of albumin is used instead. This may cause a higher degree of 
non-specifically bound radioactive hormone after the washing of an immunopre-
cipitate in the tubes of the standards. If this is not accounted for, falsely high hor­
mone concentrations will be calculated for the unknowns. The error may be as 
high as 50 % or even more. 
G. MILHAUD : Thank you. Dr. Felber, would you like to make a few com­
ments on general problems and pitfalls which you have experienced. 
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J. P. FELBER : If one has a well-labelled hormone, potent antisera and good 
standard curve, some difficulties still remain in the estimation of the hormone in 
plasma : incubation damage, mentioned in Dr. Yalow's communication and failure 
to reach equilibrium in the incubation mixture. The incubation mixture contains 
free labelled hormone, free unlabelled hormone, free antibody, antibody-bound 
labelled hormone and antibody-bound unlabelled hormone. Any modification of 
the concentration of one of the components will have repercussions on the equi-
librium. For example, dilution of the antiserum will delay the time needed to reach 
equilibrium. 
The plasma to be tested will replace the unlabelled hormone in the incubation 
mixture. As it differs from the buffered solution of the hormone used for the standard 
curve, by the presence of the plasma proteins, a change may occur in the equili-
brium, increasing the time needed to reach equilibrium. It seems, therefore, very 
important to make sure that complete equilibrium has been reached before starting 
the separation of bound and free labelled hormone. 
Adding of plasma also has a different effect according to the system of sepa-
ration used. It slows down the precipitation in the double antibody system, and 
this may produce falsely high values if the precipitation is not complete. If one uses 
cellulose (in powder form or in the form used in chromatoelectrophoresis) or resin 
for the separation of free and bound labelled hormone, the presence of plasma 
may decrease the binding of free labelled hormone to cellulose or resin, and there-
fore produce falsely low values. All these difficulties can be avoided, as long as 
one is aware of them. 
G. MILHAUD : Thank you. Now the last speaker on the procedure of immu-
noassay is Dr. Freedlender, who is using a slightly different technique. 
A. E. FREEDLENDER : We are using the double antibody radioimmunoassay 
and à propos of the comments just made by Dr. Felber, if one assays sera at a 
dilution of 1 to 20 the damage due to incubation is not greater than that in the buffer 
system alone. We are adding to our system of standard or unknown serum again 
diluted 1 to 20, 05 n^g labelled growth hormone, 1/10 mg of guinea-pig anti-growth 
hormone serum and maintaining the first reaction at 4° C for 7 days. Following 
this we precipitate with rabbit anti-guinea-pig globulin serum in the presence of 
carrier to form an adequate precipitate. In view of the report of Sharp and Parker 
who carry their first incubation for only 2 days in the double antibody method, 
we have investigated the time period necessary for achieving equilibrium and it 
should be noted that there is a sharp increase in the initial point of the curve result-
ing in a marked increase in both sensitivity and precision of the assay, as the incu-
bation period is prolonged. I might point out that the curve does not look as deep 
as Dr. Yalow's because it is on a different plot but I think they are quite equivalent. 
A propos of Dr. Quabbe's comments regarding the interference in precipi-
tation we normally titrate our second antibody to achieve maximum precipitation 
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and then aibitrarily double it and have seen no interference by crossreaction with 
human gamma globulin. 
The equilibrium is obtained in 18 hours and we have had again no trouble 
with interference in the immunoprecipitation. The reason for the dilution of 1 to 
20, as suggested by Dr. Yalow, is that one human serum is representative of 20 
recovery experiments, with the theoretical recovery line of added human growth 
hormone. When assayed at 1 to 20, these sera fall within experimental error, on 
the recovery line, however at 1 to 10 and, in particular, at 1 to 5, excess growth 
hormone was recovered presumably due to incubation damage with sera. 
G. MILHAUD : Thank you. Now we shall go to another hormone, whose assay 
is still in experimental procedure, and first we will ask Dr. Potts to tell us something 
about the preparation of bovine parathormone. 
J. T. POTTS : Dr. Milhaud indicated it might be of value to review our studies 
concerned with the isolation and chemical characterization of bovine parathyroid 
hormone. These studies represent the collaborative efforts of Drs. Gerald Aurbach, 
Louis Sherwood, J. L. H. O'Riordan and Henry Keutmann, working in Dr. Aur-
bach's group in the National Institute of Arthritis and Metabolic Diseases and our 
group in the National Heart Institute. The hormone is extracted from beef glands 
with phenol by the procedure of Aurbach U3), fractionated with salt and obtained 
as a partially purified product by trichloroacetic acid precipitation (this interme-
diate product, TCA-PTH, is active at 200-300 USP units/mg(14)). Complete puri-
fication requires gel filtration on Sephadex followed by chromatography on car-
boxymethylcellulose; the bovine hormone obtained in this manner (CMC-PTH) 
is free of non-hormonal contaminants (15). Our studies of the amino acid sequence 
of the hormone and the relationship of structure to function have progressed suf-
ficiently to provide a working model of the structure including regions that are 
important for both biological and immunological activity (16) (Figure 12). A region 
of 29 amino acids located at the carboxyl-terminus of the molecule contains a mini-
mum structure requisite for both immunological and biological activity. Selective 
chemical modification of one of the two methionines and the single tryptophan 
and tyrosine residue of the polypeptide largely or totally destroys biological activity. 
These modified amino acid residues, shown with darkened borders in Figure 12 
are contained within the 20 amino acid region at the carboxyl-terminus of the hor-
mone. 
Biological activity is retained when the last four amino acids at the COOH-
terminus, 81 through 84, illustrated by cross-hatching in Figure 12, are removed 
from the native polypeptide by carboxypeptidase. The details of this work have 
been summarised elsewhere (15> 16). Immunological activity has been estimated, so 
far, only by the radioimmunoassay techniques, employing two of the high-energy 
antisera used in the radioimmunoassays. Some dissociations between biological and 
immunological activity have been detected <15- 16) but it was gratifying to find that 
the same region of the molecule is important for both activities. 
ROUND TABLE ON PROSPECTS IN RADIOIMMUNOASSAY 427 
- H P , -
FIGURE 12.— Tentative model of the parathyroid hormone molecule illustrating regions important 
for biological and immunological activity. The regions corresponding to each of the tryptic 
peptides (Tl through T7) are outlined by the parentheses and dotted lines; absolute sequence 
within these regions is not known but the individual residues arc arranged to reflect the partial 
sequence information deduced from exopeptidase studies, the characteristic specificity of 
tryptic attack, and the composition of fragments produced by other means of cleavage (indica-
ted by the designations HP.¡, P. , C : etc.). The cross-hatched residues at the COOH-terminus 
were not necessary for biological activity but alteration of methionine, tryptophan and tyro-
sine residues (shown by symbols with darkened borders) caused marked loss of biological acti-
vity. The 20-amino region (HP-3) at the carboxyl terminus was a biologically and immuno-
logically active fragment. 
The single tyrosine of the polypeptide is not buried in the interior of the mole-
cule but rather is solvent accessible'15'. Estimates made after iodination (performed 
by the technique of Hunter and Greenwood) indicate that this residue may be labelled 
to the extent of 50 % or more thereby providing a suitable tracer of high specific 
activity and purity. In preliminary tests it has been established that hormone isolated 
from bovine and human parathyroid tissue and the hormones circulating in the 
blood of the cow, goat and sheep are immunologically similar. Figure 13 compares 
the slope of the curves showing displacement of 131I beef PTH from antibody by 
each of these unlabelled hormone preparations. Since only the beef hormone is 
sufficiently purified to use as a reference standard, the curves from the plasma sam-
ples and human hormone preparation, where hormone concentration is unknown, 
must be superimposed on the beef PTH standard curve to provide the best possible 
fit. It has been assumed that if such curves completely superimpose, the preparations 
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have identical immunological crossreactivity. By this criterion the hormone cir­
culating in the blood of the cow and our purified beef hormone, CMC­PTH, are 
identical in their immunological reactivity; this would indicate that much of the 
essential chemical features of the native hormone have been preseved during isola­
tion. (Figure 13). This comparison further suggests that immunologically human 
and beef parathyroid hormones are identical and that goat and sheep hormones are 
quite similar to beef PTH. This finding should eliminate the need to work with 
human parathyroid hormone for measurements in human plasma. However, it is 
not certain that the method of curve fitting is a sufficient test of the degree of immu­
nological crossreactivity of two different hormone preparations. Accordingly, Dr. 
O'Riordan is continuing his efforts with us and with Drs. Berson and Yalow to 
purify and characterise the hormone from human adenoma tissue. It is hoped that 
a sufficient quantity of pure human hormone can be obtained to unequivocally 
«stablish the comparative immunological reactivity of known, identical quantities 
of human and beef hormone. 
These studies are of great importance in determining the eventual success of 
efforts to measure hormone concentration in human blood. We have measured 
hormone concentration in the blood of the cow, goat and sheep, working with 
dilutions of plasma as great as 1 to 5. However, as Dr. Yalow will discuss, one can 
only infrequently measure hormone concentration in human plasma. 
If the immunological crossreactivity of human and beef hormone is identical 
these difficulties must mean that hormone concentration in blood is lower in man 
than in ruminant animals; extraction from plasma would then be required for satis­
factory immunoassay. On the other hand, if the immunological reactivity of human 
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and beef hormone is different, the problems might be circumvented by using human 
parathyroid hormone in the assay. This seems formidable at best in that the weight 
yield of hormone from parathyroid glands is probably only about 0.004 %; it will 
be difficult to obtain enough pure human hormone to use with the radioimmu-
noassay technique for tesis in human subjects. 
G. MILHAUD : Thank you Dr. Potts. As to the availability of the pure hormone 
no bovine hormone is available at present, to say nothing of the availability of any 
human hormone. So it seems to me that it would be very important to start collect-
ing human adenoma and to have a central information storing system indicating 
the location and the weight of the adenoma. The fresh tissue should be put, imme-
diately after removal, on dry ice and then kept in the deepfrozen state. When we 
obtain sufficient adenomas, then we should consider a joint project for extracting 
fractionating and getting some purified parathormone. At the National Institute 
for Health, they have now already 100 g of this material but you have to know 
that the yield may be 1 or 2 milligrams of pure human parathormone from 100 g 
fresh tissue. Therefore it would be really time for us to start to collect this in Europe. 
As to the labelling 1 think there is no special problem and we could go over 
to the next point which is the availability of antiserum. Dr. Yalow would you say 
a few words on your experience in getting the antisera with impure preparations ? 
R. S. YALOW : In addition to supplying Dr. Latimer with HGH antiserum, 
we have also been supplying insulin antiserum to a large number of investigators. 
However, the situation with respect to parathyroid hormone antiserum is quite 
different. The supply of antiserum suitable for detecting parathyroid hormone even 
in hyperparathyroid patients is at present in very short supply and it does not appear 
likely that such an antiserum will be available for general distribution for at least 
another year or two. If you plan to attempt to produce your own antiserum, perhaps 
you may profit from some of our experience. The antisera most suitable for assay 
purposes were produced in animals immunized with beef parathyroid hormone 
which assayed at about 200 U/mg. When the same number of animals were immu-
nized with beef parathyroid hormone which assayed about 2000 U/mg, we did not 
get as sensitive an antiserum on similar immunization schedules. It would seem 
therefore that immunization with a very highly purified preparation probably offers 
no advantage. We have not investigated whether very low purity commercially 
available parathyroid hormone is suitable but it certainly seems worthwhile inves-
tigating this. 
The following is the technique we have used for immunization of guinea-pigs : 
Beef parathyroid hormone is dissolved in 0.005 N HCl at a concentration equivalent 
to 1 mg pure beef parathyroid hormone per ml and homogenized with an equal 
volume Freund's complete adjuvant. Then each animal is injected subcutaneously 
(inside of thigh) with 0.5 ml of this mixture. Animals are re-immunized similarly 
at 2-5 week intervals for a total of 3-6 doses. About 8-12 days after the third or 
subsequent immunizations blood is taken by cardiac puncture with a heparinized 
syringe while the animal is under chloroform anesthesia. Animals producing sui-
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table antisera are reimmunized at intervals and blood taken during the 8-12 day 
period following the booster. Antisera are not pooled. Guinea- pigs have survived 
for us as long as 4 years with as many as 20 cardiac punctures. It should be empha-
sized that a good animal should not be exsanguinated. We take about 10 ml blood 
for each puncture and the animal can be milked regularly every few months. 
G. MILHAUD : I think that now we have to discuss some results. The results 
concerning animals will be presented by Dr. Potts, and the results concerning human 
sera will be presented by Dr. Yalow. 
J. T. POTTS : Gerald Aurbach, Louis Sherwood and I, working with Dr. Anthony 
Care of the Rowett Research Institute in Great Britain and Drs. David Kronfeld, 
Pat Mayer and Charles Ramberg of the Veterinary School cf the University of 
Pennsylvania have measured the concentration of parathyroid hormone in the 
blood of the cow, goat and sheep. The concentration in an unstimulated cow varies 
between 0.5 and 1.5 mu.g/mL The ease with which measurements can be made in 
the blood of the cow has permitted a variety of studies to define the factors which 
control the secretion of parathyroid hormone. The concentration of hormone in 
blood increases within minutes or less following induced hypocalcemia, increasing 
tenfold or more between suppression with high calcium and maximal stimulation 
with hypocalcemia (17). A typical study with a cow is summarized in Figure 14. 
In the studies with Dr. Care, the concentration of parathyroid hormone in 
the venous effluent from parathyroid in the sheep and goat was measured1181. Results 
were similar to those seen in the blood of the cow, indicating actual changes in the 
secretion rate of hormone rather than only alteration of the distribution, excre-
tion, or fate of hormone. Furthermore, it suggested that the parathyroid gland 
itself is the receptor tissue which responds to changing serum calcium. High concen-
trations of magnesium also suppress hormone secretion; phosphate, on the other 
hand, has no direct effect on the secretion of parathyroid hormone but only secon-
darily affects its secretion through changes induced in serum calcium concentration 
(Figure 15). 
While we are continuing our collaborative efforts with Drs. Berson and Yalow 
on the application of the assay to measurements in human plasmas we are extending 
the experiments with animals. 
We will study how rapidh' hormone concentration changes in response to 
hypocalcemia as well as the relative importance of various ions in influencing hor-
mone production by affecting release and/or synthesis. Also of interest is whether 
parathyroid hormone is continuously secreted and whether constant increments 
in secretion follow given degrees of hypocalcemia. Since blood calcium is a specific 
and direct regulator of parathyroid hormone production, these studies with the 
radioimmunoassay technique provide an unusual opportunity to carefully evaluate 
the physiological control of the secretion of this peptide hormone. 
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FIGURE 14.— Infusions of calcium to raise or EDTA to lower the concentration of calcium in the 
blood of the cow. The secretion of parathyroid hormone rises in response to hypocalcemia and 
is suppressed by hypercalcemia. 
FIGURE 15.— Infusions of phosphate, sufficient to markedly elevate its concentration in blood 
( O — O X if accompanied by concomitant infusion of calcium to prevent hypocalcemia < · — · ) . 
does not significantly alter the concentration of parathyroid hormone in the blood of the cow 
( Δ - Δ ) · 
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R. S. YALOW : I will report briefly some of the results Dr. Berson and I have 
obtained in the immunoassay of human parathyroid hormone. We have been detect­
ing elevated levels of plasma parathyroid hormone in cases of proven parathyroid 
adenoma, but frequently even higher levels in many cases of uremia. In the fasting 
state, normal subjects generally have values less than 0.5 n^g/ml. We have also 
studied the disappearance of endogenous parathyroid hormone following extir­
pation of parathyroid adenomas and have found turnover half-times of the order 
of 10-20 minutes, similar to those of endogenous ACTH, growth hormone and 
insulin. One interesting finding we have observed not infrequently is the marked 
stimulation of parathyroid hormone secretion associated with handling the tumour 
during surgery. Determination of parathyroid hormone levels following surgery 
has been of value in predicting whether or not complete removal of adenomas 
has been effected and whether clinical remission can be anticipated. 
G. MILHAUD : Thank you Dr. Yalow. We have two more points to discuss con­
cerning eventual prospects in radioimmunoassay. The first one concerns the use 
of 125I. Would you like, Dr. Luyckx to comment on this ? 
A. LUYCKX : For labelling human growth-hormone with 125I we use the Hunter 
and Greenwood method, 10 μg of the Wilhelmi 612 A preparation being put in 
the presence of 4 mC of 125I. The labelled product is immediately applied on a G 50 
Sephadex column and the protein peak obtained is then filtered on a G 200 Sepha­
dex column. If a comparison is made of the radioactivity in the eluted fractions 
of the G 200 column, it appears that in the case of 125I-labelled hormone the radio 
activity corresponding to the largest fraction is at exactly the same place as with 
131I-labelled hormone. However the radioactivity eluted before this main peak 
seemed to us in our first experiment to be appreciably lower than in the case of 
131I-labelled hormone. 
By means of an immunoprecipitation technique usually used in our assays we 
have studied the binding of this preparation to the antibody. With 125I-labelled 
hormone we obtained a maximum binding of 97 % whereas in similar conditions 
with 131I-labelled hormone the binding was only 80-85 %. Finally we have used the 
same 125I-labelled preparation for a series of standard successive curves over a period 
of three weeks. 125I-labelling has obviously two advantages : a 60-day half-life and 
less radiation damage to the hormone. 
At the bottom of the figure 16 is illustrated what I was saying just now, namely, 
the substantial reduction in the eluted material before the main radioactivity peak 
in the case of 125I-labelled hormone. The top of the figure shows the usual radio­
activity distribution for 131I-labelled hormone. 
G. MILHAUD : Dr. Greenwood would you like to comment? 
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F. C. GREENWOOD : I would like to summarise briefly and dogmatically Dr. 
Hunter's experiences with 125I. These were reported at the 9th Symposium on the 
use of radioactive isotopes in medicine (Oak Ridge Institute of Nuclear Science, 
October 1965). Essentially 125I has given lower yields than 1311 in our method but, 
at least, a yield has always been obtained. The stability of different preparations 
of 125I-human growth hormone is variable. A preparation may last a week or a 
month. The amount of isotope reacted has been to 0.75 mC otherwise damage is 
excessive. In our experience there is little to choose between the two isotopes. Cer­
tainly 125I does not answer the problems outlined by Dr. Yalow and myself. A dis­
cussion of the radioimmunoassay technique, the labelling of protein hormones 
and the specificity of radioimmunoassays is to be published (19). 
G MILHAUD : Another possibility is to use 51Cr and I think that Dr. Brauman 
has some experience to report with this isotope. 
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H. BRAUMAN : A batch of Raben's HGH was labelled according to the Hunter 
and Greenwood technique; the undamaged 131I-HGH was successfully utilised 
in the Berson and Yalow radioimmunoassay. 
Freshly prepared 51Cr-chloride (Amersham or Saclay) had specific activities 
from 50 to 100 mC/mg. The labelling was obtained by incubation of small amounts 
of dissolved HGH at room temperature. All the radioactivity showed to be imme-
diately fixed on the HGH with specific activités up to 100 mC/mg. No attempt 
has been made to obtain higher specific activities. When submitted to chromato-
electrophoresis on Whatman 3 MM paper strips, following Berson and Yalow 
technique, the labelled product showed only one single symmetric radioactive peak 
at the origin. This single peak is not displaced by the addition of serum bovine albu-
min or horse serum. These results are comparable with those obser-
ved with undamaged 131I-HGH. 
Before drawing any conclusion for the future from these preliminary results, 
the reproducibility of the labelling procedure, the ability of the 51Cr-HGH to react 
with specific HGH antibody and to be displaced by non-labelled HGH has to be 
tested. 
G. MILHAUD : I should like to thank all the participants : those who came from 
far to give us the benefit of their experience and those who came to tell us of their suc-
cesses and their difficulties. Finally, I would like to thank the institutions which made 
these discussions possible, Euratom and the University of Pisa and enabled such 
eminent experts to gather round this table. In this city, where every stone evokes 
a historical memory, we know that the past record of the University of Pisa and the 
efforts which have resulted in today's conference are the most reliable guarantees 
of the future for which we hope. It is time to conclude our discussions. The perfor-
mance of the radioimmunoassay of human growth hormone should not involve 
major difficulties anymore and most european laboratories should be able to obtain 
very good results. The situation is unfortunately very different in respect to para-
thormone, as human parathormone has never been obtained in pure form. All 
the work is done with beef parathormone, which is scarcely available as well as 
the corresponding antisera. This means that one has to assume the identity of beha-
viour of the animal and human hormone for the immunoassay, even though this 
may well not be the case. These considerations emphasize the importance to collect 
as much parathyroid tissue as possible from patients operated upon in the european 
institutions. This material should be frozen and stored to be made available for 
fractionation and purification. I would be glad to centralise these informations from 
all interested investigators and we could meet again as soon as sufficient glands 
are available and discuss together the preparation of pure human parathyroid hor-
mone. 
There are two final comments I should like to make. 
There is a source of error common to all immunological assays : we assay 
a protein by using its immunological reactivity, but it is not certain that the biolo-
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gical activity behaves in the same way as the immunological activity, since it has 
not been established that the same chemical groups in the molecule take part in 
the two types of biological and immunological reaction. Whenever possible, there­
fore, the immunological assay should be supplemented by a biological assay, whe­
reby the proportion of the hormone present in an inactived form can be estimated. 
Finally, radioimmunoassays often represent an important stage in the elu­
cidation of the relations between the chemical messenger and the receptor. Over­
production or underproduction of the messenger must give raise to a variation in 
the intensity of response of a particular receptor. Now the receptor will respond or 
fail to respond to variations in the stimulus provided by the hormone, according 
to whether or not it is intact. Consequently, with underproduction the response 
will always be smaller, with overproduction the increase in the response requires 
an intact receptor, which may not be the case <20). 
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